Induction_NN of_IN NF-KB_NNP during_IN monocyte_`` differentiation_NN by_IN HIV_NNP type_NN 1_CD infection_NN ._.
The_DT production_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_-LRB- HIV-1_NN )_-RRB- progeny_NN was_VBD followed_VBN in_IN the_DT U937_`` promonocytic_JJ cell_NN line_NN after_IN stimulation_NN either_CC with_IN retinoic_JJ acid_NN or_CC PMA_NNP ,_, and_CC in_IN purified_`` human_JJ monocytes_NNS and_CC macrophages_NNS ._.
Electrophoretic_-LRB- mobility_`` shift_NN assays_NNS and_CC Southwestern_NNP blotting_VBG experiments_NNS were_VBD used_VBN to_TO detect_VB the_DT binding_NN of_IN cellular_JJ transactivation_NN factor_NN NF-KB_`` to_TO the_DT double_JJ repeat-KB_NN enhancer_NN sequence_NN located_VBN in_IN the_DT long_JJ terminal_NN repeat_NN ._.
PMA_-LRB- treatment_NN ,_, and_CC not_RB retinoic_JJ acid_NN treatment_NN of_IN the_DT U937_`` cells_NNS acts_NNS in_IN inducing_VBG NF-KB_NNP expression_NN in_IN the_DT nuclei_`` ._.
In_IN nuclear_JJ extracts_NNS from_IN monocytes_NNS or_CC macrophages_NNS ,_, induction_NN of_IN NF-KB_NNP occurred_VBD only_RB if_IN the_DT cells_NNS were_VBD previously_RB infected_VBN with_IN HIV-1_NN ._.
When_WRB U937_`` cells_NNS were_VBD infected_VBN with_IN HIV-1_`` ,_, no_DT induction_NN of_IN NF-KB_NNP factor_NN was_VBD detected_VBN ,_, whereas_IN high_JJ level_NN of_IN progeny_`` virions_NNS was_VBD produced_VBN ,_, suggesting_VBG that_IN this_DT factor_NN was_VBD not_RB required_VBN for_IN viral_JJ replication_NN ._.
These_DT results_NNS indicate_VBP that_IN in_IN monocytic_JJ cell_NN lineage_NN ,_, HIV-1_NNP could_MD mimic_VB some_DT differentiation/activation_`` stimuli_NNS allowing_VBG nuclear_JJ NF-KB_NNP expression_NN ._.
Positive_JJ and_CC negative_JJ regulation_NN of_IN immunoglobulin_`` gene_NN expression_NN by_IN a_DT novel_JJ B-cell-specific_NNP enhancer_`` element_NN ._.
A_DT new_JJ B-cell-specific_NNP enhancer_`` element_NN has_VBZ been_VBN identified_VBN 3'_`` of_IN E4_`` and_CC the_DT octamerlike_JJ motifs_NNS in_IN the_DT human_JJ immunoglobulin_NN heavy-chain_JJ gene_NN enhancer_NN ._.
Tandem_NNP copies_NNS of_IN this_DT 67-bp_JJ MnlI-AluI_JJ fragment_NN ,_, when_WRB fused_VBN to_TO the_DT chloramphenicol_NN acetyltransferase_`` gene_NN driven_VBN by_IN the_DT conalbumin_NN promoter_NN ,_, stimulated_VBD transcription_NN in_IN B_NNP cells_NNS but_CC not_RB in_IN Jurkat_NNP T_NNP cells_NNS or_CC HeLa_NNP cells_NNS ._.
Footprinting_VBG analysis_NN revealed_VBD that_IN the_DT identical_JJ sequence_NN CCGAAACTGAAAAGG_`` ,_, designated_VBN E6_NNP ,_, was_VBD protected_VBN by_IN nuclear_JJ extracts_NNS from_IN B_NNP cells_NNS ,_, T_JJ cells_NNS ,_, or_CC HeLa_NNP cells_NNS ._.
Gel_NNP mobility_`` shift_NN assays_VBZ using_VBG a_DT synthetic_JJ E6_NNP motif_`` detected_VBD a_DT B-cell-specific_`` complex_JJ in_IN addition_NN to_TO a_DT ubiquitous_JJ band_NN found_VBD also_RB in_IN T_JJ cells_NNS and_CC HeLa_NNP cells_NNS ._.
In_IN agreement_NN with_IN the_DT results_NNS of_IN gel_`` retardation_`` assays_NNS ,_, tandem_# copies_NNS of_IN the_DT E6_NNP motif_`` stimulated_VBD transcription_NN in_IN ARH77_CD and_CC Raji_NNP cells_NNS but_CC not_RB in_IN Jurkat_NNP or_CC HeLa_NNP cells_NNS ._.
Furthermore_RB ,_, a_DT mutant_JJ E6_NNP motif_`` lost_VBD both_DT in_IN vitro_`` binding_JJ activity_NN and_CC in_IN vivo_`` enhancer_JJ activity_NN ._.
In_IN striking_JJ contrast_NN to_TO the_DT mouse_NN Ig_`` heavy-chain_JJ enhancer_NN ,_, in_IN which_WDT the_DT octamer_`` motif_`` acts_NNS as_IN a_DT B-cell-specific_JJ enhancer_NN element_NN ,_, the_DT human_JJ enhancer_NN contains_VBZ an_DT octamerlike_JJ sequence_NN with_IN one_CD base_NN substitution_NN which_WDT bound_VBD octamer-binding_JJ proteins_NNS with_IN only_RB very_RB low_JJ affinity_NN and_CC showed_VBD no_DT enhancer_NN activity_NN of_IN its_PRP$ own_JJ ._.
Interestingly_RB ,_, the_DT MnlI-AluI_JJ fragment_NN could_MD suppress_VB the_DT basal-level_`` activity_NN of_IN the_DT conalbumin_`` promoter_NN in_IN both_DT Jurkat_NNP and_CC HeLa_NNP cells_NNS ._.
Moreover_RB ,_, simian_'' virus_NN 40_CD enhancer_NN activity_NN was_VBD blocked_VBN by_IN the_DT MnlI-AluI_JJ fragment_NN in_IN HeLa_NNP cells_NNS but_CC not_RB in_IN B_NNP cells_NNS ._.
Thus_RB ,_, the_DT novel_JJ enhancer_NN element_NN identified_VBN in_IN this_DT study_NN is_VBZ probably_RB a_DT target_NN site_NN for_IN both_DT positive_JJ and_CC negative_JJ factors_NNS ._.
The_DT NF_NNP kappa_NN B_NNP independent_JJ cis-acting_JJ sequences_NNS in_IN HIV-1_NNP LTR_NNP responsive_JJ to_TO T-cell_NNP activation_NN ._.
The_DT rate_NN of_IN transcription_NN initiation_NN directed_VBN by_IN the_DT long_JJ terminal_NN repeat_NN (_-LRB- LTR_NNP )_-RRB- of_IN HIV-1_`` increases_NNS in_IN response_NN to_TO mitogenic_JJ stimuli_NNS of_IN T_JJ cells_NNS ._.
Here_RB we_PRP show_VBP that_IN the_DT response_NN of_IN the_DT HIV-1_NNP LTR_NNP may_MD be_VB governed_VBN by_IN two_CD independent_JJ sequences_NNS located_VBN 5'_'' to_TO the_DT site_NN of_IN transcription_NN initiation_NN sequences_`` that_IN bind_NN either_DT NFAT-1_NNP or_CC NF_NNP kappa_`` B_NNP ._.
The_DT rate_NN of_IN LTR-directed_JJ gene_NN expression_NN increased_VBN in_IN response_NN to_TO treatment_NN with_IN either_CC a_DT phorbol_NN ester_NN or_CC tumor_NN necrosis_`` factor_NN alpha_NN if_IN either_CC the_DT NFAT-1_NN or_CC NF_NNP kappa_`` B_NNP binding_# sites_NNS were_VBD deleted_VBN ,_, but_CC failed_VBD to_TO respond_VB to_TO these_DT mitogenic_JJ stimuli_NNS if_IN both_DT sequences_NNS were_VBD absent_JJ ._.
The_DT HIV-1_`` mutant_JJ virus_NN containing_VBG both_DT NF_NNP kappa_`` B_NNP and_CC NFAT-1_NNP deletion_NN was_VBD able_JJ to_TO replicate_VB although_IN at_IN a_DT much_JJ decreased_VBN growth_NN rate_NN ,_, while_IN the_DT deletion_NN of_IN NFAT-1_NNP alone_RB increased_VBD the_DT viral_`` growth_NN rate_NN in_IN Jurkat_NNP cells_NNS ._.
Neither_DT deletion_NN of_IN NF_NNP kappa_-RRB- B_NNP nor_CC deletion_NN of_IN NFAT-1_NNP decreased_VBD activation_NN of_IN viral_JJ replication_NN by_IN phorbol_NN ester_NN ._.
Specific_JJ depletion_NN of_IN the_DT B-cell_NNP population_NN induced_`` by_IN aberrant_JJ expression_NN of_IN human_JJ interferon_`` regulatory_JJ factor_NN 1_CD gene_NN in_IN transgenic_JJ mice_NNS ._.
Interferons_NNS (_-LRB- IFNs_NNP )_-RRB- are_VBP well_RB known_VBN both_DT as_IN antiviral_JJ proteins_NNS and_CC as_IN potent_JJ regulators_NNS of_IN cell_NN growth_NN and_CC differentiation_NN ._.
In_IN fact_NN ,_, IFNs_# inhibit_VB growth_NN of_IN various_JJ normal_JJ and_CC transformed_VBD cell_NN types_NNS ._.
Previously_RB ,_, a_DT nuclear_JJ factor_NN ,_, IRF-1_# (_-LRB- interferon_`` regulatory_JJ factor_NN 1_CD )_-RRB- ,_, which_WDT binds_VBZ to_TO type_NN I_PRP IFN_`` and_CC some_DT IFN-inducible_JJ gene_NN promoters_NNS ,_, was_VBD identified_VBN and_CC cloned_VBN ._.
Since_IN the_DT IRF-1_NNP gene_NN is_VBZ both_DT virus_NN and_CC IFN_`` inducible_JJ ,_, an_DT intriguing_JJ issue_NN is_VBZ raised_VBN as_IN to_TO whether_IN the_DT IRF-1_`` gene_NN is_VBZ functioning_VBG in_IN IFN-mediated_JJ regulation_NN of_IN cell_NN growth_NN and_CC differentiation_NN ._.
In_IN this_DT study_NN ,_, we_PRP generated_VBD transgenic_JJ mice_NNS carrying_VBG the_DT human_JJ IRF-1_NNP gene_NN linked_VBN to_TO the_DT human_JJ immunoglobulin_NN heavy-chain_NN enhancer_NN ._.
In_IN the_DT transgenic_JJ mice_NNS ,_, all_PDT the_DT lymphoid_JJ tissues_NNS examined_VBN showed_VBD a_DT dramatic_JJ reduction_NN in_IN the_DT number_NN of_IN B_NNP lymphocytes_`` (_-LRB- B_NN cells_NNS )_-RRB- ._.
Preparation_NN and_CC analysis_NN of_IN bone_NN marrow_JJ cells_NNS from_IN the_DT chimeric_JJ mice_NNS indicated_VBD that_IN the_DT bone_NN marrow_`` is_VBZ the_DT effective_JJ site_NN for_IN specific_JJ depletion_NN of_IN the_DT B-cell_NNP population_NN ._.
In_IN fact_NN ,_, transgenic_JJ bone_NN marrow_# cells_NNS cocultured_`` with_IN a_DT bone_NN marrow-derived_JJ stromal_JJ cell_NN line_NN revealed_VBD an_DT altered_VBN B-cell_NNP maturation_`` pattern_NN ._.
Identification_NN and_CC cloning_NN of_IN TCF-1_NNP ,_, a_DT T_JJ lymphocyte-specific_JJ transcription_NN factor_NN containing_VBG a_DT sequence-specific_JJ HMG_NNP box_NN ._.
CD3-epsilon_JJ expression_NN is_VBZ controlled_VBN by_IN a_DT downstream_`` T_`` lymphocyte-specific_JJ enhancer_NN element_NN ._.
We_PRP report_VBP the_DT identification_NN of_IN a_DT T_JJ cell-specific_JJ transcription_NN factor_NN ,_, TCF-1_NNP ,_, binding_'' to_TO this_DT element_NN ._.
The_DT multimerized_JJ recognition_NN motif_NN of_IN TCF-1_NNP constituted_VBD a_DT T_JJ cell-specific_JJ enhancer_NN ._.
Subsequent_JJ cloning_NN of_IN TCF-1_NNP identified_VBD three_CD splice_`` alternatives_NNS ._.
TCF-1_NNP contained_VBD a_DT single_JJ DNA-binding_NNP HMG_NNP box_NN most_RBS closely_RB related_VBN to_TO similar_JJ boxes_NNS in_IN the_DT putative_JJ mammalian_`` sex-determining_JJ gene_NN SRY_NN and_CC in_IN the_DT Schizosaccharomyces_`` pombe_`` Mc_NNP mating_`` type_NN gene_NN ._.
TCF-1_NNP mRNA_NNP was_VBD expressed_VBN uniquely_RB in_IN T_JJ lymphocytes_NNS ._.
Upon_IN cotransfection_NN into_IN non-T_JJ cells_NNS ,_, TCF-1_NNP could_MD transactivate_VB through_IN its_PRP$ cognate_`` motif_NN ._.
These_DT results_NNS identify_VBP TCF-1_`` as_IN a_DT T_JJ cell-specific_JJ transcription_NN factor_NN ,_, which_WDT might_MD play_VB a_DT role_NN in_IN the_DT establishment_NN of_IN the_DT mature_JJ T_JJ cell_NN phenotype_NN ._.
Nuclear_JJ factor_NN kappa_# B_NNP activates_`` proenkephalin_`` transcription_NN in_IN T_JJ lymphocytes_NNS ._.
Upon_IN activation_NN ,_, T_JJ lymphocytes_NNS accumulate_VBP high_JJ levels_NNS of_IN the_DT neuropeptide_`` enkephalin_`` which_WDT correlate_`` with_IN high_JJ levels_NNS of_IN proenkephalin_`` mRNA_`` in_IN the_DT cells_NNS ._.
Here_RB we_PRP investigated_VBD the_DT transcriptional_JJ basis_NN for_IN these_DT changes_NNS ._.
The_DT proenkephalin_NN promoter_NN contains_VBZ a_DT sequence_NN GGGGACGTCCCC_NNP ,_, named_VBN B2_NN ,_, which_WDT is_VBZ similar_JJ to_TO the_DT kappa_`` B_NNP sequence_NN GGGGACTTTCC_NNP ,_, the_DT binding_`` site_NN of_IN the_DT transcription_NN factor_NN nuclear_JJ factor_NN (_-LRB- NF_NNP )_-RRB- -kappa_`` B_NN ._.
Activation_NN of_IN T_JJ lymphocytes_NNS induces_VBZ an_DT NF-kappa_NNP B-like_`` binding_JJ activity_NN to_TO the_DT B2_NN site_NN ,_, concomitant_'' with_IN activation_NN of_IN the_DT proenkephalin_NN promoter_NN ._.
Mutations_NNS at_IN the_DT B2_JJ site_NN abolish_VB this_DT transcriptional_JJ activation_NN ._.
The_DT purified_`` homodimer_NN (_-LRB- two_CD p50s_NNS )_-RRB- of_IN the_DT DNA-binding_`` subunit_NN of_IN NF-kappa_NNP B_NNP binds_VBZ the_DT B2_`` site_NN of_IN proenkephalin_`` relatively_RB better_JJR than_IN does_VBZ the_DT heterotetramer_`` (_-LRB- two_CD p65s_NNS plus_CC two_CD p50s_NNS )_-RRB- form_VBP of_IN the_DT factor_NN ._.
Thus_RB ,_, it_PRP appears_VBZ that_IN the_DT T-cell-specific_JJ activation_NN of_IN the_DT proenkephalin_NN promoter_NN is_VBZ mediated_VBN by_IN NF-kappa_NNP B_NNP ._.
However_RB ,_, as_IN NF-kappa_NNP B_NNP is_VBZ ubiquitous_JJ and_CC the_DT transcriptional_JJ activation_NN through_IN the_DT B2_NN site_NN is_VBZ T_JJ cell_NN specific_NN ,_, yet_RB another_DT T-cell-specific_JJ factor_NN which_WDT synergizes_VBZ with_IN NF-kappa_NNP B_NNP should_MD be_VB considered_VBN ._.
Expression_NN of_IN c-jun_NN ,_, jun_NN B_NNP and_CC jun_`` D_NNP proto-oncogenes_`` in_IN human_JJ peripheral-blood_`` granulocytes_NNS ._.
We_PRP have_VBP found_VBN that_IN purified_`` human_JJ peripheral-blood_`` granulocytes_NNS express_VBP constitutively_RB significant_JJ levels_NNS of_IN proto-oncogenes_`` c-jun_`` ,_, jun_NN B_NNP and_CC jun_`` D_NNP mRNA_NNP ._.
Upon_IN functional_JJ activation_NN of_IN granulocytes_NNS by_IN 4_CD beta-phorbol_`` 12-myristate_JJ 13-acetate_`` (_-LRB- PMA_NNP )_-RRB- ,_, the_DT levels_NNS of_IN c-jun_NN ,_, jun_NN B_NNP and_CC jun_`` D_NNP transcripts_NNS were_VBD increased_VBN ._.
The_DT three_CD jun_`` genes_NNS showed_VBD a_DT similar_JJ time_NN course_NN in_IN their_PRP$ induction_NN by_IN PMA_NNP ,_, maximal_'' mRNA_`` levels_NNS being_VBG reached_VBN after_IN 60_CD min_NN of_IN induction_NN ._.
These_DT results_NNS suggest_VBP that_IN expression_NN of_IN c-jun_NN ,_, jun_NN B_NNP and_CC jun_`` D_NNP genes_NNS might_MD be_VB involved_VBN in_IN terminal_NN granulocyte_NN differentiation_NN or_CC in_IN regulating_`` granulocyte_JJ functionality_NN ._.
Platelet-activating_JJ factor_NN induces_`` phospholipid_JJ turnover_NN ,_, calcium_NN flux_NN ,_, arachidonic_'' acid_NN liberation_NN ,_, eicosanoid_JJ generation_NN ,_, and_CC oncogene_`` expression_NN in_IN a_DT human_JJ B_NNP cell_NN line_NN ._.
Platelet-activating_JJ factor_NN is_VBZ a_DT potent_JJ mediator_NN of_IN the_DT inflammatory_JJ response_NN ._.
Studies_NNS of_IN the_DT actions_NNS of_IN platelet-activating_JJ factor_NN have_VBP centered_VBN mainly_RB around_IN neutrophils_NNS ,_, monocytes_NNS ,_, and_CC platelets_NNS ._.
In_IN this_DT report_NN we_PRP begin_VBP to_TO uncover_VB the_DT influence_NN of_IN platelet-activating_JJ factor_NN on_IN B_NNP lymphocytes_NNS ._.
Employing_VBG the_DT EBV-transformed_`` human_JJ B_NNP cell_NN line_NN SKW6.4_# ,_, we_PRP demonstrate_VBP that_IN platelet-activating_JJ factor_NN significantly_RB alters_`` membrane_`` phospholipid_JJ metabolism_NN indicated_VBN by_IN the_DT incorporation_NN of_IN 32P_NNP into_IN phosphatidylcholine_NN ,_, phosphatidylinositol_NN ,_, and_CC phosphatidic_JJ acid_NN but_CC not_RB significantly_RB into_IN phosphatidylethanolamine_`` at_IN concentrations_NNS ranging_VBG from_IN 10(-9)_CD to_TO 10(-6)_CD M_NNP ._.
The_DT inactive_JJ precursor_NN ,_, lyso-platelet-activating_JJ factor_NN ,_, at_IN a_DT concentration_NN as_RB high_JJ as_IN 10(-7)_JJ M_NNP had_VBD no_DT effect_NN on_IN any_DT of_IN the_DT membrane_`` phospholipids_NNS ._.
We_PRP also_RB show_VBP that_IN platelet-activating_JJ factor_NN from_IN 10(-12)_CD to_TO 10(-6)_CD M_NNP induced_`` rapid_JJ and_CC significant_JJ elevation_NN in_IN intracellular_JJ calcium_NN levels_NNS ,_, whereas_IN lyso-platelet-activating_JJ factor_NN was_VBD again_RB ineffective_JJ ._.
We_PRP further_RB demonstrate_VBP the_DT impact_NN of_IN platelet-activating_JJ factor_NN binding_VBG to_TO B_NNP cells_NNS by_IN measuring_VBG platelet-activating_JJ factor_NN induced_`` arachidonic_`` acid_NN release_NN and_CC 5-hydroxyeicosatetraenoic_JJ acid_NN production_NN ._.
Moreover_RB ,_, platelet-activating_'' factor_NN was_VBD capable_JJ of_IN inducing_VBG transcription_NN of_IN the_DT nuclear_JJ proto-oncogenes_`` c-fos_NNS and_CC c-jun_`` ._.
Finally_RB we_PRP explored_VBD the_DT possible_JJ role_NN of_IN 5-hydroxyeicosatetraenoic_JJ acid_NN as_IN a_DT regulator_NN of_IN arachidonic_`` acid_JJ liberation_NN demonstrating_`` that_IN endogenous_JJ 5-lipoxygenase_JJ activity_NN modulates_`` platelet-activating_JJ factor_NN induced_`` arachidonic_`` acid_NN release_NN perhaps_RB acting_VBG at_IN the_DT level_NN of_IN phospholipase_JJ A2_NN ._.
In_IN summary_NN ,_, platelet-activating_'' factor_NN is_VBZ shown_VBN here_RB to_TO have_VB a_DT direct_JJ and_CC profound_JJ effect_NN on_IN a_DT pure_JJ B_NNP cell_NN line_NN ._.
A_DT novel_JJ HIV-1_NNP isolate_`` containing_VBG alterations_NNS affecting_VBG the_DT NF-kappa_NNP B_NNP element_NN ._.
Three_CD molecular_JJ clones_NNS of_IN HIV-1_-RRB- ,_, derived_VBD from_IN a_DT single_JJ isolate_`` (_-LRB- AL1_NN )_-RRB- ,_, exhibited_VBD distinct_JJ replicative_JJ and_CC cytopathic_JJ properties_NNS during_IN propagation_NN in_IN a_DT human_JJ T_JJ cell_NN line_NN ._.
The_DT phenotypic_`` differences_NNS observed_VBN were_VBD attributable_JJ ,_, in_IN large_JJ part_NN ,_, to_TO changes_NNS affecting_VBG the_DT viral_JJ LTR_NNP ._.
Nucleotide_NNP sequence_NN and_CC PCR_`` analyses_# demonstrated_VBD the_DT presence_NN of_IN novel_JJ duplications_NNS or_CC deletions_NNS involving_VBG the_DT NF-kappa_NNP B_NNP motif_NN ._.
These_DT changes_NNS in_IN the_DT enhancer_NN element_NN were_VBD identified_VBN in_IN the_DT original_JJ AL1_NN virus_NN stock_NN ._.
Subcloning_VBG of_IN the_DT variant_`` NF-kappa_NNP B_NNP segments_NNS into_IN LTR-driven_`` CAT_JJ expression_NN vectors_NNS confirmed_VBD a_DT correlation_NN between_IN promoter_NN activity_NN and_CC replicative/cytopathic_JJ capacity_NN ._.
1,25-Dihydroxyvitamin_JJ D3_NN receptor_NN RNA_`` :_: expression_NN in_IN hematopoietic_JJ cells_NNS ._.
1,25-Dihydroxyvitamin_JJ D3_`` (_-LRB- 1,25(OH)2D3_NNP )_-RRB- induces_VBZ differentiation_NN and_CC inhibits_`` proliferation_NN of_IN myeloid_`` leukemic_JJ cells_NNS from_IN various_JJ lines_NNS and_CC patients_NNS ;_: these_DT effects_NNS are_VBP probably_RB mediated_`` through_IN the_DT 1,25(OH)2D3_NNP receptor_NN ._.
Little_NNP is_VBZ known_VBN of_IN expression_NN of_IN 1,25(OH)2D3_CD receptor_NN RNA_`` in_IN hematopoietic_JJ cells_NNS ._.
We_PRP examined_VBD the_DT expression_NN and_CC modulation_NN of_IN expression_NN of_IN 1,25(OH)2D3_CD receptor_NN RNA_`` in_IN various_JJ proliferating_`` and_CC nonproliferating_`` hematopoietic_JJ cells_NNS ._.
Constitutive_JJ expression_NN of_IN 1,25(OH)2D3_CD receptor_NN RNA_NNP was_VBD detected_VBN in_IN various_JJ kinds_NNS of_IN hematopoietic_JJ cells_NNS ,_, including_VBG macrophages_NNS and_CC activated_`` T_JJ lymphocytes_NNS ,_, as_RB well_RB as_IN in_IN cell_NN lines_NNS KG-1_# (_-LRB- myeloblasts_NNS )_-RRB- ,_, HL-60_# (_-LRB- promyelocytes_`` )_-RRB- ,_, ML-3_JJ (_-LRB- myelomonoblasts_NNS )_-RRB- ,_, U937_CD ,_, THP-1_CD (_-LRB- monoblasts_NNS )_-RRB- ,_, K562_FW (_-LRB- erythroblasts_NNS )_-RRB- ,_, and_CC S-LB1_`` (_-LRB- HTLV-1-transfected_JJ T_JJ lymphocytes_NNS )_-RRB- ._.
Receptor_# transcripts_NNS were_VBD 4.6_CD kilobases_NNS (_-LRB- kb_NN )_-RRB- ,_, and_CC no_DT variant_`` sizes_NNS were_VBD observed_VBN ._.
All_DT cell_NN lines_NNS examined_VBN in_IN this_DT group_NN also_RB expressed_VBD 1,25(OH)2D3_CD receptors_NNS ._.
Most_JJS B_NNP lymphocyte_NN lines_NNS expressed_VBN negligible_JJ levels_NNS of_IN 1,25(OH)2D3_CD receptor_NN RNA_NNP and_CC protein_NN ;_: however_RB ;_: analysis_NN of_IN a_DT lymphoid/myeloid_`` somatic_JJ hybrid_NN suggested_VBD that_IN suppression_NN of_IN expression_NN of_IN 1,25(OH)2D3_CD receptor_NN RNA_NNP in_IN B_NNP lymphocytes_NNS may_MD be_VB a_DT dominant_JJ characteristic_JJ ._.
HL-60_JJ cells_NNS were_VBD cultured_`` with_IN 10(-7)_JJ mol/L_NN 1,25(OH)2D3_`` for_IN 24_CD to_TO 72_CD hours_NNS ,_, and_CC levels_NNS of_IN expression_NN of_IN 1,25(OH)2D3_CD receptor_NN and_CC its_PRP$ RNA_NNP were_VBD examined_VBN ._.
Levels_# of_IN RNA_NNP coding_`` for_IN the_DT receptor_NN were_VBD not_RB modulated_VBN by_IN exposure_NN to_TO high_JJ levels_NNS of_IN ligand_NN ._.
Levels_# of_IN occupied_JJ 1,25(OH)2D3_`` receptor_NN protein_NN increased_VBN in_IN these_DT HL-60_NNP cells_NNS ;_: but_CC the_DT total_JJ number_NN of_IN 1,25(OH)2D3_CD receptors_NNS decreased_VBN about_IN 50_CD %_NN at_IN 24_CD hours_NNS and_CC returned_VBN toward_IN normal_JJ at_IN 72_CD hours_NNS ._.
Steady-state_JJ levels_NNS of_IN 1,25(OH)2D3_CD receptor_NN RNA_NNP were_VBD not_RB affected_VBN by_IN terminal_JJ differentiation_NN of_IN HL-60_NNP toward_IN either_DT granulocytes_NNS or_CC macrophages_NNS ._.
Nondividing_VBG macrophages_NNS from_IN normal_JJ individuals_NNS also_RB expressed_VBD 1,25(OH)2D3_NNP receptor_NN RNA_NNP ._.
In_IN contrast_NN ,_, nondividing_JJ peripheral_JJ blood_NN lymphocytes_`` from_IN normal_JJ individuals_NNS did_VBD not_RB express_JJ 1,25(OH)2D3_`` receptor_NN RNA_# ;_: with_IN stimulation_NN of_IN proliferation_NN of_IN these_DT cells_NNS ,_, accumulation_NN of_IN 1,25(OH)2D3_CD receptor_NN RNA_NNP increased_VBD markedly_RB ._.
Half-life_# (_-LRB- t1/2_NN )_-RRB- of_IN 1,25(OH)2D3_CD receptor_NN RNA_NNP in_IN T_NNP lymphocytes_NNS was_VBD short_JJ (_-LRB- 1_CD hour_NN )_-RRB- as_IN determined_VBN by_IN measuring_VBG decay_NN of_IN the_DT message_NN after_IN addition_NN of_IN actinomycin_NN D_NNP ._.
Consistent_-LRB- with_IN this_DT short_JJ t1/2_NN ,_, accumulation_NN of_IN 1,25(OH)2D3_CD receptor_NN RNA_NNP increased_VBD in_IN cells_NNS as_IN their_PRP$ protein_NN synthesis_NN was_VBD inhibited_VBN ._.
Further_JJ studies_NNS are_VBP required_VBN to_TO understand_VB the_DT physiologic_`` role_NN of_IN 1,25(OH)2D3_CD receptors_NNS in_IN myeloid_JJ cells_NNS and_CC proliferating_VBG T_JJ lymphocytes_NNS ._.
Kappa_NNP B_NNP binding_# proteins_NNS are_VBP constitutively_RB expressed_VBN in_IN an_DT IL-2_JJ autocrine_NN human_JJ T_JJ cell_NN line_NN ._.
The_DT IL-2_`` and_CC the_DT IL-2-R_JJ alpha_NN genes_NNS are_VBP both_DT expressed_VBD transiently_RB in_IN normal_JJ T_`` lymphocytes_NNS after_IN Ag_NNP or_CC mitogen_NN activation_NN ._.
In_IN contrast_NN ,_, the_DT human_JJ T_JJ cell_NN line_NN ,_, IARC_-RRB- 301_CD ,_, expresses_VBZ these_DT two_CD genes_NNS constitutively_RB and_CC we_PRP have_VBP previously_RB demonstrated_VBN that_IN its_PRP$ growth_NN depends_VBZ on_IN the_DT autocrine_`` production_NN of_IN this_DT T_JJ cell_NN growth_NN factor_NN and_CC high_JJ affinity_NN IL-2R_NN ._.
To_TO dissect_VB the_DT molecular_JJ basis_NN for_IN the_DT unusual_JJ persistent_JJ expression_NN of_IN the_DT IL-2_-RRB- and_CC IL-2-R_JJ alpha_NN genes_NNS in_IN these_DT IARC_NNP 301_CD T_JJ cells_NNS ,_, we_PRP have_VBP analyzed_VBN the_DT interactions_NNS of_IN constitutively_RB expressed_VBN nuclear_JJ proteins_NNS with_IN the_DT 5'_'' flanking_NN regions_NNS of_IN the_DT IL-2_-RRB- and_CC IL-2-R_JJ alpha_`` genes_NNS using_VBG both_DT DNase_NNP I_PRP footprinting_`` and_CC gel_`` retardation_`` techniques_NNS ._.
We_PRP have_VBP found_VBN that_IN a_DT region_NN in_IN both_DT genes_NNS (_-LRB- -276_CD to_TO -250_`` for_IN IL-2-R_JJ alpha_NN and_CC -203_`` to_TO -183_`` for_IN IL-2_-RRB- )_-RRB- ,_, which_WDT corresponds_VBZ to_TO a_DT kappa_NN B_NNP enhancer_`` element_NN ,_, is_VBZ specifically_RB protected_VBN by_IN nuclear_JJ proteins_NNS from_IN IARC_NNP 301_CD ._.
In_IN agreement_NN with_IN this_DT finding_NN ,_, both_PDT the_DT IL-2_-RRB- and_CC IL-2-R_JJ alpha_NN promoters_NNS are_VBP active_JJ in_IN transient_JJ transfection_NN assays_`` in_IN IARC_NNP 301_CD cells_NNS ._.
In_IN contrast_NN ,_, mutation_NN of_IN the_DT kappa_NN B_NNP enhancer_`` results_NNS in_IN markedly_`` attenuated_JJ activities_NNS of_IN both_DT promoters_NNS ._.
Two_CD proteins_NNS binding_# the_DT kappa_NN B_NNP sequence_NN ,_, NF-kappa_NNP B_NNP and_CC KBF1_NNP ,_, are_VBP constitutively_RB expressed_VBN in_IN IARC_NNP 301_CD nuclei_`` and_CC induced_`` by_IN PMA_NNP and_CC PHA_NNP in_IN Jurkat_NNP ._.
They_PRP bind_VBP to_TO the_DT kappa_NN B_NNP motifs_`` with_IN different_JJ relative_JJ affinities_NNS that_WDT may_MD reflect_VB their_PRP$ different_JJ contribution_NN in_IN the_DT expression_NN of_IN various_JJ promoters_NNS ._.
The_DT functional_JJ domains_'' of_IN the_DT murine_`` Thy-1_`` gene_NN promoter_NN ._.
The_DT Thy-1_`` gene_NN promoter_NN resembles_VBZ a_DT "_`` housekeeping_NN "_'' promoter_NN in_IN that_IN it_PRP is_VBZ located_VBN within_IN a_DT methylation-free_JJ island_NN ,_, lacks_VBZ a_DT canonical_JJ TATA_NNP box_NN ,_, and_CC displays_NNS heterogeneity_NN in_IN the_DT 5'-end_JJ termini_NN of_IN the_DT mRNA_NN ._.
Using_VBG transgenic_JJ mice_NNS ,_, we_PRP show_VBP that_IN this_DT promoter_NN does_VBZ not_RB confer_VB any_DT tissue_NN specificity_NN and_CC is_VBZ active_JJ only_RB in_IN a_DT position-dependent_JJ manner_NN ._.
It_PRP can_MD only_RB be_VB activated_VBN in_IN a_DT tissue-specific_JJ manner_NN by_IN elements_NNS that_WDT lie_VBP downstream_`` of_IN the_DT initiation_NN site_NN ._.
We_PRP have_VBP analyzed_VBN the_DT functional_JJ domains_`` of_IN the_DT minimal_JJ Thy-1_NN promoter_NN and_CC show_NN that_IN the_DT dominant_JJ promoter_NN elements_NNS consist_VBP of_IN multiple_JJ binding_`` sites_NNS for_IN the_DT transcription_NN factor_NN Sp1_# ,_, an_DT inverted_`` CCAAT_NN box_NN ,_, and_CC sequences_NNS proximal_JJ to_TO the_DT transcription_NN start_VBP site_NN ._.
DNase_# I_PRP and_CC gel_`` mobility_JJ shift_NN assays_`` show_VB the_DT binding_`` of_IN a_DT number_NN of_IN nuclear_JJ factors_NNS to_TO these_DT elements_NNS ,_, including_VBG Sp1_NNP and_CC CP1_NNP ._.
Our_PRP$ results_NNS show_VBP that_IN the_DT structure_NN of_IN this_DT promoter_NN only_RB permits_VBZ productive_JJ interactions_NNS of_IN the_DT two_CD transcription_NN factors_NNS Sp1_`` and_CC CP1_`` with_IN the_DT basal_NN transcription_NN machinery_NN in_IN the_DT presence_NN of_IN enhancer_`` sequences_NNS ._.
Comparison_NN of_IN constitutive_JJ and_CC inducible_JJ transcriptional_JJ enhancement_NN mediated_`` by_IN kappa_`` B-related_`` sequences_NNS :_: modulation_NN of_IN activity_NN in_IN B_NNP cells_NNS by_IN human_JJ T-cell_NNP leukemia_`` virus_NN type_NN I_PRP tax_NN gene_NN ._.
The_DT kappa_NN B_NNP sequence_NN (_-LRB- GGGACTTTCC_NNP )_-RRB- binds_VBZ a_DT factor_NN ,_, NF-kappa_NNP B_NNP ,_, that_WDT is_VBZ constitutively_RB found_VBN in_IN its_PRP$ functional_JJ ,_, DNA_NNP binding_VBG form_NN only_RB in_IN B_NNP lymphocytes_NNS ._.
A_DT factor_NN with_IN apparently_RB indistinguishable_JJ sequence_NN specificity_NN can_MD be_VB induced_VBN in_IN many_JJ other_JJ cell_NN types_NNS ,_, where_WRB it_PRP is_VBZ used_VBN to_TO regulate_VB inducible_JJ gene_NN expression_NN ._.
For_IN example_NN ,_, kappa_'' B-related_`` sequences_NNS have_VBP been_VBN shown_VBN to_TO be_VB important_JJ for_IN the_DT transcription_NN of_IN a_DT few_JJ inducible_JJ genes_NNS ,_, such_JJ as_IN the_DT interleukin_NN 2_CD receptor_NN alpha-chain_NN gene_NN and_CC the_DT beta-interferon_JJ gene_NN ._.
However_RB ,_, these_DT genes_NNS are_VBP not_RB constitutively_RB active_JJ in_IN B_NNP lymphocytes_`` ,_, suggesting_VBG that_IN other_JJ regulatory_JJ mechanisms_NNS must_MD play_VB a_DT role_NN in_IN determining_VBG the_DT patterns_NNS of_IN expression_NN ._.
We_PRP have_VBP investigated_VBN the_DT constitutive_JJ and_CC inducible_JJ transcriptional_JJ activity_NN mediated_VBN by_IN five_CD kappa_`` B-related_JJ sequence_NN elements_NNS in_IN two_CD different_JJ cell_NN types_NNS ._.
We_PRP show_VBP that_IN in_IN S194_CD plasma_NN cells_NNS the_DT activity_NN of_IN each_DT element_NN correlates_VBZ well_RB with_IN the_DT relative_JJ affinity_NN of_IN B-cell-derived_NNP NF-kappa_NNP B_NNP for_IN that_DT element_NN ._.
This_DT leads_VBZ to_TO significantly_RB lower_JJR transcription_NN enhancement_`` by_IN sites_NNS derived_VBN from_IN the_DT interleukin_NN 2_CD receptor_NN or_CC T-cell_# receptor_NN genes_NNS in_IN S194_CD cells_NNS ._.
However_RB ,_, in_IN either_DT EL-4_NNP (_-LRB- T_NNP )_-RRB- cells_NNS or_CC S194_CD cells_NNS ,_, both_DT lower-affinity_`` sites_NNS can_MD be_VB significantly_RB induced_VBN by_IN the_DT tax_NN gene_NN product_NN of_IN human_JJ T-cell_NNP leukemia_`` virus_NN type_NN I_PRP ,_, showing_VBG that_IN NF-kappa_NNP B_NNP activity_NN can_MD be_VB modulated_VBN even_RB in_IN a_DT B-cell_`` line_NN that_IN constitutively_RB expresses_VBZ this_DT
Isolation_NN of_IN a_DT rel-related_`` human_JJ cDNA_NN that_WDT potentially_RB encodes_VBZ the_DT 65-kD_JJ subunit_NN of_IN NF-kappa_NNP B_NNP (_-LRB- published_VBN erratum_NN appears_VBZ in_IN Science_NNP 1991_CD Oct_NNP 4_CD ;_: 254_CD (_-LRB- 5028_CD )_-RRB- :_: 11_CD )_-RRB-
A_DT DNA_NNP probe_NN that_WDT spanned_VBD a_DT domain_NN conserved_`` among_IN the_DT proto-oncogene_JJ c-rel_NN ,_, the_DT Drosophila_NNP morphogen_`` dorsal_NN ,_, and_CC the_DT p50_`` DNA_NNP binding_`` subunit_NN of_IN NF-kappa_NNP B_NNP was_VBD generated_VBN from_IN Jurkat_NNP T_NNP cell_NN complementary_`` DNA_NN with_IN the_DT polymerase_`` chain_NN reaction_NN (_-LRB- PCR_NNP )_-RRB- and_CC degenerate_JJ oligonucleotides_NNS ._.
This_DT probe_NN was_VBD used_VBN to_TO identify_VB a_DT rel-related_JJ complementary_JJ DNA_NNP that_WDT hybridized_VBD to_TO a_DT 2.6-kilobase_JJ messenger_NN RNA_`` present_JJ in_IN human_JJ T_NNP and_CC B_NNP lymphocytes_NNS ._.
In_IN vitro_NN transcription_NN and_CC translation_NN of_IN the_DT complementary_JJ DNA_NNP resulted_VBD in_IN the_DT synthesis_NN of_IN a_DT protein_NN with_IN an_DT apparent_JJ molecular_JJ size_NN of_IN 65_CD kilodaltons_NNS (_-LRB- kD_NN )_-RRB- ._.
The_DT translated_VBN protein_NN showed_VBN weak_JJ DNA_NNP binding_`` with_IN a_DT specificity_NN for_IN the_DT kappa_NN B_NNP binding_`` motif_NN ._.
This_DT protein-DNA_`` complex_JJ comigrated_`` with_IN the_DT complex_JJ obtained_VBN with_IN the_DT purified_`` human_JJ p65_NN NF-kappa_NNP B_NNP subunit_NN and_CC binding_NN was_VBD inhibited_VBN by_IN I_PRP kappa_`` B-alpha_NNP and_CC -beta_JJ proteins_NNS ._.
In_IN addition_NN ,_, the_DT 65-kD_JJ protein_NN associated_VBN with_IN the_DT p50_`` subunit_NN of_IN NF-kappa_NNP B_NNP and_CC the_DT kappa_NN B_NNP probe_NN to_TO form_VB a_DT complex_JJ with_IN the_DT same_JJ electrophoretic_JJ mobility_NN as_IN the_DT NF-kappa_NNP B-DNA_NNP complex_JJ ._.
Therefore_RB the_DT rel-related_`` 65-kD_JJ protein_NN may_MD represent_VB the_DT p65_NN subunit_NN of_IN the_DT active_JJ NF-kappa_NNP B_NNP transcription_`` factor_NN complex_JJ ._.
Lymphocyte_NNP glucocorticoid_`` receptor_NN number_NN in_IN posttraumatic_JJ stress_NN disorder_NN ._.
OBJECTIVE_# :_: The_DT authors_NNS '_POS objective_NN was_VBD to_TO investigate_VB the_DT possibility_NN that_IN glucocorticoid_NN receptor_NN changes_NNS may_MD be_VB involved_VBN in_IN the_DT dysregulation_NN of_IN the_DT hypothalamic-pituitary-adrenal_JJ (_-LRB- HPA_`` )_-RRB- axis_`` in_IN posttraumatic_JJ stress_NN disorder_NN (_-LRB- PTSD_NNP )_-RRB- ._.
METHOD_NN :_: They_PRP measured_VBD the_DT number_NN of_IN lymphocyte_`` cytosolic_JJ glucocorticoid_`` receptors_NNS and_CC plasma_NN cortisol_NN concentrations_NNS in_IN 15_CD consecutively_RB admitted_VBN male_JJ combat_NN Vietnam_NNP veterans_NNS with_IN PTSD_NNP and_CC in_IN a_DT normal_JJ comparison_NN group_NN of_IN 11_CD subjects_NNS ._.
RESULTS_NNS :_: Both_PDT the_DT patients_NNS and_CC the_DT normal_JJ comparison_NN subjects_NNS showed_VBD a_DT morning-to-afternoon_NN decline_NN in_IN glucocorticoid_NN receptor_NN concentrations_NNS ,_, paralleling_VBG the_DT normal_JJ diurnal_JJ decline_NN in_IN cortisol_`` levels_NNS ._.
The_DT number_NN of_IN glucocorticoid_JJ receptors_NNS was_VBD 63_CD %_NN greater_JJR in_IN the_DT morning_NN and_CC 26_CD %_NN greater_JJR in_IN the_DT afternoon_NN in_IN the_DT patients_NNS with_IN PTSD_NNP than_IN in_IN the_DT normal_JJ subjects_NNS ._.
No_DT group_NN differences_NNS in_IN cortisol_`` levels_NNS were_VBD observed_VBN ,_, nor_CC were_VBD glucocorticoid_`` receptor_NN number_NN and_CC cortisol_`` levels_NNS correlated_VBD ._.
The_DT number_NN of_IN morning_NN glucocorticoid_JJ receptors_NNS was_VBD positively_RB correlated_`` with_IN symptoms_NNS of_IN PTSD_NNP and_CC anxiety_NN ._.
CONCLUSIONS_NNS :_: These_DT results_NNS provide_VBP further_JJ evidence_NN for_IN a_DT dysregulation_NN of_IN the_DT HPA_NNP axis_`` in_IN PTSD_NNP ._.
The_DT finding_NN that_IN patients_NNS with_IN PTSD_NNP had_VBD a_DT substantially_RB greater_JJR number_NN of_IN lymphocyte_`` glucocorticoid_JJ receptors_NNS than_IN normal_JJ comparison_NN subjects_NNS is_VBZ consistent_JJ with_IN the_DT authors_NNS '_POS previous_JJ observations_NNS of_IN low_JJ 24-hour_JJ urinary_`` cortisol_`` excretion_NN in_IN subjects_NNS with_IN PTSD_`` ._.
Furthermore_RB ,_, the_DT receptor_NN changes_NNS observed_VBN are_VBP opposite_IN of_IN those_DT reported_VBN in_IN major_JJ depressive_JJ disorder_NN ._.
The_DT present_JJ data_NNS ,_, along_IN with_IN other_JJ findings_NNS of_IN HPA_NNP abnormalities_`` in_IN PTSD_NNP ,_, support_NN the_DT possibility_NN of_IN a_DT greater_JJR negative_JJ feedback_NN sensitivity_NN at_IN one_CD or_CC more_JJR levels_NNS of_IN the_DT HPA_NNP axis_`` ._.
A_DT thymus-specific_JJ member_NN of_IN the_DT HMG_NNP protein_NN family_NN regulates_VBZ the_DT human_JJ T_`` cell_NN receptor_NN C_NNP alpha_`` enhancer_NN ._.
The_DT human_JJ T_`` cell-specific_JJ transcription_NN factor_NN TCF-1_`` alpha_NN plays_VBZ a_DT key_JJ role_NN in_IN the_DT tissue-specific_JJ activation_NN of_IN the_DT T_JJ cell_NN receptor_NN (_-LRB- TCR_NNP )_-RRB- C_NNP alpha_NN enhancer_NN and_CC binds_NNS to_TO pyrimidine-rich_JJ elements_NNS (_-LRB- 5'-PyCTTTG-3'_NNP )_-RRB- present_RB in_IN a_DT variety_NN of_IN other_JJ T_JJ cell-specific_JJ control_NN regions_NNS ._.
Using_VBG amino_JJ acid_NN sequence_NN information_NN derived_VBN from_IN the_DT DNA_NNP affinity-purified_JJ protein_NN ,_, we_PRP have_VBP now_RB isolated_VBN cDNA_`` clones_NNS encoding_VBG TCF-1_NNP alpha_NN ._.
The_DT TCF-1_NNP alpha_NN cDNA_`` contains_VBZ a_DT single_JJ 68-amino-acid_JJ domain_NN that_WDT is_VBZ homologous_`` to_TO a_DT region_NN conserved_`` among_IN high-mobility_JJ group_NN (_-LRB- HMG_NNP )_-RRB- and_CC nonhistone_`` chromosomal_`` proteins_NNS ._.
Expression_NN of_IN full-length_JJ and_CC mutant_JJ cDNA_`` clones_NNS in_IN bacteria_NNS reveal_VBP that_IN the_DT single_JJ HMG_NNP motif_NN ,_, which_WDT is_VBZ predicted_VBN to_TO contain_VB two_CD extended_JJ alpha-helical_JJ segments_NNS ,_, is_VBZ sufficient_JJ to_TO direct_VB the_DT sequence-specific_JJ binding_NN of_IN TCF-1_NNP alpha_# to_TO DNA_NNP ._.
Northern_JJ blot_`` experiments_NNS demonstrate_VBP further_RBR that_IN TCF-1_NNP alpha_`` mRNA_NN is_VBZ highly_RB tissue_NN specific_JJ ,_, found_VBN primarily_RB in_IN the_DT thymus_NN or_CC T_JJ cell_NN lines_NNS ._.
The_DT immature_JJ CEM_`` T_JJ cell_NN line_NN expresses_VBZ relatively_RB low_JJ levels_NNS of_IN TCF-1_NNP alpha_# mRNA_NNP ,_, which_WDT are_VBP increased_VBN upon_IN activation_NN of_IN these_DT cells_NNS by_IN phorbol_NN esters_NNS ._.
Interestingly_RB ,_, the_DT cloned_`` TCF-1_NNP alpha_# protein_NN is_VBZ a_DT potent_JJ transcriptional_JJ activator_NN of_IN the_DT human_JJ TCR_NNP alpha_NN enhancer_NN in_IN nonlymphoid_JJ cell_NN lines_NNS ,_, whereas_IN the_DT activity_NN of_IN the_DT endogenous_JJ protein_NN in_IN T_JJ cell_NN lines_NNS is_VBZ strongly_RB dependent_JJ on_IN an_DT additional_JJ T_`` cell-specific_JJ protein_NN that_WDT interacts_VBZ with_IN the_DT core_NN enhancer_NN ._.
TCF-1_JJ alpha_NN is_VBZ currently_RB unique_JJ among_IN the_DT newly_RB emerging_VBG family_NN of_IN DNA-binding_`` regulatory_JJ proteins_NNS that_WDT share_VBP the_DT HMG_NNP motif_`` in_IN that_IN it_PRP is_VBZ a_DT highly_RB tissue-specific_JJ RNA_NNP polymerase_`` II_NNP transcription_`` factor_NN ._.
Immune_JJ response_NN of_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS to_TO HBx-antigen_NNP of_IN hepatitis_NNP B_NNP virus_NN ._.
The_DT hepatitis_NN B_NNP virus_NN genome_`` encodes_VBZ a_DT transcriptional_JJ transactivator_NN protein_NN designated_VBN HBxAg_NNP ._.
We_PRP have_VBP investigated_VBN whether_IN this_DT antigen_NN is_VBZ a_DT target_NN structure_NN for_IN human_JJ T-lymphocytes_NNS ._.
Using_VBG recombinant_JJ HBxAg_NNP protein_NN ,_, we_PRP found_VBD HBxAg-specific_JJ stimulation_NN of_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS in_IN patients_NNS with_IN acute_JJ hepatitis_NN B_NNP virus_NN infection_NN (_-LRB- 6_CD of_IN 6_CD )_-RRB- and_CC chronic_JJ hepatitis_NN B_NNP virus_NN infection_NN (_-LRB- 6_CD of_IN 17_CD )_-RRB- but_CC not_RB in_IN healthy_JJ individuals_NNS ._.
With_IN HBxAg-specific_JJ synthetic_JJ polypeptides_NNS ,_, several_JJ T-cell_`` epitopes_NNS were_VBD identified_VBN ._.
Most_JJS were_VBD located_VBN in_IN the_DT carboxyterminal_`` half_NN of_IN the_DT HBxAg_NNP protein_NN ._.
Five_CD T-cell_`` clones_NNS specific_JJ for_IN a_DT T-cell_JJ epitope_NN located_VBN at_IN the_DT carboxyterminal_JJ region_NN of_IN HBxAg_NNP were_VBD established_VBN and_CC found_VBN to_TO belong_VB to_TO the_DT CD2/CD4-positive_JJ ,_, CD8-negative_JJ subtype_NN ._.
These_DT data_NNS establish_VBP for_IN the_DT first_JJ time_NN HBxAg_`` as_IN an_DT antigen_`` in_IN the_DT cellular_JJ immune_JJ response_NN ._.
A_DT study_NN on_IN the_DT circadian_JJ rhythm_NN of_IN glucocorticoid_NN receptor_NN ._.
Circadian_JJ rhythm_NN in_IN glucocorticoid_NN receptor_NN (_-LRB- GR_NNP )_-RRB- was_VBD studied_VBN in_IN the_DT rat_NN liver_NN and_CC human_JJ peripheral_`` leukocytes_NNS ._.
For_IN rats_NNS exposed_VBN to_TO a_DT natural_JJ environmental_JJ photic_JJ cycle_NN or_CC a_DT 12L_`` :_: 12D_`` artificial_JJ light_JJ regime_NN ,_, peak_JJ values_NNS of_IN hepatic_JJ GR_NNP were_VBD detected_VBN between_IN 23:00_CD and_CC 02:00_CD h_NN ._.
Except_IN for_IN a_DT 4-hour_JJ advancement_NN of_IN the_DT peak_NN ,_, a_DT similar_JJ circadian_JJ rhythm_NN of_IN hepatic_JJ GR_NNP was_VBD detected_VBN in_IN rats_NNS reared_VBD under_IN a_DT reversed_JJ lighting_NN regimen_NNS (_-LRB- 12D_CD :_: 12L_`` ;_: lights_NNS on_IN between_IN 18:30_CD and_CC 06:30_CD h_NN )_-RRB- ._.
In_IN human_JJ leukocytes_'' ,_, the_DT peak_JJ value_NN of_IN GR_NNP was_VBD found_VBN to_TO parallel_VB that_IN of_IN plasma_NN cortisol_NN with_IN high_JJ and_CC low_JJ values_NNS detected_VBN at_IN 04:00-08:00_CD h_NN and_CC 23:00-24:00_CD h_NN ,_, respectively_RB ._.
In_IN patients_NNS suffering_VBG from_IN Cushing_NNP 's_POS syndrome_NN ,_, the_DT circadian_JJ rhythm_NN of_IN plasma_NN cortisol_NN either_RB disappeared_VBD or_CC was_VBD inverted_VBN while_IN that_IN of_IN GR_NNP did_VBD not_RB significantly_RB deviate_VB from_IN the_DT normal_JJ subjects_NNS ._.
For_IN apoplexic_JJ patients_NNS with_IN lesions_NNS localized_VBN to_TO the_DT base_NN of_IN the_DT brain_NN as_IN indicated_VBN by_IN computerized_JJ tomography_NN ,_, the_DT diurnal_JJ variation_NN of_IN GR_NNP was_VBD abolished_VBN ._.
Conversely_RB ,_, diurnal_JJ rhythmicity_NN persisted_VBD in_IN apoplexy_JJ patients_NNS whose_WP$ lesions_NNS were_VBD in_IN the_DT cerebral_JJ cortex_NN ._.
Thus_RB ,_, we_PRP postulated_`` that_IN the_DT circadian_JJ modification_NN of_IN GR_NNP was_VBD independent_JJ of_IN the_DT diurnal_JJ fluctuations_NNS in_IN plasma_NN cortisol_`` level_NN or_CC the_DT circadian_JJ variations_NNS in_IN environmental_JJ lighting_NN and_CC that_IN the_DT rhythmicity_NN might_MD be_VB regulated_VBN by_IN the_DT '_'' circadian_NN pacemaker_NN '_'' located_VBN in_IN the_DT human_JJ basal_NN brain_NN ._.
These_DT diurnal_JJ variations_NNS in_IN GR_NNP might_MD serve_VB to_TO coordinate_VB the_DT reactivity_NN of_IN the_DT target_NN cells_NNS to_TO cortisol_`` because_IN the_DT diurnal_JJ rhythms_NNS of_IN a_DT GR-mediated_JJ response_NN ,_, the_DT fractional_JJ inhibition_NN of_IN chemotactic_`` migration_`` rate_NN of_IN polymorphonuclear_JJ leukocytes_NNS by_IN cortisol_NN ,_, were_VBD found_VBN to_TO be_VB synchronous_JJ with_IN those_DT of_IN GR_NNP ._.
Multiple_# Oct2_`` isoforms_NNS are_VBP generated_VBN by_IN alternative_JJ splicing_NN ._.
The_DT interaction_NN of_IN the_DT Oct2_`` transcription_NN factor_NN with_IN the_DT cognate_`` octamer_NN motif_NN ATGCAAAT_NN is_VBZ a_DT critical_JJ determinant_NN of_IN the_DT lymphoid-specific_JJ expression_NN of_IN immunoglobulin_`` genes_NNS ._.
Ectopic_JJ expression_NN of_IN cloned_`` Oct2_NNP cDNA_NNP was_VBD shown_VBN to_TO be_VB sufficient_JJ to_TO reconstitute_VB at_IN least_JJS some_DT aspects_NNS of_IN this_DT regulation_NN in_IN non-lymphoid_JJ cells_NNS ._.
We_PRP describe_VBP the_DT isolation_NN and_CC characterization_NN of_IN multiple_JJ cDNAs_# encoding_`` mouse_NN Oct2_CD from_IN a_DT mature_JJ B-cell_NNP line_NN and_CC we_PRP show_VBP that_IN a_DT variety_NN of_IN isoforms_NNS of_IN this_DT transcription_NN factor_NN is_VBZ generated_VBN from_IN a_DT single_JJ gene_NN by_IN an_DT alternative_JJ splicing_NN mechanism_NN ._.
All_PDT the_DT isoforms_`` retain_VB the_DT previously_RB characterized_VBN POU-domain_`` and_CC are_VBP therefore_RB able_JJ to_TO bind_NN to_TO the_DT octamer_NN motif_NN ._.
Different_JJ amounts_NNS of_IN the_DT various_JJ isoforms_NNS are_VBP present_JJ within_IN the_DT same_JJ B-cell_`` regardless_RB of_IN the_DT developmental_JJ stage_NN of_IN B-cell_NNP differentiation_NN and_CC at_IN least_JJS some_DT of_IN the_DT isoforms_NNS are_VBP conserved_VBN between_IN mouse_NN and_CC humans_NNS ._.
In_IN cotransfection_`` experiments_NNS we_PRP show_VBP that_IN all_PDT the_DT isoforms_NNS are_VBP able_JJ to_TO activate_VB an_DT octamer_NN containing_VBG promoter_NN element_NN in_IN fibroblasts_NNS revealing_VBG an_DT unexpected_JJ functional_JJ redundancy_NN ._.
Finally_RB ,_, we_PRP show_VBP that_IN one_CD of_IN the_DT isoforms_`` encodes_VBZ the_DT previously_RB described_VBN lymphoid-specific_JJ Oct2B_NNP protein_NN which_WDT has_VBZ been_VBN suggested_VBN to_TO be_VB involved_VBN in_IN the_DT function_NN of_IN the_DT octamer_NN motif_`` in_IN the_DT context_NN of_IN the_DT immunoglobulin_`` heavy-chain_JJ (_-LRB- IgH_# )_-RRB- enhancer_NN ._.
Murine_# and_CC human_JJ T-lymphocyte_JJ GATA-3_JJ factors_NNS mediate_JJ transcription_NN through_IN a_DT cis-regulatory_JJ element_NN within_IN the_DT human_JJ T-cell_NN receptor_NN delta_JJ gene_NN enhancer_NN ._.
A_DT family_NN of_IN transcriptional_JJ activators_NNS has_VBZ recently_RB been_VBN identified_VBN in_IN chickens_NNS ;_: these_DT transcriptional_JJ activators_NNS recognize_VBP a_DT common_JJ consensus_NN motif_`` (_-LRB- WGATAR_NN )_-RRB- through_IN a_DT conserved_`` C4_`` zinc_`` finger_NN DNA-binding_-RRB- domain_NN ._.
One_CD of_IN the_DT members_NNS of_IN this_DT multigene_JJ family_NN ,_, cGATA-3_'' ,_, is_VBZ most_RBS abundantly_RB expressed_VBN in_IN the_DT T-lymphocyte_JJ cell_NN lineage_NN ._.
Analysis_NN of_IN human_JJ and_CC murine_JJ GATA-3_JJ factors_NNS shows_VBZ a_DT striking_JJ degree_NN of_IN amino_JJ acid_NN sequence_NN identity_NN and_CC similar_JJ patterns_NNS of_IN tissue_NN specificity_NN of_IN expression_NN in_IN these_DT three_CD organisms_NNS ._.
The_DT murine_`` and_CC human_JJ factors_NNS are_VBP abundantly_RB expressed_VBN in_IN a_DT variety_NN of_IN human_JJ and_CC murine_`` T-cell_JJ lines_NNS and_CC can_MD activate_VB transcription_NN through_IN a_DT tissue-specific_JJ GATA-binding_NNP site_NN identified_VBN within_IN the_DT human_JJ T-cell_NN receptor_NN delta_JJ gene_NN enhancer_NN ._.
We_PRP infer_VBP that_IN the_DT murine_`` and_CC human_JJ GATA-3_`` proteins_NNS play_VBP a_DT central_JJ and_CC highly_RB conserved_JJ role_NN in_IN vertebrate_`` T-cell-specific_JJ transcriptional_JJ regulation_NN ._.
Processing_-RRB- of_IN the_DT precursor_NN of_IN NF-kappa_NNP B_NNP by_IN the_DT HIV-1_`` protease_NN during_IN acute_JJ infection_NN ._.
Transcription_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN type-1_NN (_-LRB- HIV-1_NNP )_-RRB- genome_# is_VBZ regulated_VBN in_IN part_NN by_IN cellular_JJ factors_NNS and_CC is_VBZ stimulated_VBN by_IN activation_NN of_IN latently_RB infected_JJ T_JJ cells_NNS ._.
T-cell_JJ activation_NN also_RB correlates_VBZ with_IN the_DT induction_NN of_IN the_DT factor_NN NF-kappa_NNP B_NNP which_WDT binds_VBZ to_TO two_CD adjacent_JJ sites_NNS in_IN the_DT HIV-1_`` long_JJ terminal_NN repeat_NN ._.
This_DT factor_NN consists_VBZ of_IN two_CD DNA-binding_JJ subunits_NNS of_IN relative_JJ molecular_JJ mass_NN 50,000_CD (_-LRB- 50K_NNP )_-RRB- associated_VBN with_IN two_CD 65K_CD subunits_NNS ._.
It_PRP is_VBZ located_VBN in_IN the_DT nucleus_`` in_IN mature_JJ B_NNP cells_NNS ,_, but_CC is_VBZ present_JJ in_IN other_JJ cell_NN types_NNS as_IN an_DT inactive_JJ cytoplasmic_JJ complex_NN ._.
External_JJ stimuli_NNS ,_, including_VBG those_DT that_WDT activate_VBP T_JJ cells_NNS ,_, result_NN in_IN nuclear_JJ translocation_NN of_IN active_JJ NF-kappa_NNP B_NNP ._.
The_DT cloning_NN of_IN the_DT complementary_JJ DNA_NNP for_IN the_DT 50K_NNP subunit_NN helped_VBD to_TO identify_VB an_DT exclusively_RB cytoplasmic_JJ 105K_CD precursor_`` (_-LRB- p105_NN )_-RRB- (_-LRB- V.B._NNP ,_, P.K._NNP and_CC A.I._NNP ,_, manuscript_'' submitted_VBN )_-RRB- ._.
The_DT expression_NN of_IN active_JJ NF-kappa_NNP B_NNP might_MD therefore_RB also_RB be_VB regulated_VBN by_IN the_DT extent_NN of_IN processing_NN of_IN p105_NN ._.
Because_IN HIV-1_-RRB- requires_VBZ active_JJ NF-kappa_NNP B_NNP for_IN efficient_JJ transcription_NN ,_, we_PRP tested_VBD the_DT effect_NN of_IN HIV-1_JJ infection_NN on_IN the_DT processing_NN of_IN the_DT human_JJ 105K_CD precursor_NN ._.
We_PRP show_VBP here_RB that_IN the_DT HIV-1_NNP protease_NN can_MD process_VB p105_CD and_CC increases_VBZ levels_NNS of_IN active_JJ nuclear_JJ NF-kappa_NNP B_NNP complex_NN ._.
Vitamin_NNP D_NNP receptor_NN expression_NN in_IN human_JJ lymphocytes_NNS ._.
Signal_NNP requirements_NNS and_CC characterization_`` by_IN western_JJ blots_NNS and_CC DNA_NNP sequencing_NN ._.
The_DT signals_NNS controlling_VBG the_DT expression_NN of_IN the_DT receptor_NN protein_NN for_IN 1_CD alpha,25-dihydroxyvitamin_NN D3_`` in_IN normal_JJ human_JJ lymphocytes_NNS and_CC the_DT relationship_NN of_IN this_DT protein_NN to_TO the_DT classical_JJ vitamin_NN D_NN receptor_NN were_VBD examined_VBN ._.
Lymphocytes_NNS activated_VBN with_IN the_DT OKT3_`` antibody_NN to_TO the_DT T-cell_`` antigen_NN receptor_NN expressed_VBD fewer_JJR binding_`` sites_NNS as_RB compared_VBN to_TO lymphocytes_NNS that_WDT were_VBD activated_VBN by_IN the_DT polyclonal_JJ activator_NN phytohemagglutinin_`` (_-LRB- PHA_NNP )_-RRB- ._.
However_RB ,_, combination_NN of_IN OKT3_`` and_CC phorbol_`` myristate_JJ acetate_NN produced_VBD a_DT concentration_NN of_IN binding_VBG sites_NNS similar_JJ to_TO the_DT PHA-activated_JJ cells_NNS ._.
The_DT receptor_NN from_IN OKT3_`` and_CC OKT3_`` +_`` phorbol_NN myristate_NN acetate-activated_`` lymphocytes_`` exhibited_`` decreased_VBD binding_`` to_TO DNA-cellulose_VB compared_VBN to_TO PHA-activated_`` lymphocytes_NNS ._.
In_IN lymphocytes_NNS activated_VBN either_RB by_IN PHA_NNP or_CC OKT3_CD (_-LRB- but_CC not_RB in_IN resting_VBG cells_NNS )_-RRB- ,_, a_DT 50-kDa_JJ species_NN cross-reacting_`` with_IN a_DT monoclonal_JJ antibody_NN against_IN the_DT intestinal_JJ vitamin_NN D_NNP receptor_NN was_VBD detected_VBN ._.
Finally_RB ,_, RNA_# from_IN activated_VBN lymphocytes_NNS was_VBD amplified_VBN by_IN polymerase_NN chain_NN reaction_NN using_VBG oligonucleotide_`` primers_NNS flanking_VBG the_DT 196_CD base_NN pair_NN long_JJ region_NN encoding_`` the_DT DNA-binding_`` domain_NN of_IN the_DT human_JJ intestinal_NN receptor_NN ._.
The_DT amplified_JJ product_NN showed_VBD an_DT identical_JJ nucleotide_`` sequence_NN to_TO the_DT DNA-binding_`` domain_NN of_IN the_DT human_JJ intestinal_NN receptor_NN ._.
These_DT findings_NNS suggest_VBP that_IN expression_NN of_IN the_DT 1,25-(OH)2D3_`` receptor_NN in_IN lymphocytes_NNS is_VBZ triggered_VBN by_IN distinct_JJ and_CC contingent_JJ signals_NNS ,_, and_CC that_IN the_DT protein_NN and_CC the_DT mRNA_NNP encoding_`` it_PRP are_VBP identical_JJ to_TO the_DT classical_JJ vitamin_NN D_NNP receptor_NN ._.
Cloning_NN of_IN murine_`` TCF-1_NNP ,_, a_DT T_JJ cell-specific_JJ transcription_NN factor_NN interacting_`` with_IN functional_JJ motifs_NNS in_IN the_DT CD3-epsilon_`` and_CC T_JJ cell_NN receptor_NN alpha_NN enhancers_NNS ._.
CD3-epsilon_JJ gene_NN expression_NN is_VBZ confined_VBN to_TO the_DT T_JJ cell_NN lineage_NN ._.
We_PRP have_VBP recently_RB identified_VBN and_CC cloned_`` a_DT human_JJ transcription_NN factor_NN ,_, TCF-1_'' ,_, that_DT binds_VBZ to_TO a_DT functional_JJ element_NN in_IN the_DT T_JJ lymphocyte-specific_JJ enhancer_NN of_IN CD3-epsilon_NNP ._.
In_IN a_DT panel_NN of_IN human_JJ cell_NN lines_NNS ,_, TCF-1_NNP expression_NN was_VBD restricted_VBN to_TO T_VB lineage_NN cells_NNS ._.
TCF-1_NN belonged_VBD to_TO a_DT novel_JJ family_NN of_IN genes_NNS that_WDT contain_VBP the_DT so-called_JJ high_JJ mobility_`` group_NN 1_CD (_-LRB- HMG_NNP )_-RRB- box_NN ._.
Here_RB we_PRP report_VBP the_DT cloning_NN of_IN murine_`` TCF-1_NNP ._.
Two_CD splice_`` alternatives_NNS were_VBD identified_VBN that_DT were_VBD not_RB previously_RB observed_VBN in_IN human_JJ TCF-1_NN ._.
Murine_# and_CC human_JJ TCF-1_NNP displayed_VBD a_DT 95.5_CD %_NN overall_JJ amino_JJ acid_NN homology_NN ._.
Recombinant_JJ murine_`` and_CC human_JJ TCF-1_NNP recognized_VBD the_DT same_JJ sequence_NN motif_`` in_IN the_DT CD3-epsilon_`` enhancer_NN as_IN judged_VBN by_IN gel_`` retardation_`` and_CC methylation_NN interference_NN assays_`` ._.
With_IN the_DT murine_`` cDNA_`` clones_NNS several_JJ aspects_NNS of_IN TCF-1_NNP were_VBD analyzed_VBN ._.
First_RB ,_, deletion_NN analysis_NN revealed_VBD that_IN a_DT region_NN of_IN TCF-1_NNP containing_VBG the_DT HMG_NNP box_NN was_VBD sufficient_JJ for_IN sequence-specific_`` binding_`` ._.
Second_JJ ,_, by_IN high_JJ stringency_`` Northern_JJ blotting_NN and_CC in_IN situ_`` hybridization_NN ,_, TCF-1_NNP expression_NN was_VBD shown_VBN to_TO be_VB confined_VBN to_TO the_DT thymus_NN and_CC to_TO the_DT T_`` cell_NN areas_NNS of_IN the_DT spleen_NN ._.
Third_JJ ,_, TCF-1_JJ bound_VBD specifically_RB to_TO a_DT functional_JJ T_`` cell-specific_JJ element_NN in_IN the_DT T_JJ cell_NN receptor_NN alpha_NN (_-LRB- TCR-alpha_NNP )_-RRB- enhancer_NN ._.
The_DT T_JJ lineage-specific_JJ expression_NN and_CC the_DT affinity_NN for_IN functional_JJ motifs_NNS in_IN the_DT TCR-alpha_NNP and_CC CD3-epsilon_NNP enhancers_NNS imply_VBP an_DT important_JJ role_NN for_IN TCF-1_# in_IN the_DT establishment_NN of_IN the_DT mature_JJ T_JJ cell_NN phenotype_NN ._.
HIV_NNP enhancer_`` activity_NN perpetuated_`` by_IN NF-kappa_NNP B_NNP induction_`` on_IN infection_NN of_IN monocytes_NNS (_-LRB- see_VB comments_NNS )_-RRB-
Permissiveness_NN to_TO replication_`` of_IN human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV_NNP )_-RRB- differs_`` in_IN T_JJ lymphocytes_NNS and_CC macrophages_NNS ._.
In_IN T_JJ cells_NNS ,_, HIV_NNP transcription_NN is_VBZ poorly_RB detected_VBN in_IN vivo_`` ._.
Cloned_VBN ,_, normal_JJ T_`` lymphocytes_NNS show_VBP very_RB little_RB ,_, if_IN any_DT ,_, basal_JJ activity_NN of_IN the_DT HIV_NNP enhancer_`` and_CC low_JJ nuclear_JJ expression_NN of_IN NF-kappa_NNP B_NNP ,_, a_DT potent_JJ transcriptional_JJ activator_NN of_IN the_DT HIV_NNP enhancer_NN ._.
In_IN contrast_NN ,_, fixed_VBN tissue_NN macrophages_NNS express_VBP detectable_JJ HIV_`` proteins_NNS ,_, indicating_VBG permanent_JJ virus_NN transcription_NN ._.
One_CD explanation_NN for_IN the_DT perpetuation_NN of_IN virus_NN infection_NN in_IN macrophages_NNS could_MD be_VB sustained_VBN nuclear_JJ NF-kappa_NNP B_NNP expression_NN ._.
However_RB ,_, the_DT U937_`` monocytic_JJ cell_NN line_NN ,_, which_WDT is_VBZ fully_RB permissive_JJ to_TO HIV_NNP replication_NN ,_, is_VBZ known_VBN to_TO express_VB only_RB low_JJ levels_NNS of_IN nuclear_JJ NF-kappa_NNP B_NNP ._.
We_PRP show_VBP here_RB that_IN chronic_NN HIV_NNP infection_NN results_NNS in_IN both_DT induction_NN of_IN a_DT nuclear_JJ factor_NN with_IN antigenic_JJ properties_NNS indistinguishable_`` from_IN those_DT of_IN NF-kappa_NNP B_NNP and_CC permanently_RB increased_VBN HIV_NNP enhancer_`` activity_NN ._.
This_DT phenomenon_NN ,_, which_WDT is_VBZ independent_JJ of_IN tumour_`` necrosis_`` factor_NN ,_, is_VBZ associated_VBN with_IN HIV_NNP replication_NN ,_, and_CC is_VBZ thus_RB likely_RB to_TO explain_VB at_IN least_JJS in_IN part_NN the_DT perpetuation_NN of_IN HIV_`` infection_NN in_IN monocytes_NNS ._.
Role_-RRB- for_IN the_DT Epstein-Barr_`` virus_NN nuclear_JJ antigen_`` 2_CD in_IN viral_`` promoter_NN switching_NN during_IN initial_JJ stages_NNS of_IN infection_NN ._.
During_IN latent_JJ Epstein-Barr_NNP virus_NN (_-LRB- EBV_NNP )_-RRB- infection_NN of_IN human_JJ B_NNP lymphocytes_`` ,_, six_CD viral_JJ nuclear_JJ antigen_`` (_-LRB- EBNAs_# )_-RRB- are_VBP expressed_VBN from_IN long_RB primary_JJ transcripts_NNS by_IN means_NNS of_IN alternative_JJ splicing_NN and_CC alternative_JJ polyadenylylation_NN sites_NNS ._.
These_DT transcripts_NNS initiate_VBP from_IN one_CD of_IN two_CD promoters_NNS ,_, Cp_# or_CC Wp_`` ,_, that_IN function_NN in_IN a_DT mutually_RB exclusive_JJ fashion_NN ._.
Wp_NN is_VBZ exclusively_RB utilized_VBN during_IN the_DT initial_JJ stages_NNS of_IN infection_NN of_IN primary_JJ B_NNP lymphocytes_NNS ,_, followed_VBN by_IN a_DT switch_NN to_TO Cp_NNP usage_NN ._.
These_DT studies_NNS have_VBP been_VBN extended_VBN to_TO show_VB that_IN (_-LRB- i_FW )_-RRB- a_DT mutant_JJ EBV_NNP strain_NN lacking_VBG the_DT gene_NN encoding_# EBNA_NNP 2_CD fails_VBZ to_TO switch_VB from_IN Wp_NNP to_TO Cp_NNP usage_NN in_IN primary_JJ B_NNP lymphocytes_NNS ,_, although_IN the_DT virus_NN contains_VBZ a_DT functional_JJ Cp_NN ;_: (_-LRB- ii_NN )_-RRB- a_DT region_NN from_IN -429_CD to_TO -245_CD base_NN pairs_NNS upstream_RB of_IN Cp_NNP is_VBZ essential_JJ for_IN Cp_`` activity_NN in_IN B_NNP lymphocytes_NNS ,_, but_CC only_RB in_IN the_DT context_NN of_IN upstream_JJ and_CC downstream_JJ sequences_NNS ;_: (_-LRB- iii_NN )_-RRB- this_DT region_NN contains_VBZ an_DT EBNA_`` 2-dependent_JJ enhancer_NN ;_: and_CC (_-LRB- iv_`` )_-RRB- DNase_NNP I_PRP protection_NN employing_VBG nuclear_JJ extracts_NNS from_IN B_NNP and_CC T_NNP lymphocytes_NNS revealed_VBD a_DT B-cell-specific_`` footprint_NN in_IN the_DT region_NN of_IN the_DT EBNA_`` 2-dependent_JJ enhancer_NN ._.
These_DT results_NNS support_VBP a_DT model_NN for_IN viral_`` promoter_NN switching_NN during_IN the_DT initial_JJ stages_NNS of_IN infection_NN in_IN which_WDT Wp_NNP activity_NN leads_VBZ to_TO the_DT expression_NN of_IN EBNA_NNP 2_CD ,_, followed_VBN by_IN activation_NN of_IN Cp_# through_IN the_DT EBNA_NNP 2-dependent_JJ enhancer_NN ._.
Glucocorticoid_JJ receptor_NN characteristics_NNS in_IN monocytes_NNS of_IN patients_NNS with_IN corticosteroid-resistant_JJ bronchial_JJ asthma_NN ._.
The_DT mechanism_NN of_IN corticosteroid_JJ resistance_NN in_IN bronchial_JJ asthma_NN has_VBZ been_VBN studied_VBN by_IN determining_VBG the_DT rank_NN order_NN of_IN potency_NN for_IN different_JJ corticosteroids_NNS in_IN inhibiting_VBG the_DT generation_NN of_IN a_DT 3_CD kD_NNP molecule_`` from_IN peripheral_JJ blood_NN monocytes_`` isolated_VBN from_IN corticosteroid-sensitive_JJ (_-LRB- CS_NNP )_-RRB- and_CC corticosteroid-resistant_JJ (_-LRB- CR_`` )_-RRB- asthmatic_JJ subjects_NNS ,_, which_WDT augments_VBZ leukotriene_`` B4_`` (_-LRB- LTB4_NN )_-RRB- generation_NN by_IN human_JJ neutrophils_NNS (_-LRB- PMN_NNP )_-RRB- stimulated_VBN by_IN calcium_`` ionophore_NN ._.
In_IN addition_NN ,_, binding_JJ studies_NNS with_IN (_-LRB- 3H_NNP )_-RRB- dexamethasone_`` have_VBP been_VBN performed_VBN to_TO determine_VB the_DT dissociation_NN constant_JJ (_-LRB- Kd_# )_-RRB- and_CC receptor_NN numbers_NNS (_-LRB- Ro_NNP )_-RRB- in_IN the_DT monocytes_NNS of_IN these_DT two_CD groups_NNS of_IN subjects_NNS ._.
The_DT concentration_NN of_IN corticosteroid_JJ producing_VBG 50_CD %_NN inhibition_`` (_-LRB- IC50_NN )_-RRB- was_VBD 600_CD nM_NNP ,_, 70_CD nM_NN ,_, and_CC 0.5_CD nM_NNP for_IN hydrocortisone_`` ,_, methylprednisolone_# ,_, and_CC dexamethasone_`` ,_, respectively_RB ,_, in_IN monocytes_NNS from_IN CS_NNP individuals_NNS ._.
There_EX was_VBD only_RB weak_JJ inhibition_`` of_IN the_DT generation_NN of_IN enhancing_VBG activity_NN by_IN the_DT corticosteroids_NNS in_IN the_DT CR_`` asthmatic_JJ individuals_NNS ._.
The_DT dexamethasone_`` Kd_NNP was_VBD 2.45_CD +/-_`` 0.58_CD nM_JJ (_-LRB- mean_VBP +/-_`` SEM_`` ,_, n_RB =_SYM 6_CD )_-RRB- in_IN the_DT CS_NNP group_NN and_CC 1.6_CD +/-_`` 0.35_CD nM_`` (_-LRB- mean_JJ +/-_`` SEM_NNP ,_, n_RB =_SYM 6_CD )_-RRB- in_IN the_DT CR_`` group_NN of_IN patients_NNS (_-LRB- p_NN =_SYM 0.14_CD )_-RRB- ._.
The_DT Ro_NNP in_IN the_DT CS_NNP group_NN was_VBD 3,605_CD +/-_JJ 984_CD binding_`` sites_NNS per_IN nucleus_`` (_-LRB- mean_NN +/-_JJ SEM_`` ,_, n_RB =_SYM 6_CD )_-RRB- and_CC 4,757_CD +/-_JJ 692_CD binding_`` sites_NNS per_IN nucleus_`` (_-LRB- mean_JJ +/-_`` SEM_NNP ,_, n_RB =_SYM 6_CD )_-RRB- in_IN the_DT CR_`` group_NN (_-LRB- p_NN =_SYM 0.23_CD )_-RRB- ._.
These_DT findings_NNS indicate_VBP that_IN corticosteroid_JJ resistance_NN in_IN bronchial_JJ asthma_NN can_MD not_RB be_VB explained_VBN by_IN abnormalities_NNS in_IN corticosteroid_`` receptor_NN characteristics_NNS ._.
Tissue-specific_JJ expression_NN of_IN the_DT platelet_'' GPIIb_NNP gene_NN ._.
One_CD of_IN the_DT major_JJ objectives_NNS in_IN the_DT study_NN of_IN thrombogenesis_NN is_VBZ to_TO determine_VB the_DT mechanisms_`` by_IN which_WDT a_DT hematopoietic_JJ progenitor_NN is_VBZ activated_VBN and_CC committed_VBN to_TO the_DT megakaryocytic_JJ lineage_NN ._.
Recent_JJ development_NN of_IN primary_JJ cultures_NNS of_IN human_JJ megakaryocytes_NNS and_CC the_DT molecular_JJ cloning_NN of_IN genes_NNS that_WDT are_VBP specific_JJ to_TO this_DT lineage_NN offer_VBP the_DT possibility_NN of_IN getting_VBG some_DT insights_NNS into_IN the_DT genetic_JJ mechanisms_NNS that_IN control_NN megakaryocytopoiesis_NN ._.
One_CD gene_NN of_IN interest_NN is_VBZ the_DT glycoprotein_NN IIb_NNP (_-LRB- GPIIb_NNP )_-RRB- gene_NN ;_: GPIIb_NNP ,_, the_DT alpha_NN subunit_NN of_IN the_DT platelet_NN cytoadhesin_NN GPIIb-IIIa_NNP ,_, is_VBZ produced_VBN in_IN megakaryocytes_NNS at_IN an_DT early_JJ stage_NN of_IN the_DT differentiation_NN ,_, whereas_IN the_DT other_JJ subunit_NN of_IN this_DT complex_JJ ,_, GPIIIa_'' ,_, is_VBZ expressed_VBN in_IN other_JJ cells_NNS ._.
For_IN these_DT reasons_NNS ,_, the_DT 5'-flanking_JJ region_NN of_IN the_DT GPIIb_NNP gene_NN was_VBD used_VBN to_TO identify_VB the_DT regions_NNS that_WDT interact_`` with_IN DNA-binding_JJ nuclear_JJ factors_NNS ._.
A_DT fragment_NN extending_VBG from_IN -643_CD to_TO +33_CD is_VBZ capable_JJ of_IN controlling_VBG the_DT tissue-specific_JJ expression_NN of_IN the_DT CAT_JJ gene_NN in_IN transfection_`` experiments_NNS ._.
Within_IN this_DT region_NN ,_, we_PRP have_VBP identified_VBN several_JJ sequences_NNS that_WDT are_VBP implicated_VBN in_IN DNA_NNP protein_NN interactions_`` as_IN shown_VBN in_IN DNAse_`` I_PRP footprints_NNS and_CC gel_`` mobility_JJ shift_NN assays_NNS ._.
One_CD region_NN ,_, centered_VBN at_IN -54_CD ,_, is_VBZ similar_JJ to_TO a_DT nuclear_JJ factor_NN E1-binding_-RRB- site_NN ,_, and_CC a_DT region_NN located_VBN at_IN position_NN -233_CD contains_VBZ a_DT CCAAT_NN motif_NN ._.
Two_CD domains_NNS centered_VBN at_IN positions_NNS -345_CD and_CC -540_CD ,_, respectively_RB ,_, bind_NN proteins_NNS that_WDT are_VBP present_JJ in_IN megakaryocytic_JJ cells_NNS and_CC nonrelated_JJ cells_NNS as_RB well_RB ._.
Finally_RB ,_, two_CD other_JJ domains_NNS ,_, located_VBN at_IN positions_NNS -460_CD and_CC -510_`` ,_, interact_'' with_IN proteins_NNS that_WDT are_VBP only_RB present_JJ in_IN megakaryocytic_JJ cells_NNS ._.
In_IN addition_NN ,_, deletion_NN of_IN the_DT region_NN containing_VBG these_DT two_CD domains_NNS results_NNS in_IN a_DT significant_JJ decrease_NN of_IN the_DT promoter_NN activity_NN ._.
It_PRP is_VBZ very_RB likely_JJ that_IN these_DT domains_VBZ bind_NN megakaryocyte-specific_JJ nuclear_JJ proteins_NNS acting_VBG as_IN positive_JJ transcription_NN factors_NNS ._.
Inhibition_NN of_IN protein_NN phosphatases_NNS by_IN okadaic_JJ acid_NN induces_VBZ AP1_`` in_IN human_JJ T_JJ cells_NNS ._.
To_TO examine_VB the_DT role_NN of_IN protein_NN phosphatases_NNS in_IN T_JJ cell_NN activation_NN ,_, Jurkat_NNP cells_NNS were_VBD treated_VBN with_IN okadaic_JJ acid_NN ,_, an_DT inhibitor_NN of_IN type_NN 1_CD and_CC 2A_`` phosphatases_NNS ,_, and_CC nuclear_JJ extracts_NNS were_VBD examined_VBN for_IN the_DT presence_NN of_IN AP1_`` as_IN a_DT measure_NN of_IN early_JJ T_JJ cell_NN activation_NN ._.
Okadaic_JJ acid_NN was_VBD found_VBN to_TO be_VB a_DT potent_JJ inducer_NN of_IN AP1_NN ._.
In_IN contrast_NN to_TO phorbol_`` esters_NNS such_JJ as_IN phorbol_`` myristate_`` acetate_`` (_-LRB- PMA_NNP )_-RRB- ,_, the_DT induction_NN of_IN AP1_CD by_IN okadaic_JJ acid_NN occurs_VBZ predominantly_RB by_IN transcriptional_JJ activation_NN of_IN the_DT jun_NN and_CC fos_`` family_NN of_IN proto-oncogenes_NNS ._.
Surprisingly_RB ,_, while_IN the_DT addition_NN of_IN phytohemagglutinin_`` further_JJ enhanced_VBD the_DT induction_NN of_IN AP1_NN ,_, the_DT addition_NN of_IN PMA_NNP inhibited_VBD it_PRP ._.
Okadaic_JJ acid_NN treatment_NN was_VBD found_VBN to_TO dramatically_RB increase_VB mRNA_NNP transcripts_NNS of_IN the_DT jun_`` family_NN of_IN proto-oncogenes_`` including_VBG c-jun_NN ,_, junD_NN ,_, and_CC junB_NNP and_CC to_TO a_DT lesser_JJR extent_NN the_DT fos_`` family_NN including_VBG c-fos_NNS and_CC fra-1_NN ._.
By_IN comparison_NN ,_, PMA_NNP is_VBZ a_DT very_RB inefficient_JJ inducer_NN of_IN the_DT jun_`` gene_NN family_NN in_IN Jurkat_NNP cells_NNS ._.
Similar_JJ to_TO its_PRP$ effect_NN on_IN the_DT induction_NN of_IN AP1_NN by_IN okadaic_JJ acid_NN ,_, PMA_NNP inhibits_VBZ the_DT induction_NN of_IN c-jun_`` mRNA_`` by_IN okadaic_JJ acid_NN ._.
Transfection_NN of_IN c-jun_NN promoter_NN constructs_`` confirmed_VBD the_DT marked_VBN difference_NN between_IN PMA_NNP and_CC okadaic_JJ acid_NN in_IN inducing_`` c-jun_JJ transcription_NN ._.
The_DT induction_NN of_IN AP1_NN by_IN okadaic_JJ acid_NN suggests_VBZ that_IN protein_NN phosphatases_NNS 1_CD and_CC 2A_`` (_-LRB- PP1_NN and_CC PP2A_`` )_-RRB- may_MD be_VB involved_VBN in_IN T_JJ cell_NN activation_NN as_IN important_JJ negative_JJ regulators_NNS of_IN the_DT transcription_`` factor_NN AP1_NN ._.
Demonstration_NN of_IN estrogen_NN and_CC progesterone_`` receptors_NNS as_RB well_RB as_IN Ki-67_CD and_CC p-145_CD antigens_NNS in_IN single_JJ tumor_NN cells_NNS from_IN blood_NN and_CC pleural_JJ effusions_NNS using_VBG a_DT slide_NN assay_NN ._.
We_PRP describe_VBP a_DT slide_NN assay_NN that_WDT allows_VBZ the_DT demonstration_NN of_IN antigens_NNS localized_VBN in_IN the_DT nucleus_`` from_IN isolated_JJ white_JJ blood_NN cells_NNS as_RB well_RB as_IN from_IN single_JJ tumor_NN cells_NNS derived_VBN from_IN malignant_JJ effusions_NNS ._.
With_IN the_DT antibodies_NNS Ki-67_# and_CC anti-p-145_`` an_DT increased_VBN rate_NN of_IN nuclear_JJ and_CC nucleolar_JJ staining_NN resulted_VBD in_IN cells_NNS from_IN highly_RB malignant_JJ lymphomas_NNS ._.
An_DT almost_RB identical_JJ reaction_NN was_VBD obtained_VBN when_WRB tumor_NN cells_NNS from_IN malignant_JJ effusions_NNS were_VBD tested_VBN ._.
Cells_NNS isolated_VBN from_IN the_DT blood_NN of_IN patients_NNS with_IN leukemic_JJ spread_NN of_IN lymphomas_NNS of_IN low_JJ malignancy_NN yielded_VBD a_DT weak_JJ staining_`` comparable_JJ to_TO that_DT of_IN normal_JJ mesothelial_JJ cells_NNS from_IN non-tumorous_JJ cavity_`` fluids_NNS ._.
The_DT detection_NN of_IN estrogen_NN and_CC progesterone_NN receptors_NNS (_-LRB- ER_NNP and_CC PR_NNP )_-RRB- localized_`` in_IN the_DT cell_NN nucleus_`` can_MD be_VB achieved_VBN by_IN the_DT same_JJ assay_NN ._.
The_DT reaction_NN is_VBZ enhanced_VBN by_IN incubation_NN of_IN the_DT tumor_NN cells_NNS for_IN 30_CD min_NN at_IN 37_CD degrees_NNS C_NN prior_RB to_TO fixation_NN ._.
Pleural_JJ effusions_NNS from_IN 20_CD patients_NNS with_IN breast_NN cancer_NN were_VBD tested_VBN ._.
ER_NN was_VBD positive_JJ in_IN 13_CD and_CC PR_NN was_VBD positive_JJ in_IN 12_CD of_IN the_DT 20_CD samples_NNS ._.
In_IN 5_CD cases_NNS there_EX was_VBD a_DT divergent_JJ reaction_NN with_IN ER_NNP and_CC PR_NNP antibody_NN ._.
The_DT hormone_NN receptors_`` of_IN the_DT primary_JJ tumor_NN were_VBD known_VBN in_IN 15_CD (_-LRB- ER_NNP )_-RRB- and_CC 14_CD (_-LRB- PR_NNP )_-RRB- patients_NNS ,_, respectively_RB ._.
In_IN each_DT cohort_`` there_EX was_VBD only_RB one_CD case_NN with_IN a_DT negative_JJ reaction_NN of_IN the_DT primary_JJ tumor_NN and_CC a_DT positive_JJ reaction_NN with_IN the_DT isolated_JJ tumor_NN cells_NNS from_IN the_DT pleural_`` effusions_NNS ._.
These_DT results_NNS indicate_VBP that_IN the_DT demonstration_NN of_IN hormone_NN receptor_NN proteins_NNS in_IN cells_NNS from_IN malignant_JJ effusions_NNS is_VBZ possible_JJ and_CC that_IN there_EX is_VBZ a_DT correlation_`` with_IN the_DT status_NN of_IN the_DT primary_JJ site_NN of_IN cancer_NN ._.
Transforming_VBG growth_NN factor-beta_`` suppresses_`` human_JJ B_NNP lymphocyte_`` Ig_`` production_NN by_IN inhibiting_VBG synthesis_NN and_CC the_DT switch_NN from_IN the_DT membrane_NN form_NN to_TO the_DT secreted_`` form_NN of_IN Ig_NNP mRNA_NNP ._.
Transforming_VBG growth_NN factor-beta_# (_-LRB- TGF-beta_NNP )_-RRB- inhibits_VBZ B_NNP cell_NN Ig_NNP secretion_NN and_CC reduces_VBZ B_NNP cell_NN membrane_NN Ig_# expression_NN ._.
The_DT addition_NN of_IN TGF-beta_JJ to_TO human_JJ B_NNP lymphocyte_`` cultures_NNS stimulated_VBD with_IN Staphylococcus_NNP aureus_`` Cowan_`` strain_VB I_PRP and_CC IL-2_`` completely_RB inhibited_JJ B_NNP cell_NN Ig_NNP secretion_`` (_-LRB- greater_JJR than_IN 90_CD %_NN )_-RRB- and_CC decreased_VBD B_NNP cell_NN surface_NN IgM_NNP ,_, IgD_NNP ,_, kappa_'' L_`` chain_NN ,_, and_CC lambda_`` L_NNP chain_NN expression_NN ._.
In_IN contrast_NN ,_, TGF-beta_NNP had_VBD only_RB minimal_JJ effects_NNS on_IN two_CD other_JJ B_NNP cell_NN membrane_NN proteins_VBZ ,_, HLA-DR_NNP and_CC CD20_NNP ._.
Internal_NNP labeling_`` with_IN (35S)methionine_NN and_CC immunoprecipitation_NN with_IN anti-IgM_JJ ,_, anti-kappa_JJ ,_, and_CC anti-lambda_JJ antibodies_NNS revealed_VBD a_DT striking_JJ reduction_NN in_IN kappa_NN L_NNP chain_NN in_IN the_DT presence_NN of_IN TGF-beta_NNP ._.
A_DT less_RBR pronounced_JJ reduction_NN in_IN lambda_-RRB- L_NNP chain_NN and_CC microH_`` chain_NN was_VBD also_RB noted_VBN ._.
Northern_JJ blot_JJ analysis_NN of_IN RNA_NNP purified_`` from_IN B_NNP cells_NNS treated_VBN with_IN TGF-beta_NNP for_IN varying_VBG time_NN intervals_NNS revealed_VBD a_DT significant_JJ decrease_NN in_IN steady_JJ state_NN kappa_NN and_CC lambda_-RRB- L_NNP chain_NN mRNA_`` levels_NNS ._.
Furthermore_RB ,_, a_DT significant_JJ decrease_NN in_IN the_DT switch_NN from_IN the_DT membrane_NN forms_NNS of_IN mu_`` and_CC gamma_NN to_TO their_PRP$ respective_JJ secreted_`` forms_NNS was_VBD noted_VBN in_IN the_DT presence_NN of_IN TGF-beta_NNP ._.
Nuclear_JJ run-on_`` experiments_NNS demonstrated_VBD decreased_VBN transcription_NN of_IN kappa_NN L_NNP chain_NN ._.
The_DT effects_NNS of_IN TGF-beta_JJ on_IN two_CD transcriptional_JJ regulatory_JJ factors_NNS ,_, Oct-2_-RRB- and_CC nuclear_JJ factor_NN (_-LRB- NF_NNP )_-RRB- kappa_`` B_NN ,_, known_VBN to_TO be_VB important_JJ in_IN Ig_`` gene_NN transcription_NN were_VBD examined_VBN ._.
Oct-2_-LRB- mRNA_`` levels_NNS and_CC both_DT Oct-2_NNP and_CC NF-kappa_NNP B_NNP proteins_VBZ in_IN nuclear_JJ extracts_NNS were_VBD not_RB altered_VBN by_IN treatment_NN with_IN TGF-beta_NNP ._.
In_IN contrast_NN ,_, levels_NNS of_IN the_DT transcriptional_JJ factor_NN AP-1_NNP ,_, which_WDT is_VBZ not_RB known_VBN to_TO be_VB important_JJ in_IN B_NNP cell_NN Ig_`` production_NN ,_, were_VBD reduced_VBN by_IN TGF-beta_NNP ._.
These_DT findings_NNS demonstrate_VBP that_IN TGF-beta_NNP decreases_VBZ B_NNP lymphocyte_# Ig_NNP secretion_`` by_IN inhibiting_VBG the_DT synthesis_NN of_IN Ig_NNP mRNA_NNP and_CC inhibiting_VBG the_DT switch_NN from_IN the_DT membrane_NN form_NN to_TO the_DT secreted_`` forms_NNS of_IN mu_NN and_CC gamma_NN mRNA_NN ._.
The_DT mechanism_NN by_IN which_WDT TGF-beta_NNP inhibits_`` Ig_`` chain_NN synthesis_NN is_VBZ unclear_JJ although_IN it_PRP does_VBZ not_RB involve_VB inhibition_NN of_IN the_DT binding_NN of_IN NF-kappa_NNP B_NNP or_CC Oct-2_NNP to_TO their_PRP$ respective_JJ target_NN sequences_NNS ._.
Differentiation-associated_JJ expression_NN of_IN the_DT Epstein-Barr_`` virus_NN BZLF1_NN transactivator_NN protein_NN in_IN oral_JJ hairy_JJ leukoplakia_`` ._.
The_DT BZLF1_`` protein_NN of_IN Epstein-Barr_NNP virus_NN (_-LRB- EBV_NNP )_-RRB- is_VBZ a_DT key_JJ immediate-early_JJ protein_NN which_WDT has_VBZ been_VBN shown_VBN to_TO disrupt_VB virus_NN latency_NN in_IN EBV-infected_# B_NNP cells_NNS ._.
We_PRP have_VBP generated_VBN a_DT monoclonal_JJ antibody_NN ,_, BZ1_'' ,_, to_TO BZLF1_NNP which_WDT reacts_VBZ in_IN immunohistology_NN ,_, immunoblotting_VBG ,_, and_CC immunoprecipitation_`` and_CC which_WDT recognizes_VBZ both_PDT the_DT active_JJ ,_, dimeric_JJ form_NN and_CC the_DT inactive_JJ ,_, monomeric_JJ form_NN of_IN the_DT protein_NN ._.
Biopsies_NNS of_IN oral_JJ hairy_JJ leukoplakia_'' ,_, an_DT AIDS-associated_JJ lesion_NN characterized_VBN by_IN high-level_JJ EBV_NNP replication_NN ,_, were_VBD examined_VBN by_IN immunohistochemistry_`` using_VBG the_DT BZ1_`` monoclonal_JJ antibody_NN ._.
A_DT differentiation-associated_JJ pattern_NN of_IN BZLF1_NNP expression_NN was_VBD observed_VBN ,_, BZ1_-RRB- reacting_VBG with_IN nuclei_`` of_IN the_DT upper_JJ spinous_JJ layer_NN of_IN the_DT lesion_NN ._.
This_DT finding_NN suggests_VBZ that_IN the_DT BZLF1_NN promoter_NN may_MD be_VB regulated_VBN by_IN the_DT degree_NN of_IN squamous_JJ differentiation_NN ._.
A_DT comparison_NN of_IN in_IN situ_`` hybridization_NN to_TO EBV_NNP DNA_NNP and_CC viral_`` capsid_JJ antigen_`` staining_`` with_IN BZ1_NNP reactivity_NN suggested_VBD that_IN BZLF1_`` expression_NN precedes_`` rampant_JJ virus_NN replication_NN ._.
The_DT inability_NN to_TO detect_VB EBV_`` in_IN the_DT lower_JJR epithelial_JJ layers_NNS of_IN oral_JJ hairy_JJ leukoplakia_`` raises_VBZ questions_NNS concerning_VBG the_DT nature_NN of_IN EBV_NNP latency_`` and_CC persistence_NN in_IN stratified_`` squamous_JJ epithelium_NN ._.
Transactivation_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN promoter_NN by_IN human_JJ herpesvirus_NN 6_CD (_-LRB- HHV-6_NNP )_-RRB- strains_NNS GS_# and_CC Z-29_NNP in_IN primary_JJ human_JJ T_`` lymphocytes_NNS and_CC identification_NN of_IN transactivating_`` HHV-6_-RRB- (_-LRB- GS_`` )_-RRB- gene_NN fragments_NNS ._.
Human_JJ herpesvirus_NN 6_CD (_-LRB- HHV-6_NNP )_-RRB- can_MD activate_VB the_DT human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV_NNP )_-RRB- promoter_NN and_CC accelerate_VB cytopathic_JJ effects_NNS in_IN HIV-infected_`` human_JJ T_`` cells_NNS ._.
This_DT study_NN examines_VBZ the_DT regions_NNS of_IN the_DT HIV_`` promoter_NN required_VBN for_IN HHV-6_`` transactivation_NN in_IN a_DT heterogeneous_JJ population_NN of_IN primary_JJ human_JJ T_`` lymphocytes_NNS with_IN or_CC without_IN antigenic_JJ stimulation_NN ._.
Two_CD different_JJ strains_NNS of_IN HHV-6_NN ,_, GS_NNP and_CC Z29_NNP ,_, transactivated_VBD the_DT HIV_NNP promoter_NN ._.
The_DT GS_NNP strain_NN transactivated_VBD the_DT promoter_NN in_IN both_DT stimulated_VBD and_CC resting_VBG T_JJ cells_NNS ,_, while_IN the_DT Z29_NNP strain_NN increased_VBD HIV_`` promoter_NN activity_NN only_RB in_IN stimulated_VBN T_JJ cells_NNS ._.
Three_CD DNA_NNP clones_NNS containing_VBG HHV-6_-RRB- (_-LRB- GS_NNP )_-RRB- genomic_`` fragments_NNS transactivated_VBD the_DT HIV_NNP promoter_NN in_IN cotransfected_`` T_JJ cells_NNS ._.
A_DT 21.4-kb_JJ DNA_NNP clone_`` ,_, pZVB70_NN ,_, showed_VBD the_DT highest_JJS transactivating_`` ability_NN ,_, while_IN two_CD other_JJ DNA_NNP fragments_NNS ,_, pZVB10_# (_-LRB- 6.2_CD kb_`` )_-RRB- and_CC pZVH14_`` (_-LRB- 8.7_CD kb_`` )_-RRB- ,_, showed_VBD lower_JJR activity_NN ._.
One_CD of_IN these_DT clones_NNS ,_, pZVH14_NN ,_, activated_VBD the_DT HIV_NNP promoter_NN construct_VB containing_VBG a_DT mutation_`` in_IN the_DT NF_NNP kappa_NN B_NNP site_NN ._.
However_RB ,_, this_DT mutated_VBD NF_NNP kappa_`` B_NNP promoter_NN was_VBD not_RB transactivated_VBN during_IN HHV-6_# (_-LRB- GS_NNP )_-RRB- infection_NN or_CC after_IN cotransfection_NN with_IN pZVB70_NN or_CC pZVB10_NN ._.
These_DT data_NNS indicate_VBP that_IN the_DT NF_NNP kappa_-LRB- B_NNP sites_NNS of_IN the_DT HIV_NNP promoter_NN are_VBP essential_JJ for_IN its_PRP$ transactivation_NN during_IN HHV-6_-RRB- (_-LRB- GS_`` )_-RRB- infection_NN ._.
By_IN increasing_VBG HIV_NNP promoter_NN activity_NN in_IN primary_JJ T_`` lymphocytes_NNS ,_, HHV-6_NNP may_MD consequently_RB increase_VB HIV_NNP replication_`` ,_, leading_VBG to_TO an_DT increase_NN in_IN the_DT cytopathic_JJ effect_NN on_IN coinfected_`` human_JJ T_`` cells_NNS ._.
The_DT rhombotin_`` family_NN of_IN cysteine-rich_JJ LIM-domain_`` oncogenes_NNS :_: distinct_JJ members_NNS are_VBP involved_VBN in_IN T-cell_`` translocations_NNS to_TO human_JJ chromosomes_NNS 11p15_CD and_CC 11p13_CD ._.
A_DT chromosomal_`` translocation_NN in_IN a_DT T-cell_NNP leukemia_NN involving_VBG the_DT short_JJ arm_NN of_IN human_JJ chromosome_NN 11_CD at_IN band_NN 11p15_CD disrupts_`` the_DT rhombotin_`` gene_NN ._.
This_DT gene_NN encodes_VBZ a_DT protein_NN with_IN duplicated_`` cysteine-rich_JJ regions_NNS called_VBD LIM_NNP domains_`` ,_, which_WDT show_VBP homology_NN to_TO zinc-binding_`` proteins_NNS and_CC to_TO iron-sulfur_`` centers_NNS of_IN ferredoxins_NNS ._.
Two_CD homologues_NNS of_IN the_DT rhombotin_NN gene_NN have_VB now_RB been_VBN isolated_VBN ._.
One_CD of_IN these_DT ,_, designated_VBN Rhom-2_NN ,_, is_VBZ located_VBN on_IN human_JJ chromosome_NN 11_CD at_IN band_NN 11p13_CD ,_, where_WRB a_DT cluster_NN of_IN T-cell_`` leukemia-specific_JJ translocations_NNS occur_VBP ;_: all_DT translocation_`` breakpoints_NNS at_IN 11p13_CD are_VBP upstream_RB of_IN the_DT Rhom-2_`` gene_NN ._.
Human_NNP and_CC mouse_NN Rhom-2_`` are_VBP highly_RB conserved_`` and_CC ,_, like_IN rhombotin_NN ,_, encode_'' two_CD tandem_`` cysteine-rich_JJ LIM_`` domains_NNS ._.
Rhom-2_NN mRNA_NN is_VBZ expressed_VBN in_IN early_JJ mouse_NN development_NN in_IN central_JJ nervous_JJ system_NN ,_, lung_NN ,_, kidney_NN ,_, liver_NN ,_, and_CC spleen_`` but_CC only_RB very_RB low_JJ levels_NNS occur_VBP in_IN thymus_NN ._.
The_DT other_JJ gene_NN ,_, designated_VBN Rhom-3_NNP ,_, is_VBZ not_RB on_IN chromosome_NN 11_CD but_CC also_RB retains_VBZ homology_NN to_TO the_DT LIM_`` domain_NN of_IN rhombotin_NN ._.
Since_IN the_DT Rhom-2_NN gene_NN is_VBZ such_PDT a_DT common_JJ site_NN of_IN chromosomal_`` damage_NN in_IN T-cell_JJ tumors_NNS ,_, the_DT consistency_NN of_IN translocations_NNS near_IN the_DT rhombotin_NN gene_NN was_VBD further_JJ examined_VBN ._.
A_DT second_JJ translocation_NN adjacent_JJ to_TO rhombotin_NN was_VBD found_VBN and_CC at_IN the_DT same_JJ position_NN as_IN in_IN the_DT previous_JJ example_NN ._.
Therefore_RB ,_, chromosome_NN bands_NNS 11p15_CD (_-LRB- rhombotin_NN )_-RRB- and_CC 11p13_CD (_-LRB- Rhom-2_NN )_-RRB- are_VBP consistent_JJ sites_NNS of_IN chromosome_NN translocation_NN in_IN T-cell_# leukemia_NN ,_, with_IN the_DT 11p15_CD target_NN more_RBR rarely_RB involved_VBN ._.
The_DT results_NNS define_VB the_DT rhombotin_`` gene_NN family_NN as_IN a_DT class_NN of_IN T-cell_NNP oncogenes_`` with_IN duplicated_`` cysteine-rich_JJ LIM_`` domains_NNS ._.
The_DT human_JJ myelomonocytic_JJ cell_NN line_NN U-937_`` as_IN a_DT model_NN for_IN studying_VBG alterations_NNS in_IN steroid-induced_`` monokine_`` gene_NN expression_NN :_: marked_VBN enhancement_NN of_IN lipopolysaccharide-stimulated_`` interleukin-1_JJ beta_NN messenger_NN RNA_NNP levels_NNS by_IN 1,25-dihydroxyvitamin_JJ D3_NN ._.
The_DT active_JJ metabolite_NN of_IN vitamin_NN D_NNP ,_, 1,25-dihydroxyvitamin_'' D3_NNP (_-LRB- 1,25-(OH)2D3_NNP )_-RRB- ,_, is_VBZ a_DT potent_JJ regulator_NN of_IN human_JJ monocyte/macrophage_NN function_NN in_IN vitro_NN ._.
To_TO establish_VB a_DT model_NN for_IN 1,25-(OH)2D3_JJ regulation_NN of_IN human_JJ monocyte_NN monokine_`` synthesis_NN ,_, three_CD human_JJ cell_NN lines_NNS (_-LRB- U-937_CD ,_, THP-1_CD ,_, and_CC HL-60_NNP )_-RRB- were_VBD examined_VBN for_IN :_: 1_CD )_-RRB- the_DT presence_NN of_IN functional_JJ 1,25-(OH)2D3_`` receptors_NNS ;_: 2_CD )_-RRB- the_DT accumulation_NN of_IN interleukin-1_NN beta_NN (_-LRB- IL-1_NNP beta_NN )_-RRB- mRNA_`` and_CC IL-1_`` beta_JJ protein_NN in_IN response_NN to_TO lipopolysaccharide_`` (_-LRB- LPS_NNP )_-RRB- ;_: and_CC 3_CD )_-RRB- the_DT regulation_NN of_IN this_DT response_NN by_IN 1,25-(OH)2D3_NNP ._.
All_DT three_CD cell_NN lines_NNS expressed_VBD vitamin_NN D_NN receptor_NN and_CC had_VBD increased_VBN levels_NNS of_IN IL-1_`` beta_JJ mRNA_NN in_IN response_NN to_TO LPS_NNP ._.
Preincubation_NN of_IN cells_NNS with_IN 1,25-(OH)2D3_`` augmented_JJ IL-1_`` beta_JJ mRNA_`` levels_NNS only_RB in_IN U-937_-RRB- and_CC HL-60_JJ cells_NNS ._.
From_IN these_DT data_NNS ,_, and_CC taking_VBG into_IN consideration_NN their_PRP$ state_NN of_IN differentiation_NN and_CC relative_JJ ease_NN of_IN culture_NN ,_, U-937_'' was_VBD chosen_VBN over_RB HL-60_`` and_CC THP-1_`` as_IN the_DT cell_NN line_NN we_PRP further_RB characterized_VBD ._.
In_IN U-937_CD cells_NNS ,_, optimum_JJ time_NN and_CC dose_NN of_IN pretreatment_NN with_IN 1,25-(OH)2D3_-RRB- were_VBD determined_VBN to_TO be_VB 12-24_`` h_NN at_IN a_DT receptor_NN saturating_VBG concentration_NN of_IN 1,25-(OH)2D3_JJ (_-LRB- 10_CD nM_`` )_-RRB- ._.
Preincubation_NN of_IN cells_NNS with_IN 1,25-(OH)2D3_NNP had_VBD no_DT effect_NN on_IN the_DT time_NN course_NN of_IN IL-1_`` beta_JJ mRNA_`` appearance_NN in_IN response_NN to_TO LPS_NNP ._.
However_RB ,_, exposure_NN of_IN U-937_CD cells_NNS to_TO 1,25-(OH)2D3_CD increased_VBN by_IN 200_CD %_NN the_DT level_NN of_IN IL-1_`` beta_JJ mRNA_`` detected_VBN and_CC decreased_VBN by_IN three_CD orders_NNS of_IN magnitude_NN the_DT concentration_NN of_IN LPS_`` required_VBN to_TO achieve_VB steady_JJ state_NN mRNA_`` levels_NNS equivalent_JJ to_TO those_DT observed_VBN in_IN U-937_`` cells_NNS not_RB preincubated_`` with_IN the_DT hormone.2+o_NN
Cortivazol_NNP mediated_VBD induction_NN of_IN glucocorticoid_NN receptor_NN messenger_NN ribonucleic_`` acid_NN in_IN wild-type_JJ and_CC dexamethasone-resistant_JJ human_JJ leukemic_`` (_-LRB- CEM_NNP )_-RRB- cells_NNS ._.
Cortivazol_NNP is_VBZ a_DT phenylpyrazolo_`` glucocorticoid_NN of_IN high_JJ potency_NN and_CC unusual_JJ structure_NN ._.
In_IN both_DT wild-type_`` and_CC highly_RB dexamethasone_`` (_-LRB- dex_NN )_-RRB- -resistant_JJ clones_NNS of_IN the_DT human_JJ leukemic_JJ cell_NN line_NN CEM_NNP ,_, exposure_NN to_TO cortivazol_NN leads_NNS to_TO cell_NN death_NN ._.
It_PRP has_VBZ been_VBN shown_VBN recently_RB that_IN in_IN wild-type_JJ CEM_`` cells_NNS but_CC not_RB in_IN a_DT dex-resistant_JJ ,_, glucocorticoid_JJ receptor_NN (_-LRB- GR_NNP )_-RRB- -defective_JJ clone_`` ICR-27_NN TK-3_NN ,_, dex_'' induces_VBZ GR_NNP mRNA_NNP ._.
To_TO test_VB the_DT hypothesis_NN that_IN cortivazol_JJ acts_NNS in_IN dex-resistant_JJ cells_NNS by_IN making_VBG use_NN of_IN the_DT residual_JJ GR_NNP found_VBD there_RB ,_, wild-type_JJ and_CC dex-resistant_JJ clones_NNS were_VBD treated_VBN with_IN various_JJ concentrations_NNS of_IN cortivazol_NN and_CC induction_NN of_IN GR_NNP mRNA_NNP was_VBD studied_VBN ._.
Cortivazol_NNP significantly_RB induced_VBD GR_NNP mRNA_`` in_IN the_DT normal_JJ CEM-C7_NN as_RB well_RB as_IN in_IN two_CD classes_NNS of_IN dex-resistant_JJ clones_NNS ,_, although_IN the_DT dex-resistant_JJ clones_NNS needed_VBN at_IN least_JJS 10_CD times_NNS more_JJR cortivazol_`` than_IN the_DT normal_JJ cells_NNS for_IN significant_JJ GR_NNP mRNA_NNP induction_NN ._.
Increased_VBN levels_NNS of_IN GR_NNP mRNA_NNP were_VBD noticed_VBN as_RB early_RB as_IN 3_CD h_NN after_IN treatment_NN ._.
A_DT general_JJ correlation_NN between_IN induction_NN of_IN GR_NNP mRNA_NNP and_CC lysis_`` of_IN the_DT normal_JJ and_CC dex-resistant_JJ cells_NNS was_VBD found_VBN ._.
Positive_JJ induction_NN of_IN GR_NNP mRNA_NNP might_MD be_VB one_CD of_IN the_DT earliest_JJS crucial_JJ steps_NNS in_IN the_DT lysis_NN of_IN normal_JJ and_CC dex-resistant_JJ CEM_`` cells_NNS ,_, or_CC might_MD serve_VB as_IN a_DT marker_NN for_IN the_DT process_NN ._.
However_RB ,_, the_DT lysis_NN pathway_NN in_IN the_DT dex-resistant_JJ cells_NNS is_VBZ defective_JJ in_IN that_DT dex-resistant_JJ clones_NNS needed_VBD significantly_RB more_RBR cortivazol_`` than_IN the_DT normal_JJ cells_NNS for_IN lysis_NN of_IN the_DT cells_NNS ._.
Expression_NN of_IN 1,25(OH)2D3_CD receptors_NNS on_IN alveolar_JJ lymphocytes_NNS from_IN patients_NNS with_IN pulmonary_`` granulomatous_JJ diseases_NNS ._.
1,25(OH)2D3_-LRB- is_VBZ known_VBN to_TO be_VB produced_VBN at_IN sites_NNS of_IN granulomatous_JJ reactions_NNS ._.
In_IN order_NN to_TO characterize_VB the_DT cell_NN types_NNS that_WDT are_VBP targets_NNS for_IN this_DT immunoregulatory_JJ hormone_NN ,_, we_PRP have_VBP evaluated_`` the_DT expression_NN of_IN 1,25(OH)2D3_CD receptors_NNS on_IN peripheral_JJ blood_NN T-lymphocytes_NNS and_CC those_DT recovered_VBN from_IN the_DT lung_NN by_IN bronchoalveolar_JJ lavage_NN from_IN patients_NNS with_IN pulmonary_`` granulomatous_JJ diseases_NNS (_-LRB- tuberculosis_NN and_CC sarcoidosis_NN )_-RRB- and_CC from_IN normal_JJ control_NN subjects_NNS using_VBG combined_VBN autoradiographic_JJ and_CC immunohistochemical_JJ techniques_NNS ._.
Lavage_# T-lymphocytes_NNS from_IN patients_NNS with_IN tuberculosis_NN or_CC with_IN sarcoidosis_NN ,_, but_CC not_RB those_DT from_IN normal_JJ control_NN subjects_NNS ,_, expressed_VBN 1,25(OH)2D3_CD receptors_NNS as_IN demonstrated_VBN by_IN binding_# of_IN (3H)1,25(OH)2D3_NNP ,_, which_WDT was_VBD inhibited_VBN by_IN the_DT presence_NN of_IN excess_JJ unlabeled_`` 1,25(OH)2D3_CD ,_, but_CC not_RB by_IN the_DT presence_NN of_IN unlabeled_`` 25(OH)D3_-RRB- (_-LRB- receptor-positive_JJ lymphocytes_NNS :_: sarcoidosis_NN ,_, 20_CD +/-_`` 12_CD %_NN ;_: tuberculosis_NN ,_, 31_CD +/-_`` 17_CD %_NN )_-RRB- ._.
In_IN contrast_NN ,_, blood_NN lymphocytes_NNS from_IN patients_NNS with_IN granulomatous_JJ diseases_NNS did_VBD not_RB express_VB detectable_JJ 1,25(OH)2D3_`` receptors_NNS ._.
The_DT percentage_NN of_IN lavage_`` T-lymphocytes_NNS expressing_VBG 1,25(OH)2D3_CD receptors_NNS was_VBD significantly_RB greater_JJR for_IN patients_NNS with_IN tuberculosis_`` presenting_VBG with_IN isolated_JJ hilar_`` adenopathy_JJ than_IN for_IN patients_NNS with_IN pulmonary_JJ infiltrates_`` and/or_`` cavities_NNS ._.
1,25(OH)2D3_CD receptors_NNS were_VBD expressed_VBN to_TO a_DT greater_JJR extent_NN on_IN CD8+_NNP T-lymphocytes_NNP than_IN on_IN CD4+_`` T-lymphocytes_NNS in_IN sarcoidosis_NN ,_, whereas_IN a_DT greater_JJR proportion_NN of_IN CD4+_NN than_IN of_IN CD8+_`` T-lymphocytes_NNS from_IN patients_NNS with_IN tuberculosis_NN were_VBD receptor-positive_JJ ._.
These_DT findings_NNS support_VBP the_DT conclusion_NN that_IN the_DT interaction_NN of_IN 1,25(OH)2D3_CD with_IN its_PRP$ receptor_NN on_IN T-lymphocytes_NNS may_MD play_VB an_DT important_JJ role_NN in_IN the_DT regulation_NN of_IN granulomatous_JJ reactions_NNS ,_, but_CC because_IN these_DT receptors_NNS are_VBP expressed_VBN on_IN different_JJ lymphocyte_`` populations_NNS ,_, the_DT net_JJ effect_NN of_IN this_DT potent_JJ immunoregulatory_JJ molecule_NN is_VBZ likely_RB different_JJ in_IN sarcoidosis_NN and_CC tuberculosis_NN ._.
Inhibition_NN of_IN transcription_NN factors_NNS belonging_VBG to_TO the_DT rel/NF-kappa_NN B_NNP family_NN by_IN a_DT transdominant_`` negative_JJ mutant_NN ._.
The_DT KBF1_`` factor_NN ,_, which_WDT binds_VBZ to_TO the_DT enhancer_`` A_DT located_VBN in_IN the_DT promoter_NN of_IN the_DT mouse_NN MHC_`` class_NN I_PRP gene_NN H-2Kb_NNP ,_, is_VBZ indistinguishable_JJ from_IN the_DT p50_CD DNA_NNP binding_`` subunit_NN of_IN the_DT transcription_NN factor_NN NF-kappa_NNP B_NNP ,_, which_WDT regulates_VBZ a_DT series_NN of_IN genes_NNS involved_VBN in_IN immune_JJ and_CC inflammatory_JJ responses_NNS ._.
The_DT KBF1/p50_`` factor_NN binds_NNS as_IN a_DT homodimer_NN but_CC can_MD also_RB form_VB heterodimers_NNS with_IN the_DT products_NNS of_IN other_JJ members_NNS of_IN the_DT same_JJ family_NN ,_, like_IN the_DT c-rel_`` and_CC v-rel_`` (_-LRB- proto_NN )_-RRB- oncogenes_`` ._.
The_DT dimerization_NN domain_NN of_IN KBF1/p50_CD is_VBZ contained_VBN between_IN amino_JJ acids_NNS 201_CD and_CC 367_CD ._.
A_DT mutant_NN of_IN KBF1/p50_CD (_-LRB- delta_NN SP_NNP )_-RRB- ,_, unable_JJ to_TO bind_NN to_TO DNA_NNP but_CC able_JJ to_TO form_VB homo-_`` or_CC heterodimers_`` ,_, has_VBZ been_VBN constructed_VBN ._.
This_DT protein_NN reduces_VBZ or_CC abolishes_VBZ in_IN vitro_`` the_DT DNA_NNP binding_`` activity_NN of_IN wild-type_JJ proteins_NNS of_IN the_DT same_JJ family_NN (_-LRB- KBF1/p50_CD ,_, c-_# and_CC v-rel_`` )_-RRB- ._.
This_DT mutant_NN also_RB functions_VBZ in_IN vivo_NN as_IN a_DT trans-acting_JJ dominant_JJ negative_JJ regulator_NN :_: the_DT transcriptional_JJ inducibility_NN of_IN the_DT HIV_NNP long_JJ terminal_NN repeat_NN (_-LRB- which_WDT contains_VBZ two_CD potential_JJ NF-kappa_NNP B_NNP binding_# sites_NNS )_-RRB- by_IN phorbol_NN ester_`` (_-LRB- PMA_NNP )_-RRB- is_VBZ inhibited_VBN when_WRB it_PRP is_VBZ co-transfected_`` into_IN CD4+_`` T_JJ cells_NNS with_IN the_DT delta_NN SP_NNP mutant_`` ._.
Similarly_RB the_DT basal_NN as_RB well_RB as_IN TNF_NNP or_CC IL1-induced_JJ activity_NN of_IN the_DT MHC_NNP class_NN I_PRP H-2Kb_-RRB- promoter_NN can_MD be_VB inhibited_VBN by_IN this_DT mutant_JJ in_IN two_CD different_JJ cell_NN lines_NNS ._.
These_DT results_NNS constitute_VBP the_DT first_JJ formal_JJ demonstration_NN that_IN these_DT genes_NNS are_VBP regulated_VBN by_IN members_NNS of_IN the_DT rel/NF-kappa_NNP B_NNP family_NN ._.
Human_NNP erythroid_`` 5-aminolevulinate_JJ synthase_NN :_: promoter_NN analysis_NN and_CC identification_NN of_IN an_DT iron-responsive_JJ element_NN in_IN the_DT mRNA_NN ._.
5-Aminolevulinate_JJ synthase_NN (_-LRB- ALAS_NNP )_-RRB- catalyzes_VBZ the_DT first_JJ step_NN of_IN the_DT heme_`` biosynthetic_JJ pathway_NN ._.
cDNA_NN clones_NNS for_IN the_DT human_JJ erythroid_NN ALAS_`` isozyme_`` were_VBD isolated_VBN from_IN a_DT fetal_`` liver_NN library_NN ._.
It_PRP can_MD be_VB deduced_VBN that_IN the_DT erythroid_`` ALAS_`` precursor_NN protein_NN has_VBZ a_DT molecular_JJ weight_NN of_IN 64.6_CD kd_`` ,_, and_CC is_VBZ similar_JJ in_IN size_NN to_TO the_DT previously_RB isolated_VBN human_JJ housekeeping_NN ALAS_`` precursor_NN of_IN molecular_JJ weight_NN 70.6_CD kd_NN ._.
The_DT mature_JJ mitochondrial_JJ forms_NNS of_IN the_DT erythroid_`` and_CC housekeeping_`` ALAS_`` isozymes_NNS are_VBP predicted_VBN to_TO have_VB molecular_JJ weights_NNS of_IN 59.5_CD kd_# and_CC 64.6_CD kd_`` ,_, respectively_RB ._.
The_DT two_CD isozymes_NNS show_VBP little_JJ amino_JJ acid_NN identity_NN in_IN their_PRP$ N-terminal_JJ signal_NN sequences_NNS but_CC have_VBP considerable_JJ sequence_NN identity_NN in_IN the_DT C-terminal_JJ two-thirds_NNS of_IN their_PRP$ proteins_NNS ._.
An_DT analysis_NN of_IN the_DT immediate_JJ promoter_NN of_IN the_DT human_JJ erythroid_NN ALAS_`` gene_NN revealed_VBD several_JJ putative_JJ erythroid-specific_JJ cis-acting_JJ elements_NNS including_VBG both_DT a_DT GATA-1_NNP and_CC an_DT NF-E2_NNP binding_`` site_NN ._.
An_DT iron-responsive_JJ element_NN (_-LRB- IRE_# )_-RRB- motif_NN has_VBZ been_VBN identified_VBN in_IN the_DT 5'-untranslated_JJ region_NN of_IN the_DT human_JJ erythroid_NN ALAS_`` mRNA_`` ,_, but_CC is_VBZ not_RB present_JJ in_IN the_DT housekeeping_NN ALAS_# mRNA_NNP ._.
Gel_-LRB- retardation_NN experiments_NNS established_VBN that_IN this_DT IRE_`` motif_`` formed_VBD a_DT protein-RNA_`` complex_JJ with_IN cytosolic_JJ extracts_NNS from_IN human_JJ K562_NN cells_NNS and_CC this_DT binding_NN was_VBD strongly_RB competed_`` with_IN IRE_`` transcripts_NNS from_IN ferritin_NN or_CC transferrin_NN receptor_NN mRNAs_`` ._.
A_DT transcript_NN of_IN the_DT ALAS_NNP IRE_NNP ,_, mutated_'' in_IN the_DT conserved_`` loop_NN of_IN the_DT IRE_`` ,_, did_VBD not_RB readily_RB form_VB this_DT protein-RNA_`` complex_JJ ._.
These_DT results_NNS suggest_VBP that_IN the_DT IRE_`` motif_`` in_IN the_DT ALAS_NNP mRNA_NNP is_VBZ functional_JJ and_CC imply_VB that_DT translation_NN of_IN the_DT mRNA_NN is_VBZ controlled_VBN by_IN cellular_JJ iron_NN availability_NN during_IN erythropoiesis_NN ._.
Human_JJ tumor_NN necrosis_NN factor_NN alpha_`` gene_NN regulation_NN in_IN phorbol_`` ester_`` stimulated_VBN T_`` and_CC B_LS cell_NN lines_NNS ._.
The_DT minimal_JJ region_NN of_IN the_DT human_JJ tumor_NN necrosis_`` factor_NN alpha_NN (_-LRB- TNF-alpha_NNP )_-RRB- gene_NN promoter_NN necessary_JJ for_IN its_PRP$ transcriptional_JJ induction_NN by_IN phorbol_`` esters_NNS (_-LRB- PMA_NNP )_-RRB- in_IN human_JJ T_NNP and_CC B_NNP lymphocyte_`` cell_NN lines_NNS has_VBZ been_VBN localized_VBN between_IN -52_CD and_CC +89_CD nucleotides_NNS (_-LRB- nt_JJ )_-RRB- relative_JJ to_TO the_DT gene_NN 's_POS transcriptional_JJ start_NN site_NN ._.
Comparison_NN of_IN these_DT sequences_NNS to_TO those_DT required_VBN to_TO mediate_JJ virus_NN or_CC lipopolysaccharide_NN (_-LRB- LPS_NNP )_-RRB- induction_NN of_IN the_DT gene_NN reveal_VBP significant_JJ differences_NNS ,_, and_CC thus_RB ,_, the_DT sequence_NN requirements_NNS for_IN PMA_NNP induction_`` are_VBP distinct_JJ from_IN those_DT that_WDT mediate_`` induction_NN by_IN virus_NN or_CC LPS_`` ._.
Although_IN three_CD sites_NNS in_IN the_DT TNF-alpha_NNP promoter_NN (_-LRB- kappa_`` 1_CD ,_, kappa_NN 2_CD ,_, and_CC kappa_`` 3_CD )_-RRB- specifically_RB bind_VBP the_DT transcription_NN factor_NN NF-kappa_NNP B_NNP in_IN lymphoid_`` nuclear_JJ extracts_NNS ,_, TNF-alpha_NNP mRNA_NNP induction_`` by_IN PMA_NNP does_VBZ not_RB correlate_`` with_IN NF-kappa_NNP B_NNP binding_# activities_NNS displayed_VBN by_IN different_JJ T_# and_CC B_NNP cell_NN lines_NNS ._.
Moreover_RB ,_, kappa_NN 1_CD -_: kappa_NN 3_CD can_MD each_DT be_VB deleted_`` from_IN the_DT TNF-alpha_`` promoter_NN with_IN little_JJ effect_NN on_IN the_DT gene_NN 's_POS inducibility_NN by_IN PMA_NNP ._.
Therefore_RB ,_, TNF-alpha_NNP mRNA_NNP induction_`` by_IN PMA_NNP ,_, like_IN its_PRP$ induction_NN by_IN virus_NN and_CC LPS_NNP ,_, is_VBZ not_RB primarily_RB mediated_VBN by_IN NF-kappa_NNP B_NNP ,_, but_CC rather_RB is_VBZ mediated_VBN through_IN other_JJ sequences_NNS and_CC protein_NN factors_NNS ._.
Surprisingly_RB ,_, multimers_NNS of_IN kappa_NN 1_CD -_: kappa_NN 3_CD can_MD confer_VB PMA_NNP inducibility_`` on_IN a_DT heterologous_`` promoter_NN in_IN a_DT B_NNP (_-LRB- Raji_NNP )_-RRB- ,_, but_CC not_RB a_DT T_JJ (_-LRB- HUT78_NN )_-RRB- cell_NN line_NN ._.
However_RB they_PRP are_VBP not_RB functional_JJ on_IN a_DT truncated_# TNF-alpha_NNP promoter_NN ,_, indicating_VBG that_IN promoter_NN context_NN and_CC cell_NN type_NN specificity_NN influence_VBP the_DT PMA_`` inducible_JJ function_NN of_IN these_DT NF-kappa_NNP B_NNP binding_# sites_NNS ._.
Towards_IN a_DT molecular_JJ understanding_NN of_IN T-cell_JJ differentiation_NN ._.
Lymphoid_JJ differentiation_NN is_VBZ one_CD of_IN the_DT best_JJS studied_VBN examples_NNS of_IN mammalian_JJ development_NN ._.
Here_RB Hans_NNP Clevers_NNP and_CC Michael_NNP Owen_NNP describe_VBP how_WRB the_DT cloning_`` of_IN the_DT genes_NNS that_WDT encode_`` T-cell-specific_JJ membrane_NN proteins_NNS allows_VBZ the_DT identification_NN of_IN transcription_`` factors_NNS that_WDT control_VBP the_DT expression_NN of_IN these_DT T-cell_NNP genes_NNS ._.
Such_JJ transcription_NN factors_NNS play_VBP a_DT key_JJ role_NN in_IN the_DT development_NN of_IN the_DT mature_JJ T-cell_NNP phenotype_`` by_IN functioning_NN as_IN '_'' master_NN regulators_NNS of_IN T-cell_NNP differentiation_NN '_'' ._.
Regulation_NN of_IN jun_`` and_CC fos_`` gene_NN expression_NN in_IN human_JJ monocytes_NNS by_IN the_DT macrophage_`` colony-stimulating_JJ factor_NN ._.
The_DT macrophage_`` colony-stimulating_JJ factor_NN (_-LRB- M-CSF_NNP )_-RRB- is_VBZ required_VBN for_IN the_DT growth_NN and_CC differentiation_NN of_IN mononuclear_JJ phagocytes_NNS ._.
However_RB ,_, the_DT signaling_VBG events_NNS responsible_JJ for_IN these_DT effects_NNS remain_VBP unclear_JJ ._.
The_DT present_JJ studies_NNS have_VBP examined_VBN the_DT effects_NNS of_IN M-CSF_NNP on_IN potential_JJ signaling_NN pathways_NNS involving_VBG expression_NN of_IN the_DT jun_NN and_CC fos_`` early_JJ response_NN genes_NNS ._.
Low_NNP levels_NNS of_IN c-jun_`` transcripts_NNS were_VBD detectable_JJ in_IN resting_VBG human_JJ peripheral_JJ blood_NN monocytes_NNS ._.
Treatment_NNP of_IN these_DT cells_NNS with_IN 10(3)_CD units/ml_`` human_JJ recombinant_NN M-CSF_NNP was_VBD associated_VBN with_IN rapid_JJ and_CC transient_JJ increases_NNS in_IN c-jun_`` mRNA_`` levels_NNS ._.
Nuclear_JJ run-on_`` assays_NNS and_CC mRNA_`` stability_NN studies_NNS demonstrated_VBD that_IN M-CSF_NNP regulates_VBZ c-jun_JJ expression_NN by_IN both_DT an_DT increase_NN in_IN transcription_NN rate_NN and_CC a_DT prolongation_NN in_IN the_DT half-life_NN of_IN c-jun_`` transcripts_NNS ._.
M-CSF_JJ treatment_NN was_VBD also_RB associated_VBN with_IN a_DT rapid_JJ induction_NN of_IN the_DT jun-B_`` gene_NN ,_, although_IN expression_NN of_IN this_DT gene_NN was_VBD prolonged_VBN compared_VBN to_TO that_IN of_IN c-jun_NN ._.
We_PRP further_RB demonstrate_VBP that_IN M-CSF_`` increases_NNS c-fos_`` mRNA_`` levels_NNS in_IN human_JJ monocytes_NNS through_IN control_NN at_IN both_DT the_DT transcriptional_JJ and_CC posttranscriptional_JJ levels_NNS ._.
Maximal_-LRB- induction_NN of_IN the_DT c-fos_`` gene_NN was_VBD followed_VBN by_IN that_DT for_IN the_DT fos-B_JJ gene_NN ._.
Moreover_RB ,_, M-CSF-induced_JJ expression_NN of_IN the_DT fos-related_JJ gene_NN ,_, fra-1_'' ,_, was_VBD delayed_VBN compared_VBN to_TO that_IN for_IN both_DT c-fos_NNS and_CC fos-B_NN ._.
Taken_VBN together_RB ,_, the_DT results_NNS indicate_VBP that_IN M-CSF_JJ treatment_NN is_VBZ associated_VBN with_IN differential_JJ activation_NN of_IN multiple_JJ members_NNS of_IN the_DT jun/fos_`` family_NN and_CC that_IN expression_NN of_IN these_DT genes_NNS could_MD contribute_VB to_TO nuclear_JJ signaling_VBG mechanisms_NNS that_IN regulate_VB a_DT specific_JJ program_NN of_IN monocyte_`` differentiation_NN ._.
Cloning_NN of_IN a_DT human_JJ homeobox_NN gene_NN that_WDT resembles_VBZ a_DT diverged_VBN Drosophila_NNP homeobox_`` gene_NN and_CC is_VBZ expressed_VBN in_IN activated_`` lymphocytes_NNS ._.
A_DT new_JJ homeobox_NN gene_NN ,_, HB24_CD ,_, has_VBZ been_VBN isolated_VBN from_IN a_DT human_JJ B-lymphocyte_NNP cDNA_NNP library_NN ._.
Northern_JJ blot_JJ analysis_NN of_IN polyadenylated_# RNA_NNP purified_`` from_IN activated_`` human_JJ B_NN cells_NNS revealed_VBD a_DT single_JJ mRNA_`` transcript_NN of_IN approximately_RB 2.3_CD kb_`` ._.
Two_CD cDNA_`` clones_NNS were_VBD sequenced_VBN and_CC provided_VBN 2,250_CD nucleotides_NNS (_-LRB- nt_JJ )_-RRB- of_IN DNA_NNP sequence_NN information_NN ._.
There_EX is_VBZ a_DT single_JJ methionine_`` codon-initiated_`` open_JJ reading_NN frame_NN of_IN 1,458_CD nt_`` in_IN frame_NN with_IN a_DT homeobox_NN and_CC a_DT CAX_`` repeat_NN ,_, and_CC the_DT open_JJ reading_NN frame_NN is_VBZ predicted_VBN to_TO encode_VB a_DT protein_NN of_IN 51,659_CD daltons_NNS ._.
When_WRB the_DT homeodomain_NN from_IN HB24_NNP was_VBD compared_VBN to_TO known_VBN mammalian_`` and_CC Drosophila_# homeodomains_NNS it_PRP was_VBD found_VBN to_TO be_VB only_RB moderately_RB conserved_VBN ,_, but_CC when_WRB it_PRP was_VBD compared_VBN to_TO a_DT highly_RB diverged_VBN Drosophila_NNP homeodomain_`` ,_, H2.0_'' ,_, it_PRP was_VBD found_VBN to_TO be_VB 80_CD %_NN identical_JJ ._.
The_DT HB24_NNP mRNA_NNP was_VBD absent_JJ or_CC present_JJ at_IN low_JJ levels_NNS in_IN normal_JJ B_NNP and_CC T_NNP lymphocytes_NNS ;_: however_RB ,_, with_IN the_DT appropriate_JJ activation_NN signal_NN HB24_NNP mRNA_NNP was_VBD induced_VBN within_IN several_JJ hours_NNS even_RB in_IN the_DT presence_NN of_IN cycloheximide_NN ._.
Characterization_NN of_IN HB24_CD expression_NN in_IN lymphoid_JJ and_CC select_JJ developing_VBG tissues_NNS was_VBD performed_VBN by_IN in_IN situ_`` hybridization_NN ._.
Positive_JJ hybridization_NN was_VBD found_VBN in_IN thymus_NN ,_, tonsil_'' ,_, bone_NN marrow_NN ,_, developing_VBG vessels_NNS ,_, and_CC in_IN fetal_JJ brain_NN ._.
HB24_NN is_VBZ likely_JJ to_TO have_VB an_DT important_JJ role_NN in_IN lymphocytes_NNS as_RB well_RB as_IN in_IN certain_JJ developing_VBG tissues_NNS ._.
Severe_JJ 5-fluorouracil_JJ toxicity_NN secondary_JJ to_TO dihydropyrimidine_`` dehydrogenase_VB deficiency_NN ._.
A_DT potentially_RB more_RBR common_JJ pharmacogenetic_JJ syndrome_NN ._.
This_DT study_NN describes_VBZ the_DT inheritance_NN of_IN a_DT defect_`` in_IN pyrimidine_NN catabolism_NN and_CC its_PRP$ association_NN with_IN drug-induced_JJ toxicity_NN in_IN a_DT patient_NN receiving_VBG 5-fluorouracil_`` (_-LRB- FUra_NNP )_-RRB- as_IN adjuvant_JJ chemotherapy_NN for_IN breast_NN carcinoma_NN ._.
The_DT study_NN population_NN included_VBD the_DT affected_JJ patient_NN (_-LRB- proband_NN )_-RRB- ,_, nine_CD of_IN her_PRP$ blood_NN relatives_NNS ,_, and_CC seven_CD healthy_JJ volunteers_NNS ._.
The_DT activity_NN of_IN dihydropyrimidine_`` dehydrogenase_`` (_-LRB- DPD_NNP )_-RRB- ,_, the_DT initial_JJ enzyme_NN of_IN pyrimidine_`` (_-LRB- and_CC FUra_NNP )_-RRB- catabolism_NN ,_, in_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS was_VBD measured_VBN in_IN each_DT subject_NN by_IN a_DT specific_JJ radiometric_JJ assay_NN using_VBG FUra_NNP as_IN the_DT substrate_NN ._.
The_DT proband_NN had_VBD no_DT detectable_JJ DPD_NNP activity_NN ._.
When_WRB enzyme_`` levels_NNS in_IN the_DT proband_NN and_CC relatives_NNS were_VBD compared_VBN with_IN that_DT in_IN controls_NNS ,_, an_DT autosomal_JJ recessive_JJ pattern_NN of_IN inheritance_NN was_VBD demonstrated_VBN ._.
This_DT is_VBZ the_DT third_JJ patient_NN with_IN severe_JJ FUra_NNP toxicity_NN secondary_JJ to_TO an_DT alteration_NN in_IN pyrimidine_NN catabolism_NN and_CC the_DT second_NN from_IN our_PRP$ clinic_NN population_NN suggesting_VBG that_IN the_DT frequency_NN of_IN this_DT genetic_JJ defect_NN may_MD be_VB greater_JJR than_IN previously_RB thought_VBN ._.
Monitoring_NNP DPD_NNP activity_NN may_MD be_VB important_JJ in_IN the_DT management_NN of_IN patients_NNS experiencing_VBG severe_JJ toxicity_NN secondary_JJ to_TO FUra_NNP chemotherapy_NN ._.
Characterization_NN of_IN an_DT immediate-early_JJ gene_NN induced_`` in_IN adherent_`` monocytes_NNS that_WDT encodes_VBZ I_PRP kappa_`` B-like_JJ activity_NN ._.
We_PRP have_VBP cloned_`` a_DT group_NN of_IN cDNAs_`` representing_VBG mRNAs_`` that_WDT are_VBP rapidly_RB induced_`` following_VBG adherence_NN of_IN human_JJ monocytes_NNS ._.
One_CD of_IN the_DT induced_`` transcripts_NNS (_-LRB- MAD-3_NN )_-RRB- encodes_VBZ a_DT protein_NN of_IN 317_CD amino_JJ acids_NNS with_IN one_CD domain_NN containing_VBG five_CD tandem_`` repeats_NNS of_IN the_DT cdc10/ankyrin_NN motif_NN ,_, which_WDT is_VBZ 60_CD %_NN similar_JJ (_-LRB- 46_CD %_NN identical_JJ )_-RRB- to_TO the_DT ankyrin_`` repeat_NN region_NN of_IN the_DT precursor_NN of_IN NF-kappa_NNP B/KBF1_NNP p50_NN ._.
The_DT C-terminus_NN has_VBZ a_DT putative_JJ protein_NN kinase_`` C_$ phosphorylation_`` site_NN ._.
In_IN vitro_`` translated_VBN MAD-3_JJ protein_NN was_VBD found_VBN to_TO specifically_RB inhibit_VB the_DT DNA-binding_`` activity_NN of_IN the_DT p50/p65_NN NF-kappa_NNP B_NNP complex_JJ but_CC not_RB that_IN of_IN the_DT p50/p50_NN KBF1_`` factor_NN or_CC of_IN other_JJ DNA-binding_JJ proteins_NNS ._.
The_DT MAD-3_NN cDNA_`` encodes_VBZ an_DT I_PRP kappa_`` B-like_JJ protein_NN that_WDT is_VBZ likely_JJ to_TO be_VB involved_VBN in_IN regulation_NN of_IN transcriptional_JJ responses_NNS to_TO NF-kappa_NNP B_NNP ,_, including_VBG adhesion-dependent_JJ pathways_`` of_IN monocyte_`` activation_NN ._.
Reactive_JJ oxygen_NN intermediates_`` as_IN apparently_RB widely_RB used_VBN messengers_NNS in_IN the_DT activation_NN of_IN the_DT NF-kappa_NNP B_NNP transcription_NN factor_NN and_CC HIV-1_NN ._.
Hydrogen_NN peroxide_NN and_CC oxygen_NN radicals_NNS are_VBP agents_NNS commonly_RB produced_VBN during_IN inflammatory_JJ processes_NNS ._.
In_IN this_DT study_NN ,_, we_PRP show_VBP that_IN micromolar_JJ concentrations_NNS of_IN H2O2_NNP can_MD induce_VB the_DT expression_NN and_CC replication_NN of_IN HIV-1_NNP in_IN a_DT human_JJ T_JJ cell_NN line_NN ._.
The_DT effect_NN is_VBZ mediated_VBN by_IN the_DT NF-kappa_NNP B_NNP transcription_NN factor_NN which_WDT is_VBZ potently_RB and_CC rapidly_RB activated_`` by_IN an_DT H2O2_`` treatment_NN of_IN cells_NNS from_IN its_PRP$ inactive_JJ cytoplasmic_JJ form_NN ._.
N-acetyl-L-cysteine_# (_-LRB- NP_NNP )_-RRB- ,_, a_DT well_RB characterized_VBN antioxidant_`` which_WDT counteracts_VBZ the_DT effects_NNS of_IN reactive_`` oxygen_NN intermediates_VBZ (_-LRB- ROI_NNP )_-RRB- in_IN living_VBG cells_NNS ,_, prevented_VBD the_DT activation_NN of_IN NF-kappa_NNP B_NNP by_IN H2O2_NNP ._.
NP_NNP and_CC other_JJ thiol_`` compounds_NNS also_RB blocked_VBD the_DT activation_NN of_IN NF-kappa_NNP B_NNP by_IN cycloheximide_`` ,_, double-stranded_JJ RNA_NNP ,_, calcium_'' ionophore_NN ,_, TNF-alpha_NNP ,_, active_JJ phorbol_NN ester_NN ,_, interleukin-1_NN ,_, lipopolysaccharide_NN and_CC lectin_NN ._.
This_DT suggests_VBZ that_IN diverse_JJ agents_NNS thought_VBD to_TO activate_VB NF-kappa_NNP B_NNP by_IN distinct_JJ intracellular_JJ pathways_`` might_MD all_DT act_VB through_IN a_DT common_JJ mechanism_NN involving_VBG the_DT synthesis_NN of_IN ROI_NNP ._.
ROI_-LRB- appear_VB to_TO serve_VB as_IN messengers_NNS mediating_VBG directly_RB or_CC indirectly_RB the_DT release_NN of_IN the_DT inhibitory_JJ subunit_NN I_PRP kappa_VBP B_NNP from_IN NF-kappa_NNP B_NNP ._.
HTLV-1_NN Tax_NNP induces_VBZ expression_NN of_IN various_JJ immediate_JJ early_JJ serum_NN responsive_JJ genes_NNS ._.
Human_NNP T-cell_NNP leukemia_`` virus_NN type_NN 1_CD (_-LRB- HTLV-1_NNP )_-RRB- is_VBZ an_DT etiological_JJ agent_NN of_IN adult_NN T-cell_NNP leukemia_`` (_-LRB- ATL_NNP )_-RRB- ._.
We_PRP showed_VBD here_RB by_IN mobility-shift_JJ assay_NN that_IN T-cell_`` lines_NNS transformed_VBN with_IN the_DT virus_NN contained_VBD high_JJ levels_NNS of_IN AP-1_NNP activities_NNS ._.
Consistent_-LRB- with_IN this_DT result_NN ,_, these_DT cell_NN lines_NNS expressed_VBN increased_VBN levels_NNS of_IN mRNAs_`` encoding_`` the_DT AP-1_`` proteins_NNS ,_, c-Fos_# ,_, Fra-1_NNP ,_, c-Jun_NNP ,_, JunB_NNP ,_, and_CC JunD_NNP ._.
Previously_RB ,_, transcription_NN of_IN the_DT c-fos_`` gene_NN has_VBZ been_VBN reported_VBN to_TO be_VB transactivated_VBN by_IN the_DT viral_JJ transcription_NN factor_NN ,_, Tax1_NN ._.
By_IN using_VBG the_DT human_JJ T-cell_NNP line_NN (_-LRB- JPX-9_-RRB- )_-RRB- ,_, in_IN which_WDT expression_NN of_IN the_DT Tax1_NN is_VBZ inducible_JJ ,_, we_PRP showed_VBD that_IN expression_NN of_IN mRNAs_`` for_IN Fra-1_NNP ,_, c-Jun_NNP ,_, and_CC JunD_NNP was_VBD also_RB transactivated_VBN by_IN Tax1_NN ._.
Moreover_RB ,_, Tax1_'' activated_`` expression_NN of_IN two_CD other_JJ transcription_NN factors_NNS having_VBG zinc_`` finger_NN motifs_NNS ,_, Egr-1_-RRB- and_CC Egr-2_# ,_, in_IN the_DT same_JJ cells_NNS ._.
The_DT Tax1-inducible_JJ transcription_NN factors_NNS identified_VBN here_RB are_VBP encoded_VBN by_IN the_DT members_NNS of_IN immediate_JJ early_JJ genes_NNS under_IN the_DT control_NN of_IN growth_NN signals_NNS ._.
Thus_RB ,_, Tax1_NN was_VBD suggested_VBN to_TO replace_VB growth_NN signals_NNS ,_, at_IN least_JJS in_IN part_NN ,_, by_IN this_DT mechanism_NN ._.
Contribution_NN of_IN NF-kappa_NNP B_NNP and_CC Sp1_NNP binding_`` motifs_`` to_TO the_DT replicative_JJ capacity_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD :_: distinct_JJ patterns_NNS of_IN viral_JJ growth_NN are_VBP determined_VBN by_IN T-cell_JJ types_NNS ._.
Starting_VBG with_IN a_DT replication-incompetent_JJ molecular_JJ clone_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ,_, lacking_VBG all_PDT the_DT NF-kappa_NNP B_NNP and_CC Sp1_NNP binding_# sites_NNS present_VBP in_IN the_DT native_JJ long_JJ terminal_NN repeat_NN (_-LRB- LTR_NNP )_-RRB- ,_, proviruses_VBZ containing_VBG reconstructed_`` LTRs_`` with_IN individual_JJ or_CC combinations_NNS of_IN NF-kappa_NNP B_NNP and_CC Sp1_NNP elements_NNS were_VBD generated_VBN and_CC evaluated_`` for_IN their_PRP$ capacity_NN to_TO produce_VB virus_NN progeny_NN following_VBG transfection-cocultivation_NN ._.
Virus_NN stocks_NNS obtained_VBN from_IN these_DT experiments_NNS exhibited_VBD a_DT continuum_NN of_IN replicative_JJ capacities_NNS in_IN different_JJ human_JJ T-cell_`` types_NNS depending_VBG on_IN which_WDT element_NN (_-LRB- s_PRP )_-RRB- was_VBD present_JJ in_IN the_DT LTR_NNP ._.
For_IN example_NN ,_, in_IN experiments_NNS involving_VBG proviral_`` clones_`` with_IN LTRs_NNS containing_VBG one_CD or_CC two_CD NF-kappa_NNP B_NNP elements_NNS (_-LRB- and_CC no_DT Sp1_`` binding_`` sites_NNS )_-RRB- ,_, a_DT hierarchy_NN of_IN cellular_JJ permissivity_NN to_TO virus_NN replication_`` (_-LRB- peripheral_JJ blood_NN lymphocytes_NNS =_SYM MT4_CD greater_JJR than_IN H9_CD greater_JJR than_IN CEM_`` greater_JJR than_IN Jurkat_NNP )_-RRB- was_VBD observed_VBN ._.
Of_IN note_NN was_VBD the_DT associated_VBN emergence_NN of_IN second-site_JJ LTR_`` revertants_NNS which_WDT involved_VBD an_DT alteration_NN of_IN the_DT TATA_NNP box_NN ._.
These_DT results_NNS suggest_VBP that_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD LTR_NNP possesses_`` functional_JJ redundancy_NN which_WDT ensures_VBZ virus_NN replication_`` in_IN different_JJ T-cell_`` types_NNS and_CC is_VBZ capable_JJ of_IN changing_VBG depending_VBG on_IN the_DT particular_JJ combination_NN of_IN transcriptional_JJ factors_NNS present_JJ ._.
Enhancement_NN of_IN human_JJ immunodeficiency_NN virus_NN 1_CD replication_NN in_IN monocytes_NNS by_IN 1,25-dihydroxycholecalciferol_`` ._.
Human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV_NNP )_-RRB- expression_NN and_CC replication_NN are_VBP under_IN tight_JJ regulatory_JJ control_NN ._.
We_PRP demonstrate_VBP that_IN 1,25-dihydroxycholecalciferol_JJ (_-LRB- 1,25-(OH)2D3_-RRB- )_-RRB- enhances_VBZ the_DT replication_NN of_IN monocyte-_`` and_CC lymphocyte-tropic_JJ strains_NNS of_IN HIV-1_`` up_RP to_TO 10,000-fold_`` in_IN monocyte_# cell_NN lines_NNS ,_, peripheral_JJ blood_NN monocytes_`` ,_, and_CC unfractionated_`` peripheral_JJ blood_NN mononuclear_JJ cells_NNS ._.
1,25(OH)2D3_-LRB- is_VBZ therefore_RB one_CD of_IN the_DT most_RBS potent_JJ regulators_NNS of_IN HIV-1_`` replication_`` described_VBN to_TO date_NN ._.
Precursors_NNS of_IN 1,25(OH)2D3_CD enhance_VB HIV-1_NNP replication_`` in_IN proportion_NN to_TO their_PRP$ affinity_NN for_IN the_DT 1,25(OH)2D3_NNP intracellular_`` receptor_NN ,_, suggesting_VBG that_IN 1,25(OH)2D3_NNP influences_VBZ HIV-1_`` replication_`` by_IN mechanisms_NNS involving_VBG this_DT receptor_NN ._.
These_DT studies_NNS may_MD have_VB important_JJ implications_NNS for_IN the_DT design_NN of_IN effective_JJ therapy_NN of_IN HIV-1_JJ infection_NN ._.
Inhibition_NN of_IN HIV-1_NNP replication_`` and_CC NF-kappa_-RRB- B_NNP activity_NN by_IN cysteine_`` and_CC cysteine_`` derivatives_NNS ._.
HIV-1_JJ proviral_`` DNA_NNP contains_VBZ two_CD binding_JJ sites_NNS for_IN the_DT transcription_NN factor_NN NF-kappa_NNP B_NNP ._.
HIV-1-infected_JJ individuals_NNS have_VBP ,_, on_IN average_NN ,_, abnormally_RB high_JJ levels_NNS of_IN tumour_`` necrosis_`` factor_NN alpha_NN (_-LRB- TNF_`` alpha_NN )_-RRB- and_CC abnormally_RB low_JJ plasma_NN cysteine_NN levels_NNS ._.
We_PRP therefore_RB investigated_VBD the_DT effects_NNS of_IN cysteine_`` and_CC related_VBN thiols_NNS on_IN HIV-1_NNP replication_`` and_CC NF-kappa_-RRB- B_NNP expression_NN ._.
The_DT experiments_NNS in_IN this_DT report_NN show_NN that_IN cysteine_`` or_CC N-acetylcysteine_# (_-LRB- NP_NNP )_-RRB- raise_VB the_DT intracellular_JJ glutathione_NN (_-LRB- GSH_NNP )_-RRB- level_NN and_CC inhibit_VB HIV-1_NNP replication_`` in_IN persistently_RB infected_JJ Molt-4_-RRB- and_CC U937_CD cells_NNS ._.
However_RB ,_, inhibition_NN of_IN HIV-1_NNP replication_NN appears_VBZ not_RB to_TO be_VB directly_RB correlated_VBN with_IN GSH_NNP levels_NNS ._.
Cysteine_NNP and_CC NP_NNP also_RB inhibit_VB NF-kappa_NNP B_NNP activity_NN as_IN determined_VBN by_IN electrophoretic_`` mobility_JJ shift_NN assays_NNS and_CC chloramphenicol_NN acetyl-transferase_# (_-LRB- CAT_NN )_-RRB- gene_NN expression_NN under_IN control_NN of_IN NF-kappa_NNP B_NNP binding_# sites_NNS in_IN uninfected_JJ cells_NNS ._.
This_DT suggests_VBZ that_IN the_DT cysteine_`` deficiency_NN in_IN HIV-1-infected_JJ individuals_NNS may_MD cause_VB an_DT over-expression_NN of_IN NF-kappa_`` B-dependent_JJ genes_NNS and_CC enhance_VB HIV-1_NNP replication_NN ._.
NP_NNP may_MD be_VB considered_VBN for_IN the_DT treatment_NN of_IN HIV-1-infected_JJ individuals_NNS ._.
Glucocorticoid_JJ receptors_NNS in_IN systemic_JJ lupus_NN erythematosus_NN ._.
Glucocorticosteroids_NNS remain_VBP the_DT major_JJ treatment_NN modality_NN for_IN systemic_JJ lupus_NN erythematosus_`` (_-LRB- SLE_NNP )_-RRB- ,_, but_CC their_PRP$ mechanism_NN of_IN action_NN is_VBZ unclear_JJ ._.
Over_IN the_DT past_JJ decade_NN it_PRP has_VBZ become_VBN clear_JJ that_IN glucocorticosteroid_`` receptors_NNS play_VBP a_DT significant_JJ role_NN in_IN the_DT mechanism_NN of_IN glucocorticosteroid_JJ action_NN ._.
We_PRP studied_VBD glucocorticosteroid_`` receptor_NN density_NN and_CC affinity_NN on_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS by_IN the_DT glucocorticosteroid_`` binding_JJ assay_NN in_IN 33_CD patients_NNS with_IN SLE_NNP who_WP had_VBD taken_VBN no_DT glucocorticosteroid_`` for_IN the_DT previous_JJ 6_CD months_NNS and_CC in_IN 32_CD healthy_JJ controls_NNS ._.
Patients_# '_'' disease_NN activity_NN was_VBD measured_VBN by_IN the_DT SLE_NNP Disease_NNP Activity_NNP Index_NNP (_-LRB- SLEDAI_NNP )_-RRB- ._.
Glucocorticosteroid_NNP receptors_`` on_IN leukocytes_NNS of_IN patients_NNS with_IN SLE_NNP were_VBD significantly_RB higher_JJR than_IN in_IN healthy_JJ controls_NNS (_-LRB- 4419_CD +/-_`` 306_CD vs_NNS 3369_CD +/-_`` 196_CD ,_, p_NN less_JJR than_IN 0.005_CD )_-RRB- ._.
The_DT binding_JJ affinity_NN was_VBD not_RB different_JJ between_IN patients_NNS and_CC controls_NNS ._.
There_EX was_VBD no_DT correlation_NN between_IN glucocorticosteroid_`` receptor_NN number_NN and_CC SLE_`` disease_NN activity_NN ._.
(_-LRB- Changes_`` in_IN leucocytic_JJ estrogen_NN receptor_NN levels_NNS in_IN patients_NNS with_IN gynecomastia_NN )_-RRB-
The_DT number_NN of_IN estrogen_NN receptor_NN (_-LRB- ER_NNP )_-RRB- in_IN human_JJ peripheral_`` leucocytes_NNS in_IN 13_CD men_NNS with_IN gynecomastia_NN were_VBD measured_VBN by_IN radioligand_`` binding_JJ method_NN ._.
The_DT results_NNS were_VBD compared_VBN with_IN those_DT of_IN 13_CD sex-_JJ and_CC age-matched_JJ healthy_JJ subjects_NNS ._.
It_PRP was_VBD found_VBN that_IN the_DT number_NN of_IN ER_NNP in_IN leucocytes_NNS was_VBD significantly_RB increased_VBN in_IN gynecomastia_`` (_-LRB- Rs_`` of_IN leucocytes_NNS were_VBD 1054_CD +/-_`` 254_CD sites/cell_`` )_-RRB- ._.
It_PRP suggested_VBD that_IN increase_NN of_IN ER_NNP levels_NNS play_VBP an_DT important_JJ role_NN in_IN the_DT pathogenesis_NN of_IN gynecomastia_NN ._.
(_-LRB- Changes_`` in_IN levels_NNS of_IN leucocytic_JJ estrogen_NN receptor_NN in_IN patients_NNS with_IN menopausal_JJ type_NN II_NNP diabetes_`` and_CC its_PRP$ significance_NN )_-RRB-
The_DT number_NN of_IN estrogen_NN receptors_NNS (_-LRB- ER_NNP )_-RRB- in_IN human_JJ peripheral_`` leucocytes_NNS in_IN 12_CD women_NNS with_IN menopausal_JJ type_NN II_NNP diabetes_NN was_VBD measured_VBN with_IN radio-ligand_`` binding_JJ method_NN ._.
The_DT results_NNS were_VBD compared_VBN with_IN those_DT of_IN 12_CD menopausal_JJ women_NNS without_IN diabetes_NN and_CC 12_CD normal_JJ women_NNS of_IN childbearing_VBG age_NN ._.
It_PRP was_VBD found_VBN that_IN the_DT number_NN of_IN ER_JJR in_IN the_DT patients_NNS was_VBD significantly_RB decreased_VBN ._.
Our_PRP$ data_NNS indicate_VBP that_IN decrease_NN of_IN ER_NNP level_NN in_IN leukocytes_NNS may_MD be_VB related_VBN to_TO the_DT pathogenesis_NN of_IN type_NN II_NNP diabetes_`` in_IN menopausal_JJ period_NN ._.
Lymphocyte_NNP glucocorticoid_`` receptor_NN binding_`` during_IN depression_NN and_CC after_IN clinical_JJ recovery_NN ._.
Lymphocyte_NNP glucocorticoid_`` receptor_NN binding_JJ parameters_NNS were_VBD studied_VBN in_IN 15_CD severely_RB depressed_JJ patients_NNS during_IN depression_NN and_CC after_IN clinical_JJ recovery_NN ,_, and_CC in_IN 15_CD healthy_JJ controls_NNS ._.
There_EX was_VBD no_DT difference_NN in_IN glucocorticoid_JJ receptor_NN number_NN or_CC affinity_NN between_IN depressed_JJ patients_NNS and_CC recovered_VBD or_CC control_NN subjects_NNS ._.
Afternoon_RB ACTH_`` and_CC cortisol_`` concentrations_NNS did_VBD not_RB differ_VB significantly_RB between_IN the_DT three_CD groups_NNS ._.
No_DT relationship_NN could_MD be_VB established_VBN between_IN glucocorticoid_NN receptor_NN binding_# and_CC antidepressant_JJ medication_NN ._.
These_DT data_NNS support_VBP the_DT view_NN of_IN an_DT impaired_JJ ligand-induced_JJ plasticity_NN of_IN glucocorticoid_NN receptor_NN regulation_NN rather_RB than_IN the_DT hypothesis_NN of_IN decreased_VBN glucocorticoid_NN receptor_NN numbers_NNS during_IN depression_NN ._.
Nuclear_JJ association_NN of_IN a_DT T-cell_JJ transcription_NN factor_NN blocked_VBN by_IN FK-506_NNP and_CC cyclosporin_`` A_DT (_-LRB- see_VB comments_NNS )_-RRB-
Cyclosporin_# A_DT and_CC FK506_NNP inhibit_VBP T-_NNS and_CC B-cell_`` activation_NN and_CC other_JJ processes_NNS essential_JJ to_TO an_DT effective_JJ immune_JJ response_NN ._.
In_IN T_JJ lymphocytes_NNS these_DT drugs_NNS disrupt_VB an_DT unknown_JJ step_NN in_IN the_DT transmission_NN of_IN signals_NNS from_IN the_DT T-cell_`` antigen_NN receptor_NN to_TO cytokine_`` genes_NNS that_WDT coordinate_VBP the_DT immune_JJ response_NN ._.
The_DT putative_JJ intracellular_JJ receptors_NNS for_IN FK506_NNP and_CC cyclosporin_`` are_VBP cis-trans_`` prolyl_`` isomerases_NNS ._.
Binding_-RRB- of_IN the_DT drug_NN inhibits_`` isomerase_`` activity_NN ,_, but_CC studies_NNS with_IN other_JJ prolyl_`` isomerase_`` inhibitors_NNS and_CC analysis_NN of_IN cyclosporin-resistant_JJ mutants_NNS in_IN yeast_NN suggest_VBP that_IN the_DT effects_NNS of_IN the_DT drug_NN result_NN from_IN the_DT formation_NN of_IN an_DT inhibitory_JJ complex_NN between_IN the_DT drug_NN and_CC isomerase_`` ,_, and_CC not_RB from_IN inhibition_NN of_IN isomerase_# activity_NN ._.
A_DT transcription_NN factor_NN ,_, NF-AT_# ,_, which_WDT is_VBZ essential_JJ for_IN early_RB T-cell_JJ gene_NN activation_NN ,_, seems_VBZ to_TO be_VB a_DT specific_JJ target_NN of_IN cyclosporin_`` A_DT and_CC FK506_`` action_NN because_IN transcription_NN directed_VBN by_IN this_DT protein_NN is_VBZ blocked_VBN in_IN T_JJ cells_NNS treated_VBN with_IN these_DT drugs_NNS ,_, with_IN little_JJ or_CC no_DT effect_NN on_IN other_JJ transcription_`` factors_NNS such_JJ as_IN AP-1_NNP and_CC NF-kappa_NNP B_NNP ._.
Here_RB we_PRP demonstrate_VBP that_IN NF-AT_NN is_VBZ formed_VBN when_WRB a_DT signal_NN from_IN the_DT antigen_NN receptor_NN induces_VBZ a_DT pre-existing_JJ cytoplasmic_JJ subunit_NN to_TO translocate_VB to_TO the_DT nucleus_`` and_CC combine_VB with_IN a_DT newly_RB synthesized_VBN nuclear_JJ subunit_NN of_IN NF-AT_`` ._.
FK506_NNP and_CC cyclosporin_`` A_DT block_NN translocation_NN of_IN the_DT cytoplasmic_JJ component_NN without_IN affecting_VBG synthesis_NN of_IN the_DT nuclear_JJ subunit_NN ._.
Regulation_NN of_IN M-CSF_JJ expression_NN by_IN M-CSF_`` :_: role_NN of_IN protein_NN kinase_`` C_$ and_CC transcription_`` factor_NN NF_NNP kappa_`` B_NNP ._.
Macrophage-colony-stimulating_JJ factor_NN (_-LRB- M-CSF_NNP )_-RRB- ,_, also_RB referred_VBD to_TO as_IN CSF-1_NNP ,_, regulates_VBZ the_DT survival_NN ,_, growth_NN ,_, differentiation_-RRB- and_CC functional_JJ activity_NN of_IN monocytes_NNS by_IN binding_`` to_TO a_DT single_JJ class_NN of_IN high-affinity_`` cell_NN surface_NN receptors_NNS ,_, known_VBN to_TO be_VB the_DT product_NN of_IN the_DT c-fms_`` protooncogene_NN ._.
The_DT detection_NN of_IN both_DT M-CSF_NNP and_CC c-fms_`` expression_NN by_IN cells_NNS of_IN the_DT monocyte_NN lineage_NN has_VBZ suggested_VBN that_IN M-CSF_NNP may_MD act_VB by_IN an_DT autocrine_NN mechanism_NN ._.
Interestingly_RB ,_, it_PRP has_VBZ been_VBN shown_VBN that_IN M-CSF_NNP can_MD induce_VB the_DT expression_NN of_IN its_PRP$ own_JJ gene_NN ._.
Although_IN sensitivity_NN to_TO M-CSF_NNP can_MD be_VB modulated_VBN by_IN regulation_NN of_IN receptor_NN expression_NN and_CC function_NN ,_, M-CSF_'' responsiveness_NN is_VBZ largely_RB determined_VBN at_IN a_DT postreceptor_NN level_NN ._.
To_TO date_NN ,_, little_JJ is_VBZ known_VBN about_IN the_DT intracellular_JJ pathway_NN of_IN M-CSF_JJ signal_NN transduction_NN ._.
We_PRP have_VBP therefore_RB investigated_VBN the_DT changes_NNS in_IN protein_NN kinase_`` C_$ (_-LRB- PKC_NNP )_-RRB- activity_NN upon_IN exposure_NN of_IN monocytes_NNS to_TO M-CSF_NNP ._.
We_PRP show_VBP that_IN M-CSF_JJ activates_NNS and_CC translocates_`` PKC_NNP ._.
Inhibition_NN of_IN PKC_NNP by_IN the_DT isoquinoline_`` derivative_JJ H7_NN abolishes_`` induction_NN of_IN M-CSF_NNP by_IN M-CSF_NNP ._.
Furthermore_RB ,_, activation_NN of_IN PKC_NNP was_VBD pertussis-toxin-sensitive_JJ and_CC was_VBD associated_VBN with_IN the_DT detection_NN of_IN an_DT NF_NNP kappa_NN B_NNP protein_NN in_IN nuclear_JJ extracts_NNS of_IN M-CSF-induced_JJ blood_NN monocytes_NNS but_CC not_RB in_IN monocytes_NNS exposed_VBN to_TO medium_NN treatment_NN only_RB ._.
The_DT results_NNS suggest_VBP that_IN M-CSF_JJ induction_NN of_IN M-CSF_NNP involves_VBZ G_NNP proteins_NNS ,_, PKC_NNP and_CC NF_NNP kappa_`` B_NNP ._.
NF-kappa_NNP B_NNP activation_`` by_IN tumor_NN necrosis_`` factor_NN alpha_NN in_IN the_DT Jurkat_`` T_JJ cell_NN line_NN is_VBZ independent_JJ of_IN protein_NN kinase_`` A_DT ,_, protein_NN kinase_`` C_NN ,_, and_CC Ca(2+)-regulated_JJ kinases_NNS ._.
NF-kappa_NNP B_NNP is_VBZ a_DT DNA-binding_`` regulatory_JJ factor_NN able_JJ to_TO control_VB transcription_NN of_IN a_DT number_NN of_IN genes_NNS ,_, including_VBG human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV_NNP )_-RRB- genes_NNS ._.
In_IN T_JJ cells_NNS ,_, NF-kappa_NNP B_NNP is_VBZ activated_VBN upon_IN cellular_JJ treatment_NN by_IN phorbol_`` esters_NNS and_CC the_DT cytokine_JJ tumor_NN necrosis_`` factor_NN alpha_NN (_-LRB- TNF_`` alpha_NN )_-RRB- ._.
In_IN the_DT present_JJ work_NN ,_, we_PRP investigated_VBD the_DT molecular_JJ events_NNS leading_VBG to_TO NF-kappa_NNP B_NNP activation_`` by_IN TNF_NNP alpha_NN in_IN a_DT human_JJ T_JJ cell_NN line_NN (_-LRB- Jurkat_NNP )_-RRB- and_CC its_PRP$ subclone_`` JCT6_NNP ,_, which_WDT presents_VBZ a_DT deficiency_NN in_IN the_DT PKA_`` transduction_NN pathway_NN ._.
We_PRP found_VBD that_IN in_IN both_DT cell_NN lines_NNS ,_, both_DT phorbol_`` ester_`` and_CC TNF_`` alpha_NN were_VBD able_JJ to_TO activate_VB NF-kappa_NNP B_NNP ._.
Phorbol_NNP activation_NN was_VBD positively_RB modulated_VBN by_IN Ca2+_NNP influx_NN while_IN TNF_JJ alpha_NN activation_NN was_VBD not_RB ._.
Furthermore_RB ,_, while_IN PMA_NNP activation_NN was_VBD inhibited_VBN by_IN the_DT PKC_NNP inhibitor_`` staurosporin_`` ,_, the_DT TNF_`` alpha_NN effect_NN was_VBD unchanged_JJ ._.
TNF_-LRB- alpha_NN did_VBD not_RB activate_`` cAMP_`` production_NN and_CC its_PRP$ signal_NN was_VBD not_RB modulated_VBN by_IN cAMP_NNP activators_NNS ._.
Moreover_RB ,_, cAMP_NNP activators_NNS did_VBD not_RB activate_`` NF-kappa_# B_NNP in_IN Jurkat_NNP cells_NNS ._.
Thus_RB ,_, TNF_'' alpha-induced_`` NF-kappa_-RRB- B_NNP activation_NN was_VBD found_VBN to_TO be_VB mediated_VBN by_IN none_NN of_IN the_DT major_JJ signal-mediating_`` kinases_NNS such_JJ as_IN protein_NN kinase_`` C_$ (_-LRB- PKC_NNP )_-RRB- ,_, protein_NN kinase_`` A_DT ,_, or_CC Ca(2+)-regulated_JJ kinases_NNS ._.
Furthermore_RB ,_, we_PRP found_VBD that_IN cytoplasmic_JJ acidification_NN facilitated_# NF-kappa_NNP B_NNP activation_`` by_IN both_DT TNF_NNP alpha_`` and_CC PKC_`` ,_, by_IN a_DT mechanism_NN that_WDT increases_VBZ NF-kappa_NNP B/I_NNP kappa_FW B_NNP dissociation_NN without_IN affecting_VBG the_DT NF-kappa_NNP B_NNP translocation_`` step_NN ._.
NF-kappa_NNP B_NNP activity_NN in_IN T_JJ cells_NNS stably_RB expressing_VBG the_DT Tax_NNP protein_NN of_IN human_JJ T_JJ cell_NN lymphotropic_`` virus_NN type_NN I_PRP ._.
The_DT effect_NN of_IN constitutive_JJ Tax_NNP expression_NN on_IN the_DT interaction_NN of_IN NF-kappa_NNP B_NNP with_IN its_PRP$ recognition_NN sequence_NN and_CC on_IN NF-kappa_NNP B-dependent_NNP gene_NN expression_NN was_VBD examined_VBN in_IN T_`` lymphoid_JJ Jurkat_NNP cell_NN lines_NNS (_-LRB- 19D_CD and_CC 9J_CD )_-RRB- stably_RB transformed_VBN with_IN a_DT Tax_NNP expression_NN vector_NN ._.
Tax_NNP expressing_VBG T_JJ cell_NN lines_NNS contained_VBD a_DT constitutive_JJ level_NN of_IN NF-kappa_NNP B_NNP binding_`` activity_NN ,_, detectable_JJ by_IN mobility_`` shift_VB assay_VB and_CC uv_`` cross-linking_`` using_VBG a_DT palindromic_JJ NF-kappa_NNP B_NNP probe_NN homologous_'' to_TO the_DT interferon_`` beta_JJ PRDII_NNP site_NN ._.
In_IN Jurkat_NNP and_CC NC2.10_NNP induction_`` with_IN phorbol_`` esters_NNS resulted_VBD in_IN the_DT appearance_NN of_IN new_JJ DNA_NNP binding_`` proteins_NNS of_IN 85_CD ,_, 75_CD ,_, and_CC 54_CD kDa_NNP ,_, whereas_IN in_IN Tax_NNP expressing_VBG cells_NNS the_DT 85-kDa_JJ protein_NN and_CC a_DT 92-kDa_NNP DNA_NNP binding_`` protein_NN were_VBD constitutively_RB induced_VBN ._.
Expression_NN of_IN Tax_NNP protein_NN in_IN 19D_CD and_CC 9J_CD resulted_VBD in_IN transcription_NN of_IN the_DT endogenous_JJ NF-kappa_NNP B-dependent_NNP granulocyte-macrophage_JJ colony_NN stimulating_`` factor_NN gene_NN and_CC increased_VBD basal_JJ level_NN expression_NN of_IN transfected_`` NF-kappa_NNP B-regulated_NNP promoters_NNS ._.
Nonetheless_RB transcription_`` of_IN both_DT the_DT endogenous_JJ and_CC the_DT transfected_VBN gene_NN was_VBD inducible_`` by_IN PMA_NNP treatment_NN ._.
Tax_NNP expression_NN in_IN Jurkat_`` T_JJ cells_NNS may_MD alter_VB the_DT stoichiometry_NN of_IN NF-kappa_NNP B_NNP DNA_NNP binding_# proteins_NNS and_CC thus_RB change_VB the_DT expression_NN of_IN NF-kappa_NNP B-regulated_NNP promoters_NNS ._.
Regulation_NN of_IN glucocorticoid_JJ receptors_NNS in_IN human_JJ mononuclear_JJ cells_NNS :_: effects_NNS of_IN glucocorticoid_JJ treatment_NN ,_, Cushing_NNP 's_POS disease_NN and_CC ketoconazole_NN ._.
Glucocorticoid_JJ receptors_NNS (_-LRB- GcR_NNP )_-RRB- were_VBD determined_VBN by_IN a_DT whole_JJ cell_NN assay_NN in_IN human_JJ mononulear_`` leukocytes_NNS (_-LRB- hMNL_NNP )_-RRB- from_IN control_NN subjects_NNS ,_, patients_NNS receiving_VBG glucocorticoid_JJ therapy_NN for_IN systemic_JJ diseases_NNS and_CC Cushing_NNP 's_POS disease_NN patients_NNS with_IN or_CC without_IN ketoconazole_JJ therapy_NN ._.
Prolonged_-LRB- corticosteroid_`` treatment_NN resulted_VBN in_IN down-regulation_NN of_IN GcR_NNP ,_, while_IN the_DT mean_JJ level_NN of_IN GcR_NNP in_IN Cushing_NNP 's_POS disease_NN was_VBD normal_JJ ._.
In_IN this_DT group_NN ,_, however_RB ,_, receptor_NN levels_NNS and_CC morning_NN plasma_NN cortisol_`` values_NNS showed_VBD a_DT negative_JJ correlation_NN ,_, indicating_VBG a_DT subtle_JJ down-regulatory_JJ effect_NN ._.
Furthermore_RB ,_, GcR_NNP were_VBD unaltered_`` after_IN these_DT patients_NNS received_VBD ketoconazole_NN ,_, in_IN spite_NN of_IN a_DT marked_VBN reduction_NN in_IN morning_NN plasma_NN cortisol_NN and_CC urinary_`` free_JJ cortisol_NN ._.
We_PRP also_RB observed_VBD that_IN ketoconazole_NN was_VBD a_DT weak_JJ competitor_NN of_IN GcR_NNP in_IN intact_JJ cells_NNS ,_, although_IN it_PRP significantly_RB inhibited_VBD (3H)_NNP dexamethasone_`` binding_NN in_IN cytosolic_JJ preparations_NNS from_IN rat_NN tissues_NNS ._.
The_DT results_NNS suggested_VBD that_IN GcR_NNP in_IN hMNL_NNP are_VBP down-regulated_`` by_IN synthetic_JJ steroids_NNS given_VBN in_IN vivo_`` ,_, but_CC they_PRP showed_VBD very_RB mild_JJ down-regulation_NN in_IN hypercortisolemic_JJ patients_NNS suffering_VBG from_IN Cushing_NNP 's_POS disease_NN ._.
Finally_RB ,_, we_PRP did_VBD not_RB observed_VBN either_CC up-regulation_`` or_CC antagonism_NN of_IN GcR_NNP by_IN ketoconazole_`` treatment_NN ,_, at_IN the_DT time_NN that_IN cortisol_`` levels_NNS of_IN patients_NNS with_IN Cushing_NNP 's_POS disease_NN were_VBD reduced_VBN ._.
This_DT indicates_VBZ that_IN the_DT beneficial_JJ effects_NNS of_IN ketoconazole_NN in_IN Cushing_NNP 's_POS disease_NN are_VBP due_JJ to_TO adrenal_JJ cortisol_NN suppression_NN and_CC not_RB to_TO interaction_`` with_IN GcR_NN of_IN target_NN cells_NNS ,_, and_CC that_IN the_DT process_NN of_IN GcR_`` regulation_NN in_IN hMNL_NNP is_VBZ a_DT complex_JJ phenomenon_NN awaiting_VBG further_RBR elucidation_NN ._.
Glucocorticoid_JJ receptors_NNS in_IN lymphocytes_NNS in_IN anorexia_DT nervosa_NN ._.
OBJECTIVE_# :_: The_DT aim_NN was_VBD to_TO explore_VB the_DT down-regulation_NN of_IN the_DT glucocorticoid_`` receptors_`` during_IN hypercortisolaemia_NN in_IN anorexia_DT nervosa_NN ._.
DESIGN_NNP :_: Urine_`` and_CC plasma_NN samples_NNS were_VBD obtained_VBN for_IN cortisol_JJ determination_NN and_CC blood_NN lymphocytes_NNS were_VBD isolated_VBN for_IN receptor_NN binding_JJ studies_NNS ._.
PATIENTS_NNS :_: Sixteen_CD anorexic_`` patients_NNS ,_, aged_VBN 16-27_CD years_NNS ,_, with_IN a_DT mean_JJ +/-_JJ SEM_`` body_NN mass_NN index_NN of_IN 14.2_CD +/-_`` 2.0_CD (_-LRB- ranging_VBG from_IN 11.1_CD to_TO 17.4_CD )_-RRB- ,_, and_CC 15_CD normal_JJ women_NNS were_VBD studied_VBN ._.
Six_CD patients_NNS were_VBD reinvestigated_VBN after_IN a_DT significant_JJ weight_NN gain_NN ._.
MEASUREMENTS_NNS :_: The_DT binding_JJ capacity_NN and_CC affinity_NN of_IN the_DT glucocorticoid_`` receptors_NNS were_VBD measured_VBN with_IN dexamethasone_NN as_IN ligand_`` on_IN lymphocytes_NNS ._.
RESULTS_NNS :_: In_IN patients_NNS ,_, both_DT total_JJ and_CC free_JJ plasma_NN cortisol_`` concentrations_NNS were_VBD higher_JJR than_IN in_IN the_DT normal_JJ women_NNS ,_, as_IN was_VBD their_PRP$ urinary_JJ free_JJ cortisol_`` ;_: the_DT number_NN of_IN glucocorticoid_JJ receptors_NNS per_IN cell_NN (_-LRB- Ro_NNP )_-RRB- and_CC the_DT binding_JJ affinity_NN (_-LRB- Kd_NNP )_-RRB- for_IN dexamethasone_NN were_VBD ,_, however_RB ,_, not_RB significantly_RB different_JJ (_-LRB- Ro_NNP :_: 7687_CD +/-_`` 1750_CD vs_`` 7347_CD +/-_JJ 1285_CD sites/cell_NN ;_: Kd_NNP :_: 7.7_CD +/-_`` 2.4_CD vs_`` 7.4_CD +/-_JJ 1.7_CD nM_`` at_IN 24_CD degrees_NNS C_NN )_-RRB- ._.
After_IN weight_NN gain_NN (_-LRB- 14_CD +/-_`` 2_CD to_TO 16_CD +/-_`` 2_CD kg/m2_CD )_-RRB- ,_, receptor_NN numbers_NNS were_VBD 8421_CD +/-_`` 2126_CD (_-LRB- pre_NN )_-RRB- and_CC 9011_CD +/-_`` 500_CD (_-LRB- post_NN )_-RRB- sites/cell_NN ,_, which_WDT are_VBP not_RB significantly_RB different_JJ (_-LRB- P_NNP greater_JJR than_IN 0.2_CD )_-RRB- ;_: the_DT Kd_`` was_VBD unchanged_JJ (_-LRB- 9.3_CD +/-_`` 2.6_CD vs_`` 9.2_CD +/-_JJ 2.4_CD nM_NNP )_-RRB- ._.
CONCLUSIONS_NNS Hypercortisolaemia_NNP does_VBZ not_RB down-regulate_# the_DT lymphocyte_`` glucocorticoid_JJ receptors_NNS in_IN anorexia_`` nervosa_`` and_CC a_DT post-receptor_`` defect_`` might_MD be_VB involved_VBN in_IN peripheral_`` tissue_NN resistance_NN to_TO the_DT effects_NNS of_IN glucocorticoid_JJ hormones_NNS in_IN undernutrition_NN ._.
Tumor_NN necrosis_NN factor-alpha_`` mRNA_`` accumulation_NN in_IN human_JJ myelomonocytic_`` cell_NN lines_NNS ._.
Role_NNP of_IN transcriptional_JJ regulation_NN by_IN DNA_NNP sequence_NN motifs_NNS and_CC mRNA_`` stabilization_NN ._.
The_DT cytokine_`` TNF_`` mediates_NNS many_JJ of_IN the_DT pathologic_NN signs_NNS of_IN cachexia_NN ,_, inflammation_NN ,_, and_CC sepsis_NN ._.
The_DT current_JJ work_NN describes_VBZ the_DT regulation_NN of_IN TNF_NNP in_IN human_JJ myelomonocytic_`` cell_NN lines_NNS after_IN PMA_NNP stimulation_NN ._.
The_DT cell_NN lines_NNS exhibit_VBP a_DT low_JJ level_NN of_IN constitutive_`` TNF_NNP mRNA_NNP expression_NN ._.
Within_IN 2_CD to_TO 4_CD h_NN of_IN PMA_NNP exposure_NN ,_, steady_JJ state_NN levels_NNS of_IN TNF_NNP mRNA_NNP are_VBP markedly_RB elevated_JJ in_IN all_DT myelomonocytic_JJ cell_NN lines_NNS studied_VBN ._.
This_DT rise_NN is_VBZ due_JJ to_TO increased_VBN mRNA_# stability_NN ,_, which_WDT increased_VBD by_IN almost_RB twofold_`` ,_, and_CC to_TO an_DT overall_JJ increase_NN in_IN transcription_NN ,_, which_WDT rises_VBZ by_IN more_JJR than_IN sixfold_`` ._.
At_IN the_DT level_NN of_IN the_DT genomic_JJ TNF_NNP gene_NN ,_, a_DT DNase_NNP I_PRP hypersensitive_`` site_NN is_VBZ detected_VBN within_IN the_DT TNF_`` promoter_NN between_IN -200_CD to_TO -100_CD bp_`` relative_JJ to_TO the_DT transcription_NN initiation_NN site_NN ._.
Although_IN absent_JJ in_IN nonexpressing_`` erythroleukemia_`` cell_NN lines_NNS ,_, the_DT DNase_`` I_PRP site_NN is_VBZ present_JJ in_IN uninduced_JJ myelomonocytic_JJ cell_NN lines_NNS and_CC is_VBZ not_RB changed_VBN after_IN PMA_NNP induction_NN ._.
The_DT PMA_NNP induction_NN of_IN c-fos_`` mRNA_NNP correlated_`` well_RB with_IN TNF_`` gene_NN induction_NN ;_: expression_NN of_IN genes_NNS encoding_VBG other_JJ proteins_NNS in_IN the_DT AP-1_NN complex_JJ (_-LRB- junB_NN and_CC junD_NN )_-RRB- were_VBD also_RB induced_VBN by_IN PMA_NNP ._.
The_DT nuclear_JJ extracts_NNS from_IN resting_VBG and_CC induced_`` ML-1_JJ cells_NNS contain_VBP proteins_NNS binding_VBG specifically_RB to_TO the_DT AP-1_NN ,_, AP-2_NN ,_, and_CC NF_NNP kappa_`` B_NNP sequence_NN located_VBN within_IN the_DT TNF_`` promoter_NN ._.
PMA_-LRB- induction_NN increases_VBZ the_DT level_NN of_IN a_DT number_NN of_IN specific_JJ binding_JJ complexes_NNS relative_JJ to_TO the_DT resting_VBG cells_NNS ._.
The_DT regulatory_JJ mechanisms_NNS of_IN the_DT human_JJ and_CC murine_JJ TNF_`` genes_NNS are_VBP discussed_VBN ._.
USF-related_JJ transcription_NN factor_NN ,_, HIV-TF1_'' ,_, stimulates_VBZ transcription_NN of_IN human_JJ immunodeficiency_NN virus-1_NN ._.
The_DT transcription_NN factor_NN HIV-TF1_# ,_, which_WDT binds_VBZ to_TO a_DT region_NN about_IN 60_CD bp_`` upstream_RB from_IN the_DT enhancer_NN of_IN the_DT human_JJ immunodeficiency_NN virus-1_`` (_-LRB- HIV-1_NN )_-RRB- ,_, was_VBD purified_VBN from_IN human_JJ B_NNP cells_NNS ._.
HIV-TF1_NN had_VBD a_DT molecular_JJ weight_NN of_IN 39,000_CD ._.
Binding_# of_IN HIV-TF1_-RRB- to_TO the_DT HIV_NNP long_JJ terminal_NN repeat_NN (_-LRB- LTR_NNP )_-RRB- activated_`` transcription_NN from_IN the_DT HIV_NNP promoter_NN in_IN vitro_NN ._.
The_DT HIV-TF1-binding_JJ site_NN in_IN HIV_NNP LTR_NNP was_VBD similar_JJ to_TO the_DT site_NN recognized_VBN by_IN upstream_RB stimulatory_JJ factor_NN (_-LRB- USF_NNP )_-RRB- in_IN the_DT adenovirus_NN major_JJ late_JJ promoter_NN ._.
DNA-binding_JJ properties_NNS of_IN HIV-TF1_-RRB- suggested_VBD that_IN HIV-TF1_`` might_MD be_VB identical_JJ or_CC related_VBN to_TO USF_NNP ._.
Interestingly_RB ,_, treatment_NN of_IN purified_`` HIV-TF1_`` by_IN phosphatase_`` greatly_RB reduced_VBN its_PRP$ DNA-binding_JJ activity_NN ,_, suggesting_VBG that_IN phosphorylation_NN of_IN HIV-TF1_-RRB- was_VBD essential_JJ for_IN DNA_NNP binding_`` ._.
The_DT disruption_NN of_IN HIV-TF1-binding_JJ site_NN induced_VBD a_DT 60_CD %_NN decrease_NN in_IN the_DT level_NN of_IN transcription_NN from_IN the_DT HIV_`` promoter_NN in_IN vivo_`` ._.
These_DT results_NNS suggest_VBP that_IN HIV-TF1_-RRB- is_VBZ involved_VBN in_IN transcriptional_JJ regulation_NN of_IN HIV-1_NNP ._.
The_DT effect_NN of_IN toremifene_JJ therapy_NN on_IN serum_NN immunoglobulin_NN levels_NNS in_IN breast_NN cancer_NN ._.
Estrogens_NNS and_CC anti-estrogens_`` enhance_VB the_DT number_NN of_IN immunoglobulin_`` (_-LRB- Ig_NN )_-RRB- -secreting_JJ cells_NNS in_IN pokeweed_NN mitogen_NN (_-LRB- PWM_NNP )_-RRB- -stimulated_`` lymphocyte_`` cultures_NNS ._.
Lymphocytes_NNS from_IN patients_NNS who_WP have_VBP received_VBN anti-estrogen_`` therapy_NN show_NN similar_JJ enhancement_NN of_IN Ig-secreting_JJ cells_NNS after_IN PWM_NNP stimulation_NN ._.
In_IN this_DT study_NN the_DT effect_NN of_IN anti-estrogen_JJ (_-LRB- toremifene_NN )_-RRB- therapy_NN on_IN serum_NN immunoglobulin_`` (_-LRB- IgA_NNP ,_, IgM_NNP ,_, IgG_NNP )_-RRB- levels_NNS in_IN breast_NN cancer_NN patients_NNS was_VBD investigated_VBN ._.
Serum_NNP Ig_NNP levels_NNS were_VBD followed_VBN up_RP to_TO two_CD years_NNS after_IN or_CC during_IN the_DT therapy_NN ._.
An_DT unexpected_JJ finding_NN was_VBD that_IN the_DT Ig_# levels_NNS decreased_VBN during_IN the_DT follow-up_JJ period_NN ._.
This_DT decrease_NN was_VBD seen_VBN in_IN patients_NNS who_WP responded_VBD to_TO the_DT therapy_NN as_RB well_RB as_IN in_IN those_DT who_WP did_VBD not_RB ._.
HIV1_PRP$ infection_NN of_IN human_JJ monocytes_NNS and_CC macrophages_NNS promotes_VBZ induction_NN or_CC translocation_NN of_IN NF-KB-related_JJ factors_NNS ._.
In_IN 1991_CD ,_, we_PRP demonstrated_VBD ,_, using_VBG electrophoretic_JJ mobility_`` shift_NN assays_'' ,_, that_DT 3_CD different_JJ factors_NNS (_-LRB- termed_VBN B1_NN ,_, B2_NN and_CC B3_NN )_-RRB- with_IN affinity_NN for_IN the_DT KB-enhancer_`` target_NN sequence_NN were_VBD specifically_RB detected_VBN in_IN nuclear_JJ extracts_NNS from_IN HIV1-infected_JJ monocytes_NNS and_CC macrophages_NNS ._.
The_DT B2_JJ factor_NN was_VBD induced_VBN in_IN the_DT nuclei_`` of_IN these_DT cells_NNS only_RB upon_IN HIV1_# infection_NN ._.
The_DT B3_NNP factor_NN was_VBD only_RB slightly_RB evident_JJ in_IN nuclei_`` of_IN uninfected_JJ cells_NNS but_CC was_VBD readily_RB detectable_`` in_IN nuclei_`` of_IN infected_JJ monocytes_NNS ._.
Its_PRP$ expression_NN remained_VBD very_RB low_JJ in_IN nuclei_# of_IN HIV1-infected_JJ macrophages_NNS ._.
In_IN this_DT paper_NN ,_, we_PRP demonstrate_VBP that_IN the_DT B2_JJ factor_NN is_VBZ expressed_VBN in_IN the_DT cytosol_`` of_IN monocytes_NNS and_CC macrophages_NNS as_IN a_DT DNA-binding_`` protein_NN ,_, indicating_VBG that_IN it_PRP is_VBZ not_RB associated_VBN with_IN an_DT inhibitor_`` (_-LRB- IKB_NNP )_-RRB- ._.
This_DT factor_NN remained_VBD clustered_`` in_IN the_DT cytosol_`` and_CC was_VBD translocated_VBN to_TO the_DT nuclei_`` only_RB after_IN HIV1_-RRB- infection_NN ._.
The_DT B3_NNP factor_NN is_VBZ detected_VBN in_IN the_DT cytosol_NN only_RB when_WRB cells_NNS are_VBP HIV1-infected_JJ ._.
The_DT role_NN of_IN HIV1_CD infection_NN in_IN the_DT expression_NN and_CC the_DT translocation_NN of_IN these_DT factors_NNS is_VBZ discussed_VBN ._.
Induction_NN of_IN NF-kappa_NNP B_NNP during_IN monocyte_`` differentiation_NN is_VBZ associated_VBN with_IN activation_NN of_IN HIV-gene_JJ expression_NN ._.
Cells_# of_IN the_DT monocyte-macrophage_NN lineage_NN are_VBP important_JJ targets_NNS of_IN HIV_NNP infection_NN ._.
We_PRP report_VBP here_RB that_IN the_DT phenotypic_JJ differentiation_NN of_IN monocyte_# cell_NN lines_NNS induced_VBN by_IN phorbol_`` esters_NNS or_CC tumour_`` necrosis_`` factor_NN alpha_NN (_-LRB- TNF_NNP alpha_NN )_-RRB- is_VBZ associated_VBN with_IN expression_NN of_IN nuclear_JJ factor_NN kappa_NN B_NNP (_-LRB- NF-kappa_NNP B_NNP )_-RRB- ._.
In_IN parallel_RB with_IN such_JJ differentiation_NN ,_, HIV_NNP transcription_NN ,_, monitored_VBD using_VBG an_DT HIV_`` long_JJ terminal_NN repeat_NN reporter_NN gene_NN construct_VB ,_, is_VBZ activated_VBN in_IN such_JJ cells_NNS under_IN the_DT influence_NN of_IN enhanced_JJ NF-kappa_NNP B_NNP expression_NN ._.
Also_RB ,_, in_IN a_DT promonocyte_JJ cell_NN line_NN chronically_RB infected_JJ with_IN HIV_NNP ,_, NF-kappa_NNP B_NNP expression_NN and_CC HIV_NNP transcription_NN were_VBD enhanced_VBN on_IN stimulation_NN with_IN phorbol_`` ester_`` or_CC TNF_`` alpha_NN ._.
Thus_RB ,_, stimulation_NN of_IN monocyte_# cell_NN lines_NNS by_IN phorbol_`` esters_NNS or_CC TNF_NNP alpha_`` induces_`` cell_NN differentiation_NN and_CC activates_NNS HIV_NNP transcription_NN ._.
Such_PDT a_DT process_NN may_MD have_VB fundamental_JJ implications_NNS in_IN AIDS_NNP pathogenesis_NN in_IN vivo_`` and_CC may_MD be_VB important_JJ in_IN disease_NN progression_NN induced_`` by_IN opportunistic_`` infections_NNS directly_RB or_CC indirectly_RB involving_VBG macrophages_NNS ._.
A_DT nuclear_JJ factor_NN NF-GM2_`` that_IN interacts_NNS with_IN a_DT regulatory_JJ region_NN of_IN the_DT GM-CSF_JJ gene_NN essential_JJ for_IN its_PRP$ induction_NN in_IN responses_NNS to_TO T-cell_NNP activation_NN :_: purification_`` from_IN human_JJ T-cell_NNP leukemia_NN line_NN Jurkat_NNP cells_NNS and_CC similarity_NN to_TO NF-kappa_NNP B_NNP ._.
Activation_NN of_IN T_JJ cells_NNS by_IN antigen_`` ,_, lectin_'' ,_, or_CC a_DT combination_NN of_IN phorbol-12-myristate_JJ acetate_`` (_-LRB- PMA_NNP )_-RRB- and_CC calcium_`` ionophore_`` (_-LRB- A23187_NN )_-RRB- leads_VBZ to_TO the_DT induction_NN of_IN genes_NNS for_IN a_DT set_NN of_IN lymphokines_NNS ,_, including_VBG granulocyte-macrophage_NN colony-stimulating_JJ factor_NN (_-LRB- GM-CSF_NNP )_-RRB- ._.
We_PRP demonstrated_VBD in_IN earlier_JJR studies_NNS that_IN the_DT upstream_JJ region_NN of_IN the_DT mouse_NN GM-CSF_`` promoter_NN at_IN positions_NNS between_IN -95_`` and_CC -73_`` is_VBZ essential_JJ for_IN transcriptional_JJ activation_NN in_IN response_NN to_TO PMA/A23187_CD ._.
This_DT region_NN contains_VBZ two_CD DNA-binding_JJ motifs_NNS ,_, GM2_NNP and_CC GC-box_NNP ._.
The_DT GM2_NNP sequence_NN (_-LRB- GGTAGTTCCC_NNP )_-RRB- is_VBZ recognized_VBN by_IN an_DT inducible_JJ factor_NN NF-GM2_`` ;_: the_DT other_JJ (_-LRB- CCGCCC_`` )_-RRB- by_IN constitutive_JJ factors_NNS A1_CD ,_, A2_CD ,_, and_CC B_NNP ._.
To_TO elucidate_VB the_DT mechanism_NN of_IN GM-CSF_JJ gene_NN activation_NN ,_, we_PRP have_VBP purified_`` the_DT inducible_JJ factor_NN NF-GM2_`` from_IN the_DT nuclear_JJ extract_VB of_IN stimulated_VBN Jurkat_NNP cells_NNS on_IN the_DT basis_NN of_IN specific_JJ DNA-binding_JJ activity_NN ._.
The_DT purified_`` NF-GM2_NNP consists_VBZ of_IN 50_CD (_-LRB- p50_NN )_-RRB- and_CC 65_CD kDa_NNP (_-LRB- p65_NN )_-RRB- polypeptides_`` and_CC has_VBZ a_DT binding_`` activity_NN specific_NN for_IN both_DT the_DT GM-CSF_`` and_CC immunoglobulin_`` kappa_FW (_-LRB- GGAAAGTCCC_NNP )_-RRB- enhancers_`` ._.
Electrophoretically_RB purified_VBN p50_`` alone_RB can_MD form_VB a_DT protein-DNA_`` complex_JJ ,_, but_CC in_IN the_DT mixture_NN ,_, p50_CD associates_NNS preferentially_RB with_IN p65_NN to_TO form_VB the_DT NF-GM2_`` complex_JJ ._.
In_IN addition_NN ,_, p65_NN gave_VBD per_IN se_NN ,_, with_IN low_JJ affinity_NN ,_, a_DT protein-DNA_`` complex_JJ that_IN migrated_VBN more_RBR slowly_RB than_IN native_JJ NF-GM2_`` complex_JJ ._.
Furthermore_RB ,_, an_DT antiserum_NN against_IN KBF1_CD (_-LRB- identical_JJ to_TO 50_CD kDa_NNP NF-kappa_NNP B_NNP protein_NN )_-RRB- reacted_VBD with_IN the_DT p50_CD of_IN NF-GM2_CD ,_, indicating_VBG that_IN the_DT NF-GM2_CD polypeptide_NN can_MD not_RB be_VB immunologically_RB differentiated_VBN from_IN the_DT 50_CD kDa_NNP subunit_NN of_IN NF-kappa_NNP B_NNP ._.
The_DT purified_`` NF-GM2_`` activated_VBN in_IN vitro_`` transcription_NN from_IN the_DT kappa_NN B_NNP enhancer_NN ,_, while_IN it_PRP failed_VBD to_TO stimulate_VB transcription_NN from_IN the_DT GM-CSF_`` promoter_NN harboring_VBG the_DT GM2_NNP sequence_NN ._.
This_DT suggests_VBZ that_IN the_DT activation_NN mechanism_NN of_IN the_DT GM-CSF_JJ gene_NN through_IN the_DT GM2/GC-box_`` sequence_NN is_VBZ different_JJ from_IN that_DT of_IN genes_NNS carrying_VBG the_DT kappa_NN B_NNP enhancer_`` alone_RB ._.
Glucocorticoid_JJ receptors_NNS in_IN normal_JJ leukocytes_NNS :_: effects_NNS of_IN age_NN ,_, gender_NN ,_, season_NN ,_, and_CC plasma_`` cortisol_`` concentrations_NNS ._.
We_PRP measured_VBD glucocorticoid_JJ receptors_NNS (_-LRB- GR_NNP )_-RRB- in_IN mononuclear_JJ leukocytes_NNS (_-LRB- MNL_NNP )_-RRB- isolated_VBD from_IN peripheral_JJ blood_NN of_IN 145_CD apparently_RB healthy_JJ volunteers_NNS (_-LRB- 86_CD men_NNS and_CC 59_CD women_NNS )_-RRB- ._.
An_DT age-related_JJ decrease_NN in_IN the_DT number_NN of_IN GR_NNP was_VBD suggested_VBN between_IN subjects_NNS younger_JJR than_IN 20_CD years_NNS and_CC elderly_JJ subjects_NNS ;_: there_EX was_VBD no_DT apparent_JJ seasonal_JJ variation_NN in_IN GR_NNP ._.
Gender_-LRB- difference_NN in_IN the_DT number_NN of_IN GR_NNP was_VBD not_RB significant_JJ ,_, although_IN women_NNS showed_VBD slightly_RB fewer_JJR GR_NNP ._.
Eight_CD patients_NNS with_IN dermatomyositis/polymyositis_NN were_VBD examined_VBN to_TO determine_VB whether_IN the_DT number_NN of_IN GR_NNP in_IN MNL_NNP could_MD be_VB down-regulated_JJ by_IN their_PRP$ cognate_# ligands_NNS ._.
The_DT number_NN of_IN GR_NNP in_IN MNL_NNP from_IN these_DT patients_NNS was_VBD significantly_RB decreased_VBN one_CD month_NN after_IN the_DT initiation_NN of_IN prednisolone_JJ therapy_NN ._.
However_RB ,_, in_IN normal_JJ subjects_NNS ,_, the_DT GR_NNP in_IN MNL_NNP did_VBD not_RB demonstrate_VB circadian_JJ variation_NN ,_, in_IN contrast_NN to_TO concentrations_NNS of_IN plasma_NN cortisol_NN ._.
Anti-CD2_-LRB- receptor_NN antibodies_NNS activate_VBP the_DT HIV_`` long_JJ terminal_NN repeat_NN in_IN T_JJ lymphocytes_NNS ._.
The_DT CD2_NNP T_NNP lymphocyte_`` glycoprotein_NN surface_NN molecule_JJ mediates_`` both_DT cell_NN to_TO cell_NN adhesion_NN and_CC T_JJ cell_NN activation_NN ,_, two_CD processes_NNS that_WDT are_VBP involved_VBN in_IN the_DT spread_NN of_IN HIV_NNP infection_NN ._.
Treatment_NNP of_IN chronically_RB HIV-infected_JJ PBMC_NNP with_IN anti-CD2_JJ mAb_NN has_VBZ been_VBN shown_VBN to_TO induce_VB the_DT expression_NN of_IN infectious_JJ virus_NN from_IN these_DT cultures_NNS ._.
In_IN this_DT study_NN we_PRP investigated_VBD the_DT mechanisms_NNS whereby_WRB anti-CD2_JJ antibodies_NNS stimulate_VB viral_JJ production_NN ._.
We_PRP demonstrate_VBP that_IN treatment_NN of_IN transiently_RB transfected_VBN T_JJ lymphocytes_NNS with_IN anti-CD2_JJ antibodies_NNS results_NNS in_IN activation_NN of_IN the_DT HIV_NNP long_JJ terminal_NN repeat_NN ._.
Furthermore_RB ,_, CAT_'' assays_`` using_VBG mutated_JJ HIV_NNP long_JJ terminal_NN repeat-CAT_NN constructs_NNS and_CC gel_`` shift_VB assays_RB demonstrate_VBP that_IN this_DT activation_NN is_VBZ dependent_JJ on_IN the_DT NF-kappa_NNP B_NNP enhancer_NN ._.
These_DT studies_NNS suggest_VBP that_IN interaction_NN of_IN CD2_NN with_IN its_PRP$ natural_JJ ligand_NN ,_, LFA-3_'' ,_, may_MD play_VB a_DT role_NN in_IN regulation_NN of_IN HIV_NNP expression_NN ._.
Nuclear_JJ transcription_`` factors_NNS that_WDT bind_VBP to_TO elements_NNS of_IN the_DT IL-2_NN promoter_NN ._.
Induction_NN requirements_NNS in_IN primary_JJ human_JJ T_`` cells_NNS ._.
Prior_RB studies_NNS have_VBP identified_VBN several_JJ elements_NNS that_WDT contribute_VBP to_TO the_DT activity_NN of_IN the_DT IL-2_`` promoter_NN in_IN the_DT stimulated_VBN T_JJ cell_NN line_NN ,_, Jurkat_NNP ._.
The_DT sites_NNS and_CC their_PRP$ corresponding_JJ nuclear_JJ binding_`` factors_NNS include_VBP :_: NF-kappa_NNP B_NNP ,_, AP-1_NNP ,_, AP-3_NNP ,_, OCT-1_NNP ,_, and_CC NF-AT_RB ._.
The_DT latter_JJ "_`` nuclear_JJ factor_NN for_IN activated_`` T_JJ cells_NNS "_`` likely_JJ contributes_'' to_TO the_DT tissue_NN specificity_NN of_IN IL-2_JJ gene_NN expression_NN ._.
Using_VBG electrophoretic_JJ mobility_NN shift_NN assays_VBZ ,_, we_PRP have_VBP studied_VBN these_DT transcription_NN factors_NNS in_IN primary_JJ T_JJ cells_NNS from_IN human_JJ blood_NN to_TO verify_VB their_PRP$ presence_NN in_IN a_DT physiologic_NN setting_NN and_CC to_TO identify_VB the_DT signals_NNS that_WDT stimulate_VB factor_VB activity_NN ._.
All_DT factors_NNS are_VBP induced_`` in_IN the_DT nuclei_`` of_IN T_JJ cells_NNS upon_IN activation_NN with_IN mitogens_NNS but_CC not_RB with_IN exogenous_JJ IL-2_`` growth_NN factor_NN ._.
However_RB ,_, the_DT signaling_NN requirements_NNS and_CC sensitivity_NN to_TO protein_NN synthesis_NN inhibitors_NNS differ_VBP considerably_RB ._.
Only_RB the_DT activities_NNS for_IN NF-AT_NNP and_CC AP-1_NNP sites_NNS require_VBP two_CD signals_NNS for_IN optimal_JJ induction_NN ,_, i.e._FW ,_, PMA_NNP plus_IN either_DT lectin_NN or_CC antibody_NN to_TO the_DT CD3_`` or_CC CD28_-RRB- surface_NN molecules_NNS ._.
Other_JJ factors_NNS are_VBP induced_VBN by_IN lectin_NN ,_, antibody_NN ,_, and/or_CC PMA_NNP alone_RB ._.
After_IN appropriate_JJ stimulation_NN ,_, both_DT NF-AT_NNP and_CC AP-1_NNP are_VBP peculiarly_RB sensitive_JJ to_TO the_DT protein_NN synthesis_NN inhibitor_NN anisomycin_NN ._.
Our_PRP$ data_NNS correlate_`` the_DT activity_NN of_IN NF-AT_`` and_CC AP-1_-LRB- in_IN gel_`` shift_VB assays_`` with_IN the_DT two_CD signals_NNS requirements_NNS for_IN IL-2_JJ gene_NN expression_NN ._.
An_DT erythroid_`` specific_JJ enhancer_`` upstream_RB to_TO the_DT gene_NN encoding_`` the_DT cell-type_`` specific_JJ transcription_NN factor_NN GATA-1_NNP ._.
The_DT transcription_NN factor_NN GATA-1_NNP is_VBZ expressed_VBN in_IN a_DT subset_`` of_IN hemopoietic_JJ cells_NNS ,_, where_WRB it_PRP mediates_VBZ the_DT cell-type_`` specific_JJ expression_NN of_IN several_JJ genes_NNS ._.
We_PRP have_VBP cloned_`` the_DT mouse_NN and_CC human_JJ GATA-1_NNP genes_NNS ._.
A_DT region_NN upstream_RB to_TO the_DT first_JJ exon_NN ,_, and_CC highly_RB conserved_`` between_IN mouse_NN and_CC man_NN ,_, acts_VBZ as_IN an_DT erythroid_`` specific_JJ enhancer_NN in_IN transient_JJ assays_`` ,_, if_IN linked_VBN to_TO the_DT GATA-1_`` or_CC to_TO the_DT SV40_`` promoter_NN ._.
The_DT activity_NN of_IN the_DT enhancer_NN is_VBZ almost_RB completely_RB dependent_JJ on_IN the_DT integrity_NN of_IN a_DT dimeric_JJ GATA-1_NNP binding_`` site_NN ._.
Demonstration_NN of_IN a_DT 1,25-dihydroxyvitamin_`` D3-responsive_JJ protein_NN in_IN human_JJ lymphocytes_NNS :_: immunologic_`` crossreactivity_NN and_CC inverse_NN regulation_NN with_IN the_DT vitamin_NN D_NNP receptor_NN ._.
Using_VBG Western_JJ blot_NN analysis_NN with_IN a_DT monoclonal_JJ antibody_NN recognizing_VBG a_DT 17-amino_JJ acid_NN epitope_NN of_IN the_DT 1,25-dihydroxyvitamin_JJ D3_`` (_-LRB- 1,25(OH)2D3_`` )_-RRB- receptor_NN ,_, we_PRP have_VBP detected_VBN two_CD crossreacting_`` proteins_NNS in_IN activated_`` normal_JJ human_JJ lymphocytes_NNS ._.
The_DT smaller_JJR of_IN the_DT two_CD proteins_NNS (_-LRB- 50_CD kDa_NNP )_-RRB- was_VBD indistinguishable_`` from_IN the_DT classical_JJ 1,25(OH)2D3_NNP receptor_NN and_CC ,_, similar_JJ to_TO the_DT classical_JJ 1,25(OH)2D3_`` receptor_NN ,_, was_VBD upregulated_VBN in_IN a_DT dose-dependent_JJ fashion_NN by_IN 1,25(OH)2D3_NNP ._.
The_DT larger_JJR crossreacting_NN protein_NN exhibited_VBD an_DT electrophoretic_JJ mobility_'' of_IN 80_CD kDa_NNP ,_, was_VBD localized_VBN in_IN the_DT cell_NN cytosol_NN ,_, and_CC appeared_VBD to_TO be_VB specific_JJ for_IN activated_VBN lymphocytes_NNS since_IN it_PRP was_VBD not_RB detected_VBN in_IN several_JJ other_JJ human_JJ cells_NNS including_VBG monocytes_NNS ._.
More_RBR strikingly_RB ,_, the_DT 80-kDa_JJ protein_NN was_VBD downregulated_`` in_IN a_DT dose-dependent_JJ fashion_NN by_IN 1,25(OH)2D3_CD ;_: this_DT effect_NN was_VBD independent_JJ of_IN the_DT mode_NN of_IN lymphocyte_`` activation_NN and_CC specific_JJ for_IN the_DT 1,25(OH)2D3_`` metabolite_NN of_IN vitamin_NN D3_NNP ._.
However_RB ,_, two_CD potent_JJ immunosuppressive_`` agents_NNS ,_, glucocorticoids_NNS and_CC cyclosporin_`` A_DT ,_, also_RB inhibited_VBD the_DT 80-kDa_JJ protein_NN ._.
T-helper-cell_JJ determinants_NNS in_IN protein_NN antigens_NNS are_VBP preferentially_RB located_VBN in_IN cysteine-rich_JJ antigen_`` segments_NNS resistant_# to_TO proteolytic_`` cleavage_`` by_IN cathepsin_NN B_NNP ,_, L_NNP ,_, and_CC D_NNP ._.
We_PRP report_VBP on_IN a_DT computer_NN algorithm_`` capable_JJ of_IN predicting_VBG the_DT location_NN of_IN T-helper-cell_NNP epitopes_`` in_IN protein_NN antigen_`` (_-LRB- Ag_NNP )_-RRB- by_IN analysing_VBG the_DT Ag_NNP amino_`` acid_NN sequence_NN ._.
The_DT algorithm_NN was_VBD constructed_VBN with_IN the_DT aim_NN of_IN identifying_VBG segments_NNS in_IN Ag_NNP which_WDT are_VBP resistant_JJ to_TO proteolytic_`` degradation_`` by_IN the_DT enzymes_`` cathepsin_NN B_NNP ,_, L_NNP ,_, and_CC D_NNP ._.
These_DT are_VBP prominent_JJ enzymes_NNS in_IN the_DT endocytic_JJ pathway_NN through_IN which_WDT soluble_JJ protein_NN Ag_NNP enter_VB APC_NNP ,_, and_CC resistant_JJ segments_NNS in_IN Ag_NNP may_MD ,_, therefore_RB ,_, be_VB expected_VBN to_TO contain_VB more_RBR T-cell_JJ determinants_NNS than_IN susceptible_JJ segments_NNS ._.
From_IN information_NN available_JJ in_IN the_DT literature_NN on_IN the_DT substrate_`` specificity_NN of_IN the_DT three_CD enzymes_NNS ,_, it_PRP is_VBZ clear_JJ that_IN a_DT cysteine_NN is_VBZ not_RB accepted_VBN in_IN any_DT of_IN the_DT S2_NN ,_, S1_'' ,_, S1'_NN ,_, and_CC S2'_NNP subsites_`` of_IN cathepsin_NN B_NNP and_CC L_NNP ,_, and_CC not_RB in_IN the_DT S1_`` and_CC S1'_`` subsites_NNS of_IN cathepsin_NN D_NNP ._.
Moreover_RB ,_, we_PRP have_VBP noticed_VBN that_IN cysteine-containing_JJ T-cell_`` determinants_NNS in_IN a_DT number_NN of_IN protein_NN Ag_NNP are_VBP particularly_RB rich_JJ in_IN the_DT amino_`` acids_NNS alanine_# ,_, glycine_NN ,_, lysine_'' ,_, leucine_NN ,_, serine_NN ,_, threonine_CD ,_, and_CC valine_NN ._.
By_IN searching_VBG protein_NN Ag_`` for_IN clusters_NNS of_IN amino_`` acids_NNS containing_VBG cysteine_`` and_CC two_CD of_IN the_DT other_JJ amino_`` acids_NNS we_PRP were_VBD able_JJ to_TO predict_VB 17_CD out_IN of_IN 23_CD empirically_RB known_VBN T-cell_NNP determinants_NNS in_IN the_DT Ag_NNP with_IN a_DT relatively_RB low_JJ number_NN of_IN false_JJ (_-LRB- positive_JJ )_-RRB- predictions_NNS ._.
Furthermore_RB ,_, we_PRP present_VBP a_DT new_JJ principle_NN for_IN searching_VBG Ag_NNP for_IN potential_JJ amphipatic_JJ alpha-helical_JJ protein_NN segments_NNS ._.
Such_JJ segments_NNS accord_NN well_RB with_IN empirically_RB known_VBN T-cell_`` determinants_NNS and_CC our_PRP$ algorithm_NN produces_VBZ a_DT lower_JJR number_NN of_IN false_JJ positive_JJ predictions_NNS than_IN the_DT principle_NN based_VBN on_IN discrete_`` Fourier_`` transformations_NNS previously_RB described_VBN ._.
A_DT human_JJ putative_`` lymphocyte_`` G0/G1_`` switch_NN gene_NN containing_VBG a_DT CpG-rich_JJ island_NN encodes_VBZ a_DT small_JJ basic_JJ protein_NN with_IN the_DT potential_NN to_TO be_VB phosphorylated_VBN ._.
Genes_# actively_RB involved_VBN in_IN the_DT G0/G1_NN switch_NN (_-LRB- G0S_`` genes_NNS )_-RRB- may_MD be_VB differentially_RB expressed_VBN during_IN the_DT lectin-induced_JJ switch_NN of_IN lymphocytes_NNS from_IN the_DT G0_CD to_TO the_DT G1_`` phases_`` of_IN the_DT cell_NN cycle_NN ._.
This_DT paper_NN presents_VBZ studies_NNS of_IN G0S2_NNP ,_, a_DT member_NN of_IN a_DT set_NN of_IN putative_JJ G0S_`` genes_NNS ,_, for_IN which_WDT cDNAs_`` were_VBD cloned_VBN and_CC selected_VBN on_IN the_DT basis_NN of_IN differential_JJ cDNA_NNP hybridization_NN ._.
G0S2_NN mRNA_`` increases_NNS transiently_RB within_IN 1-2_CD hr_NN of_IN the_DT addition_NN of_IN lectin_NN or_CC cycloheximide_`` to_TO cultured_`` blood_NN mononuclear_JJ cells_NNS ._.
Comparison_NN of_IN a_DT nearly_RB full-length_JJ cDNA_`` sequence_NN with_IN the_DT corresponding_JJ genomic_JJ sequence_NN reveals_VBZ one_CD small_JJ intron_`` and_CC an_DT open_JJ reading_NN frame_NN in_IN the_DT second_JJ exon_NN ._.
The_DT derived_VBN 103-amino-acid_JJ basic_JJ protein_NN has_VBZ two_CD potential_JJ alpha-helical_JJ domains_NNS separated_VBN by_IN a_DT hydrophobic_JJ region_NN with_IN the_DT potential_NN to_TO generate_VB turns_NNS and_CC assume_VB a_DT beta-sheet_NN conformation_NN ._.
Consistent_-LRB- with_IN involvement_NN in_IN the_DT G0/G1_`` switch_NN ,_, the_DT protein_NN contains_VBZ potential_JJ sites_NNS for_IN phosphorylation_NN by_IN protein_NN kinase_`` C_$ and_CC casein_`` kinase_# II_NNP ._.
The_DT gene_NN contains_VBZ a_DT CpG-rich_JJ island_NN suggesting_VBG expression_NN in_IN the_DT germ_NN line_NN ._.
An_DT upstream_JJ segment_NN contains_VBZ tandem_`` dinucleotide_`` repeats_NNS (CT)19/(CA)16_CD ._.
There_EX is_VBZ a_DT suitably_RB located_VBN TATA_`` box_NN ,_, but_CC potential_JJ sites_NNS for_IN CCAAT-box_`` binding_JJ factors_NNS are_VBP far_RB upstream_RB ,_, embedded_'' in_IN a_DT 42-nucleotide_JJ repeat_NN element_NN ._.
Potential_JJ sites_NNS for_IN transcription_NN factors_NNS AP1_# ,_, AP2_NN ,_, and_CC AP3_NNP are_VBP consistent_JJ with_IN rapid_JJ transcriptional_JJ activation_NN in_IN response_NN to_TO inducing_VBG agents_NNS ._.
Synergism_NN between_IN two_CD distinct_JJ elements_NNS of_IN the_DT HTLV-I_`` enhancer_NN during_IN activation_NN by_IN the_DT trans-activator_NN of_IN HTLV-I_NNP ._.
We_PRP have_VBP conducted_VBN functional_JJ studies_NNS of_IN the_DT enhancer_# elements_NNS of_IN human_JJ T-cell_NNP leukemia_`` virus_NN type_NN I_PRP (_-LRB- HTLV-I_NNP )_-RRB- using_VBG the_DT human_JJ T-cell_`` lines_NNS Jurkat_NNP and_CC MOLT_NNP 4_CD ,_, which_WDT are_VBP negative_JJ for_IN HTLV-I_# ,_, and_CC MT-2_`` and_CC TL-Mor_# ,_, which_WDT carry_VBP the_DT proviral_`` genome_NN of_IN HTLV-I_NNP ._.
Two_CD distinct_JJ elements_NNS have_VBP been_VBN implicated_VBN in_IN function_NN of_IN the_DT HTLV-I_NNP enhancer_NN ._.
One_CD is_VBZ the_DT 21-base-pair_JJ (_-LRB- bp_NN )_-RRB- core_NN element_NN that_WDT is_VBZ responsible_JJ for_IN trans-activation_NN by_IN the_DT HTLV-I_`` trans-activator_NN p40tax_NN and_CC that_DT has_VBZ the_DT ability_NN to_TO bind_NN to_TO cyclic-AMP_`` responsive_JJ element_NN binding_JJ factor_NN (_-LRB- CREB_NNP )_-RRB- -like_JJ factor_NN (_-LRB- s_PRP )_-RRB- ._.
The_DT other_JJ is_VBZ a_DT region_NN interposed_`` between_IN the_DT 21-bp_`` elements_NNS ._.
In_IN this_DT study_NN we_PRP demonstrate_VBP that_IN a_DT subfragment_NN (_-LRB- C26_CD )_-RRB- in_IN the_DT region_NN between_IN the_DT 21-bp_CD elements_NNS is_VBZ involved_VBN in_IN trans-activation_NN by_IN p40tax_NN ,_, possibly_RB through_IN binding_NN to_TO an_DT NF-kappa_`` B-like_JJ nuclear_JJ factor_NN or_CC factors_NNS ._.
Formation_NN of_IN the_DT protein-DNA_`` complex_JJ with_IN the_DT C26_CD subfragment_NN was_VBD positively_RB affected_VBN by_IN p40tax_NN ._.
The_DT C26_NNP element_NN conferred_`` partial_JJ responsiveness_NN to_TO p40tax_NN when_WRB linked_VBN to_TO one_CD copy_NN of_IN the_DT 21-bp_JJ element_NN that_IN ,_, by_IN itself_PRP ,_, showed_VBD little_JJ activation_NN in_IN response_NN to_TO p40tax_NN ._.
However_RB ,_, the_DT C26_CD element_NN alone_RB ,_, even_RB when_WRB repeated_VBN ,_, could_MD not_RB be_VB activated_VBN by_IN p40tax_NN ,_, unlike_IN other_JJ NF-kappa_NNP B-binding_# elements_NNS ._.
In_IN contrast_NN ,_, the_DT C26_CD element_NN itself_PRP was_VBD profoundly_RB activated_VBN upon_IN stimulation_NN with_IN 12-O-tetradecanoylphorbol-13-acetate_-RRB- ._.
These_DT findings_NNS therefore_RB suggest_VBP that_IN the_DT HTLV-I_NNP enhancer_`` contains_VBZ multiple_JJ functional_JJ elements_NNS ,_, including_VBG binding_# sites_NNS for_IN at_IN least_JJS CREB-_`` and_CC NF-kappa_`` B-like_JJ factors_NNS ,_, which_WDT synergistically_RB cooperate_VBP in_IN activation_NN of_IN the_DT HTLV-I_`` enhancer_NN in_IN response_NN to_TO p40tax_NN ._.
Our_PRP$ results_NNS also_RB demonstrate_VBP that_IN TPA-dependent_JJ activation_NN of_IN the_DT HTLV-I_`` enhancer_`` may_MD be_VB mediated_VBN through_IN the_DT C26_NNP element_NN ._.
v-erbA_JJ overexpression_NN is_VBZ required_VBN to_TO extinguish_VB c-erbA_JJ function_NN in_IN erythroid_`` cell_NN differentiation_NN and_CC regulation_NN of_IN the_DT erbA_NNP target_NN gene_NN CAII_`` ._.
The_DT v-erbA_NNP oncoprotein_NN represents_VBZ a_DT retrovirus-transduced_`` oncogenic_JJ version_NN of_IN the_DT thyroid_NN hormone_NN (_-LRB- T3/T4_CD )_-RRB- receptor_NN c-erbA_# (_-LRB- type_NN alpha_NN )_-RRB- ._.
It_PRP contributes_VBZ to_TO virus-induced_`` erythroleukemia_`` by_IN efficiently_RB arresting_VBG differentiation_NN of_IN red_JJ cell_NN progenitors_NNS and_CC by_IN suppressing_VBG transcription_NN of_IN erythrocyte-specific_JJ genes_NNS ._.
Here_RB ,_, we_PRP show_VBP that_IN v-erbA_NNP and_CC c-erbA_NNP bind_NN directly_RB to_TO sequences_NNS within_IN the_DT promoter_NN of_IN the_DT erythrocyte-specific_JJ carbonic_JJ anhydrase_`` II_NNP (_-LRB- CAII_NNP )_-RRB- ,_, a_DT gene_NN whose_WP$ transcription_NN is_VBZ efficiently_RB suppressed_VBN by_IN v-erbA_NNP ._.
This_DT erbA-binding_NNP site_NN confers_`` thyroid_`` hormone_NN responsiveness_NN to_TO a_DT heterologous_`` promoter_NN in_IN transient_JJ expression_NN experiments_NNS and_CC is_VBZ a_DT target_NN for_IN efficient_JJ down-regulation_NN of_IN CAII_`` transcription_NN by_IN the_DT v-erbA_`` oncoprotein_NN ._.
In_IN stably_RB transformed_VBN erythroblasts_NNS coexpressing_VBG the_DT v-erbA_`` oncoprotein_`` and_CC the_DT c-erbA/T3_NN receptor_NN at_IN an_DT approximately_RB equimolar_JJ ratio_NN ,_, c-erbA_JJ activity_NN is_VBZ dominant_JJ over_IN v-erbA_NN ._.
T3_CD efficiently_RB induced_`` erythroid_`` differentiation_NN in_IN these_DT cells_NNS ,_, thus_RB overcoming_VBG the_DT v-erbA-mediated_JJ differentiation_NN arrest_NN ._.
Likewise_RB ,_, T3_NNP activated_VBD CAII_NNP transcription_NN as_RB well_RB as_IN transient_JJ expression_NN of_IN a_DT T3-responsive_JJ reporter_NN gene_NN containing_VBG the_DT CAII-specific_JJ erbA-binding_NNP site_NN ._.
The_DT c-erbA-dependent_JJ activation_NN of_IN this_DT CAII_`` reporter_NN construct_VB could_MD only_RB be_VB suppressed_VBN by_IN very_RB high_JJ amounts_NNS of_IN v-erbA_NN ._.
Our_PRP$ results_NNS suggest_VBP that_IN overexpression_NN of_IN v-erbA_NN is_VBZ required_VBN for_IN its_PRP$ function_NN as_IN an_DT oncoprotein_NN ._.
Inhibition_NN of_IN phorbol_`` ester-induced_`` monocytic_JJ differentiation_NN by_IN dexamethasone_NN is_VBZ associated_VBN with_IN down-regulation_NN of_IN c-fos_`` and_CC c-jun_`` (_-LRB- AP-1_NN )_-RRB- ._.
Previous_JJ studies_NNS have_VBP shown_VBN that_IN treatment_NN of_IN human_JJ myeloid_`` leukemia_`` cells_NNS with_IN 12-O-tetradecanoylphorbol-13-acetate_-RRB- (_-LRB- TPA_NNP )_-RRB- is_VBZ associated_VBN with_IN induction_NN of_IN monocytic_JJ differentiation_NN and_CC expression_NN of_IN the_DT c-jun_`` and_CC c-fos_`` early_JJ response_NN genes_NNS ._.
The_DT present_JJ work_NN demonstrates_VBZ that_IN the_DT glucocorticoid_JJ dexamethasone_`` inhibits_NNS TPA-induced_# increases_NNS in_IN c-jun_`` and_CC c-fos_`` mRNA_`` levels_NNS in_IN U-937_CD leukemia_NN cells_NNS ._.
These_DT findings_NNS were_VBD associated_VBN with_IN a_DT block_NN in_IN appearance_NN of_IN the_DT monocytic_JJ phenotype_NN ,_, including_VBG inhibition_NN of_IN TPA-induced_NNP increases_NNS in_IN lamin_NN A_DT ,_, lamin_NN C_NNP ,_, and_CC vimentin_`` transcripts_NNS ._.
Other_JJ studies_NNS have_VBP demonstrated_VBN that_IN TPA-induced_`` monocytic_JJ differentiation_NN and_CC expression_NN of_IN the_DT c-jun_`` and_CC c-fos_`` genes_NNS in_IN myeloid_`` leukemia_`` cells_NNS are_VBP regulated_VBN by_IN protein_NN kinase_`` C_$ (_-LRB- PKC_NNP )_-RRB- ._.
The_DT finding_NN that_IN dexamethasone_NN has_VBZ no_DT effect_NN on_IN TPA-induced_NNP activation_NN of_IN PKC_NNP suggests_VBZ that_IN this_DT glucocorticoid_JJ inhibits_`` signals_NNS downstream_RB or_CC parallel_RB to_TO this_DT enzyme_NN ._.
Nuclear_JJ run-on_`` assays_NNS demonstrate_VBP that_IN :_: (_-LRB- 1_CD )_-RRB- induction_NN of_IN c-jun_`` and_CC c-fos_`` expression_NN by_IN TPA_NNP is_VBZ regulated_VBN by_IN transcriptional_JJ mechanisms_NNS ,_, (_-LRB- 2_CD )_-RRB- TPA-induced_`` expression_NN of_IN c-jun_`` and_CC c-fos_`` does_VBZ not_RB require_VB protein_NN synthesis_NN ,_, and_CC (_-LRB- 3_CD )_-RRB- TPA-induced_JJ expression_NN of_IN both_DT genes_NNS is_VBZ inhibited_VBN at_IN the_DT transcriptional_JJ level_NN by_IN dexamethasone_`` ._.
To_TO further_RBR define_VB the_DT effects_NNS of_IN dexamethasone_NN at_IN the_DT molecular_JJ level_NN ,_, we_PRP prepared_VBD a_DT series_NN of_IN deleted_`` c-jun_JJ promoter_NN fragments_NNS linked_VBN to_TO the_DT chloramphenicol_NN acetyltransferase_`` (_-LRB- CAT_NN )_-RRB- gene_NN ._.
Increases_NNS in_IN CAT_JJ activity_NN during_IN transient_JJ expression_NN of_IN these_DT constructs_NNS in_IN TPA-treated_`` U-937_JJ cells_NNS could_MD be_VB assigned_VBN to_TO the_DT region_NN (_-LRB- -97_CD to_TO -20_CD )_-RRB- of_IN the_DT promoter_NN that_WDT contains_VBZ the_DT AP-1_NNP binding_. site_NN ._.
This_DT induction_NN of_IN CAT_JJ activity_NN was_VBD sensitive_JJ to_TO dexamethasone_`` ._.
These_DT findings_NNS suggest_VBP that_IN dexamethasone_`` down-regulates_`` TPA-induced_JJ transcription_NN of_IN the_DT c-jun_JJ gene_NN during_IN monocytic_JJ differentiation_NN by_IN inhibiting_VBG activation_NN of_IN the_DT AP-1_NNP site_NN ._.
Charybdotoxin-sensitive_JJ ,_, Ca(2+)-dependent_JJ membrane_`` potential_JJ changes_NNS are_VBP not_RB involved_VBN in_IN human_JJ T_CD or_CC B_NNP cell_NN activation_NN and_CC proliferation_NN ._.
The_DT involvement_NN of_IN ion_`` channels_NNS in_IN B_NNP and_CC T_NNP lymphocyte_`` activation_NN is_VBZ supported_VBN by_IN many_JJ reports_NNS of_IN changes_NNS in_IN ion_NN fluxes_NNS and_CC membrane_`` potential_JJ after_IN mitogen_NN binding_NN ._.
Human_NNP T_NNP and_CC B_NNP lymphocytes_`` demonstrate_VB an_DT early_JJ and_CC transient_JJ hyperpolarization_NN after_IN ligand_NN binding_NN ._.
Inasmuch_RB as_IN the_DT change_NN in_IN membrane_NN potential_NN is_VBZ dependent_JJ on_IN elevation_NN of_IN free_JJ cytosolic_JJ calcium_NN ,_, the_DT hyperpolarization_NN is_VBZ presumably_RB through_IN opening_NN of_IN Ca(2+)-stimulated_JJ K+_NNP channels_NNS ._.
We_PRP have_VBP used_VBN charybdotoxin_NN ,_, a_DT known_VBN inhibitor_NN of_IN Ca(2+)-dependent_JJ K+_`` channels_NNS ,_, to_TO study_VB the_DT role_NN of_IN these_DT channels_NNS in_IN lymphocyte_`` activation_NN and_CC mitogenesis_NN ._.
We_PRP demonstrate_VBP that_IN charybdotoxin_NN inhibits_VBZ the_DT ligand-induced_`` transient_JJ membrane_NN hyperpolarization_NN in_IN B_NNP and_CC T_NNP cells_NNS in_IN a_DT dose-dependent_JJ fashion_NN ,_, without_IN affecting_VBG changes_NNS in_IN cytosolic_JJ Ca2+_NN ._.
However_RB ,_, blockade_'' of_IN the_DT Ca(2+)-activated_JJ K+_NNP channel_NN is_VBZ not_RB associated_VBN with_IN changes_NNS in_IN cell-cycle_`` gene_NN activation_NN ,_, IL-2_JJ production_NN ,_, IL-2R_JJ expression_NN or_CC B_NNP and_CC T_NNP cell_NN mitogenesis_NN ._.
These_DT results_NNS imply_VBP that_DT membrane_`` potential_JJ changes_NNS secondary_JJ to_TO the_DT ligand-dependent_JJ opening_NN of_IN Ca(2+)-activated_NNP K+_NNP channels_NNS are_VBP not_RB involved_VBN in_IN B_NNP and_CC T_NNP lymphocyte_`` activation_NN and_CC mitogenesis_NN ._.
Evaluation_NN of_IN the_DT role_NN of_IN ligand_NN and_CC thermal_JJ activation_NN of_IN specific_JJ DNA_NNP binding_`` by_IN in_IN vitro_`` synthesized_`` human_JJ glucocorticoid_NN receptor_NN ._.
We_PRP have_VBP used_VBN a_DT DNA-binding/immunoprecipitation_`` assay_NN to_TO analyze_VB the_DT capacity_NN of_IN human_JJ glucocorticoid_NN receptor_NN (_-LRB- hGR_NN )_-RRB- ,_, generated_VBN in_IN rabbit_NN reticulocyte_NN lysates_NNS ,_, to_TO bind_NN DNA_NNP ._.
In_IN vitro_NN translated_VBN hGR_NN was_VBD indistinguishable_JJ from_IN native_JJ hGR_NN ,_, as_IN determined_VBN by_IN migration_NN on_IN sodium_`` dodecyl_JJ sulfate-polyacrylamide_`` gels_NNS ,_, sedimentation_`` on_IN sucrose_`` density_`` gradients_NNS ,_, and_CC reactivity_`` with_IN antipeptide_NN antibodies_NNS generated_VBN against_IN hGR_NN ._.
In_IN addition_NN ,_, cell-free_JJ synthesized_`` hGR_NN was_VBD capable_JJ of_IN specific_JJ binding_VBG to_TO glucocorticoid_JJ response_NN element_NN (_-LRB- GRE_NNP )_-RRB- -containing_# DNA_NNP fragments_NNS ._.
Using_VBG this_DT assay_NN system_NN ,_, we_PRP have_VBP evaluated_`` the_DT contributions_NNS of_IN ligand_NN binding_NN and_CC heat_NN activation_NN to_TO DNA_NNP binding_`` by_IN these_DT glucocorticoid_JJ receptors_NNS ._.
In_IN vitro_NN translated_VBN hGR_NN was_VBD capable_JJ of_IN selective_JJ DNA_NNP binding_`` even_RB in_IN the_DT absence_NN of_IN glucocorticoid_NN ._.
Treatment_NNP with_IN dexamethasone_`` or_CC the_DT antiglucocorticoid_JJ RU486_NNP had_VBD no_DT additional_JJ effect_NN on_IN the_DT DNA-binding_`` capacity_NN when_WRB receptor_NN preparations_NNS were_VBD maintained_VBN at_IN 0_CD C_$ (_-LRB- no_DT activation_NN )_-RRB- ._.
In_IN contrast_NN ,_, addition_NN of_IN either_DT ligand_`` or_CC antagonist_`` in_IN combination_NN with_IN a_DT heat_NN activation_NN step_NN promoted_VBD DNA_NNP binding_`` by_IN approximately_RB 3-fold_JJ over_IN that_DT of_IN heat-activated_JJ unliganded_`` receptors_NNS ._.
Agonist_# (_-LRB- dexamethasone_NN )_-RRB- was_VBD slightly_RB more_RBR effective_JJ in_IN supporting_VBG specific_JJ DNA_NNP binding_`` than_IN antagonist_NN (_-LRB- RU486_NNP )_-RRB- ._.
DNA_NNP binding_`` by_IN in_IN vitro_`` synthesized_`` GR_NNP was_VBD blocked_VBN by_IN the_DT addition_NN of_IN sodium_NN molybdate_NN to_TO the_DT receptor_NN preparations_NNS before_IN steroid_JJ addition_NN and_CC thermal_JJ activation_NN ._.
Addition_NN of_IN KCl_NNP resulted_VBD in_IN less_JJR DNA_NNP binding_`` either_RB due_JJ to_TO blockage_NN of_IN DNA-receptor_`` complex_JJ formation_NN or_CC disruption_NN of_IN the_DT complexes_NNS ._.
The_DT specificity_NN of_IN DNA_NNP binding_`` by_IN cell-free_JJ synthesized_# hGR_NN was_VBD analyzed_VBN further_RBR by_IN examining_VBG the_DT abilities_NNS of_IN various_JJ DNAs_`` to_TO compete_VB for_IN binding_`` to_TO a_DT naturally_RB occurring_VBG GRE_NNP found_VBD in_IN the_DT mouse_NN mammary_`` tumor_NN virus-long_JJ terminal_JJ repeat_NN ._.
Oligonucleotides_# containing_VBG the_DT consensus_NN GRE_NNP were_VBD the_DT most_RBS efficient_JJ competitors_NNS ,_, and_CC fragments_NNS containing_VBG regulatory_JJ sequences_NNS from_IN glucocorticoid-repressible_JJ genes_NNS were_VBD somewhat_RB competitive_JJ ,_, whereas_IN single_JJ stranded_VBN oligonucleotides_NNS were_VBD unable_JJ to_TO compete_VB for_IN mouse_NN mammary_`` tumor_NN virus-long_JJ terminal_JJ repeat_NN DNA_NNP binding_`` ,_, except_IN when_WRB competitor_NN was_VBD present_JJ at_IN extremely_RB high_JJ concentrations_NNS ._.
Together_RB these_DT studies_NNS indicate_VBP that_IN hGR_NN synthesized_`` in_IN rabbit_NN reticulocyte_NN lysates_NNS displays_NNS many_JJ of_IN the_DT same_JJ properties_NNS ,_, including_VBG GRE-specific_JJ DNA_NNP binding_`` ,_, observed_VBN for_IN glucocorticoid_NN receptor_NN present_NN in_IN cytosolic_JJ extracts_NNS of_IN mammalian_JJ cells_NNS and_CC tissues_NNS ._.
Similarities_NNS between_IN the_DT effects_NNS of_IN dexamethasone_`` and_CC RU486_`` suggest_VB that_IN the_DT antiglucocorticoid_JJ properties_NNS of_IN RU486_NNP do_VBP not_RB occur_VB at_IN the_DT level_NN of_IN specific_JJ DNA_NNP binding_NN ._.
One_CD base_NN pair_NN change_NN abolishes_VBZ the_DT T_`` cell-restricted_JJ activity_NN of_IN a_DT kB-like_JJ proto-enhancer_`` element_NN from_IN the_DT interleukin_NN 2_CD promoter_NN ._.
The_DT inducible_JJ ,_, T_JJ cell-specific_JJ enhancers_NNS of_IN murine_`` and_CC human_JJ Interleukin_NNP 2_CD (_-LRB- Il-2_NN )_-RRB- genes_NNS contain_VBP the_DT kB-like_JJ sequence_NN GGGATTTCACC_`` as_IN an_DT essential_JJ cis-acting_JJ enhancer_NN motif_NN ._.
When_WRB cloned_`` in_IN multiple_JJ copies_NNS this_DT so-called_JJ TCEd_NNP (_-LRB- distal_`` T_JJ cell_NN element_NN )_-RRB- acts_VBZ as_IN an_DT inducible_JJ proto-enhancer_NN element_NN in_IN E14_`` T_JJ lymphoma_`` cells_NNS ,_, but_CC not_RB in_IN HeLa_NNP cells_NNS ._.
In_IN extracts_NNS of_IN induced_# ,_, Il-2_-RRB- secreting_VBG El4_CD cells_NNS three_CD individual_JJ protein_NN factors_NNS bind_VBP to_TO TCEd_NNP DNA_NNP ._.
The_DT binding_`` of_IN the_DT most_RBS prominent_JJ factor_NN ,_, named_VBN TCF-1_NNP (_-LRB- T_`` cell_NN factor_NN 1_CD )_-RRB- ,_, is_VBZ correlated_VBN with_IN the_DT proto-enhancer_`` activity_NN of_IN TCEd_NNP ._.
TCF-1_NNP consists_VBZ of_IN two_CD polypeptides_NNS of_IN about_IN 50_CD kD_# and_CC 105_CD kD_`` ;_: the_DT former_JJ seems_VBZ to_TO be_VB related_VBN to_TO the_DT 50_CD kD_NNP polypeptide_NN of_IN NF-kB_NNP ._.
Purified_VBN NF-kB_NNP is_VBZ also_RB able_JJ to_TO bind_NN to_TO the_DT TCEd_NNP ,_, but_CC TCF-1_NNP binds_`` stronger_JJR than_IN NF-kB_NNP to_TO TCEd_NNP DNA_NNP ._.
The_DT conversion_NN of_IN the_DT TCEd_NNP to_TO a_DT '_'' perfect_JJ '_'' NF-kB_NNP binding_`` site_NN leads_VBZ to_TO a_DT tighter_JJR binding_NN of_IN NF-kB_NNP to_TO TCEd_NNP DNA_NNP and_CC ,_, as_IN a_DT functional_JJ consequence_NN ,_, to_TO the_DT activity_NN of_IN the_DT '_'' converted_VBN '_'' TCEd_NNP motifs_`` in_IN HeLa_NNP cells_NNS ._.
Thus_RB ,_, the_DT substitution_NN of_IN the_DT underlined_`` A_DT residue_`` to_TO a_DT C_$ within_IN the_DT GGGATTTCACC_NNP motif_`` abolishes_VBZ its_PRP$ T_NNP cell-restricted_JJ activity_NN and_CC leads_VBZ to_TO its_PRP$ functioning_NN in_IN both_DT El4_CD cells_NNS and_CC HeLa_NNP cells_NNS ._.
These_DT results_NNS indicate_VBP that_IN lymphocyte-specific_JJ factors_NNS binding_VBG to_TO the_DT TCEd_NNP are_VBP involved_VBN in_IN the_DT control_NN of_IN T_JJ cell_NN specific-transcription_NN of_IN the_DT Il-2_JJ gene_NN ._.
Negative_JJ regulation_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD expression_NN in_IN monocytes_`` :_: role_NN of_IN the_DT 65-kDa_NNP plus_CC 50-kDa_NNP NF-kappa_NNP B_NNP dimer_NN ._.
Although_IN monocytic_JJ cells_NNS can_MD provide_VB a_DT reservoir_NN for_IN viral_JJ production_NN in_IN vivo_`` ,_, their_PRP$ regulation_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_-LRB- HIV-1_NN )_-RRB- transcription_NN can_MD be_VB either_RB latent_JJ ,_, restricted_VBN ,_, or_CC productive_JJ ._.
These_DT differences_NNS in_IN gene_NN expression_NN have_VBP not_RB been_VBN molecularly_RB defined_VBN ._.
In_IN THP-1_JJ cells_NNS with_IN restricted_JJ HIV_NNP expression_NN ,_, there_EX is_VBZ an_DT absence_NN of_IN DNA-protein_NNP binding_`` complex_JJ formation_NN with_IN the_DT HIV-1_NNP promoter-enhancer_NN associated_VBN with_IN markedly_RB less_JJR viral_JJ RNA_NNP production_NN ._.
This_DT absence_NN of_IN binding_NN was_VBD localized_VBN to_TO the_DT NF-kappa_NNP B_NNP region_NN of_IN the_DT HIV-1_`` enhancer_NN ;_: the_DT 65-kDa_JJ plus_CC 50-kDa_JJ NF-kappa_NNP B_NNP heterodimer_NN was_VBD preferentially_RB lost_VBN ._.
Adding_VBG purified_`` NF-kappa_NNP B_NNP protein_NN to_TO nuclear_JJ extracts_NNS from_IN cells_NNS with_IN restricted_JJ expression_NN overcomes_`` this_DT lack_NN of_IN binding_NN ._.
In_IN addition_NN ,_, treatment_NN of_IN these_DT nuclear_JJ extracts_NNS with_IN sodium_`` deoxycholate_`` restored_VBN their_PRP$ ability_NN to_TO form_VB the_DT heterodimer_`` ,_, suggesting_VBG the_DT presence_NN of_IN an_DT inhibitor_NN of_IN NF-kappa_NNP B_NNP activity_NN ._.
Furthermore_RB ,_, treatment_NN of_IN nuclear_JJ extracts_NNS from_IN these_DT cells_NNS that_WDT had_VBD restricted_VBN expression_NN with_IN lipopolysaccharide_NN increased_VBN viral_JJ production_NN and_CC NF-kappa_NNP B_NNP activity_NN ._.
Antiserum_WP$ specific_JJ for_IN NF-kappa_NNP B_NNP binding_# proteins_NNS ,_, but_CC not_RB c-rel-specific_JJ antiserum_# ,_, disrupted_VBD heterodimer_`` complex_JJ formation_NN ._.
Thus_RB ,_, both_DT NF-kappa_NNP B-binding_`` complexes_NNS are_VBP needed_VBN for_IN optimal_`` viral_JJ transcription_NN ._.
Binding_-RRB- of_IN the_DT 65-kDa_NNP plus_CC 50-kDa_NNP heterodimer_`` to_TO the_DT HIV-1_`` enhancer_NN can_MD be_VB negatively_RB regulated_VBN in_IN monocytes_NNS ,_, providing_VBG one_CD mechanism_NN restricting_VBG HIV-1_`` gene_NN expression_NN ._.
Isolation_NN of_IN a_DT candidate_NN repressor/activator_NN ,_, NF-E1_WP$ (_-LRB- YY-1_NN ,_, delta_NN )_-RRB- ,_, that_WDT binds_VBZ to_TO the_DT immunoglobulin_`` kappa_`` 3'_`` enhancer_`` and_CC the_DT immunoglobulin_`` heavy-chain_JJ mu_NN E1_`` site_NN ._.
We_PRP have_VBP determined_VBN that_IN the_DT developmental_JJ control_NN of_IN immunoglobulin_JJ kappa_NN 3'_`` enhancer_`` (_-LRB- kappa_NN E3'_NN )_-RRB- activity_NN is_VBZ the_DT result_NN of_IN the_DT combined_VBN influence_NN of_IN positive-_`` and_CC negative-acting_JJ elements_NNS ._.
We_PRP show_VBP that_IN a_DT central_JJ core_NN in_IN the_DT kappa_NN E3'_`` enhancer_NN is_VBZ active_JJ at_IN the_DT pre-B-cell_JJ stage_NN but_CC is_VBZ repressed_VBN by_IN flanking_VBG negative-acting_JJ elements_NNS ._.
The_DT negative-acting_JJ sequences_NNS repress_`` enhancer_`` activity_NN in_IN a_DT position-_NN and_CC orientation-independent_JJ manner_NN at_IN the_DT pre-B-cell_JJ stage_NN ._.
We_PRP have_VBP isolated_VBN a_DT human_JJ cDNA_NN clone_`` encoding_`` a_DT zinc_`` finger_NN protein_NN (_-LRB- NF-E1_CD )_-RRB- that_WDT binds_VBZ to_TO the_DT negative-acting_JJ segment_NN of_IN the_DT kappa_NN E3'_NNP enhancer_NN ._.
This_DT protein_NN also_RB binds_VBZ to_TO the_DT immunoglobulin_`` heavy-chain_JJ enhancer_NN mu_`` E1_`` site_NN ._.
NF-E1_# is_VBZ encoded_VBN by_IN the_DT same_JJ gene_NN as_IN the_DT YY-1_NNP protein_NN ,_, which_WDT binds_VBZ to_TO the_DT adeno-associated_JJ virus_NN P5_CD promoter_NN ._.
NF-E1_NN is_VBZ also_RB the_DT human_JJ homologue_NN of_IN the_DT mouse_NN delta_JJ protein_NN ,_, which_WDT binds_VBZ to_TO ribosomal_JJ protein_NN gene_NN promoters_NNS ._.
The_DT predicted_VBN amino_IN acid_JJ sequence_NN of_IN this_DT protein_NN contains_VBZ features_NNS characteristic_JJ of_IN transcriptional_JJ activators_NNS as_RB well_RB as_IN transcriptional_JJ repressors_NNS ._.
Cotransfection_NN studies_NNS with_IN this_DT cDNA_NNP indicate_VBP that_IN it_PRP can_MD repress_VB basal_`` promoter_NN activity_NN ._.
The_DT apparent_JJ dual_JJ function_NN of_IN this_DT protein_NN is_VBZ discussed_VBN ._.
Clone_JJ pAT_NN 133_`` identifies_VBZ a_DT gene_NN that_WDT encodes_VBZ another_DT human_JJ member_NN of_IN a_DT class_NN of_IN growth_NN factor-induced_# genes_NNS with_IN almost_RB identical_JJ zinc-finger_`` domains_NNS ._.
We_PRP report_VBP the_DT structure_NN and_CC regulation_NN of_IN a_DT gene_NN represented_VBN by_IN clone_`` pAT_NN 133_CD ,_, which_WDT is_VBZ induced_VBN upon_IN transition_NN from_IN a_DT resting_VBG state_NN (_-LRB- G0_NNP )_-RRB- through_IN the_DT early_JJ phase_NN of_IN the_DT cell_NN cycle_NN (_-LRB- G1_NNP )_-RRB- ._.
The_DT pAT_NN 133_CD gene_NN is_VBZ immediately_RB induced_`` ,_, with_IN FOS-like_JJ kinetics_NNS ,_, in_IN human_JJ T_JJ cells_NNS and_CC in_IN fibroblasts_NNS ._.
Primary_JJ structure_NN analysis_NN showed_VBD that_IN the_DT encoded_JJ protein_NN contains_VBZ three_CD tandem_`` zinc-finger_`` sequences_NNS of_IN the_DT type_NN Cys2-Xaa12-His2_NN ._.
This_DT zinc-finger_`` region_NN ,_, which_WDT is_VBZ thought_VBN to_TO bind_NN DNA_NNP in_IN a_DT sequence-specific_JJ manner_NN ,_, is_VBZ similar_JJ (_-LRB- greater_JJR than_IN 80_CD %_NN on_IN the_DT amino_JJ acid_NN level_NN )_-RRB- to_TO two_CD previously_RB described_VBN transcription_NN factors_NNS pAT_JJ 225/EGR1_`` and_CC pAT_NN 591/EGR2_# ._.
Except_IN for_IN the_DT conserved_`` zinc-finger_`` domains_NNS ,_, the_DT amino_JJ acid_NN sequences_`` of_IN the_DT three_CD proteins_NNS are_VBP distinct_JJ ._.
This_DT structural_JJ similarity_NN suggests_VBZ that_IN the_DT pAT_NN 133_CD gene_NN encodes_VBZ a_DT transcription_NN factor_NN with_IN a_DT specific_JJ biological_JJ function_NN ._.
Comparing_VBG the_DT regulation_NN of_IN these_DT related_VBN zinc-finger-encoding_`` genes_NNS showed_VBD coordinate_VB induction_NN upon_IN mitogenic_JJ stimulation_NN of_IN resting_VBG T_JJ lymphocytes_NNS and_CC of_IN resting_VBG fibroblasts_NNS ._.
However_RB ,_, upon_IN transition_NN from_IN a_DT proliferating_# (_-LRB- G1_NN )_-RRB- to_TO a_DT resting_VBG state_NN of_IN the_DT cell_NN cycle_NN the_DT three_CD genes_NNS were_VBD differently_RB regulated_VBN ._.
In_IN human_JJ histiocytic_`` U937_`` cells_NNS mRNA_# of_IN clone_`` pAT_NN 133_CD was_VBD constitutively_RB expressed_VBN ,_, whereas_IN mRNA_NNP of_IN pAT_NN 225/EGR1_CD was_VBD induced_VBN upon_IN induction_NN of_IN terminal_JJ differentiation_NN ._.
In_IN contrast_NN mRNA_`` representing_VBG pAT_NN 591/EGR2_NN was_VBD not_RB expressed_VBN in_IN these_DT cells_NNS ._.
This_DT difference_NN in_IN gene_NN regulation_NN suggests_VBZ distinct_JJ biological_JJ roles_NNS in_IN the_DT control_NN of_IN cell_NN proliferation_NN for_IN the_DT respective_JJ proteins_NNS ._.
cAMP-dependent_JJ regulation_NN of_IN proenkephalin_# by_IN JunD_NNP and_CC JunB_NNP :_: positive_JJ and_CC negative_JJ effects_NNS of_IN AP-1_`` proteins_NNS ._.
We_PRP demonstrate_VBP that_IN JunD_NNP ,_, a_DT component_NN of_IN the_DT AP-1_NNP transcription_`` factor_NN complex_JJ ,_, activates_NNS transcription_NN of_IN the_DT human_JJ proenkephalin_NN gene_NN in_IN a_DT fashion_NN that_WDT is_VBZ completely_RB dependent_JJ upon_IN the_DT cAMP-dependent_JJ protein_NN kinase_`` ,_, protein_NN kinase_`` A_DT ._.
Activation_NN of_IN proenkephalin_`` transcription_NN by_IN JunD_NNP is_VBZ dependent_JJ upon_IN a_DT previously_RB characterized_VBN cAMP-_NN ,_, phorbol_NN ester-_NN ,_, and_CC Ca(2+)-inducible_JJ enhancer_NN ,_, and_CC JunD_NNP is_VBZ shown_VBN to_TO bind_NN the_DT enhancer_NN as_IN a_DT homodimer_NN ._.
Another_DT component_NN of_IN the_DT AP-1_NNP transcription_`` complex_JJ ,_, JunB_'' ,_, is_VBZ shown_VBN to_TO inhibit_VB activation_`` mediated_VBN by_IN JunD_NNP ._.
As_IN a_DT homodimer_NN JunB_NNP is_VBZ unable_JJ to_TO bind_NN the_DT enhancer_NN ;_: however_RB in_IN the_DT presence_NN of_IN c-Fos_# ,_, high-affinity_'' binding_NN is_VBZ observed_VBN ._.
Furthermore_RB ,_, JunD_'' is_VBZ shown_VBN to_TO activate_VB transcription_NN of_IN genes_NNS linked_VBN to_TO both_DT cAMP_NNP and_CC phorbol_`` ester_`` response_NN elements_NNS in_IN a_DT protein_NN kinase_`` A-dependent_JJ fashion_NN ,_, further_JJ blurring_VBG the_DT distinction_NN between_IN these_DT response_NN elements_NNS ._.
These_DT results_NNS demonstrate_VBP that_IN the_DT transcriptional_JJ activity_NN of_IN an_DT AP-1-related_JJ protein_NN is_VBZ regulated_VBN by_IN the_DT cAMP-dependent_JJ second-messenger_NN pathway_NN and_CC suggest_VB that_IN JunD_NNP and_CC other_JJ AP-1-related_JJ proteins_NNS may_MD play_VB an_DT important_JJ role_NN in_IN the_DT regulation_NN of_IN gene_NN expression_NN by_IN cAMP-dependent_JJ intracellular_`` signaling_VBG pathways_NNS ._.
Glucocorticoid_JJ resistance_NN in_IN chronic_JJ asthma_NN ._.
Glucocorticoid_JJ pharmacokinetics_NNS ,_, glucocorticoid_JJ receptor_NN characteristics_NNS ,_, and_CC inhibition_NN of_IN peripheral_JJ blood_NN T_`` cell_NN proliferation_NN by_IN glucocorticoids_NNS in_IN vitro_NN ._.
A_DT total_NN of_IN 37_CD chronic_NN ,_, severe_JJ ,_, nonsmoking_JJ asthmatic_JJ patients_NNS with_IN documented_VBN reversible_`` airways_NNS obstruction_NN were_VBD classified_VBN as_IN glucocorticoid-sensitive_JJ or_CC -resistant_JJ on_IN the_DT basis_NN of_IN changes_NNS in_IN FEV1_CD ,_, FVC_NNP ,_, and_CC peak_VB expiratory_JJ flow_NN (_-LRB- PEF_NN )_-RRB- after_IN oral_JJ prednisolone_`` ._.
The_DT resistant_`` patients_NNS showed_VBD no_DT significant_JJ improvements_NNS in_IN airflow_NN limitation_NN ._.
Phytohemagglutinin_NNP (_-LRB- PHA_NNP )_-RRB- -induced_`` proliferation_NN of_IN peripheral_JJ blood_NN T_`` lymphocytes_`` from_IN the_DT sensitive_JJ but_CC not_RB the_DT resistant_JJ asthmatic_JJ patients_NNS was_VBD significantly_RB (_-LRB- p_NN less_JJR than_IN 0.01_CD )_-RRB- inhibited_`` by_IN dexamethasone_`` (_-LRB- 10(-7)_JJ mol/L_NN )_-RRB- ,_, reflecting_VBG a_DT shift_NN of_IN the_DT dose-response_JJ curve_NN ._.
When_WRB all_PDT the_DT asthmatic_JJ patients_NNS were_VBD analyzed_VBN together_RB ,_, there_EX was_VBD a_DT significant_JJ correlation_NN between_IN the_DT degree_NN of_IN sensitivity_NN of_IN T_JJ cells_NNS to_TO dexamethasone_`` and_CC the_DT clinical_JJ responsiveness_NN to_TO prednisolone_`` (_-LRB- p_NN less_JJR than_IN 0.01_CD )_-RRB- ._.
No_DT differences_NNS were_VBD observed_JJ between_IN six_CD of_IN the_DT sensitive_JJ and_CC resistant_JJ patients_NNS in_IN the_DT clearance_NN of_IN plasma_NN prednisolone_`` derived_VBD from_IN orally_RB administered_VBN prednisone_NN ._.
Peripheral_JJ blood_NN mononuclear_`` cell_NN glucocorticoid_JJ receptors_NNS were_VBD also_RB characterized_VBN in_IN five_CD sensitive_JJ and_CC seven_CD resistant_JJ patients_NNS ._.
The_DT numbers_NNS and_CC binding_JJ affinities_NNS of_IN these_DT receptors_NNS could_MD not_RB account_VB for_IN the_DT observed_JJ difference_NN in_IN the_DT susceptibility_NN of_IN these_DT cells_NNS to_TO functional_JJ inhibition_NN by_IN dexamethasone_NN in_IN vitro_NN ._.
These_DT results_NNS suggest_VBP that_IN clinical_JJ glucocorticoid_JJ resistance_NN in_IN chronic_NN asthma_NN does_VBZ not_RB reflect_VB abnormal_JJ glucocorticoid_JJ clearance_NN but_CC may_MD be_VB due_JJ at_IN least_JJS partly_RB to_TO a_DT relative_JJ insensitivity_NN of_IN T_JJ lymphocytes_NNS to_TO glucocorticoids_NNS ._.
This_DT lack_NN of_IN sensitivity_NN is_VBZ unexplained_JJ but_CC is_VBZ not_RB attributable_JJ to_TO abnormalities_NNS of_IN cellular_JJ glucocorticoid_JJ receptors_NNS ._.
Regulation_NN of_IN interleukin-1_`` beta_JJ production_NN by_IN glucocorticoids_NNS in_IN human_JJ monocytes_`` :_: the_DT mechanism_NN of_IN action_NN depends_VBZ on_IN the_DT activation_NN signal_NN ._.
Glucocorticoids_NNS are_VBP known_VBN to_TO downregulate_VB interleukin-1_JJ beta_NN production_NN in_IN monocytic_JJ cells_NNS by_IN two_CD different_JJ mechanims_NNS :_: direct_JJ inhibition_NN of_IN the_DT gene_NN transcription_NN and_CC destabilization_NN of_IN the_DT preformed_`` interleukin-1_JJ beta_NN mRNA_NN ._.
Now_RB we_PRP have_VBP examined_VBN the_DT effect_NN of_IN the_DT nature_NN of_IN the_DT monocyte_NN activating_VBG signal_NN on_IN these_DT two_CD inhibitory_JJ mechanims_NNS ._.
When_WRB human_JJ monocytes_NNS were_VBD preincubated_VBN with_IN dexamethasone_NN for_IN 1_CD hour_NN and_CC then_RB stimulated_VBD either_CC with_IN bacterial_JJ lipopolysaccharide_NN or_CC phorbol_NN myristate_NN ,_, it_PRP was_VBD found_VBN that_IN dexamethasone_`` inhibited_VBD the_DT lipopolysaccharide-induced_`` interleukin-1_JJ beta_JJ protein_NN production_NN ,_, but_CC the_DT phorbol_`` myristate-induced_JJ production_NN was_VBD increased_VBN 3-10_JJ fold_NN ._.
This_DT difference_NN was_VBD also_RB seen_VBN at_IN the_DT mRNA_NNP level_NN ._.
When_WRB dexamethasone_NN was_VBD added_VBN to_TO the_DT cultures_NNS 3_CD hours_NNS after_IN the_DT stimulators_NNS ,_, it_PRP clearly_RB decreased_VBD the_DT interleukin-1_JJ beta_NN mRNA_`` levels_NNS regardless_RB of_IN the_DT stimulator_NN used_VBN (_-LRB- although_IN the_DT effect_NN was_VBD clearly_RB weaker_JJR on_IN the_DT PMA-induced_NNP mRNA_NNP )_-RRB- ._.
Thus_RB these_DT data_NNS suggest_VBP that_IN the_DT phorbol_NN myristate-induced_JJ signal_NN (_-LRB- prolonged_JJ protein_NN kinase_`` C_$ activation_NN ?_. )_-RRB- can_MD not_RB be_VB inhibited_VBN by_IN prior_JJ incubation_NN with_IN dexamethasone_`` and_CC it_PRP also_RB protects_VBZ the_DT induced_`` mRNA_`` for_IN the_DT degradative_JJ action_NN of_IN dexamethasone_NN ._.
Identification_NN of_IN transcriptional_JJ suppressor_NN proteins_NNS that_WDT bind_VBP to_TO the_DT negative_JJ regulatory_JJ element_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ._.
Two_CD different_JJ proteins_NNS which_WDT independently_RB bound_VBD to_TO neighboring_VBG sequences_NNS within_IN the_DT negative_JJ regulatory_JJ element_NN (_-LRB- NRE_NNP )_-RRB- of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_-LRB- HIV-1_NNP )_-RRB- were_VBD detected_VBN in_IN the_DT nuclear_JJ extract_VB of_IN a_DT virus-infected_JJ human_JJ T_JJ cell_NN line_NN ._.
One_CD of_IN the_DT factors_NNS bound_VBN to_TO a_DT novel_JJ dyad_`` symmetrical_JJ sequence_NN ._.
This_DT sequence_NN is_VBZ well_RB conserved_`` in_IN various_JJ HIV-1_`` isolates_NNS and_CC partial_JJ homology_NN was_VBD found_VBN with_IN the_DT promoter_NN region_NN of_IN the_DT human_JJ retinoblastoma_NN gene_NN ._.
Similar_JJ DNA_NNP binding_`` activity_NN was_VBD detected_VBN in_IN a_DT variety_NN of_IN virus-uninfected_`` human_JJ T_# cell_NN lines_NNS and_CC HeLa_NNP cells_NNS by_IN means_NNS of_IN a_DT gel_'' mobility_NN shift_NN assay_NN ._.
The_DT other_JJ factor_NN bound_VBN to_TO a_DT putative_JJ AP-1_NNP recognition_NN sequence_NN predicted_VBD for_IN the_DT HIV-1_NNP NRE_NNP ._.
However_RB ,_, this_DT factor_NN did_VBD not_RB bind_NN to_TO a_DT typical_JJ AP-1_NNP site_NN ._.
The_DT insertion_NN of_IN multiple_JJ copies_NNS of_IN the_DT binding_`` site_NN for_IN the_DT former_JJ or_CC latter_JJ factor_NN into_IN a_DT heterologous_`` promoter_NN reduced_VBD the_DT promoter_NN activity_NN to_TO one-tenth_`` or_CC one-third_NN ,_, respectively_RB ._.
Thus_RB ,_, each_DT factor_NN may_MD function_VB as_IN a_DT novel_JJ negative_JJ regulator_NN of_IN transcription_NN ._.
Constitutive_JJ activation_NN of_IN NF-kB_NNP in_IN human_JJ thymocytes_NNS ._.
NF-kB_NNP is_VBZ a_DT eukaryotic_JJ transcription_`` regulatory_JJ factor_NN ._.
In_IN T_JJ cells_NNS and_CC T_JJ cell_NN lines_NNS ,_, NF-kB_NNP is_VBZ bound_VBN to_TO a_DT cytoplasmic_JJ proteic_JJ inhibitor_NN ,_, the_DT IkB_NNP ._.
Treatment_NNP of_IN T_JJ cells_NNS with_IN mitogens_NNS (_-LRB- phorbol_NN esters_NNS )_-RRB- or_CC cytokines_NNS (_-LRB- TNF_NN alpha_NN )_-RRB- induces_VBZ NF-kB_JJ nuclear_JJ translocation_NN and_CC the_DT subsequent_JJ expression_NN of_IN NF-kB_NNP dependent_JJ T_JJ cell_NN genes_NNS ._.
Here_RB we_PRP examined_VBD the_DT activation_NN of_IN NF-kB_NNP in_IN human_JJ T_`` cell_NN thymic_JJ progenitors_NNS ._.
We_PRP report_VBP differences_NNS in_IN (Ca2+)i_JJ requirement_NN for_IN NF-kB_NNP activation_NN in_IN thymocytes_# as_IN compared_VBN to_TO mature_VB T_JJ cells_NNS ._.
Furthermore_RB ,_, our_PRP$ results_NNS indicated_VBD that_IN thymocytes_NNS have_VBP a_DT constitutively_RB active_JJ form_NN of_IN NF-kB_NNP ,_, suggesting_VBG that_IN they_PRP are_VBP activated_VBN in_IN vivo_`` ._.
The_DT role_NN of_IN jun_`` and_CC fos_`` gene_NN family_NN members_NNS in_IN 12-O-tetradecanoylphorbol-13-acetate_JJ induced_`` hemopoietic_JJ differentiation_NN ._.
Terminal_JJ differentiation_NN of_IN the_DT leukemic_JJ cell_NN lines_NNS U-937_`` and_CC HL-60_`` by_IN 12-O-tetradecanoylphorbol-13-acetate_-RRB- is_VBZ accompanied_VBN by_IN marked_JJ changes_NNS in_IN gene_NN expression_NN ._.
In_IN this_DT study_NN ,_, we_PRP demonstrate_VBP that_IN the_DT expression_NN of_IN jun_`` and_CC fos_`` gene_NN family_NN members_NNS is_VBZ induced_VBN with_IN variable_JJ kinetics_NNS during_IN 12-O-tetradecanoylphorbol-13-acetate_JJ induced_`` differentiation_NN ,_, with_IN c-jun_JJ expression_NN best_JJS paralleling_`` differentiation_NN ._.
The_DT generation_NN of_IN AP-1_NNP complexes_`` ,_, as_IN measured_VBN by_IN DNA_NNP binding_`` activity_NN ,_, closely_RB parallels_`` morphological_JJ differentiation_NN ._.
Furthermore_RB ,_, the_DT ability_NN of_IN these_DT complexes_NNS to_TO regulate_VB gene_NN expression_NN is_VBZ demonstrated_VBN by_IN increased_VBN transcription_NN from_IN an_DT AP-1_NN driven_VBN reporter_NN construct_VB and_CC marked_VBD increases_NNS in_IN the_DT expression_NN of_IN endogenous_JJ AP-1_`` regulated_JJ genes_NNS ._.
Differentiation_# assays_`` using_VBG water_NN soluble_`` phorbol_`` esters_NNS reveal_VBP that_IN differentiation_NN becomes_VBZ irreversible_`` soon_RB after_IN AP-1_NNP appears_VBZ ._.
This_DT tight_JJ correlation_NN between_IN c-jun_JJ expression_NN ,_, the_DT generation_NN of_IN AP-1_JJ activity_NN ,_, and_CC differentiation_NN suggests_VBZ a_DT critical_JJ role_NN for_IN this_DT gene_NN and_CC transcriptional_`` complex_JJ during_IN this_DT process_NN ._.
TCF-1_NN ,_, a_DT T_JJ cell-specific_JJ transcription_NN factor_NN of_IN the_DT HMG_NNP box_NN family_NN ,_, interacts_'' with_IN sequence_NN motifs_NNS in_IN the_DT TCR_NNP beta_NN and_CC TCR_`` delta_JJ enhancers_NNS ._.
We_PRP have_VBP recently_RB identified_VBN and_CC cloned_VBN TCF-1_NNP ,_, a_DT T_JJ cell-specific_JJ transcription_NN factor_NN with_IN specificity_NN for_IN the_DT AACAAAG_NNP motif_`` in_IN the_DT CD3_`` epsilon_`` enhancer_NN and_CC for_IN the_DT TTCAAAG_NNP motif_`` in_IN the_DT TCR_NNP alpha_NN enhancer_NN ._.
TCF-1_NN belongs_VBZ to_TO the_DT family_NN of_IN transcription-regulating_`` proteins_NNS which_WDT share_VBP a_DT region_NN of_IN homology_NN termed_VBD the_DT HMG-box_`` ._.
Here_RB ,_, we_PRP show_VBP by_IN gel_`` retardation_`` analysis_NN that_IN TCF-1_NNP specifically_RB recognizes_VBZ the_DT T_JJ beta_JJ 5_CD element_NN of_IN the_DT TCR_`` beta_JJ enhancer_NN and_CC the_DT T_JJ delta_NN 7_CD element_NN of_IN the_DT TCR_`` delta_JJ enhancer_NN ._.
Comparison_NN of_IN the_DT sequences_NNS of_IN all_DT elements_NNS recognized_VBN by_IN TCF-1_NNP defines_`` a_DT consensus_NN motif_`` A/T_NNP A/T_NNP C_NNP A_DT A/G_`` A_DT G_NNP ._.
These_DT observations_NNS imply_VBP that_IN TCF-1_NNP is_VBZ involved_VBN in_IN the_DT control_NN of_IN several_JJ T_`` cell-specific_JJ genes_NNS and_CC might_MD thus_RB play_VB an_DT important_JJ role_NN in_IN the_DT establishment_NN and_CC maintenance_NN of_IN the_DT mature_JJ T_JJ cell_NN phenotype_NN ._.
The_DT cellular_JJ oncogene_NN c-myb_`` can_MD interact_VB synergistically_RB with_IN the_DT Epstein-Barr_`` virus_NN BZLF1_CD transactivator_NN in_IN lymphoid_JJ cells_NNS ._.
Regulation_NN of_IN replicative_JJ functions_NNS in_IN the_DT Epstein-Barr_`` virus_NN (_-LRB- EBV_NNP )_-RRB- genome_`` is_VBZ mediated_VBN through_IN activation_NN of_IN a_DT virally_RB encoded_`` transcription_`` factor_NN ,_, Z_NN (_-LRB- BZLF1_NNP )_-RRB- ._.
We_PRP have_VBP shown_VBN that_IN the_DT Z_NN gene_NN product_NN ,_, which_WDT binds_VBZ to_TO AP-1_`` sites_NNS as_IN a_DT homodimer_NN and_CC has_VBZ sequence_NN similarity_NN to_TO c-Fos_`` ,_, can_MD efficiently_RB activate_VB the_DT EBV_NNP early_JJ promoter_NN ,_, BMRF1_NNP ,_, in_IN certain_JJ cell_NN types_NNS (_-LRB- i.e._NN ,_, HeLa_NNP cells_NNS )_-RRB- but_CC not_RB others_NNS (_-LRB- i.e._NN ,_, Jurkat_NNP cells_NNS )_-RRB- ._.
Here_RB we_PRP demonstrate_VBP that_IN the_DT c-myb_JJ proto-oncogene_NN product_NN ,_, which_WDT is_VBZ itself_PRP a_DT DNA-binding_`` protein_NN and_CC transcriptional_JJ transactivator_NN ,_, can_MD interact_VB synergistically_RB with_IN Z_NN in_IN activating_VBG the_DT BMRF1_`` promoter_NN in_IN Jurkat_NNP cells_NNS (_-LRB- a_DT T-cell_`` line_NN )_-RRB- or_CC Raji_NNP cells_NNS (_-LRB- an_DT EBV-positive_JJ B-cell_NNP )_-RRB- ,_, whereas_IN the_DT c-myb_JJ gene_NN product_NN by_IN itself_PRP has_VBZ little_JJ effect_NN ._.
The_DT simian_`` virus_NN 40_CD early_JJ promoter_NN is_VBZ also_RB synergistically_RB activated_VBN by_IN the_DT Z/c-myb_JJ combination_NN ._.
Synergistic_JJ transactivation_NN of_IN the_DT BMRF1_`` promoter_NN by_IN the_DT Z/c-myb_JJ combination_NN appears_VBZ to_TO involve_VB direct_JJ binding_NN by_IN the_DT Z_NN protein_NN but_CC not_RB the_DT c-myb_JJ protein_NN ._.
A_DT 30-bp_JJ sequence_NN in_IN the_DT BMRF1_NN promoter_NN which_WDT contains_VBZ a_DT Z_NN binding_`` site_NN (_-LRB- a_DT consensus_NN AP-1_`` site_NN )_-RRB- is_VBZ sufficient_JJ to_TO transfer_VB high-level_JJ lymphoid-specific_JJ responsiveness_NN to_TO the_DT Z/c-myb_JJ combination_NN to_TO a_DT heterologous_`` promoter_NN ._.
That_PDT the_DT c-myb_JJ oncogene_NN product_NN can_MD interact_VB synergistically_RB with_IN an_DT EBV-encoded_JJ member_NN of_IN the_DT leucine_`` zipper_NN protein_NN family_NN suggests_VBZ c-myb_`` is_VBZ likely_JJ to_TO engage_VB in_IN similar_JJ interactions_NNS with_IN cellularly_`` encoded_JJ transcription_NN factors_NNS ._.
The_DT 29-kDa_NNP proteins_VBZ phosphorylated_`` in_IN thrombin-activated_`` human_JJ platelets_NNS are_VBP forms_NNS of_IN the_DT estrogen_NN receptor-related_`` 27-kDa_JJ heat_NN shock_NN protein_NN ._.
Thrombin_NN plays_VBZ a_DT critical_JJ role_NN in_IN platelet_NN activation_NN ,_, hemostasis_NN ,_, and_CC thrombosis_NN ._.
Cellular_NNP activation_`` by_IN thrombin_NN leads_NNS to_TO the_DT phosphorylation_NN of_IN multiple_JJ proteins_NNS ,_, most_JJS of_IN which_WDT are_VBP unidentified_JJ ._.
We_PRP have_VBP characterized_VBN several_JJ 29-kDa_`` proteins_NNS that_WDT are_VBP rapidly_RB phosphorylated_`` following_VBG exposure_NN of_IN intact_JJ human_JJ platelets_NNS to_TO thrombin_`` ._.
A_DT murine_`` monoclonal_JJ antibody_NN raised_VBD to_TO an_DT unidentified_JJ estrogen_NN receptor-related_`` 29-kDa_JJ protein_NN selectively_RB recognized_VBD these_DT proteins_NNS as_RB well_RB as_IN a_DT more_JJR basic_JJ ,_, unphosphorylated_JJ 27-kDa_JJ protein_NN ._.
Cellular_NNP activation_`` by_IN thrombin_NN led_VBD to_TO a_DT marked_JJ shift_NN in_IN the_DT proportion_NN of_IN protein_NN from_IN the_DT 27-kDa_`` unphosphorylated_JJ form_NN to_TO the_DT 29-kDa_JJ phosphoprotein_NN species_NNS ._.
Using_VBG this_DT antibody_NN ,_, we_PRP isolated_VBD and_CC sequenced_VBD a_DT human_JJ cDNA_NN clone_`` encoding_`` a_DT protein_NN that_WDT was_VBD identical_JJ to_TO the_DT mammalian_`` 27-kDa_JJ heat_NN shock_NN protein_NN (_-LRB- HSP27_NN )_-RRB- ,_, a_DT protein_NN of_IN uncertain_JJ function_NN that_IN is_VBZ known_VBN to_TO be_VB phosphorylated_VBN to_TO several_JJ forms_NNS and_CC to_TO be_VB transcriptionally_RB induced_VBN by_IN estrogen_NN ._.
The_DT 29-kDa_NNP proteins_NNS were_VBD confirmed_VBN to_TO be_VB phosphorylated_JJ forms_NNS of_IN HSP27_CD by_IN immunoprecipitation_`` studies_NNS ._.
Thus_RB ,_, the_DT "_`` estrogen_`` receptor-related_JJ protein_NN "_`` is_VBZ HSP27_CD ,_, and_CC the_DT three_CD major_JJ 29-kDa_JJ proteins_NNS phosphorylated_VBN in_IN thrombin-activated_`` platelets_NNS are_VBP forms_NNS of_IN HSP27_NN ._.
These_DT data_NNS suggest_VBP a_DT role_NN for_IN HSP27_NN in_IN the_DT signal_NN transduction_NN events_NNS of_IN platelet_NN activation_NN ._.
Characterization_NN of_IN a_DT cofactor_NN that_WDT regulates_VBZ dimerization_NN of_IN a_DT mammalian_JJ homeodomain_NN protein_NN ._.
Dimerization_# among_IN transcription_NN factors_NNS has_VBZ become_VBN a_DT recurrent_JJ theme_NN in_IN the_DT regulation_NN of_IN eukaryotic_JJ gene_NN expression_NN ._.
Hepatocyte_JJ nuclear_JJ factor-1_NN alpha_NN (_-LRB- HNF-1_NNP alpha_NN )_-RRB- is_VBZ a_DT homeodomain-containing_JJ protein_NN that_WDT functions_VBZ as_IN a_DT dimer_NN ._.
A_DT dimerization_NN cofactor_NN of_IN HNF-1_NNP alpha_# (_-LRB- DCoH_NNP )_-RRB- was_VBD identified_VBN that_IN displayed_VBD a_DT restricted_VBN tissue_NN distribution_NN and_CC did_VBD not_RB bind_NN to_TO DNA_NNP ,_, but_CC ,_, rather_RB ,_, selectively_RB stabilized_VBN HNF-1_NNP alpha_NN dimers_NNS ._.
The_DT formation_NN of_IN a_DT stable_JJ tetrameric_JJ DCoH-HNF-1_`` alpha_NN complex_NN ,_, which_WDT required_VBD the_DT dimerization_`` domain_NN of_IN HNF-1_NNP alpha_NN ,_, did_VBD not_RB change_VB the_DT DNA_NNP binding_`` characteristics_NNS of_IN HNF-1_NNP alpha_NN ,_, but_CC enhanced_VBD its_PRP$ transcriptional_JJ activity_NN ._.
However_RB ,_, DCoH_NNP did_VBD not_RB confer_`` transcriptional_JJ activation_NN to_TO the_DT GAL4_NNP DNA_NNP binding_`` domain_NN ._.
These_DT results_NNS indicate_VBP that_IN DCoH_NNP regulates_VBZ formation_NN of_IN transcriptionally_RB active_JJ tetrameric_JJ complexes_NNS and_CC may_MD contribute_VB to_TO the_DT developmental_JJ specificity_NN of_IN the_DT complex_NN ._.
High_JJ affinity_NN aldosterone_`` binding_# to_TO plasma_`` membrane_`` rich_JJ fractions_NNS from_IN mononuclear_JJ leukocytes_NNS :_: is_VBZ there_RB a_DT membrane_NN receptor_NN for_IN mineralocorticoids_NNS ?_.
In_IN vitro_JJ effects_NNS of_IN aldosterone_NN on_IN the_DT intracellular_JJ concentrations_NNS of_IN sodium_NN ,_, potassium_NN and_CC calcium_NN ,_, cell_NN volume_NN and_CC the_DT sodium-proton-antiport_`` have_VBP been_VBN described_VBN in_IN intact_JJ human_JJ mononuclear_`` leukocytes_NNS (_-LRB- HML_NNP )_-RRB- ._.
In_IN the_DT present_JJ paper_NN ,_, the_DT binding_NN of_IN a_DT (125I)-labeled_JJ aldosterone_NN derivative_NN to_TO plasma_`` membrane_`` rich_JJ fractions_NNS of_IN HML_NNP was_VBD studied_VBN ._.
High_JJ affinity_NN binding_`` of_IN the_DT radioligand_NN with_IN an_DT apparent_JJ Kd_NN of_IN approximately_RB 0.1_CD nM_NNP was_VBD found_VBN ._.
Aldosterone_NNP displaced_VBD the_DT tracer_NN at_IN a_DT similar_JJ Kd_NNP ._.
Both_DT canrenone_NN and_CC cortisol_NN were_VBD inactive_JJ as_IN ligands_NNS up_IN to_TO concentrations_NNS of_IN 0.1_CD microM_NN ._.
The_DT findings_NNS are_VBP the_DT first_JJ to_TO demonstrate_VB membrane_`` binding_`` sites_NNS with_IN a_DT high_JJ affinity_NN for_IN aldosterone_NN ,_, but_CC not_RB for_IN cortisol_NN ._.
These_DT data_NNS are_VBP perfectly_RB compatible_JJ with_IN major_JJ properties_NNS of_IN steroidal_JJ effects_NNS on_IN the_DT sodium-proton-antiport_`` in_IN HML_NNP and_CC thus_RB very_RB likely_JJ represent_VBP membrane_# receptors_NNS for_IN aldosterone_NN ._.
Transcription_-LRB- factor_NN requirements_NNS for_IN U2_`` snRNA-encoding_JJ gene_NN activation_NN in_IN B_NNP lymphoid_JJ cells_NNS ._.
Transcription_NN of_IN a_DT human_JJ U2_`` small_JJ nuclear_JJ RNA_NNP (_-LRB- snRNA_NNP )_-RRB- -encoding_`` gene_NN in_IN HeLa_NNP cells_NNS requires_VBZ a_DT distal_JJ enhancer_NN element_NN ,_, which_WDT is_VBZ composed_VBN of_IN one_CD octamer_NN motif_`` (_-LRB- Oct_NNP )_-RRB- and_CC three_CD Sp_`` 1-binding_JJ sites_NNS ._.
To_TO study_VB the_DT transcription_`` factor_NN requirement_NN in_IN B-cells_# ,_, different_JJ U2_`` enhancer_`` constructions_NNS were_VBD transfected_VBN into_IN the_DT lymphoid_JJ cell_NN line_NN ,_, BJA-B_'' ._.
The_DT results_NNS showed_VBD that_IN the_DT activation_NN of_IN U2_NNP snRNA_NNP transcription_NN in_IN B-cells_# also_RB requires_VBZ an_DT enhancer_JJ comprising_`` both_CC the_DT Oct_NNP and_CC at_IN least_JJS one_CD Sp_`` 1-binding_JJ site_NN ._.
Deletion_NN of_IN all_PDT the_DT Sp_`` 1-binding_JJ sites_NNS from_IN the_DT enhancer_NN reduces_VBZ transcription_NN by_IN 80-90_CD %_NN in_IN HeLa_NNP ,_, as_RB well_RB as_IN in_IN BJA-B_`` cells_NNS ,_, whereas_IN the_DT removal_NN of_IN the_DT octamer-binding_`` site_NN reduces_VBZ transcription_NN to_TO levels_NNS below_IN detection_NN in_IN both_DT cell_NN types_NNS ._.
Enhancers_NNS containing_VBG a_DT single_JJ Oct_NNP have_VBP ,_, nevertheless_RB ,_, the_DT capacity_NN to_TO partially_RB activate_JJ U2_NNP snRNA_`` transcription_NN in_IN both_DT HeLa_NNP cells_NNS ,_, in_IN which_WDT only_JJ OTF-1_NN is_VBZ expressed_VBN ,_, and_CC in_IN BJA-B_JJ cells_NNS in_IN which_WDT OTF-2_`` is_VBZ the_DT predominantly_RB expressed_VBN octamer-binding_JJ factor_NN ._.
The_DT most_RBS likely_JJ interpretation_NN of_IN our_PRP$ results_NNS is_VBZ that_IN both_PDT the_DT ubiquitous_JJ transcription_NN factor_NN ,_, OTF-1_NNP ,_, and_CC the_DT B-cell-specific_JJ transcription_NN factor_NN ,_, OTF-2_'' ,_, can_MD activate_VB U2_NNP snRNA_NNP transcription_NN ._.
The_DT results_NNS also_RB revealed_VBD a_DT similar_JJ functional_JJ cooperation_NN between_IN the_DT transcription_NN factors_NNS which_WDT bind_VBP to_TO the_DT Oct_NNP and_CC the_DT adjacent_JJ Sp_`` 1-binding_JJ site_NN in_IN BJA-B_JJ cells_NNS ,_, as_IN has_VBZ been_VBN observed_VBN in_IN HeLa_`` cells_NNS ,_, since_IN a_DT template_NN which_WDT contains_VBZ a_DT weak_JJ binding_`` site_NN for_IN OTFs_NNP expresses_`` wild-type_JJ levels_NNS of_IN U2_NNP snRNA_`` in_IN both_DT cell_NN types_NNS when_WRB the_DT weak_JJ octamer-binding_`` site_NN is_VBZ combined_VBN with_IN a_DT Sp_`` 1-binding_JJ site_NN ._.
Cortisol_NN receptor_NN resistance_NN :_: the_DT variability_NN of_IN its_PRP$ clinical_JJ presentation_NN and_CC response_NN to_TO treatment_NN ._.
Primary_JJ (_-LRB- partial_JJ )_-RRB- cortisol_`` receptor_NN resistance_NN was_VBD previously_RB reported_VBN in_IN a_DT total_NN of_IN 7_CD patients_NNS and_CC 14_CD asymptomatic_JJ family_NN members_NNS ._.
Its_PRP$ occurrence_NN is_VBZ considered_VBN to_TO be_VB extremely_RB rare_JJ ._.
In_IN the_DT present_JJ study_NN we_PRP report_VBP on_IN 6_CD patients_NNS (_-LRB- 2_CD males_NNS and_CC 4_CD females_NNS )_-RRB- with_IN the_DT syndrome_NN ._.
The_DT first_JJ male_JJ patient_NN presented_VBN with_IN mild_JJ hypertension_NN ._.
Hydrochlorothiazide_JJ therapy_NN resulted_VBD in_IN life-threatening_JJ hypokalemia_NN ._.
The_DT second_JJ male_JJ patient_NN had_VBD slight_JJ hypertension_NN without_IN hypokalemia_NN ._.
All_DT four_CD female_NN patients_NNS presented_VBD between_IN the_DT age_NN of_IN 20-30_`` yr_`` with_IN acne_NN ,_, hirsutism_NN ,_, and_CC irregular_`` menstruations_NNS ._.
Low_NNP dose_NN dexamethasone_NN therapy_NN (_-LRB- 1-1.5_CD mg/day_`` )_-RRB- was_VBD of_IN clinical_JJ benefit_NN in_IN these_DT patients_NNS ._.
All_DT patients_NNS showed_VBD insufficient_JJ suppression_NN of_IN serum_`` cortisol_`` concentrations_NNS in_IN the_DT overnight_JJ 1-mg_JJ dexamethasone_NN test_NN ._.
The_DT diurnal_JJ rhythm_NN of_IN ACTH_NNP and_CC cortisol_`` was_VBD intact_JJ ,_, albeit_IN at_IN an_DT elevated_JJ level_NN ._.
There_EX was_VBD a_DT normal_JJ increase_NN in_IN ACTH_NNP ,_, cortisol_NN ,_, and_CC GH_NNP (_-LRB- except_IN in_IN one_CD obese_`` patient_NN )_-RRB- in_IN response_NN to_TO insulin-induced_`` hypoglycemia_NN ,_, while_IN cortisol_`` production_NN was_VBD elevated_VBN in_IN three_CD patients_NNS ._.
Circulating_VBG adrenal_`` androgen_`` levels_NNS were_VBD increased_VBN in_IN all_DT patients_NNS ._.
Glucocorticoid_JJ receptors_NNS were_VBD investigated_VBN in_IN a_DT whole_JJ cell_NN dexamethasone_`` binding_JJ assay_NN in_IN mononuclear_JJ leukocytes_NNS ._.
In_IN the_DT first_JJ male_JJ patient_NN ,_, the_DT number_NN of_IN receptors_NNS was_VBD very_RB low_JJ ,_, while_IN the_DT affinity_NN was_VBD lower_JJR than_IN that_DT in_IN controls_NNS ._.
A_DT lowered_VBD affinity_NN to_TO dexamethasone_NN was_VBD found_VBN in_IN one_CD female_JJ patient_NN ,_, while_IN a_DT lowered_VBN number_NN of_IN receptors_NNS was_VBD found_VBN in_IN three_CD patients_NNS ._.
In_IN the_DT second_JJ male_JJ patient_NN ,_, no_DT abnormalities_NNS were_VBD found_VBN ._.
As_IN a_DT bioassay_NN for_IN glucocorticoid_JJ action_NN we_PRP also_RB measured_VBD dexamethasone_`` suppressibility_NN of_IN mitogen-stimulated_JJ incorporation_NN of_IN (3H)thymidine_NNP in_IN mononuclear_`` leukocytes_NNS ._.
In_IN the_DT male_JJ patient_NN with_IN normal_JJ receptor_NN status_NN ,_, dexamethasone_# suppressibility_NN of_IN (3H)thymidine_NNP incorporation_NN was_VBD significantly_RB lower_JJR than_IN that_DT in_IN healthy_JJ controls_NNS with_IN respect_NN to_TO both_DT maximal_`` suppression_NN and_CC IC50_`` ._.
Partial_JJ cortisol_NN receptor_NN resistance_NN might_MD be_VB less_RBR rare_JJ than_IN previously_RB thought_VBN ._.
In_IN the_DT six_CD patients_NNS presented_VBN ,_, at_IN least_JJS three_CD different_JJ forms_NNS can_MD be_VB recognized_VBN ._.
Therapy_# with_IN dexamethasone_NN was_VBD successful_JJ in_IN female_JJ patients_NNS with_IN acne_NN and_CC hirsutism_NN ,_, as_IN the_DT secondary_JJ increase_NN in_IN the_DT production_NN of_IN adrenal_JJ androgens_NNS was_VBD effectively_RB controlled_VBN ._.
Kappa_NNP B-specific_NNP DNA_NNP binding_# proteins_NNS are_VBP differentially_RB inhibited_VBN by_IN enhancer_`` mutations_NNS and_CC biological_JJ oxidation_NN ._.
Kappa_NN B_LS (_-LRB- kappa_NN B_NNP )_-RRB- enhancer_`` binding_JJ proteins_NNS isolated_VBN from_IN the_DT nuclei_`` of_IN activated_`` human_JJ T_`` cells_NNS produce_VBP two_CD distinct_JJ nucleoprotein_`` complexes_NNS when_WRB incubated_VBN with_IN the_DT kappa_`` B_NNP element_NN from_IN the_DT interleukin-2_NN receptor-alpha_`` (_-LRB- IL-2R_JJ alpha_NN )_-RRB- gene_NN ._.
These_DT two_CD DNA-protein_NNP complexes_NNS are_VBP composed_VBN of_IN at_IN least_JJS four_CD host_NN proteins_NNS (_-LRB- p50_CD ,_, p55_CD ,_, p75_CD ,_, p85_CD )_-RRB- ,_, each_DT of_IN which_WDT shares_NNS structural_JJ similarity_NN with_IN the_DT v-rel_`` oncogene_JJ product_NN ._.
Nuclear_JJ expression_NN of_IN these_DT proteins_NNS is_VBZ induced_`` with_IN distinctly_RB biphasic_JJ kinetics_NNS following_VBG phorbol_`` ester_`` activation_NN of_IN T_JJ cells_NNS (_-LRB- p55/p75_CD early_RB and_CC p50/p85_`` late_JJ )_-RRB- ._.
DNA-protein_# crosslinking_VBG studies_NNS have_VBP revealed_VBN that_IN the_DT more_RBR rapidly_RB migrating_JJ B2_NN complex_JJ contains_VBZ both_DT p50_`` and_CC p55_`` while_IN the_DT more_RBR slowly_RB migrating_JJ B1_NN complex_NN is_VBZ composed_VBN of_IN p50_CD ,_, p55_CD ,_, p75_CD ,_, and_CC p85_NN ._.
Site-directed_JJ mutagenesis_NN of_IN the_DT wild-type_JJ IL-2R_JJ alpha_NN kappa_NN B_NNP enhancer_`` (_-LRB- GGGGAATCTCCC_NNP )_-RRB- has_VBZ revealed_VBN that_IN the_DT binding_`` of_IN p50_NN and_CC p55_`` (_-LRB- B2_NN complex_JJ )_-RRB- is_VBZ particularly_RB sensitive_JJ to_TO alteration_`` of_IN the_DT 5'_`` triplet_NN of_IN deoxyguanosine_`` residues_NNS ._.
In_IN contrast_NN ,_, formation_NN of_IN the_DT B1_`` complex_NN ,_, reflecting_VBG the_DT binding_`` of_IN p75_NN and_CC p85_NN ,_, critically_RB depends_VBZ upon_IN the_DT more_JJR 3'_`` sequences_NNS of_IN this_DT enhancer_NN element_NN ._.
DNA_NNP binding_-RRB- by_IN all_DT four_CD of_IN these_DT Rel-related_JJ factors_NNS is_VBZ blocked_VBN by_IN selective_JJ chemical_NN modification_NN of_IN lysine_`` and_CC arginine_`` residues_`` ,_, suggesting_VBG that_IN both_DT of_IN these_DT basic_JJ amino_`` acids_NNS are_VBP required_VBN for_IN binding_`` to_TO the_DT kappa_NN B_NNP element_NN ._.
Similarly_RB ,_, covalent_JJ modification_NN of_IN free_JJ sulfhydryl_`` groups_NNS with_IN diamide_`` (_-LRB- reversible_JJ )_-RRB- or_CC N-ethylmaleimide_NNP (_-LRB- irreversible_`` )_-RRB- results_NNS in_IN a_DT complete_JJ loss_NN of_IN DNA_NNP binding_`` activity_NN ._.
In_IN contrast_NN ,_, mild_JJ oxidation_NN with_IN glucose_`` oxidase_`` selectively_RB inhibits_NNS p75_CD and_CC p85_CD binding_`` while_IN not_RB blocking_VBG p50_CD and_CC p55_CD interactions_NNS ._.
These_DT findings_NNS suggest_VBP that_IN reduced_VBN cysteine_`` thiols_NNS play_VBP an_DT important_JJ role_NN in_IN the_DT DNA_NNP binding_`` activity_NN of_IN this_DT family_NN of_IN Rel-related_JJ transcription_NN factors_NNS ._.
A_DT novel_JJ mitogen-inducible_JJ gene_NN product_NN related_VBN to_TO p50/p105-NF-kappa_NN B_NNP participates_`` in_IN transactivation_NN through_IN a_DT kappa_NN B_NNP site_NN ._.
A_DT Rel-related_JJ ,_, mitogen-inducible_JJ ,_, kappa_'' B-binding_`` protein_NN has_VBZ been_VBN cloned_VBN as_IN an_DT immediate-early_JJ activation_NN gene_NN of_IN human_JJ peripheral_`` blood_NN T_JJ cells_NNS ._.
The_DT cDNA_NN has_VBZ an_DT open_JJ reading_NN frame_NN of_IN 900_CD amino_`` acids_NNS capable_JJ of_IN encoding_VBG a_DT 97-kDa_JJ protein_NN ._.
This_DT protein_NN is_VBZ most_RBS similar_JJ to_TO the_DT 105-kDa_JJ precursor_NN polypeptide_NN of_IN p50-NF-kappa_NN B_NNP ._.
Like_IN the_DT 105-kDa_JJ precursor_NN ,_, it_PRP contains_VBZ an_DT amino-terminal_JJ Rel-related_JJ domain_NN of_IN about_IN 300_CD amino_JJ acids_NNS and_CC a_DT carboxy-terminal_JJ domain_NN containing_VBG six_CD full_JJ cell_NN cycle_NN or_CC ankyrin_# repeats_NNS ._.
In_IN vitro-translated_JJ proteins_NNS ,_, truncated_VBD downstream_`` of_IN the_DT Rel_NNP domain_NN and_CC excluding_VBG the_DT repeats_NNS ,_, bind_NN kappa_# B_NNP sites_NNS ._.
We_PRP refer_VBP to_TO the_DT kappa_`` B-binding_# ,_, truncated_JJ protein_NN as_IN p50B_NN by_IN analogy_NN with_IN p50-NF-kappa_NN B_NNP and_CC to_TO the_DT full-length_JJ protein_NN as_IN p97_NN ._.
p50B_NN is_VBZ able_JJ to_TO form_VB heteromeric_JJ kappa_`` B-binding_# complexes_`` with_IN RelB_NNP ,_, as_RB well_RB as_IN with_IN p65_CD and_CC p50_CD ,_, the_DT two_CD subunits_NNS of_IN NF-kappa_NNP B_NNP ._.
Transient-transfection_JJ experiments_NNS in_IN embryonal_JJ carcinoma_NN cells_NNS demonstrate_VBP a_DT functional_JJ cooperation_NN between_IN p50B_NN and_CC RelB_`` or_CC p65_`` in_IN transactivation_NN of_IN a_DT reporter_NN plasmid_`` dependent_JJ on_IN a_DT kappa_NN B_NNP site_NN ._.
The_DT data_NNS imply_VBP the_DT existence_NN of_IN a_DT complex_JJ family_NN of_IN NF-kappa_NNP B-like_JJ transcription_NN factors_NNS ._.
(_-LRB- Changes_`` in_IN leucocytic_JJ estrogen_NN receptor_NN levels_NNS in_IN patients_NNS with_IN climacteric_JJ syndrome_NN and_CC therapeutic_JJ effect_NN of_IN liuwei_`` dihuang_`` pills_NNS )_-RRB-
The_DT numbers_NNS of_IN estrogen_NN receptor_NN (_-LRB- ER_NNP )_-RRB- in_IN human_JJ peripheral_`` leucocytes_NNS in_IN 22_CD women_NNS with_IN climacteric_JJ syndrome_NN were_VBD measured_VBN by_IN radioligand_NN method_NN ._.
The_DT results_NNS were_VBD compared_VBN with_IN those_DT of_IN 12_CD normal_JJ child-bearing-age_`` women_NNS ._.
It_PRP wat_`` found_VBD that_IN the_DT contents_NNS of_IN leucocytic_JJ ER_NNP in_IN climacteric_JJ syndrome_NN patients_NNS were_VBD significantly_RB lower_JJR than_IN normal_JJ child-bearing-age_`` women_NNS ._.
The_DT authors_NNS used_VBD a_DT Chinese_JJ prescription_NN --_: Liuwei_NNP Dihuang_NNP Pills_NNP (_-LRB- LDP_NNP )_-RRB- to_TO treat_VB the_DT patients_NNS for_IN 2_CD months_NNS ._.
The_DT numbers_NNS of_IN leucocytic_JJ ER_NNP were_VBD significantly_RB increased_VBN after_IN treatment_NN ._.
The_DT data_NNS indicate_VBP that_IN decrease_NN of_IN ER_JJR levels_NNS in_IN cell_NN may_MD involve_VB in_IN the_DT pathogenesis_NN of_IN climacteric_JJ syndrome_NN ._.
LDP_NNP not_RB only_RB increases_VBZ plasma_NN estradiol_NN levels_NNS ,_, but_CC also_RB increases_VBZ the_DT leucocytic_JJ ER_NNP levels_NNS ._.
This_DT may_MD be_VB the_DT basis_NN of_IN the_DT therapeutic_JJ effect_NN on_IN the_DT disease_NN ._.
A_DT novel_JJ primer_NN extension_NN method_NN to_TO detect_VB the_DT number_NN of_IN CAG_NNP repeats_`` in_IN the_DT androgen_`` receptor_NN gene_NN in_IN families_NNS with_IN X-linked_JJ spinal_`` and_CC bulbar_`` muscular_JJ atrophy_NN ._.
X-linked_JJ spinal_`` and_CC bulbar_`` muscular_JJ atrophy_`` (_-LRB- SBMA_NNP )_-RRB- ,_, an_DT adult-onset_JJ form_NN of_IN motor_NN neuron_`` disease_NN ,_, was_VBD recently_RB reported_VBN to_TO be_VB caused_VBN by_IN amplification_NN of_IN the_DT CAG_NNP repeats_`` in_IN the_DT androgen_`` receptor_NN gene_NN ._.
We_PRP report_VBP here_RB a_DT simple_NN and_CC rapid_JJ strategy_NN to_TO detect_VB the_DT precise_JJ number_NN of_IN the_DT CAGs_NNS ._.
After_IN the_DT DNA_NNP fragment_NN containing_VBG the_DT CAG_NNP repeats_`` is_VBZ amplified_VBN by_IN the_DT polymerase_`` chain_NN reaction_NN ,_, a_DT primer_NN extension_NN is_VBZ carried_VBN out_RP ;_: the_DT extension_NN of_IN the_DT end-labelled_JJ reverse_NN primer_`` adjacent_JJ to_TO 3'_JJ end_NN of_IN CAG_NNP repeats_`` stops_VBZ at_IN the_DT first_JJ T_NNP after_IN CAG_NNP repeats_`` with_IN the_DT incorporation_NN of_IN dideoxy_`` ATP_NNP in_IN the_DT reaction_NN mixture_NN ._.
The_DT resultant_`` primer_`` products_NNS are_VBP analysed_VBN by_IN denaturing_VBG polyacrylamide_`` gel_`` electrophoresis_NN and_CC autoradiography_NN ._.
This_DT method_NN could_MD be_VB quite_RB useful_JJ to_TO detect_VB not_RB only_RB CAG_`` repeats_`` in_IN SBMA_NNP but_CC also_RB other_JJ polymorphic_JJ dinucleotide_NN and_CC trinucleotide_# repeats_NNS ._.
Activity_NN of_IN the_DT kappa_NN B_NNP enhancer_`` of_IN the_DT interleukin-2_NN receptor_NN alpha_NN chain_NN in_IN somatic_JJ cell_NN hybrids_`` is_VBZ accompanied_VBN by_IN the_DT nuclear_JJ localization_NN of_IN NF-kappa_NNP B_NNP ._.
The_DT two_CD nuclear_JJ proteins_NNS NF-kappa_# B_NNP (_-LRB- consisting_VBG of_IN subunits_NNS p50_CD and_CC p65_CD )_-RRB- and_CC the_DT DNA-binding_`` subunit_NN of_IN NF-kappa_NNP B_NNP (_-LRB- p50_NN )_-RRB- by_IN itself_PRP ,_, also_RB called_VBN KBF1_NNP ,_, are_VBP constitutively_RB expressed_VBN and_CC localized_VBN in_IN the_DT nucleus_`` of_IN the_DT human_JJ T-cell_NNP line_NN IARC_NNP 301.5_CD ._.
In_IN order_NN to_TO define_VB the_DT roles_NNS of_IN these_DT two_CD factors_NNS ,_, which_WDT bind_VBP to_TO the_DT same_JJ kappa_NN B_NNP enhancers_`` ,_, in_IN transcription_NN activation_NN we_PRP have_VBP prepared_VBN somatic_JJ cell_NN hybrids_`` between_IN IARC_NNP 301.5_CD and_CC a_DT murine_NN myeloma_NN ._.
Most_JJS hybrids_`` express_VB both_DT KBF1_NNP and_CC NF-kappa_NNP B_NNP in_IN their_PRP$ nuclei_`` ,_, but_CC one_CD hybrid_NN expresses_`` only_RB KBF1_CD ._.
The_DT kappa_NN B_NNP enhancer_`` of_IN the_DT gene_NN encoding_`` the_DT interleukin-2_`` (_-LRB- IL-2_NN )_-RRB- receptor_NN alpha_NN chain_NN (_-LRB- IL-2R_JJ alpha_NN )_-RRB- is_VBZ functional_JJ only_RB in_IN the_DT hybrids_NNS expressing_VBG nuclear_JJ NF-kappa_NNP B_NNP ._.
These_DT findings_NNS show_VBP that_IN nuclear_JJ NF-kappa_NNP B_NNP is_VBZ necessary_JJ to_TO activate_VB the_DT kappa_NN B_NNP enhancer_NN ,_, while_IN KBF1_CD by_IN itself_PRP is_VBZ not_RB sufficient_JJ ._.
We_PRP propose_VBP that_IN KBF1_NNP is_VBZ a_DT competitive_JJ inhibitor_NN of_IN NF-kappa_NNP B_NNP and_CC discuss_VB how_WRB these_DT factors_NNS may_MD be_VB involved_VBN in_IN the_DT transient_JJ expression_NN of_IN IL-2_`` and_CC IL-2_`` alpha_`` genes_NNS during_IN the_DT immune_JJ response_NN ._.
Influence_NN of_IN estradiol_`` and_CC tamoxifen_`` on_IN susceptibility_NN of_IN human_JJ breast_NN cancer_NN cell_NN lines_NNS to_TO lysis_`` by_IN lymphokine-activated_JJ killer_NN cells_NNS ._.
The_DT design_NN of_IN combination_NN hormonal_JJ and_CC immunotherapeutic_JJ protocols_NNS for_IN breast_NN cancer_NN patients_NNS may_MD be_VB facilitated_VBN by_IN analysis_NN of_IN preclinical_JJ in_IN vitro_JJ model_NN systems_NNS ._.
Estrogen_NN receptor_NN positive_JJ (_-LRB- ER+_NN :_: MCF-7_`` )_-RRB- and_CC negative_JJ (_-LRB- ER-_`` :_: MDA-MB-231_`` )_-RRB- human_JJ breast_NN cancer_NN cell_NN lines_NNS were_VBD utilized_VBN to_TO evaluate_VB the_DT effects_NNS of_IN tamoxifen_`` (_-LRB- TAM_NN )_-RRB- and_CC estradiol_`` (_-LRB- E2_NN )_-RRB- on_IN modulation_NN of_IN breast_NN cancer_NN target_NN susceptibility_NN to_TO lysis_`` by_IN lymphokine-activated_JJ killer_NN (_-LRB- LAK_NNP )_-RRB- cells_NNS ._.
E2-stimulated_JJ ER+_`` cells_NNS were_VBD more_RBR susceptible_JJ to_TO lysis_`` by_IN LAK_`` cells_NNS than_IN corresponding_JJ TAM-treated_`` or_CC control_NN cells_NNS ,_, while_IN treatment_NN of_IN ER-_JJ cells_NNS with_IN either_DT E2_NNP or_CC TAM_NNP alone_RB did_VBD not_RB alter_VB from_IN control_NN their_PRP$ susceptibility_`` to_TO this_DT immune-mediated_JJ lysis_NN ._.
All_DT ER+_NNP and_CC ER-_# cells_NNS tested_VBN remained_VBD sensitive_JJ after_IN treatment_NN with_IN TAM_# to_TO lysis_`` by_IN LAK_NNP cells_NNS ._.
In_IN addition_NN ,_, an_DT adenocarcinoma_`` reactive_`` human-mouse_NN chimeric_JJ monoclonal_JJ antibody_NN (_-LRB- ING-1_NNP )_-RRB- was_VBD able_JJ to_TO significantly_RB boost_VB in_IN vivo_`` generated_VBD LAK_NNP cell-mediated_JJ lysis_NN of_IN control_NN ,_, E2-treated_JJ ,_, and_CC TAM-treated_JJ ER+_NNP and_CC ER-_NNP cells_NNS ._.
These_DT in_IN vitro_`` results_NNS provide_VBP a_DT preclinical_JJ rationale_NN for_IN in_IN vivo_`` testing_NN of_IN TAM_NN ,_, interleukin-2_JJ (_-LRB- IL-2_NN )_-RRB- ,_, and_CC breast_NN cancer_NN reactive_`` antibody-dependent_JJ cellular_JJ cytotoxicity_NN facilitating_VBG antibody_NN in_IN patients_NNS with_IN refractory_JJ or_CC high_JJ risk_NN breast_NN cancer_NN ._.
Glucocorticoid_JJ receptor_NN and_CC inhibition_NN of_IN 3-O-methyl-D-glucose_`` uptake_`` by_IN glucocorticoids_NNS in_IN peripheral_JJ blood_NN leukocytes_`` from_IN normal_JJ humans_NNS :_: correlation_`` between_IN receptor_NN level_NN and_CC hormone_NN effect_NN in_IN vitro_NN ._.
We_PRP have_VBP measured_VBN the_DT glucocorticoid_NN receptor_NN concentration_NN in_IN mononuclear_JJ and_CC polymorphonuclear_JJ leukocytes_NNS ,_, both_DT of_IN which_WDT were_VBD isolated_VBN from_IN peripheral_JJ blood_NN from_IN ten_CD healthy_JJ male_JJ volunteers_NNS ._.
In_IN parallel_RB ,_, the_DT inhibitory_JJ effect_NN of_IN dexamethasone_NN on_IN 3-O-methyl-D-glucose_JJ uptake_NN was_VBD assayed_VBN in_IN the_DT corresponding_JJ mononuclear_`` leukocytes_NNS ._.
The_DT glucocorticoid_NN receptor_NN levels_NNS in_IN mononuclear_JJ leukocytes_NNS correlated_VBN with_IN those_DT in_IN polymorphonuclear_JJ leukocytes_NNS ,_, and_CC there_EX was_VBD a_DT linear_JJ relationship_NN between_IN the_DT cellular_JJ glucocorticoid_NN receptor_NN levels_NNS and_CC glucocorticoid-mediated_JJ inhibition_NN of_IN the_DT uptake_NN of_IN 3-O-methyl-D-glucose_JJ in_IN mononuclear_JJ leukocytes_NNS ._.
When_WRB mononuclear_`` leukocytes_NNS were_VBD incubated_VBN in_IN the_DT presence_NN of_IN 8-bromo-cAMP_NNP ,_, cellular_JJ glucocorticoid_NN receptor_NN levels_NNS increased_VBD and_CC a_DT more_RBR pronounced_JJ inhibitory_JJ effect_NN of_IN dexamethasone_NN was_VBD observed_VBN on_IN the_DT transport_NN of_IN 3-O-methyl-D-glucose_JJ ._.
We_PRP conclude_VBP that_IN the_DT cellular_JJ glucocorticoid_NN receptor_NN levels_NNS in_IN peripheral_JJ blood_NN leukocytes_NNS reflect_VBP in_IN vitro_NN responsiveness_NN to_TO glucocorticoids_NNS in_IN mononuclear_JJ leukocytes_NNS from_IN healthy_JJ males_NNS ,_, and_CC that_IN the_DT individual_JJ responsiveness_NN may_MD alter_VB upon_IN changes_NNS in_IN the_DT cellular_JJ levels_NNS of_IN glucocorticoid_NN receptor_NN ._.
Stimulation_NN of_IN interferon_`` beta_JJ gene_NN transcription_NN in_IN vitro_NN by_IN purified_VBN NF-kappa_NNP B_NNP and_CC a_DT novel_NN TH_IN protein_NN ._.
The_DT human_JJ interferon_`` beta_JJ (_-LRB- IFN-beta_JJ )_-RRB- regulatory_JJ element_NN consists_VBZ of_IN multiple_JJ enhanson_`` domains_NNS which_WDT are_VBP targets_NNS for_IN transcription_NN factors_NNS involved_VBN in_IN inducible_JJ expression_NN of_IN the_DT promoter_NN ._.
To_TO further_RBR characterize_VB the_DT protein-DNA_`` interactions_NNS mediating_VBG IFN-beta_NNP induction_NN ,_, positive_JJ regulatory_JJ domain_NN (_-LRB- PRD_NNP )_-RRB- II_NNP binding_# proteins_NNS were_VBD purified_VBN from_IN phorbol_`` ester_`` induced_`` Jurkat_NNP T-cells_NNP and_CC from_IN IFN_NNP primed_`` ,_, cycloheximide/polyinosinic-polycytidylic_JJ acid_NN treated_VBN HeLa_NNP S3_NNP cells_NNS ._.
From_IN HeLa_NNP cells_NNS ,_, two_CD major_JJ proteins_NNS of_IN 52_CD and_CC 45_CD kilodaltons_NNS (_-LRB- kD_NN )_-RRB- copurified_`` with_IN DNA_NNP binding_`` activity_NN ,_, whereas_IN from_IN T-cells_NNS ,_, four_CD proteins_NNS --_: a_DT major_JJ protein_NN of_IN 52_CD kD_NN and_CC three_CD minor_JJ proteins_NNS of_IN 82_CD ,_, 67_CD ,_, and_CC 43-47_CD kD_NNP --_: were_VBD purified_VBN ._.
Also_RB ,_, an_DT induction_`` specific_JJ DNA_NNP binding_JJ protein_NN was_VBD purified_VBN from_IN HeLa_NNP cells_NNS that_WDT interacted_`` with_IN the_DT (_-LRB- AAGTGA_NNP )_-RRB- 4_CD tetrahexamer_NN sequence_NN and_CC the_DT PRDI_NNP domain_NN ._.
This_DT protein_NN is_VBZ immunologically_RB distinct_JJ from_IN IRF-1/ISGF2_NN ._.
Uninduced_NNP or_CC Sendai_NNP virus_NN induced_VBD HeLa_NNP extracts_NNS were_VBD used_VBN to_TO examine_VB transcription_NN in_IN vitro_NN using_VBG a_DT series_NN of_IN IFN_`` beta_JJ promoter_NN deletions_NNS ._.
Deletions_NNS upstream_RB of_IN the_DT PRDII_NNP element_NN increased_VBD transcription_`` in_IN the_DT uninduced_JJ extract_VB ,_, indicating_VBG predominantly_RB negative_JJ regulation_NN of_IN the_DT promoter_NN ._.
A_DT 2-4-fold_JJ increase_NN in_IN IFN-beta_NNP promoter_NN transcription_NN was_VBD observed_VBN in_IN Sendai_NNP virus_NN induced_VBD extracts_NNS ,_, and_CC deletion_NN of_IN PRDI_NNP and_CC PRDII_NNP elements_NNS decreased_VBD this_DT induced_`` level_NN of_IN transcription_NN ._.
When_WRB purified_VBN PRDII_`` and_CC tetrahexamer_`` binding_JJ proteins_NNS were_VBD added_VBN to_TO the_DT induced_`` extract_VB ,_, a_DT 4-fold_JJ increase_NN in_IN transcription_NN was_VBD observed_VBN ._.
These_DT experiments_NNS demonstrate_VBP that_IN it_PRP is_VBZ possible_JJ to_TO modulate_VB IFN-beta_JJ transcription_NN in_IN vitro_`` but_CC indicate_VBP that_IN additional_JJ proteins_NNS may_MD be_VB required_VBN to_TO fully_RB activate_JJ IFN-beta_NNP transcription_NN ._.
Structure_JJ function_NN analysis_NN of_IN vitamin_NN D_NNP analogs_`` with_IN C-ring_# modifications_NNS ._.
Analogs_NNS of_IN 1_CD alpha,25-dihydroxyvitamin_NN D3_`` (_-LRB- 1_CD alpha,25-(OH)_JJ 2D3_`` )_-RRB- with_IN substitutions_NNS on_IN C-11_NN were_VBD synthesized_VBN ._.
Small_JJ apolar_JJ substitutions_NNS (_-LRB- 11_CD alpha-methyl_NN ,_, 11_CD alpha-fluoromethyl_NN )_-RRB- did_VBD not_RB markedly_`` decrease_VB the_DT affinity_NN for_IN the_DT vitamin_NN D_NNP receptor_NN ,_, but_CC larger_JJR (_-LRB- 11_CD alpha-chloromethyl_`` or_CC 11_CD alpha-_`` or_CC 11_CD beta-phenyl_JJ )_-RRB- or_CC more_JJR polar_`` substitutions_NNS (_-LRB- 11_CD alpha-hydroxymethyl_NN ,_, 11_CD alpha-(2-hydroxyethyl_NN )_-RRB- decreased_VBD the_DT affinity_NN to_TO less_JJR than_IN 5_CD %_NN of_IN that_IN of_IN 1_CD alpha,25-OH)2D3_NN ._.
Their_PRP$ affinity_NN for_IN the_DT vitamin_NN D-binding_-RRB- protein_NN ,_, however_RB ,_, increased_VBD up_RP to_TO 4-fold_`` ._.
The_DT biological_JJ activity_NN of_IN 11_CD alpha-methyl-1_NN alpha,25-(OH)2D3_NN closely_RB resembled_VBD that_IN of_IN the_DT natural_JJ hormone_NN on_IN normal_JJ and_CC leukemic_JJ cell_NN proliferation_NN and_CC bone_NN resorption_NN ,_, whereas_IN its_PRP$ in_IN vivo_JJ effect_NN on_IN calcium_NN metabolism_NN of_IN the_DT rachitic_JJ chick_NN was_VBD about_IN 50_CD %_NN of_IN that_IN of_IN 1_CD alpha,25-(OH)2D3_NN ._.
The_DT 11_CD beta-methyl_NN analog_NN had_VBD a_DT greater_JJR than_IN 10-fold_CD lower_JJR activity_NN ._.
The_DT differentiating_VBG effects_NNS of_IN the_DT other_JJ C-11_NN analogs_`` on_IN human_JJ promyeloid_JJ leukemia_NN cells_NNS (_-LRB- HL-60_NNP )_-RRB- agreed_VBD well_RB with_IN their_PRP$ bone-resorbing_JJ activity_NN and_CC receptor_NN affinity_NN ,_, but_CC they_PRP demonstrated_VBD lower_JJR calcemic_JJ effects_NNS in_IN vivo_`` ._.
Large_JJ or_CC polar_JJ substitutions_NNS on_IN C-11_NN of_IN 1_CD alpha,25-(OH)2D3_NN thus_RB impair_VB the_DT binding_`` of_IN the_DT vitamin_NN D_NNP receptor_NN but_CC increase_NN the_DT affinity_NN to_TO vitamin_NN D-binding_# protein_NN ._.
The_DT effects_NNS of_IN many_JJ C-11-substituted_JJ 1_CD alpha,25-(OH)2D3_NN analogs_`` on_IN HL-60_`` cell_NN differentiation_NN exceeded_VBD their_PRP$ activity_NN on_IN calcium_NN metabolism_NN ._.
Transcriptional_JJ regulation_NN during_IN T-cell_NNP development_NN :_: the_DT alpha_NN TCR_`` gene_NN as_IN a_DT molecular_JJ model_NN ._.
The_DT regulation_NN of_IN gene_NN expression_NN during_IN lymphocyte_`` differentiation_NN is_VBZ a_DT complex_JJ process_NN involving_VBG interactions_NNS between_IN multiple_JJ positive_JJ and_CC negative_JJ transcriptional_JJ regulatory_JJ elements_NNS ._.
In_IN this_DT article_NN ,_, transcriptional_JJ regulation_NN of_IN the_DT archetypal_`` T-cell-specific_JJ gene_NN ,_, alpha_'' TCR_NNP ,_, is_VBZ discussed_VBN ._.
Major_JJ recent_JJ developments_NNS ,_, including_VBG the_DT identification_NN of_IN novel_JJ families_NNS of_IN transcription_`` factors_NNS that_WDT regulate_VB multiple_JJ T-cell_`` genes_NNS during_IN thymocyte_`` ontogeny_JJ and_CC T-cell_JJ activation_NN ,_, are_VBP described_VBN ._.
Cortisol_NNP resistance_NN in_IN acquired_VBN immunodeficiency_NN syndrome_NN ._.
This_DT study_NN concerns_VBZ 9_CD iv_`` drug_NN abusers_NNS with_IN acquired_JJ immunodeficiency_NN syndrome_NN (_-LRB- AIDS_NNP )_-RRB- who_WP developed_VBD hypercortisolism_NN without_IN the_DT clinical_JJ signs_NNS or_CC metabolic_JJ consequences_NNS of_IN hypercortisolism_NN ._.
All_DT patients_NNS were_VBD characterized_VBN by_IN an_DT Addisonian_JJ picture_NN (_-LRB- weakness_NN ,_, weight_NN loss_NN ,_, hypotension_NN ,_, hyponatremia_NN ,_, and_CC intense_JJ mucocutaneous_JJ melanosis_NN )_-RRB- ._.
An_DT acquired_VBN form_NN of_IN peripheral_JJ resistance_NN to_TO glucocorticoids_NNS was_VBD suspected_VBN ._.
We_PRP ,_, therefore_RB ,_, examined_VBD glucocorticoid_NN receptor_NN characteristics_NNS on_IN mononuclear_`` leukocytes_`` by_IN measuring_VBG (3H)dexamethasone_NNP binding_`` and_CC the_DT effect_NN of_IN dexamethasone_NN on_IN (3H)thymidine_NNP incorporation_NN ,_, which_WDT is_VBZ one_CD of_IN the_DT effects_NNS of_IN glucocorticoid_NN receptor_NN activation_NN ._.
Glucocorticoid_JJ receptor_NN density_NN was_VBD increased_VBN in_IN AIDS_NNP patients_NNS with_IN an_DT Addisonian_JJ picture_NN (_-LRB- group_NN 1_CD ;_: 16.2_CD +/-_`` 9.4_CD fmol/million_JJ cells_NNS )_-RRB- compared_VBN to_TO values_NNS in_IN 12_CD AIDS_NNP patients_NNS without_IN an_DT Addisonian_`` picture_NN (_-LRB- group_NN 2_CD ;_: 6.05_CD +/-_`` 2.6_CD fmol/million_JJ cells_NNS ;_: P_`` less_RBR than_IN 0.01_CD )_-RRB- and_CC sex-_JJ and_CC age-matched_JJ controls_NNS (_-LRB- 3.15_CD +/-_`` 2.3_CD fmol/million_JJ cells_NNS ;_: P_`` less_RBR than_IN 0.01_CD )_-RRB- ._.
The_DT affinity_NN of_IN glucocorticoid_JJ receptors_NNS (_-LRB- Kd_NNP )_-RRB- was_VBD strikingly_RB decreased_VBN (_-LRB- 9.36_CD +/-_`` 3.44_CD nM_`` in_IN group_NN 1_CD ;_: 3.2_CD +/-_`` 1.5_CD nM_`` in_IN group_NN 2_CD ;_: 2.0_CD +/-_`` 0.8_CD nM_`` in_IN controls_NNS ;_: P_`` less_RBR than_IN 0.01_CD )_-RRB- ._.
(3H)Thymidine_JJ incorporation_NN was_VBD decreased_VBN dose-dependently_RB by_IN dexamethasone_NN in_IN controls_NNS and_CC patients_NNS ;_: the_DT effect_NN was_VBD significantly_RB blunted_VBN (_-LRB- P_NNP less_JJR than_IN 0.05_CD )_-RRB- in_IN group_NN 1_CD patients_NNS ,_, which_WDT suggests_VBZ that_IN activation_NN of_IN glucocorticoid_NN receptor_NN is_VBZ impaired_VBN as_IN a_DT result_NN of_IN the_DT glucocorticoid_NN receptor_NN abnormality_NN ._.
In_IN conclusion_NN ,_, AIDS_NNP patients_NNS with_IN hypercortisolism_NN and_CC clinical_JJ features_NNS of_IN peripheral_JJ resistance_NN to_TO glucocorticoids_NNS are_VBP characterized_VBN by_IN abnormal_JJ glucocorticoid_JJ receptors_NNS on_IN lymphocytes_NNS ._.
Resistance_NN to_TO glucocorticoids_NNS implies_VBZ a_DT complex_JJ change_NN in_IN immune-endocrine_JJ function_NN ,_, which_WDT may_MD be_VB important_JJ in_IN the_DT course_NN of_IN immunodeficiency_NN syndrome_NN ._.
Induction_NN of_IN monocytic_JJ differentiation_NN and_CC NF-kappa_`` B-like_JJ activities_NNS by_IN human_JJ immunodeficiency_NN virus_NN 1_CD infection_NN of_IN myelomonoblastic_JJ cells_NNS ._.
The_DT effects_NNS of_IN human_JJ immunodeficiency_NN virus_NN 1_CD (_-LRB- HIV-1_NN )_-RRB- infection_NN on_IN cellular_JJ differentiation_NN and_CC NF-kappa_NNP B_NNP DNA_NNP binding_`` activity_NN have_VBP been_VBN investigated_VBN in_IN a_DT new_JJ model_NN of_IN myeloid_JJ differentiation_NN ._.
PLB-985_CD cells_NNS represent_VBP a_DT bipotential_JJ myelomonoblastic_JJ cell_NN population_NN capable_JJ of_IN either_DT granulocytic_JJ or_CC monocytic_JJ differentiation_NN after_IN induction_NN with_IN appropriate_JJ inducers_NNS ._.
By_IN virtue_NN of_IN the_DT presence_NN of_IN CD4_-RRB- on_IN the_DT cell_NN surface_NN ,_, PLB-985_CD cells_NNS were_VBD chronically_RB infected_JJ with_IN HIV-1_`` strain_VB IIIB_NNP ._.
PLB-IIIB_JJ cells_NNS clearly_RB possessed_VBD a_DT more_RBR monocytic_JJ phenotype_`` than_IN the_DT parental_JJ myeloblasts_NNS ,_, as_IN determined_VBN by_IN differential_JJ staining_NN ,_, increased_VBD expression_NN of_IN the_DT myeloid-specific_JJ surface_NN markers_NNS ,_, and_CC transcription_NN of_IN the_DT c-fms_`` proto-oncogene_NN ._.
NF-kappa_NNP B_NNP binding_`` activity_NN was_VBD inducible_`` by_IN tumor_NN necrosis_NN factor_NN and_CC phorbol_`` myristate_`` acetate_NN in_IN PLB-985_CD ._.
However_RB ,_, in_IN PLB-IIIB_JJ cells_NNS ,_, constitutive_JJ expression_NN of_IN a_DT novel_NN NF-kappa_NNP B_NNP complex_NN was_VBD detected_VBN ,_, composed_VBN of_IN proteins_NNS ranging_VBG between_IN 70_CD and_CC 110_CD kD_NNP ._.
These_DT proteins_NNS interacted_VBD specifically_RB with_IN the_DT symmetric_`` NF-kappa_NNP B_NNP site_NN from_IN the_DT interferon_`` beta_JJ (_-LRB- IFN-beta_JJ )_-RRB- promoter_NN ._.
Mutations_NNS affecting_VBG the_DT 5'_`` guanine_`` residues_NNS of_IN the_DT kappa_NN B_NNP site_NN were_VBD unable_JJ to_TO compete_VB for_IN these_DT NF-kappa_NNP B-related_# proteins_NNS ._.
Inducibility_NN of_IN endogenous_JJ IFN-beta_NNP and_CC IFN-alpha_NNP RNA_NNP was_VBD also_RB increased_VBN in_IN PLB-IIIB_JJ cells_NNS ._.
These_DT studies_NNS indicate_VBP that_IN HIV-1_PRP$ infection_NN of_IN myelomonoblastic_JJ cells_NNS may_MD select_VB for_IN a_DT more_RBR mature_JJ monocytic_JJ phenotype_`` and_CC that_IN unique_JJ subunit_NN associations_NNS of_IN NF-kappa_NNP B_NNP DNA_NNP binding_`` proteins_NNS may_MD contribute_VB to_TO differential_JJ NF-kappa_NNP B-mediated_`` gene_NN expression_NN ._.
The_DT AP-1_NNP site_NN at_IN -150_CD bp_NN ,_, but_CC not_RB the_DT NF-kappa_NNP B_NNP site_NN ,_, is_VBZ likely_JJ to_TO represent_VB the_DT major_JJ target_NN of_IN protein_NN kinase_`` C_$ in_IN the_DT interleukin_NN 2_CD promoter_NN ._.
Stimulation_NN of_IN T_JJ cells_NNS with_IN antigen_JJ results_NNS in_IN activation_NN of_IN several_JJ kinases_NNS ,_, including_VBG protein_NN kinase_`` C_$ (_-LRB- PKC_NNP )_-RRB- ,_, that_WDT may_MD mediate_VB the_DT later_JJ induction_NN of_IN activation-related_JJ genes_NNS ._.
We_PRP have_VBP examined_VBN the_DT potential_JJ role_NN of_IN PKC_NNP in_IN induction_NN of_IN the_DT interleukin_`` 2_CD (_-LRB- IL-2_NN )_-RRB- gene_NN in_IN T_JJ cells_NNS stimulated_VBN through_IN the_DT T_JJ cell_NN receptor/CD3_NN complex_NN ._.
We_PRP have_VBP previously_RB shown_VBN that_IN prolonged_JJ treatment_NN of_IN the_DT untransformed_JJ T_JJ cell_NN clone_`` Ar-5_`` with_IN phorbol_`` esters_NNS results_NNS in_IN downmodulation_NN of_IN the_DT alpha_NN and_CC beta_JJ isozymes_NNS of_IN PKC_NNP ,_, and_CC abrogates_`` induction_NN of_IN IL-2_`` mRNA_`` and_CC protein_NN ._.
Here_RB we_PRP show_VBP that_IN phorbol_JJ ester_NN treatment_NN also_RB abolishes_VBZ induction_NN of_IN chloramphenicol_NN acetyltransferase_`` activity_NN in_IN Ar-5_`` cells_NNS transfected_VBN with_IN a_DT plasmid_NN containing_VBG the_DT IL-2_JJ promoter_NN linked_VBN to_TO this_DT reporter_NN gene_NN ._.
The_DT IL-2_NN promoter_NN contains_VBZ binding_VBG sites_NNS for_IN nuclear_JJ factors_NNS including_VBG NFAT-1_NNP ,_, Oct_NNP ,_, NF-kappa_NNP B_NNP ,_, and_CC AP-1_NNP ,_, which_WDT are_VBP all_DT potentially_RB sensitive_JJ to_TO activation_`` of_IN PKC_NNP ._.
We_PRP show_VBP that_IN induction_NN of_IN a_DT trimer_`` of_IN the_DT NFAT_NN and_CC Oct_NNP sites_NNS is_VBZ not_RB sensitive_JJ to_TO phorbol_`` ester_VB treatment_NN ,_, and_CC that_IN mutations_NNS in_IN the_DT NF-kappa_NNP B_NNP site_NN have_VBP no_DT effect_NN on_IN inducibility_NN of_IN the_DT IL-2_NN promoter_NN ._.
In_IN contrast_NN ,_, mutations_'' in_IN the_DT AP-1_NNP site_NN located_VBN at_IN -150_CD bp_NN almost_RB completely_RB abrogate_JJ induction_NN of_IN the_DT IL-2_`` promoter_NN ,_, and_CC appearance_NN of_IN an_DT inducible_JJ nuclear_JJ factor_NN binding_# to_TO this_DT site_NN is_VBZ sensitive_JJ to_TO PKC_NNP depletion_NN ._.
Moreover_RB ,_, cotransfections_NNS with_IN c-fos_NNS and_CC c-jun_JJ expression_NN plasmids_NNS markedly_RB enhance_VB induction_NN of_IN the_DT IL-2_`` promoter_NN in_IN minimally_RB stimulated_VBN T_JJ cells_NNS ._.
Our_PRP$ results_NNS indicate_VBP that_IN the_DT AP-1_NNP site_NN at_IN -150_CD bp_NN represents_VBZ a_DT major_JJ ,_, if_IN not_RB the_DT only_RB ,_, site_NN of_IN PKC_NNP responsiveness_NN in_IN the_DT IL-2_NN promoter_NN ._.
Interleukin_NNP 6-induced_JJ differentiation_NN of_IN a_DT human_JJ B_NNP cell_NN line_NN into_IN IgM-secreting_JJ plasma_NN cells_NNS is_VBZ mediated_VBN by_IN c-fos_NNS ._.
The_DT role_NN of_IN the_DT protooncogene_NN c-fos_`` in_IN interleukin_# (_-LRB- IL_NNP )_-RRB- 6-induced_`` B_NN cell_NN differentiation_NN was_VBD assessed_VBN ._.
Treatment_NNP of_IN SKW_NNP 6.4_CD cells_NNS with_IN IL_NNP 6_CD induced_VBD a_DT transient_`` and_CC early_JJ stimulation_NN of_IN c-fos_`` sense_NN mRNA_# expression_NN ._.
The_DT effect_NN appeared_VBD within_IN 30_CD min_NN and_CC returned_VBD to_TO basal_`` levels_NNS after_IN 2_CD h_NN ._.
The_DT addition_NN of_IN antisense_`` oligonucleotides_NNS to_TO c-fos_`` significantly_RB inhibited_JJ IL_NNP 6-induced_`` IgM_`` production_NN by_IN SKW_NNP 6.4_CD cells_NNS (_-LRB- p_NN less_JJR than_IN 0.001_CD )_-RRB- ,_, whereas_IN control_NN oligonucleotides_NNS had_VBD no_DT inhibitory_JJ effect_NN ._.
These_DT results_NNS indicate_VBP that_IN activation_NN of_IN c-fos_NNS is_VBZ involved_VBN in_IN IL_`` 6-induced_JJ differentiation_NN of_IN SKW_NNP 6.4_CD cells_NNS into_IN IgM-secreting_JJ cells_NNS ._.
Binding_# of_IN erythroid_`` and_CC non-erythroid_JJ nuclear_JJ proteins_NNS to_TO the_DT silencer_NN of_IN the_DT human_JJ epsilon-globin-encoding_JJ gene_NN ._.
To_TO clarify_VB the_DT molecular_JJ mechanisms_NNS involved_VBN in_IN the_DT developmental_JJ control_NN of_IN hemoglobin-encoding_JJ genes_NNS we_PRP have_VBP been_VBN studying_VBG the_DT expression_NN of_IN these_DT genes_NNS in_IN human_JJ cells_NNS in_IN continuous_JJ culture_NN ._.
We_PRP have_VBP previously_RB reported_VBN the_DT presence_NN of_IN a_DT transcriptional_JJ control_NN element_NN with_IN the_DT properties_NNS of_IN a_DT silencer_NN extending_VBG from_IN -392_CD to_TO -177_CD bp_`` relative_JJ to_TO the_DT cap_NN site_NN of_IN the_DT human_JJ epsilon-globin-encoding_NN gene_NN (_-LRB- Cao_NNP et_NNP al._`` ,_, Proc.Natl.Acad.Sci.USA_NNP 86_CD (_-LRB- 1989_CD )_-RRB- 5306-5309_`` )_-RRB- ._.
We_PRP also_RB showed_VBD that_IN this_DT silencer_NN has_VBZ stronger_JJR inhibitory_`` activity_NN in_IN HeLa_NNP cells_NNS ,_, as_IN compared_VBN to_TO K562_`` human_JJ erythroleukemia_NN cells_NNS ._.
Using_VBG deletion_NN mutants_NNS and_CC cis-cloned_`` synthetic_JJ oligodeoxyribonucleotides_NNS in_IN transient_JJ expression_NN assays_`` ,_, nucleotide_# sequences_`` responsible_JJ for_IN this_DT effect_NN have_VB now_RB been_VBN further_RB delimited_VBN to_TO 44_CD bp_`` located_VBN from_IN -294_CD to_TO -251_CD bp_NN ._.
Gel_NNP electrophoresis_`` mobility_JJ shift_NN assays_NNS and_CC DNaseI_`` footprinting_`` assays_NNS demonstrate_VBP that_IN these_DT negative_JJ regulatory_JJ sequences_NNS are_VBP recognized_VBN differently_RB by_IN proteins_NNS present_JJ in_IN nuclear_JJ extracts_NNS obtained_VBN from_IN HeLa_NNP and_CC K562_NNP cells_NNS ._.
Two_CD binding_JJ proteins_NNS are_VBP detected_VBN in_IN K562_`` nuclear_JJ extracts_NNS ,_, while_IN only_RB one_CD is_VBZ found_VBN in_IN extracts_# from_IN HeLa_NNP cells_NNS ._.
Possible_JJ mechanisms_NNS by_IN which_WDT these_DT proteins_NNS may_MD regulate_VB transcription_NN of_IN the_DT epsilon-globin-encoding_JJ gene_NN in_IN erythroid_`` and_CC non-erythroid_JJ cells_NNS are_VBP discussed_VBN ._.
Gangliosides_# suppress_`` tumor_NN necrosis_NN factor_NN production_NN in_IN human_JJ monocytes_NNS ._.
Both_DT normal_JJ and_CC malignant_JJ cells_NNS contain_VBP gangliosides_`` as_IN important_JJ cell_NN membrane_`` constituents_NNS that_WDT ,_, after_IN being_VBG shed_VBN ,_, may_MD influence_VB cells_NNS of_IN the_DT immune_JJ system_NN ._.
We_PRP have_VBP studied_VBN the_DT impact_NN of_IN gangliosides_NNS on_IN the_DT expression_NN of_IN TNF_NNP in_IN blood_NN monocytes_NNS and_CC in_IN the_DT monocytic_JJ cell_NN line_NN Mono_NNP Mac_NNP 6_CD ._.
Although_IN under_IN standard_JJ culture_NN conditions_NNS ,_, bovine_# brain_NN gangliosides_NNS (_-LRB- 100_CD micrograms/ml_`` )_-RRB- suppressed_`` LPS-stimulated_JJ TNF_NN production_NN 5-fold_RB in_IN PBMC_NNP and_CC 10-fold_-LRB- in_IN Mono_NNP Mac_NNP 6_CD cells_NNS ,_, suppression_NN was_VBD more_RBR efficient_JJ under_IN serum-free_JJ conditions_NNS ._.
Looking_VBG at_IN highly_RB purified_VBN gangliosides_NNS ,_, GD3_NNP ,_, GD1a_NNP ,_, GM3_NNP ,_, GM2_NNP ,_, and_CC GM1_NNP were_VBD all_DT effective_JJ in_IN reducing_VBG TNF_JJ production_NN in_IN PBMC_NNP ,_, and_CC in_IN Mono_NNP Mac_NNP 6_CD by_IN factor_NN 10_CD to_TO 50_CD ._.
The_DT suppressive_JJ activity_NN was_VBD lost_VBN in_IN molecules_NNS ,_, lacking_VBG the_DT sugar_NN moiety_NN or_CC the_DT lipid_JJ moiety_NN ._.
Gangliosides_NNPS appear_VBP to_TO act_VB at_IN an_DT early_JJ step_NN of_IN activation_NN in_IN that_DT TNF_NNP transcripts_NNS were_VBD reduced_VBN and_CC the_DT mobilization_NN of_IN the_DT nuclear_JJ factor_NN kappa_NN B_NNP was_VBD blocked_VBN ._.
Furthermore_RB ,_, in_IN time_NN kinetics_NNS ,_, gangliosides_NNS were_VBD effective_JJ for_IN up_RB to_TO 30_CD min_`` after_IN addition_NN of_IN LPS_NNP ,_, but_CC not_RB thereafter_RB ._.
However_RB ,_, the_DT expression_NN of_IN the_DT CD14_`` Ag_NNP ,_, a_DT receptor_NN molecule_NN for_IN LPS-LPS_`` binding_JJ protein_NN complexes_`` ,_, was_VBD unaffected_JJ by_IN gangliosides_NNS ._.
Finally_RB ,_, when_WRB using_VBG Staphylococcus_NNP aureus_`` or_CC platelet_`` activating_JJ factor_NN as_IN a_DT stimulus_NN ,_, gangliosides_NNS were_VBD able_JJ to_TO suppress_VB TNF_JJ production_NN in_IN Mono_NNP Mac_NNP 6_CD cells_NNS by_IN factor_NN 5_CD to_TO 10_CD ,_, as_RB well_RB ._.
On_IN the_DT other_JJ hand_NN ,_, phorbol_'' ester-induced_`` production_NN of_IN O2-_NN was_VBD similar_JJ in_IN cells_NNS treated_VBN with_IN and_CC without_IN gangliosides_NNS ._.
Taken_VBN together_RB ,_, our_PRP$ data_NNS demonstrate_VBP that_IN TNF_`` gene_NN expression_NN in_IN monocytes_NNS induced_VBN by_IN different_JJ types_NNS of_IN stimuli_NNS can_MD be_VB blocked_VBN by_IN gangliosides_NNS at_IN an_DT early_JJ step_NN of_IN signal_NN transduction_NN ._.
T_JJ cell-specific_`` negative_JJ regulation_NN of_IN transcription_NN of_IN the_DT human_JJ cytokine_NN IL-4_NN ._.
IL-4_NN secreted_`` by_IN activated_`` T_JJ cells_NNS is_VBZ a_DT pleiotropic_`` cytokine_`` affecting_VBG growth_NN and_CC differentiation_NN of_IN diverse_JJ cell_NN types_NNS such_JJ as_IN T_JJ cells_NNS ,_, B_NNP cells_NNS ,_, and_CC mast_NN cells_NNS ._.
We_PRP investigated_VBD the_DT upstream_JJ regulatory_JJ elements_NNS of_IN the_DT human_JJ IL-4_NN promoter_NN ._.
A_DT novel_JJ T_NNP cell-specific_`` negative_JJ regulatory_JJ element_NN (_-LRB- NRE_`` )_-RRB- composed_VBN of_IN two_CD protein-binding_`` sites_NNS were_VBD mapped_VBN in_IN the_DT 5'_`` flanking_JJ region_NN of_IN the_DT IL-4_`` gene_NN :_: -311CTCCCTTCT-303_`` (_-LRB- NRE-I_NNP )_-RRB- and_CC -288CTTTTTGCTT-TGC-300_`` (_-LRB- NRE-II_NNP )_-RRB- ._.
A_DT T_JJ cell-specific_JJ protein_NN Neg-1_`` and_CC a_DT ubiquitous_JJ protein_NN Neg-2_`` binding_`` to_TO NRE-I_NNP and_CC NRE-II_NNP ,_, respectively_RB ,_, were_VBD identified_VBN ._.
Furthermore_RB ,_, a_DT positive_JJ regulatory_JJ element_NN was_VBD found_VBN 45_CD bp_`` downstream_`` of_IN the_DT NRE_`` ._.
The_DT enhancer_`` activity_NN of_IN the_DT PRE_'' was_VBD completely_RB suppressed_VBN when_WRB the_DT NRE_NNP was_VBD present_JJ ._.
These_DT data_NNS suggest_VBP that_IN IL-4_`` promoter_NN activity_NN is_VBZ normally_RB down-regulated_`` by_IN an_DT NRE_`` via_IN repression_NN of_IN the_DT enhancer_`` positive_JJ regulatory_JJ element_NN ._.
These_DT data_NNS may_MD have_VB implications_NNS for_IN the_DT stringent_JJ control_NN of_IN IL-4_JJ expression_NN in_IN T_JJ cells_NNS ._.
(_-LRB- Regulatory_NNP effect_NN of_IN insulin_NN on_IN glucocorticoid_NN receptor_NN in_IN human_JJ peripheral_`` leukocytes_NNS )_-RRB-
The_DT regulatory_JJ effect_NN of_IN insulin_NN on_IN the_DT specific_JJ binding_JJ power_NN of_IN glucocorticoid_JJ receptor_NN (_-LRB- GR_NNP )_-RRB- of_IN human_JJ leukocytes_NNS was_VBD assessed_VBN by_IN the_DT unoccupied_JJ receptor_NN sites_NNS capable_JJ of_IN combining_VBG with_IN (3H)_NNP labelled_VBD dexamethasone_`` measured_VBN at_IN 3_CD and_CC 24_CD h_NN after_IN incubation_NN with_IN various_JJ concentrations_NNS of_IN insulin_NN added_VBN to_TO the_DT medium_NN ._.
After_IN 3_CD h_NN incubation_NN the_DT specific_JJ binding_JJ power_NN with_IN (3H)_NNP Dex_NNP was_VBD decreased_VBN by_IN 23.3_CD +/-_`` 10.0_CD ,_, 32.2_CD +/-_`` 13.2_CD and_CC 54.3_CD +/-_JJ 9.2_CD %_NN (_-LRB- P_NNP greater_JJR than_IN 0.05_CD ,_, P_NNP greater_JJR than_IN 0.05_CD and_CC P_NNP less_JJR than_IN 0.01_CD as_IN compared_VBN with_IN the_DT control_NN value_NN of_IN 100_CD in_IN the_DT absence_NN of_IN insulin_NN )_-RRB- respectively_RB in_IN the_DT presence_NN of_IN 20_CD mU/L_`` (_-LRB- physiological_`` testing_NN concentration_NN )_-RRB- ,_, 200_CD mU/L_`` (_-LRB- physiological_JJ upper_JJ limit_NN )_-RRB- and_CC 2,000_CD mU/L_`` (_-LRB- pharmacological_JJ concentration_NN )_-RRB- insulin_NN in_IN the_DT incubation_NN medium_NN ._.
After_IN 24_CD h_NN incubation_# the_DT decrease_NN of_IN these_DT values_NNS increased_VBD respectively_RB to_TO 43.5_CD +/-_`` 19.0_CD ,_, 56.1_CD +/-_`` 20.7_CD and_CC 80.2_CD +/-_`` 15.5_CD (_-LRB- P_NNP less_JJR than_IN 0.05_CD ,_, P_NNP less_JJR than_IN 0.01_CD and_CC P_`` less_JJR than_IN 0.01_CD compared_VBN with_IN control_NN )_-RRB- ._.
Thus_RB the_DT inhibitory_JJ effect_NN of_IN insulin_NN on_IN the_DT GR_NNP binding_`` power_NN is_VBZ both_DT dose-_`` and_CC time-dependent_NN ,_, which_WDT strongly_RB suggests_VBZ that_IN GR_NNP is_VBZ tonically_RB controlled_VBN by_IN insulin_NN concentration_NN change_NN under_IN physiological_JJ conditions_NNS ._.
Human_JJ T_JJ cell_NN activation_NN through_IN the_DT activation-inducer_NN molecule/CD69_NN enhances_VBZ the_DT activity_NN of_IN transcription_NN factor_NN AP-1_NN ._.
The_DT induction_NN of_IN the_DT AP-1_`` transcription_NN factor_NN has_VBZ been_VBN ascribed_VBN to_TO the_DT early_JJ events_NNS leading_VBG to_TO T_VB cell_NN differentiation_NN and_CC activation_NN ._.
We_PRP have_VBP studied_VBN the_DT regulation_NN of_IN AP-1_`` activity_NN in_IN human_JJ peripheral_`` blood_NN T_JJ lymphocytes_NNS stimulated_VBN through_IN the_DT activation_NN inducer_NN molecule_`` (_-LRB- AIM_NNP )_-RRB- /CD69_NNP activation_NN pathway_NN ._.
Phorbol_NN esters_NNS are_VBP required_VBN to_TO induce_VB AIM/CD69_NNP cell-surface_`` expression_NN as_RB well_RB as_IN for_IN triggering_VBG the_DT proliferation_NN of_IN T_JJ cells_NNS in_IN conjunction_NN with_IN anti-AIM_JJ mAb_NN ._.
Mobility_-LRB- shift_NN assays_`` showed_VBD that_IN addition_NN of_IN anti-AIM_JJ mAb_NN to_TO PMA-treated_`` T_VB lymphocytes_NNS markedly_RB enhanced_VBD the_DT binding_JJ activity_NN of_IN AP-1_NN to_TO its_PRP$ cognate_`` sequence_NN ,_, the_DT phorbol_`` ester_`` response_NN element_NN ._.
In_IN contrast_NN ,_, anti-AIM_JJ mAb_NNP did_VBD not_RB induce_VB any_DT change_NN in_IN the_DT binding_JJ activity_NN of_IN NF-kappa_NNP B_NNP ,_, a_DT transcription_NN factor_NN whose_WP$ activity_NN is_VBZ also_RB regulated_VBN by_IN protein_NN kinase_`` C_$ ._.
The_DT increase_NN in_IN AP-1-binding_JJ activity_NN was_VBD accompanied_VBN by_IN the_DT marked_JJ stimulation_NN of_IN the_DT transcription_NN of_IN c-fos_`` but_CC not_RB that_IN of_IN c-jun_NN ._.
Blockade_NN of_IN the_DT DNA-binding_# complexes_NNS with_IN an_DT anti-Fos_# mAb_NNP demonstrated_VBD a_DT direct_JJ participation_NN of_IN c-Fos_-RRB- in_IN the_DT AP-1_`` complexes_`` induced_VBN by_IN anti-AIM_JJ mAb_NN ._.
Most_JJS of_IN the_DT AP-1_NNP activity_NN could_MD be_VB eliminated_VBN when_WRB the_DT anti-AIM_JJ mAb_NNP was_VBD added_VBN to_TO the_DT culture_NN medium_NN in_IN the_DT presence_NN of_IN cycloheximide_`` ,_, suggesting_VBG that_IN de_FW novo_`` protein_NN synthesis_NN is_VBZ crucial_JJ for_IN the_DT induction_NN of_IN AP-1-binding_JJ activity_NN ._.
These_DT data_NNS provide_VBP the_DT evidence_NN that_IN activation_NN of_IN human_JJ peripheral_`` blood_NN T_JJ cells_NNS through_IN the_DT AIM_NNP activation_NN pathway_NN regulate_VB the_DT activity_NN of_IN AP-1_NNP ._.
Therefore_RB ,_, this_DT pathway_NN appears_VBZ as_IN a_DT crucial_JJ step_NN in_IN the_DT initiation_NN of_IN early_JJ T_JJ cell_NN activation_NN events_NNS ._.
cis-acting_JJ sequences_NNS required_VBN for_IN inducible_JJ interleukin-2_NN enhancer_`` function_NN bind_NN a_DT novel_NN Ets-related_NNP protein_NN ,_, Elf-1_NNP ._.
The_DT recent_JJ definition_NN of_IN a_DT consensus_NN DNA_NNP binding_`` sequence_NN for_IN the_DT Ets_`` family_NN of_IN transcription_NN factors_NNS has_VBZ allowed_VBN the_DT identification_NN of_IN potential_JJ Ets_`` binding_`` sites_NNS in_IN the_DT promoters_NNS and_CC enhancers_`` of_IN many_JJ inducible_JJ T-cell_NNP genes_NNS ._.
In_IN the_DT studies_NNS described_VBN in_IN this_DT report_NN ,_, we_PRP have_VBP identified_VBN two_CD potential_JJ Ets_`` binding_`` sites_NNS ,_, EBS1_NNP and_CC EBS2_NNP ,_, which_WDT are_VBP conserved_`` in_IN both_DT the_DT human_JJ and_CC murine_JJ interleukin-2_NN enhancers_NNS ._.
Within_IN the_DT human_JJ enhancer_NN ,_, these_DT two_CD sites_NNS are_VBP located_VBN within_IN the_DT previously_RB defined_VBN DNase_NNP I_PRP footprints_NNS ,_, NFAT-1_NNP and_CC NFIL-2B_NNP ,_, respectively_RB ._.
Electrophoretic_-LRB- mobility_`` shift_NN and_CC methylation_NN interference_NN analyses_`` demonstrated_VBD that_IN EBS1_NNP and_CC EBS2_NNP are_VBP essential_JJ for_IN the_DT formation_NN of_IN the_DT NFAT-1_NNP and_CC NFIL-2B_`` nuclear_JJ protein_NN complexes_NNS ._.
Furthermore_RB ,_, in_IN vitro_`` mutagenesis_`` experiments_NNS demonstrated_VBD that_IN inducible_JJ interleukin-2_JJ enhancer_NN function_NN requires_VBZ the_DT presence_NN of_IN either_DT EBS1_NNP or_CC EBS2_NNP ._.
Two_CD well-characterized_JJ Ets_# family_NN members_NNS ,_, Ets-1_-RRB- and_CC Ets-2_`` ,_, are_VBP reciprocally_RB expressed_VBN during_IN T-cell_NNP activation_NN ._.
Surprisingly_RB ,_, however_RB ,_, neither_RB of_IN these_DT proteins_NNS bound_VBN in_IN vitro_NN to_TO EBS1_NNP or_CC EBS2_NNP ._.
We_PRP therefore_RB screened_VBD a_DT T-cell_NNP cDNA_NNP library_NN under_IN low-stringency_JJ conditions_NNS with_IN a_DT probe_NN from_IN the_DT DNA_NNP binding_`` domain_NN of_IN Ets-1_NNP and_CC isolated_VBD a_DT novel_JJ Ets_NNP family_NN member_NN ,_, Elf-1_NNP ._.
Elf-1_NNP contains_VBZ a_DT DNA_NNP binding_`` domain_NN that_WDT is_VBZ nearly_RB identical_JJ to_TO that_IN of_IN E74_CD ,_, the_DT ecdysone-inducible_JJ Drosophila_NNP transcription_NN factor_NN required_VBN for_IN metamorphosis_`` (_-LRB- hence_RB the_DT name_NN Elf-1_NNP ,_, for_IN E74-like_JJ factor_NN 1_CD )_-RRB- ._.
Elf-1_NNP bound_VBD specifically_RB to_TO both_DT EBS1_NNP and_CC EBS2_NNP in_IN electrophoretic_`` mobility_JJ shift_NN assays_NNS ._.
It_PRP also_RB bound_VBD to_TO the_DT purine-rich_`` CD3R_`` element_NN from_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 2_CD long_JJ terminal_NN repeat_NN ,_, which_WDT is_VBZ required_VBN for_IN inducible_JJ virus_NN expression_NN in_IN response_NN to_TO signalling_`` through_IN the_DT T-cell_NNP receptor_NN ._.
Taken_VBN together_RB ,_, these_DT results_NNS demonstrate_VBP that_IN multiple_JJ Ets_# family_NN members_NNS with_IN apparently_RB distinct_JJ DNA_NNP binding_# specificities_`` regulate_VB differential_JJ gene_NN expression_NN in_IN resting_VBG and_CC activated_VBN T_JJ cells_NNS ._.
Mineralocorticoids_NNS and_CC mineralocorticoid_JJ receptors_NNS in_IN mononuclear_JJ leukocytes_NNS in_IN patients_NNS with_IN pregnancy-induced_JJ hypertension_NN ._.
To_TO examine_VB the_DT role_NN of_IN mineralocorticoids_NNS in_IN the_DT pathophysiology_NN of_IN pregnancy-induced_JJ hypertension_NN (_-LRB- PIH_NNP )_-RRB- ,_, we_PRP studied_VBD plasma_NN aldosterone_NN and_CC 18-hydroxycorticosterone_JJ levels_NNS in_IN 25_CD women_NNS with_IN PIH_NNP and_CC 25_CD normal_JJ pregnant_JJ women_NNS ,_, as_IN controls_NNS ._.
Furthermore_RB ,_, we_PRP evaluated_VBD the_DT mineralocorticoid_NN receptor_NN (_-LRB- MR_NNP )_-RRB- status_NN in_IN mononuclear_JJ leukocytes_NNS in_IN the_DT 2_CD groups_NNS ._.
MR_NN count_NN was_VBD significantly_RB (_-LRB- P_`` less_JJR than_IN 0.0005_CD )_-RRB- decreased_VBD in_IN the_DT PIH_NNP group_NN (_-LRB- 148_CD +/-_`` 9_CD binding_JJ sites/cell_NN )_-RRB- compared_VBN with_IN the_DT control_NN group_NN (_-LRB- 300_CD +/-_`` 17_CD binding_JJ sites/cell_NN ;_: mean_JJ +/-_JJ SEM_NNP )_-RRB- ._.
Plasma_NNP aldosterone_`` in_IN women_NNS with_IN PIH_NNP was_VBD 281_CD +/-_JJ 61_CD pmol/L_NN ;_: in_IN normal_JJ pregnant_JJ women_NNS it_PRP was_VBD 697_CD +/-_`` 172_CD pmol/L_`` (_-LRB- P_NNP less_JJR than_IN 0.025_CD )_-RRB- ._.
Plasma_NNP 18-hydroxycorticosterone_-RRB- was_VBD also_RB significantly_RB (_-LRB- P_`` less_JJR than_IN 0.025_CD )_-RRB- lower_JJR (_-LRB- PIH_NNP ,_, 1071_CD +/-_`` 149_CD pmol/L_`` ;_: controls_NNS ,_, 1907_CD +/-_`` 318_CD pmol/L_`` )_-RRB- ._.
These_DT values_NNS were_VBD determined_VBN at_IN the_DT onset_`` of_IN clinical_JJ symptoms_NNS of_IN PIH_NNP ._.
These_DT results_NNS can_MD not_RB be_VB explained_VBN by_IN receptor_NN down-regulation_`` due_JJ to_TO higher_JJR levels_NNS of_IN mineralocorticoids_NNS in_IN PIH_NNP ;_: a_DT hitherto_`` unknown_JJ mineralocorticoid_NN may_MD ,_, thus_RB ,_, be_VB responsible_JJ for_IN the_DT hypertension_NN and_CC altered_VBD MR_NNP status_NN ._.
Mineralocorticoid_JJ effector_NN mechanism_NN in_IN preeclampsia_NN ._.
Mineralocorticoid_JJ effector_`` mechanisms_NNS were_VBD evaluated_VBN in_IN 29_CD patients_NNS with_IN preeclampsia_`` and_CC in_IN 25_CD uncomplicated_JJ pregnancies_NNS by_IN measurement_NN of_IN plasma_NN aldosterone_NN ,_, levels_NNS of_IN mineralocorticoid_NN receptor_NN (_-LRB- MR_NNP )_-RRB- in_IN mononuclear_JJ leucocytes_NNS ,_, and_CC subtraction_`` potential_JJ difference_NN (_-LRB- SPD_`` ;_: rectal_JJ minus_CC oral_JJ values_NNS )_-RRB- ._.
Mean_JJ values_NNS for_IN plasma_NN aldosterone_NN were_VBD not_RB different_JJ between_IN the_DT two_CD groups_NNS ,_, but_CC significant_JJ differences_NNS were_VBD observed_VBN for_IN MR_`` (_-LRB- preeclampsia_NN ,_, 81_CD +/-_JJ 44_CD receptors/cell_NN ;_: controls_NNS ,_, 306_CD +/-_`` 168_CD )_-RRB- and_CC SPD_`` (_-LRB- preeclampsia_NN ,_, 65_CD +/-_`` 7_CD mV_NNP ;_: controls_NNS ,_, 12_CD +/-_`` 5_CD mV_NNP )_-RRB- ._.
In_IN six_CD cases_NNS we_PRP determined_VBD MR_NNP ,_, plasma_NN aldosterone_NN ,_, and_CC SPD_`` in_IN patients_NNS with_IN preeclampsia_NN before_IN and_CC 3_CD months_NNS after_IN delivery_NN ._.
MR_NNP were_VBD reduced_VBN before_IN delivery_NN (_-LRB- 96_CD +/-_JJ 27_CD receptors/cell_NN )_-RRB- ,_, and_CC SPD_NNP increased_VBD (_-LRB- 64_CD +/-_`` 8_CD mV_NNP )_-RRB- ,_, with_IN both_DT parameters_`` normalizing_`` after_IN delivery_NN (_-LRB- MR_NNP ,_, 242_CD +/-_`` 79_CD ;_: SPD_`` ,_, 14.0_CD +/-_`` 4_CD mV_NNP )_-RRB- ._.
Aldosterone_WP$ levels_NNS returned_VBD to_TO normal_JJ nonpregnant_JJ values_NNS after_IN delivery_NN ._.
These_DT data_NNS suggest_VBP an_DT important_JJ role_NN for_IN abnormalities_NNS in_IN mineralocorticoid_`` effector_`` mechanisms_NNS in_IN the_DT etiology_NN of_IN preeclampsia_`` and_CC could_MD be_VB an_DT useful_JJ marker_NN for_IN diagnosis_NN ._.
A_DT lymphoid_JJ cell-specific_JJ nuclear_JJ factor_NN containing_VBG c-Rel-like_JJ proteins_NNS preferentially_RB interacts_`` with_IN interleukin-6_JJ kappa_NN B-related_NNP motifs_`` whose_WP$ activities_NNS are_VBP repressed_`` in_IN lymphoid_JJ cells_NNS ._.
The_DT proto-oncoprotein_NN c-Rel_NNP is_VBZ a_DT member_NN of_IN the_DT nuclear_JJ factor_NN kappa_NN B_NNP transcription_NN factor_NN family_NN ,_, which_WDT includes_VBZ the_DT p50_NN and_CC p65_NN subunits_NNS of_IN nuclear_JJ factor_NN kappa_NN B_NNP ._.
We_PRP show_VBP here_RB that_IN c-Rel_NNP binds_VBZ to_TO kappa_VB B_NNP sites_NNS as_RB homodimers_NNS as_RB well_RB as_IN heterodimers_NNS with_IN p50_NN ._.
These_DT homodimers_NNS and_CC heterodimers_NNS show_VBP distinct_JJ DNA-binding_`` specificities_NNS and_CC affinities_NNS for_IN various_JJ kappa_NN B_NNP motifs_`` ._.
In_IN particular_JJ ,_, the_DT c-Rel_`` homodimer_NN has_VBZ a_DT high_JJ affinity_NN for_IN interleukin-6_`` (_-LRB- IL-6_NN )_-RRB- and_CC beta_JJ interferon_# kappa_`` B_NNP sites_NNS ._.
In_IN spite_NN of_IN its_PRP$ association_NN with_IN p50_NN in_IN vitro_NN ,_, however_RB ,_, we_PRP found_VBD a_DT lymphoid_JJ cell-specific_JJ nuclear_JJ factor_NN in_IN vivo_`` that_WDT contains_VBZ c-Rel_`` but_CC not_RB p50_`` epitopes_NNS ;_: this_DT factor_NN ,_, termed_VBD IL-6_-RRB- kappa_NN B_NNP binding_JJ factor_NN II_NNP ,_, appears_VBZ to_TO contain_VB the_DT c-Rel_`` homodimer_NN and_CC preferentially_RB recognizes_VBZ several_JJ IL-6_NNP kappa_`` B-related_`` kappa_NN B_NNP motifs_`` ._.
Although_IN it_PRP has_VBZ been_VBN previously_RB shown_VBN that_IN the_DT IL-6_NNP kappa_NN B_NNP motif_`` functions_NNS as_IN a_DT potent_JJ IL-1/tumor_NN necrosis_`` factor-responsive_JJ element_NN in_IN nonlymphoid_JJ cells_NNS ,_, its_PRP$ activity_NN was_VBD found_VBN to_TO be_VB repressed_VBN in_IN lymphoid_JJ cells_NNS such_JJ as_IN a_DT Jurkat_NNP T-cell_NNP line_NN ._.
We_PRP also_RB present_JJ evidence_NN that_IN IL-6_NNP kappa_`` B_NNP binding_JJ factor_NN II_NNP functions_VBZ as_IN a_DT repressor_`` specific_JJ for_IN IL-6_JJ kappa_NN B-related_NNP kappa_`` B_NNP motifs_`` in_IN lymphoid_JJ cells_NNS ._.
Modulation_NN of_IN normal_JJ erythroid_`` differentiation_NN by_IN the_DT endogenous_JJ thyroid_NN hormone_NN and_CC retinoic_JJ acid_NN receptors_NNS :_: a_DT possible_JJ target_NN for_IN v-erbA_`` oncogene_JJ action_NN ._.
The_DT v-erbA_NNP oncogene_NN ,_, a_DT mutated_JJ version_NN of_IN the_DT thyroid_`` hormone_NN receptor_NN alpha_NN (_-LRB- c-erbA/TR-alpha_NNP )_-RRB- ,_, inhibits_VBZ erythroid_`` differentiation_`` and_CC constitutively_RB represses_VBZ transcription_NN of_IN certain_JJ erythrocyte_`` genes_NNS ,_, suggesting_VBG a_DT normal_JJ function_NN of_IN the_DT proto-oncogene_NN c-erbA_`` in_IN erythropoiesis_NN ._.
Here_RB we_PRP demonstrate_VBP that_IN the_DT endogenous_JJ thyroid_`` hormone_NN receptor_NN alpha_`` (_-LRB- c-erbA/TR-alpha_NN )_-RRB- and_CC the_DT closely_RB related_JJ retinoic_JJ acid_NN receptor_NN alpha_NN (_-LRB- RAR-alpha_NNP )_-RRB- play_VB a_DT role_NN in_IN the_DT regulation_NN of_IN normal_JJ erythroid_`` differentiation_NN ._.
Retinoic_JJ acid_NN (_-LRB- RA_NNP )_-RRB- distinctly_RB modulated_# the_DT erythroid_`` differentiation_`` program_NN of_IN normal_JJ erythroid_`` progenitors_NNS and_CC erythroblasts_NNS reversibly_RB transformed_VBN by_IN a_DT conditional_JJ tyrosine_NN kinase_`` oncogene_NN ._.
When_WRB added_VBD pulsewise_RB to_TO immature_JJ cells_NNS ,_, differentiation_NN was_VBD accelerated_VBN while_IN more_RBR mature_JJ cells_NNS underwent_`` premature_JJ cell_NN death_NN ._.
Thyroid_-LRB- hormone_NN (_-LRB- T3_CD )_-RRB- alone_RB caused_VBD similar_JJ but_CC weaker_JJR effects_NNS ._.
Interestingly_RB ,_, T3_NNP strongly_RB enhanced_VBD the_DT action_NN of_IN RA_NNP ,_, suggesting_VBG cooperative_JJ action_NN of_IN the_DT two_CD receptors_NNS in_IN modulating_`` erythroid_JJ differentiation_NN ._.
Expression_NN of_IN the_DT human_JJ RAR-alpha_NN in_IN receptor-negative_JJ erythroblasts_NNS conferred_`` RA-induced_`` regulation_NN of_IN differentiation_NN to_TO the_DT otherwise_RB unresponsive_JJ cells_NNS ,_, thus_RB showing_VBG that_IN the_DT RAR-alpha_NNP is_VBZ essential_JJ for_IN the_DT RA_NNP effect_NN ._.
Likewise_RB ,_, enhanced_JJ expression_NN of_IN exogenous_JJ c-erbA/TR-alpha_NN in_IN erythroblasts_NNS rendered_VBD them_PRP susceptible_JJ to_TO modulation_`` of_IN differentiation_NN by_IN T3_CD ,_, suggesting_VBG a_DT similar_JJ function_NN of_IN both_DT receptors_NNS ._.
Leukotriene_NNP B4_NNP stimulates_VBZ c-fos_NNS and_CC c-jun_JJ gene_NN transcription_NN and_CC AP-1_`` binding_JJ activity_NN in_IN human_JJ monocytes_NNS ._.
We_PRP have_VBP examined_VBN the_DT effect_NN of_IN leukotriene_`` B4_# (_-LRB- LTB4_NN )_-RRB- ,_, a_DT potent_JJ lipid_`` proinflammatory_JJ mediator_NN ,_, on_IN the_DT expression_NN of_IN the_DT proto-oncogenes_`` c-jun_`` and_CC c-fos_`` ._.
In_IN addition_NN ,_, we_PRP looked_VBD at_IN the_DT modulation_NN of_IN nuclear_JJ factors_NNS binding_VBG specifically_RB to_TO the_DT AP-1_`` element_NN after_IN LTB4_NNP stimulation_NN ._.
LTB4_NN increased_VBD the_DT expression_NN of_IN the_DT c-fos_`` gene_NN in_IN a_DT time-_NN and_CC concentration-dependent_JJ manner_NN ._.
The_DT c-jun_`` mRNA_NNP ,_, which_WDT is_VBZ constitutively_RB expressed_VBN in_IN human_JJ peripheral-blood_`` monocytes_NNS at_IN relatively_RB high_JJ levels_NNS ,_, was_VBD also_RB slightly_RB augmented_VBN by_IN LTB4_NNP ,_, although_IN to_TO a_DT much_RB lower_JJR extent_NN than_IN c-fos_`` ._.
The_DT kinetics_NNS of_IN expression_NN of_IN the_DT two_CD genes_NNS were_VBD also_RB slightly_RB different_JJ ,_, with_IN c-fos_`` mRNA_`` reaching_VBG a_DT peak_NN at_IN 15_CD min_NN after_IN stimulation_NN and_CC c-jun_`` at_IN 30_CD min_NN ._.
Both_DT messages_NNS rapidly_RB declined_VBD thereafter_RB ._.
Stability_NN of_IN the_DT c-fos_NNS and_CC c-jun_JJ mRNA_NNP was_VBD not_RB affected_VBN by_IN LTB4_NNP ,_, as_IN assessed_VBN after_IN actinomycin_# D_NNP treatment_NN ._.
Nuclear_JJ transcription_NN studies_NNS in_IN vitro_NN showed_VBD that_IN LTB4_NNP increased_VBD the_DT transcription_NN of_IN the_DT c-fos_JJ gene_NN 7-fold_RB and_CC the_DT c-jun_JJ gene_NN 1.4-fold_`` ._.
Resting_VBG monocytes_NNS contained_VBN nuclear_JJ factors_NNS binding_VBG to_TO the_DT AP-1_NNP element_NN ,_, but_CC stimulation_NN of_IN monocytes_NNS with_IN LTB4_`` induced_`` greater_JJR AP-1-binding_JJ activity_NN of_IN nuclear_JJ proteins_NNS ._.
These_DT results_NNS indicate_VBP that_IN LTB4_NNP may_MD regulate_VB the_DT production_NN of_IN different_JJ cytokines_NNS by_IN modulating_VBG the_DT yield_NN and/or_CC the_DT function_NN of_IN transcription_NN factors_NNS such_JJ as_IN AP-1-binding_JJ proto-oncogene_NN products_NNS ._.
An_DT 11-base-pair_JJ DNA_NNP sequence_NN motif_`` apparently_RB unique_JJ to_TO the_DT human_JJ interleukin_NN 4_CD gene_NN confers_VBZ responsiveness_`` to_TO T-cell_NNP activation_NN signals_NNS ._.
We_PRP have_VBP identified_VBN a_DT DNA_NNP segment_NN that_WDT confers_VBZ responsiveness_NN to_TO antigen_# stimulation_NN signals_NNS on_IN the_DT human_JJ interleukin_# (_-LRB- IL_NNP )_-RRB- 4_CD gene_NN in_IN Jurkat_NNP cells_NNS ._.
The_DT human_JJ IL-4_NN gene_NN ,_, of_IN 10_CD kilobases_NNS ,_, is_VBZ composed_VBN of_IN four_CD exons_NNS and_CC three_CD introns_NNS ._.
A_DT cis-acting_JJ element_NN (_-LRB- P_NNP sequence_NN )_-RRB- resides_`` in_IN the_DT 5'_`` upstream_JJ region_NN ;_: no_DT additional_JJ DNA_NNP segments_NNS with_IN enhancer_NN activity_NN were_VBD identified_VBN in_IN the_DT human_JJ IL-4_NN gene_NN ._.
For_IN further_JJ mapping_NN purposes_NNS ,_, a_DT fusion_NN promoter_NN was_VBD constructed_VBN with_IN the_DT granulocyte/macrophage_`` colony-stimulating_JJ factor_NN basic_NN promoter_NN containing_VBG 60_CD base_NN pairs_NNS of_IN sequence_NN upstream_RB from_IN the_DT cap_NN site_NN of_IN the_DT mouse_NN granulocyte/macrophage_NN colony-stimulating_JJ factor_NN gene_NN and_CC various_JJ lengths_NNS of_IN the_DT 5'_`` upstream_JJ sequence_NN of_IN the_DT IL-4_`` gene_NN ._.
The_DT P_NNP sequence_NN was_VBD located_VBN between_IN positions_NNS -79_CD and_CC -69_CD relative_JJ to_TO the_DT transcription_NN start_VBP site_NN of_IN the_DT human_JJ IL-4_NN gene_NN ,_, and_CC this_DT location_NN was_VBD confirmed_VBN by_IN base-substitution_NN mutations_NNS ._.
The_DT plasmids_NNS carrying_VBG multiple_JJ copies_NNS of_IN the_DT P_NNP sequence_NN showed_VBD higher_JJR responsiveness_NN to_TO the_DT stimulation_NN ._.
The_DT binding_JJ protein_NN (_-LRB- s_PRP )_-RRB- that_WDT recognize_VBP the_DT P_NNP sequence_NN of_IN the_DT IL-4_`` gene_NN were_VBD identified_VBN by_IN DNA-mobility-shift_NNP assays_`` ._.
The_DT binding_NN of_IN NF(P)_NNP (_-LRB- a_DT DNA_NNP binding_`` protein_NN that_IN specifically_RB recognizes_VBZ the_DT P_NNP sequence_NN )_-RRB- to_TO the_DT P_NNP sequence_NN was_VBD abolished_VBN when_WRB oligonucleotides_NNS carrying_VBG base_NN substitutions_NNS were_VBD used_VBN ,_, indicating_VBG that_IN the_DT NF(P)_NNP interaction_NN is_VBZ sequence-specific_`` and_CC that_IN binding_JJ specificity_NN of_IN the_DT protein_NN paralleled_VBD the_DT sequence_NN requirements_NNS for_IN IL-4_JJ expression_NN in_IN vivo_`` ._.
The_DT P_NNP sequence_NN does_VBZ not_RB share_VB homology_NN with_IN the_DT 5'_`` upstream_JJ sequence_NN of_IN the_DT IL-2_`` gene_NN ,_, even_RB though_IN surrounding_VBG sequences_NNS of_IN the_DT IL-4_JJ gene_NN share_NN high_JJ homology_NN with_IN the_DT IL-2_JJ gene_NN ._.
We_PRP conclude_VBP that_IN a_DT different_JJ set_NN of_IN proteins_NNS recognize_VBP IL-2_-RRB- and_CC IL-4_JJ genes_NNS ._.
Glucocorticoid_JJ receptor_NN binding_NN in_IN three_CD different_JJ cell_NN types_NNS in_IN major_JJ depressive_JJ disorder_NN :_: lack_NN of_IN evidence_NN of_IN receptor_NN binding_JJ defect_NN ._.
1_LS ._. In_IN order_NN to_TO further_RB understand_VB the_DT apparent_JJ glucocorticoid_JJ resistance_NN in_IN major_JJ depressive_JJ disorder_NN ,_, circadian_JJ variation_NN in_IN cortisol_`` concentration_NN ,_, dexamethasone_'' suppression_NN and_CC glucocorticoid_NN receptor_NN binding_`` in_IN mononuclear_JJ leukocytes_NNS ,_, polymorphonuclear_JJ leukocytes_NNS and_CC cultured_JJ skin_NN fibroblasts_NNS were_VBD measured_VBN in_IN rigidly_RB defined_VBN major_JJ depressive_JJ disorder_NN patients_NNS and_CC non-depressed_JJ psychiatric_JJ controls_NNS ._.
2_LS ._. Mononuclear_`` leukocytes_NNS binding_# to_TO glucocorticoid_`` correlated_`` significantly_RB with_IN polymorphonuclear_`` leukocytes_NNS binding_VBG to_TO glucocorticoid_`` ,_, but_CC both_DT determinations_NNS failed_VBD to_TO differentiate_VB major_JJ depressive_JJ disorder_NN and_CC control_NN subjects_NNS ._.
3_LS ._. Initial_JJ and_CC post-dexamethasone_`` in_IN vitro_`` fibroblast_JJ binding_NN to_TO glucocorticoid_'' was_VBD not_RB different_JJ between_IN major_JJ depressive_JJ disorder_NN and_CC non-depressed_JJ control_NN subjects_NNS ._.
4_LS ._. The_DT phenomenon_NN of_IN glucocorticoid_JJ resistance_NN in_IN major_JJ depressive_JJ disorder_NN remains_VBZ unexplained_JJ ._.
Kinetics_NNS of_IN nuclear_JJ translocation_NN and_CC turnover_NN of_IN the_DT vitamin_NN D_NNP receptor_NN in_IN human_JJ HL60_NNP leukemia_NN cells_NNS and_CC peripheral_JJ blood_NN lymphocytes_NNS --_: coincident_JJ rise_NN of_IN DNA-relaxing_JJ activity_NN in_IN nuclear_JJ extracts_NNS ._.
High_JJ affinity_NN receptors_NNS (_-LRB- VDR_NN )_-RRB- for_IN 1,25-dihydroxycholecalciferol_`` (_-LRB- calcitriol_NN )_-RRB- are_VBP expressed_VBN in_IN HL60_`` human_JJ leukemia_NN cells_NNS and_CC in_IN low_JJ numbers_NNS in_IN peripheral_JJ blood_NN lymphocytes_NNS (_-LRB- PBL_NNP )_-RRB- ._.
HL60_-LRB- cells_NNS ,_, expressing_VBG some_DT characteristics_NNS of_IN promyelocytes_NNS ,_, can_MD be_VB induced_VBN to_TO monocytoid_`` differentiation_`` by_IN calcitriol_NN ._.
Specific_JJ nuclear_JJ translocation_NN of_IN (3H)calcitriol/VDR_NN was_VBD examined_VBN after_IN exposure_NN of_IN whole_JJ cells_NNS to_TO 10(-9)_CD M/l_NNP calcitriol_`` in_IN the_DT presence_NN and_CC absence_NN of_IN a_DT 500-fold_JJ excess_NN of_IN unlabeled_`` ligand_`` and_CC subsequent_JJ isolation_NN of_IN nuclei_`` ._.
Specific_JJ nuclear_JJ translocation_NN of_IN (3H)calcitriol/VDR_NN was_VBD found_VBN to_TO be_VB time_NN dependent_JJ reaching_VBG a_DT maximum_NN of_IN approximately_RB 2100_CD binding_`` sites/nucleus_NN after_IN 3_CD h_NN of_IN incubation_NN in_IN HL60_CD cells_NNS ,_, whereas_IN a_DT maximum_NN of_IN approximately_RB 310_`` binding_VBG sites/nucleus_NN was_VBD found_VBN after_IN 3_CD h_NN in_IN PBL_NNP ._.
Pulse_JJ exposure_NN of_IN HL60_NNP to_TO radiolabeled_`` hormone_NN for_IN 3_CD h_NN followed_VBN by_IN culture_NN in_IN medium_NN without_IN serum_`` and_CC calcitriol_`` lead_NN to_TO nuclear_JJ retention_NN of_IN approximately_RB 1600_CD radiolabeled_VBD VDR_NNP by_IN 8_CD h_NN and_CC approximately_RB 1000_CD VDR_`` by_IN 24_CD h_NN ._.
Radiolabeled_VBN VDR_NNP disappeared_VBD from_IN the_DT nuclear_JJ compartment_NN with_IN a_DT halflife_NN of_IN approximately_RB 30_CD min_NN if_IN cells_NNS were_VBD cultured_`` with_IN identical_JJ concentrations_NNS of_IN unlabeled_`` hormone_NN after_IN the_DT pulse_NN (_-LRB- pulse/chase-experiments_`` )_-RRB- ._.
No_DT difference_NN of_IN VDR_`` retention_NN in_IN pulse_NN and_CC pulse/chase-experiments_NNS was_VBD seen_VBN in_IN PBL_NNP ,_, where_WRB VDR_`` halflife_NN was_VBD approximately_RB 30_CD min_NN ._.
No_DT specific_JJ translocation_NN into_IN the_DT nuclear_JJ compartment_NN was_VBD seen_VBN when_WRB isolated_VBN nuclei_# were_VBD incubated_VBN in_IN (3H)calcitriol_NNP ._.
Radiolabeled_-LRB- hormone/receptor_NN complexes_NNS of_IN nuclei_`` isolated_VBN from_IN cells_NNS exposed_VBN for_IN 3_CD h_NN to_TO radiolabeled_# hormone_NN --_: in_IN contrast_NN to_TO identical_JJ experiments_NNS with_IN intact_JJ cells_NNS --_: did_VBD not_RB disappear_VB from_IN the_DT nuclear_JJ compartment_NN upon_IN incubation_NN of_IN nuclei_`` with_IN identical_JJ concentrations_NNS of_IN the_DT unlabeled_JJ compound_NN ._.
The_DT activity_NN of_IN DNA_NNP relaxing_VBG enzymes_NNS (_-LRB- e.g._FW topoisomerases_`` I_PRP and_CC II_NNP )_-RRB- in_IN nuclear_JJ extracts_NNS was_VBD measured_VBN using_VBG a_DT PBR_NNP 322-relaxation-assay_`` ._.
Enhanced_VBN overall_JJ enzyme_`` activity_NN was_VBD found_VBN in_IN nuclear_JJ extracts_NNS by_IN 1_CD h_NN after_IN incubation_NN with_IN calcitriol_`` (_-LRB- final_JJ ethanol_NN concentration_NN 0.0001_CD %_NN v/v_NN )_-RRB- in_IN HL60_NNP and_CC PBL_NNP ._.
The_DT enhanced_JJ activity_NN disappeared_VBD after_IN 2_CD h_NN in_IN PBL_NNP ,_, whereas_IN it_PRP was_VBD still_RB enhanced_VBN by_IN 4_CD h_NN in_IN HL60_NNP ._.
No_DT effect_NN was_VBD seen_VBN in_IN ethanol_`` treated_VBN controls_NNS ._.
We_PRP conclude_VBP that_IN a_DT specific_JJ nuclear_JJ translocation_NN mechanism_NN exists_VBZ for_IN calcitriol_NN in_IN both_DT cell_NN types_NNS examined_VBN ,_, most_RBS likely_JJ due_JJ to_TO translocation_NN of_IN receptor_NN proteins_NNS after_IN hormone_NN binding_NN ._.
Translocated_VBN hormone/receptor_`` complexes_NNS compete_VBP for_IN a_DT limited_JJ number_NN of_IN specific_JJ nuclear_JJ binding_JJ sites_NNS ._.
Enhanced_VBN activity_NN of_IN topoisomerases_NNS in_IN nuclear_JJ extracts_`` upon_IN translocation_NN of_IN VDR_NNP might_MD reflect_VB interaction_NN of_IN both_DT within_IN the_DT nuclear_JJ compartment_NN ,_, thus_RB initiating_VBG DNA-unwinding_# ,_, a_DT prerequisite_`` of_IN transcription_NN initiation_NN ._.
The_DT B_NNP cell-specific_`` nuclear_JJ factor_NN OTF-2_NNP positively_RB regulates_VBZ transcription_NN of_IN the_DT human_JJ class_NN II_NNP transplantation_`` gene_NN ,_, DRA_NNP ._.
The_DT promoter_NN of_IN the_DT major_JJ histocompatibility_NN class_NN II_NNP gene_NN DRA_NNP contains_VBZ an_DT octamer_NN element_NN (_-LRB- ATTTGCAT_# )_-RRB- that_DT is_VBZ required_VBN for_IN efficient_JJ DRA_`` expression_NN in_IN B_NNP cells_NNS ._.
Several_JJ DNA-binding_`` proteins_NNS are_VBP known_VBN to_TO bind_NN this_DT sequence_NN ._.
The_DT best_JJS characterized_VBN are_VBP the_DT B_NNP cell-specific_`` OTF-2_`` and_CC the_DT ubiquitous_JJ OTF-1_NN ._.
This_DT report_NN directly_RB demonstrates_VBZ that_IN OTF-2_`` but_CC not_RB OTF-1_NNP regulates_VBZ the_DT DRA_NNP gene_NN ._.
In_IN vitro_`` transcription_NN analysis_NN using_VBG protein_NN fractions_NNS enriched_`` for_IN the_DT octamer-binding_JJ protein_NN OTF-2_`` demonstrate_VBP a_DT positive_JJ functional_JJ role_NN for_IN OTF-2_NNP in_IN DRA_NNP gene_NN transcription_NN ._.
In_IN contrast_NN ,_, OTF-1-enriched_JJ protein_NN fractions_NNS did_VBD not_RB affect_VB DRA_`` gene_NN transcription_NN although_IN it_PRP functionally_RB enhanced_VBD the_DT transcription_NN of_IN another_DT gene_NN ._.
Recombinant_JJ OTF-2_NN protein_NN produced_VBN by_IN in_IN vitro_`` transcription/translation_NN could_MD also_RB enhance_VB DRA_NNP gene_NN transcription_NN in_IN vitro_NN ._.
In_IN vivo_`` transient_JJ transfection_NN studies_NNS utilizing_VBG an_DT OTF-2_`` expression_NN vector_NN resulted_VBD in_IN similar_JJ findings_NNS :_: that_IN OTF-2_`` protein_NN enhanced_JJ DRA_`` gene_NN transcription_NN ,_, and_CC that_IN this_DT effect_NN requires_VBZ an_DT intact_JJ octamer_NN element_NN ._.
Together_RB these_DT results_NNS constitute_VBP the_DT first_JJ direct_JJ evidence_NN of_IN a_DT positive_JJ role_NN for_IN the_DT lymphoid-specific_JJ octamer-binding_JJ factor_NN in_IN DRA_NNP gene_NN transcription_NN ._.
(_-LRB- Regulation_NN of_IN intracellular_JJ cholesterol_NN synthesis_NN in_IN hypercholesterolemia_NN by_IN glucocorticoids_NNS )_-RRB-
The_DT rate_NN of_IN endogenous_JJ cholesterol_NN synthesis_NN in_IN blood_NN lymphocytes_NNS and_CC skin_NN fibroblasts_NNS from_IN patients_NNS with_IN type_NN IIa_NNP hyperlipidemia_NN was_VBD found_VBN to_TO be_VB increased_VBN in_IN comparison_NN with_IN healthy_JJ donors_NNS ._.
The_DT cells_NNS of_IN hyperlipidemic_JJ patients_NNS had_VBD lowered_VBN levels_NNS of_IN glucocorticoid_`` receptors_NNS concomitantly_RB with_IN a_DT partial_JJ loss_NN of_IN their_PRP$ sensitivity_NN to_TO glucocorticoids_NNS ._.
In_IN fibroblasts_NNS from_IN patients_NNS with_IN hereditary_JJ hypercholesteremia_NN of_IN homozygous_JJ type_NN the_DT number_NN of_IN glucocorticoid_JJ receptors_NNS did_VBD not_RB exceed_VB 10_CD %_NN of_IN their_PRP$ content_NN in_IN normal_JJ cells_NNS ._.
The_DT decrease_NN of_IN the_DT number_NN of_IN glucocorticoid_JJ receptors_NNS in_IN patients_NNS with_IN type_NN IIa_NNP hyperlipidemia_NN seems_VBZ to_TO be_VB a_DT compensatory_JJ response_NN of_IN cells_NNS culminating_VBG in_IN activation_NN of_IN endogenous_JJ cholesterol_NN synthesis_NN ._.
Transcription_WP$ factor_NN activation_NN and_CC functional_JJ stimulation_NN of_IN human_JJ monocytes_NNS ._.
Activation_NN of_IN expression_NN of_IN genes_NNS encoding_`` transcription_`` factors_NNS :_: c-fos_NNS and_CC c-jun_`` and_CC formation_NN of_IN AP1_NNP transcriptional_`` complex_JJ in_IN human_JJ monocytes_NNS was_VBD investigated_VBN ._.
It_PRP was_VBD found_VBN that_IN lipopolysaccharide_NN induced_`` strongly_RB both_DT c-fos_NNS and_CC c-jun_JJ expression_NN as_RB well_RB as_IN AP1_CD formation_NN ._.
Interferon_NNP gamma_# activated_VBN strongly_RB c-fos_`` and_CC weakly_RB c-jun_`` and_CC AP1_`` ._.
Tumor_NN necrosis_NN factor_NN induced_`` slightly_RB c-fos_`` and_CC had_VBD almost_RB no_DT effect_NN on_IN c-jun_`` and_CC AP1_`` ._.
The_DT data_NNS suggest_VBP that_IN differences_NNS in_IN functional_JJ responses_NNS elicited_`` in_IN monocytes_NNS by_IN all_DT three_CD factors_NNS may_MD be_VB dependent_JJ on_IN different_JJ routes_NNS on_IN nuclear_JJ signalling_NN employed_VBN by_IN the_DT factors_NNS ._.
Corticosteroid_NNP receptors_`` and_CC lymphocyte_# subsets_NNS in_IN mononuclear_JJ leukocytes_NNS in_IN aging_VBG ._.
Plasma_NNP cortisol_`` and_CC aldosterone_# levels_NNS and_CC number_NN of_IN related_VBN receptors_NNS in_IN mononuclear_`` leukocytes_NNS were_VBD measured_VBN in_IN 49_CD healthy_JJ aged_JJ subjects_NNS (_-LRB- 62-97_CD yr_`` )_-RRB- and_CC in_IN 21_CD adult_NN controls_NNS (_-LRB- 21-50_CD yr_`` )_-RRB- ._.
In_IN all_DT subjects_NNS ,_, in_IN addition_NN ,_, lymphocyte_NN subsets_NNS were_VBD determined_VBN as_IN an_DT index_NN of_IN corticosteroid_JJ action_NN ._.
The_DT mean_JJ number_NN of_IN type_NN I_PRP and_CC type_NN II_NNP receptors_NNS was_VBD significantly_RB lower_JJR in_IN aged_JJ subjects_NNS than_IN in_IN controls_NNS (_-LRB- respectively_RB ,_, 198_CD +/-_`` 96_CD and_CC 272_CD +/-_`` 97_CD receptors/cell_`` for_IN type_NN I_PRP ,_, and_CC 1,794_CD +/-_JJ 803_CD and_CC 3,339_CD +/-_`` 918_CD for_IN type_NN II_NNP receptors_`` )_-RRB- ._.
Plasma_NNP aldosterone_`` and_CC cortisol_`` and_CC lymphocyte_`` subsets_NNS were_VBD not_RB different_JJ in_IN the_DT two_CD groups_NNS ._.
All_DT of_IN the_DT parameters_NNS were_VBD also_RB tested_VBN for_IN correlation_NN ,_, and_CC a_DT significant_JJ inverse_NN correlation_NN was_VBD found_VBN between_IN age_NN and_CC type_NN I_PRP and_CC type_NN II_NNP receptors_NNS when_WRB all_DT subjects_NNS were_VBD plotted_`` and_CC between_IN aged_VBN and_CC CD4_`` and_CC age_NN and_CC CD4/CD8_`` in_IN the_DT aged_JJ group_NN ._.
These_DT data_NNS show_VBP that_IN aged_JJ subjects_NNS have_VBP reductions_NNS of_IN corticosteroid_`` receptors_NNS that_WDT are_VBP not_RB associated_VBN with_IN increase_NN of_IN related_JJ steroids_NNS and_CC that_IN this_DT situation_NN probably_RB represents_VBZ a_DT concomitant_`` of_IN the_DT normal_JJ aging_VBG process_NN ._.
Stable_JJ expression_NN of_IN HB24_NNP ,_, a_DT diverged_`` human_JJ homeobox_NN gene_NN ,_, in_IN T_CD lymphocytes_NNS induces_VBZ genes_NNS involved_VBN in_IN T_JJ cell_NN activation_NN and_CC growth_NN ._.
A_DT diverged_VBN homeobox_NN gene_NN ,_, HB24_NNP ,_, which_WDT is_VBZ known_VBN to_TO be_VB induced_VBN following_VBG lymphocyte_`` activation_NN ,_, was_VBD introduced_VBN into_IN Jurkat_NNP T_JJ cells_NNS under_IN the_DT control_NN of_IN a_DT constitutive_JJ promoter_NN ._.
Stable_JJ transfectants_NNS of_IN HB24_CD were_VBD established_VBN that_IN expressed_VBN high_JJ levels_NNS of_IN HB24_NNP mRNA_NNP and_CC possessed_VBD an_DT altered_VBN phenotype_`` suggestive_`` of_IN activated_`` T_JJ cells_NNS ._.
A_DT number_NN of_IN genes_NNS known_VBN to_TO be_VB induced_VBN following_VBG T_JJ cell_NN activation_NN and_CC associated_VBN with_IN cell_NN growth_NN were_VBD increased_VBN in_IN the_DT transfectants_NNS ,_, including_VBG c-fos_NNS ,_, c-myc_JJ ,_, c-myb_JJ ,_, HLA-DR_'' ,_, lck_NN ,_, NF-kappa_NNP B_NNP ,_, interleukin-2_NN and_CC interleukin-2_NN receptor_NN alpha_# (_-LRB- IL-2R_JJ alpha_NN )_-RRB- ._.
Analysis_NN of_IN IL-2R_JJ alpha_NN expression_NN by_IN transient_JJ transfection_NN of_IN IL-2R_JJ alpha_NN promoter_NN constructs_`` into_IN the_DT HB24_`` transfectants_NNS revealed_VBD constitutive_JJ expression_NN (_-LRB- about_IN 60_CD %_NN of_IN phytohemagglutinin-_`` and_CC phorbol_`` ester-activated_`` Jurkat_`` cells_NNS )_-RRB- that_WDT was_VBD dependent_JJ on_IN the_DT kappa_NN B_NNP site_NN in_IN the_DT IL-2R_JJ alpha_NN promoter_NN ._.
Furthermore_RB ,_, as_IN a_DT consequence_NN of_IN the_DT increased_VBN HB24_`` mRNA_`` levels_NNS ,_, the_DT Jurkat_NNP HB24_NNP transfectants_`` proliferated_`` more_RBR rapidly_RB than_IN control_VB cell_NN lines_NNS ._.
Thus_RB ,_, stable_JJ expression_NN of_IN HB24_NNP confers_VBZ an_DT activation_NN phenotype_`` on_IN a_DT human_JJ T_JJ cell_NN line_NN ,_, implicating_VBG this_DT gene_NN as_IN an_DT important_JJ transcriptional_JJ factor_NN during_IN T_JJ cell_NN activation_NN and_CC growth_NN ._.
Studies_NNS on_IN the_DT biological_JJ activity_NN of_IN triiodothyronine_CD sulfate_NN ._.
Hepatic_JJ microsomes_NNS and_CC isolated_VBN hepatocytes_NNS in_IN short_JJ term_NN culture_NN desulfate_`` T3_CD sulfate_`` (_-LRB- T3SO4_NN )_-RRB- ._.
We_PRP ,_, therefore_RB ,_, wished_VBD to_TO determine_VB whether_IN T3SO4_`` could_MD mimic_VB the_DT action_NN of_IN thyroid_`` hormone_NN in_IN vitro_NN ._.
T3SO4_NN had_VBD no_DT thyromimetic_JJ effect_NN on_IN the_DT activity_NN of_IN Ca(2+)-ATPase_NNP in_IN human_JJ erythrocyte_`` membranes_NNS at_IN doses_NNS up_IN to_TO 10,000_CD times_NNS the_DT maximally_`` effective_JJ dose_NN of_IN T3_CD (_-LRB- 10/(-10)_JJ mol/L_NN )_-RRB- ._.
In_IN GH4C1_`` pituitary_JJ cells_NNS ,_, T3SO4_# failed_VBD to_TO displace_VB (125I)T3_-LRB- from_IN nuclear_JJ receptors_NNS in_IN intact_JJ cells_NNS or_CC soluble_JJ preparations_NNS ._.
Thus_RB ,_, T3SO4_'' was_VBD not_RB directly_RB thyromimetic_`` in_IN either_DT an_DT isolated_JJ human_JJ membrane_NN system_NN or_CC a_DT pituitary_JJ cell_NN system_NN in_IN which_WDT nuclear_JJ receptor_NN occupancy_NN correlates_`` with_IN GH_NNP synthesis_NN ._.
Thyroid_WP$ hormones_NNS inhibit_VBP (3H)glycosaminoglycan_JJ synthesis_NN by_IN cultured_`` human_JJ dermal_`` fibroblasts_NNS ,_, and_CC T3SO4_NNP displayed_VBD about_IN 0.5_CD %_NN the_DT activity_NN of_IN T3_CD at_IN 72_CD h_NN ._.
Human_JJ fibroblasts_NNS contained_VBN roughly_RB the_DT same_JJ level_NN of_IN microsomal_JJ p-nitrophenyl_JJ sulfatase_`` activity_NN as_IN that_DT previously_RB observed_VBN in_IN hepatic_JJ microsomes_NNS ._.
Propylthiouracil_# (_-LRB- 50_CD mumol/L_`` )_-RRB- did_VBD not_RB affect_VB the_DT action_NN of_IN T3SO4_CD ,_, suggesting_VBG that_IN deiodination_NN was_VBD not_RB important_JJ for_IN this_DT activity_NN of_IN T3SO4_NNP ._.
Thus_RB ,_, it_PRP appears_VBZ T3SO4_`` has_VBZ no_DT intrinsic_JJ biological_JJ activity_NN ,_, but_CC ,_, under_IN certain_JJ circumstances_NNS ,_, may_MD be_VB reactivated_VBN by_IN desulfation_NN
Nuclear_JJ factor_NN of_IN activated_`` T_JJ cells_NNS contains_VBZ Fos_NNP and_CC Jun_NNP ._.
The_DT nuclear_JJ factor_NN NF-AT_`` (_-LRB- ref._`` 1_CD )_-RRB- is_VBZ induced_VBN in_IN T_JJ cells_NNS stimulated_VBN through_IN the_DT T-cell_`` receptor/CD3_NN complex_JJ ,_, and_CC is_VBZ required_VBN for_IN interleukin-2_`` (_-LRB- IL-2_NN )_-RRB- gene_NN induction_NN ._.
Although_IN NF-AT_NNP has_VBZ not_RB been_VBN cloned_VBN or_CC purified_VBN ,_, there_EX is_VBZ evidence_NN that_IN it_PRP is_VBZ a_DT major_JJ target_NN for_IN immunosuppression_NN by_IN cyclosporin_VBG A_DT (_-LRB- CsA_NN )_-RRB- and_CC FK506_CD (_-LRB- refs_`` 2-7_JJ )_-RRB- ._.
NF-AT_JJ induction_NN may_MD require_VB two_CD activation-dependent_JJ events_NNS :_: the_DT CsA-sensitive_JJ translocation_NN of_IN a_DT pre-existing_JJ component_NN and_CC the_DT CsA-resistant_JJ synthesis_NN of_IN a_DT nuclear_JJ component_NN ._.
Here_RB we_PRP report_VBP that_IN the_DT newly_RB synthesized_VBN nuclear_JJ component_NN of_IN NF-AT_NN is_VBZ the_DT transcription_`` factor_NN AP-1_NN ._.
We_PRP show_VBP that_IN the_DT inducible_JJ nuclear_JJ form_NN of_IN NF-AT_NNP contains_VBZ Fos_# and_CC Jun_NNP proteins_NNS ._.
Furthermore_RB ,_, we_PRP identify_VBP a_DT pre-existing_`` NF-AT-binding_JJ factor_NN that_WDT is_VBZ present_JJ in_IN hypotonic_JJ extracts_NNS of_IN unstimulated_`` T_JJ cells_NNS ._.
On_IN the_DT basis_NN of_IN binding_# ,_, reconstitution_NN and_CC cotransfection_NN experiments_NNS ,_, we_PRP propose_VBP that_IN activation_NN of_IN NF-AT_`` occurs_VBZ in_IN at_IN least_JJS two_CD stages_NNS :_: a_DT CsA-sensitive_JJ stage_NN involving_VBG modification_`` and/or_`` translocation_NN of_IN the_DT pre-existing_JJ NF-AT_`` complex_JJ ,_, and_CC a_DT CsA-insensitive_JJ stage_NN involving_VBG the_DT addition_NN of_IN newly_RB synthesized_VBN Fos_NNP or_CC Fos/Jun_NNP proteins_VBZ to_TO the_DT pre-existing_JJ complex_NN ._.
Interferon-gamma_NNP potentiates_VBZ the_DT antiviral_JJ activity_NN and_CC the_DT expression_NN of_IN interferon-stimulated_JJ genes_NNS induced_VBN by_IN interferon-alpha_NN in_IN U937_CD cells_NNS ._.
Binding_-RRB- of_IN type_NN I_PRP interferon_`` (_-LRB- IFN-alpha/beta_NNP )_-RRB- to_TO specific_JJ receptors_NNS results_NNS in_IN the_DT rapid_JJ transcriptional_JJ activation_NN ,_, independent_JJ of_IN protein_NN synthesis_NN ,_, of_IN IFN-alpha-stimulated_JJ genes_NNS (_-LRB- ISGs_NNP )_-RRB- in_IN human_JJ fibroblasts_NNS and_CC HeLa_NNP and_CC Daudi_NNP cell_NN lines_NNS ._.
The_DT binding_NN of_IN ISGF3_`` (_-LRB- IFN-stimulated_`` gene_NN factor_NN 3_CD )_-RRB- to_TO the_DT conserved_`` IFN-stimulated_JJ response_NN element_NN (_-LRB- ISRE_`` )_-RRB- results_NNS in_IN transcriptional_JJ activation_NN ._.
This_DT factor_NN is_VBZ composed_VBN of_IN a_DT DNA-binding_JJ protein_NN (_-LRB- ISGF3_`` gamma_NN )_-RRB- ,_, which_WDT normally_RB is_VBZ present_JJ in_IN the_DT cytoplasm_NN ,_, and_CC other_JJ IFN-alpha-activated_`` proteins_NNS which_WDT preexist_`` as_IN latent_JJ cytoplasmic_JJ precursors_NNS (_-LRB- ISGF3_NN alpha_NN )_-RRB- ._.
We_PRP have_VBP found_VBN that_IN ISG_NNP expression_NN in_IN the_DT monocytic_JJ U937_`` cell_NN line_NN differs_VBZ from_IN most_JJS cell_NN lines_NNS previously_RB examined_VBN ._.
U937_CD cells_NNS express_VB both_DT type_NN I_PRP and_CC type_NN II_NNP IFN_NNP receptors_NNS ,_, but_CC only_RB IFN-alpha_NNP is_VBZ capable_JJ of_IN inducing_VBG antiviral_JJ protection_NN in_IN these_DT cells_NNS ._.
Pretreatment_-LRB- with_IN IFN-gamma_NNP potentiates_VBZ the_DT IFN-alpha-induced_NNP protection_NN ,_, but_CC IFN-gamma_NNP alone_RB does_VBZ not_RB have_VB any_DT antiviral_JJ activity_NN ._.
ISG15_-LRB- mRNA_`` accumulation_NN in_IN U937_CD cells_NNS is_VBZ not_RB detectable_JJ before_IN 6_CD h_NN of_IN IFN-alpha_NNP treatment_NN ,_, peaks_NNS at_IN 24_CD h_NN ,_, and_CC requires_VBZ protein_NN synthesis_NN ._.
Although_IN IFN-gamma_NNP alone_RB does_VBZ not_RB induce_VB ISG_`` expression_NN ,_, IFN-gamma_NNP pretreatment_`` markedly_RB increases_NNS and_CC hastens_VBZ ISG_NNP expression_NN and_CC transcriptional_JJ induction_NN ._.
Nuclear_NNP extracts_`` assayed_`` for_IN the_DT presence_NN of_IN ISRE_`` binding_JJ factors_NNS by_IN electrophoretic_`` mobility_JJ shift_NN assays_`` show_NN that_IN ISGF3_-RRB- is_VBZ induced_VBN by_IN IFN-alpha_NNP within_IN 6_CD h_NN from_IN undetectable_JJ basal_NN levels_NNS in_IN untreated_JJ U937_NN cells_NNS ._.
Activation_NN of_IN ISGF3_NNP alpha_NN ,_, the_DT latent_JJ component_NN of_IN ISGF3_NNP ,_, occurs_VBZ rapidly_RB ._.
However_RB ,_, the_DT increase_NN in_IN ISGF3_NNP activity_NN ultimately_RB correlates_VBZ with_IN the_DT accumulation_NN of_IN ISGF3_NNP gamma_`` induced_`` by_IN IFN-alpha_NNP or_CC IFN-gamma_NNP ._.
(_-LRB- ABSTRACT_`` TRUNCATED_JJ AT_`` 250_CD WORDS_NNS )_-RRB-
The_DT mechanism_NN of_IN action_NN of_IN cyclosporin_`` A_DT and_CC FK506_NNP ._.
CsA_NNP and_CC FK506_NNP are_VBP powerful_JJ suppressors_NNS of_IN the_DT immune_JJ system_NN ,_, most_RBS notably_RB of_IN T_JJ cells_NNS ._.
They_PRP act_VBP at_IN a_DT point_NN in_IN activation_NN that_WDT lies_VBZ between_IN receptor_NN ligation_NN and_CC the_DT transcription_NN of_IN early_JJ genes_NNS ._.
Here_RB ,_, Stuart_NNP Schreiber_NNP and_CC Gerald_NNP Crabtree_NNP review_VBP recent_JJ findings_NNS that_IN indicate_VBP CsA_NNP and_CC FK506_NNP operate_VBP as_IN prodrugs_`` :_: they_PRP bind_VBP endogenous_JJ intracellular_JJ receptors_NNS ,_, the_DT immunophilins_`` ,_, and_CC the_DT resulting_VBG complex_JJ targets_NNS the_DT protein_NN phosphatase_NN ,_, calcineurin_NN ,_, to_TO exert_VB the_DT immunosuppressive_JJ effect_NN ._.
(_-LRB- Plasma_`` cortisol_NN concentration_NN and_CC blood_NN leukocyte_JJ content_NN of_IN glucocorticoid_JJ receptors_NNS in_IN patients_NNS with_IN deficiency-cold_JJ vs_`` deficiency-heat_`` syndromes_NNS )_-RRB-
Plasma_NNP cortisol_`` concentration_NN and_CC blood_NN leukocyte_JJ content_NN of_IN glucocorticoid_JJ receptors_NNS (_-LRB- GCR_NNP )_-RRB- were_VBD assayed_VBN in_IN 20_CD patients_NNS with_IN deficiency_NN syndromes_NNS ,_, 10_CD cold_JJ in_IN property_NN (_-LRB- deficiency-cold_NN )_-RRB- ,_, the_DT other_JJ 10_CD hot_JJ in_IN property_NN (_-LRB- deficiency-heat_NN )_-RRB- ,_, and_CC also_RB in_IN 10_CD healthy_JJ individuals_NNS as_IN normal_JJ control_NN for_IN the_DT purpose_NN of_IN investigating_VBG the_DT nature_NN of_IN cold_JJ and_CC heat_NN syndromes_NNS ._.
As_IN a_DT result_NN ,_, the_DT cases_NNS of_IN deficiency-cold_JJ syndrome_NN (_-LRB- DCS_NNP )_-RRB- had_VBD a_DT normal_JJ concentration_NN of_IN plasma_`` cortisol_`` but_CC a_DT lowered_VBN content_NN of_IN GCR_NNP in_IN leukocytes_`` when_WRB compared_VBN with_IN the_DT normal_JJ control_NN (_-LRB- P_NNP less_JJR than_IN 0.05_CD )_-RRB- ;_: the_DT cases_NNS of_IN deficiency-heat_NN syndrome_NN (_-LRB- DHS_NNP )_-RRB- had_VBD a_DT higher_JJR concentration_NN of_IN plasma_`` cortisol_`` than_IN the_DT normal_JJ control_NN (_-LRB- P_NNP less_JJR than_IN 0.05_CD )_-RRB- and_CC a_DT slightly_RB higher_JJR content_NN of_IN GCR_NNP in_IN leukocytes_`` ._.
It_PRP was_VBD concluded_VBN that_IN the_DT DCS_NNP is_VBZ characterized_VBN by_IN diminished_JJ biological_JJ effects_NNS of_IN adrenocortical_JJ activity_NN ,_, while_IN the_DT DHS_`` ,_, by_IN augmented_JJ biological_JJ effects_NNS of_IN adrenocortical_JJ activity_NN ._.
Specific_NNP NF-kappa_NNP B_NNP subunits_`` act_NN in_IN concert_NN with_IN Tat_# to_TO stimulate_VB human_JJ immunodeficiency_NN virus_NN type_NN 1_CD transcription_NN ._.
NF-kappa_NNP B_NNP is_VBZ a_DT protein_NN complex_NN which_WDT functions_VBZ in_IN concert_NN with_IN the_DT tat-I_JJ gene_NN product_NN to_TO stimulate_VB human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV_NNP )_-RRB- transcription_NN ._.
To_TO determine_VB whether_IN specific_JJ members_NNS of_IN the_DT NF-kappa_NNP B_NNP family_NN contribute_VBP to_TO this_DT effect_NN ,_, we_PRP have_VBP examined_VBN the_DT abilities_NNS of_IN different_JJ NF-kappa_NNP B_NNP subunits_`` to_TO act_VB with_IN Tat-I_NNP to_TO stimulate_VB transcription_NN of_IN HIV_NNP in_IN Jurkat_NNP T-leukemia_NNP cells_NNS ._.
We_PRP have_VBP found_VBN that_IN the_DT p49_NN (_-LRB- 100_CD )_-RRB- DNA_NNP binding_`` subunit_NN ,_, together_RB with_IN p65_NN ,_, can_MD act_VB in_IN concert_NN with_IN Tat-I_NNP to_TO stimulate_VB the_DT expression_NN of_IN HIV-CAT_JJ plasmid_NN ._.
Little_JJ effect_NN was_VBD observed_VBN with_IN 50-kDa_JJ forms_NNS of_IN p105_`` NF-kappa_NNP B_NNP or_CC rel_`` ,_, in_IN combination_NN with_IN p65_CD or_CC full-length_JJ c-rel_NN ,_, which_WDT do_VBP not_RB stimulate_VB the_DT HIV_NNP enhancer_`` in_IN these_DT cells_NNS ._.
These_DT findings_NNS suggest_VBP that_IN the_DT combination_NN of_IN p49_NN (_-LRB- 100_CD )_-RRB- and_CC p65_CD NF-kappa_NNP B_NNP can_MD act_VB in_IN concert_NN with_IN the_DT tat-I_JJ gene_NN product_NN to_TO stimulate_VB the_DT synthesis_NN of_IN HIV_NNP RNA_NNP ._.
Activation_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD enhancer_NN is_VBZ not_RB dependent_JJ on_IN NFAT-1_NNP ._.
The_DT function_NN of_IN a_DT putative_JJ NFAT-1_NNP site_NN in_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD enhancer_NN has_VBZ been_VBN analyzed_VBN ._.
Activation_NN by_IN the_DT T-cell_`` antigen_NN receptor_NN is_VBZ minimal_JJ in_IN Jurkat_NNP cells_NNS and_CC is_VBZ mediated_VBN by_IN the_DT kappa_`` B_NNP sites_NNS ._.
The_DT putative_JJ NFAT-1_NNP region_NN is_VBZ not_RB required_VBN for_IN the_DT response_NN to_TO anti-CD3_`` or_CC to_TO mitogens_NNS in_IN T-cell_NNP ,_, B-cell_NNP ,_, or_CC monocyte/macrophage_`` leukemia_NN lines_NNS ,_, nor_CC is_VBZ it_PRP a_DT cis-acting_JJ negative_JJ regulatory_JJ element_NN ._.
Protein_NNP kinase_-RRB- C_NNP activation_`` and_CC protooncogene_`` expression_NN in_IN differentiation/retrodifferentiation_NN of_IN human_JJ U-937_`` leukemia_NN cells_NNS ._.
Human_NNP U-937_NNP leukemia_`` cells_NNS differentiate_VBP along_IN the_DT monocytic_JJ lineage_NN following_VBG 3-day_JJ exposures_NNS to_TO 12-O-tetradecanoylphorbol-13-acetate_-RRB- (_-LRB- TPA_NNP )_-RRB- ._.
This_DT induction_NN of_IN differentiation_NN is_VBZ accompanied_VBN by_IN adherence_NN and_CC loss_NN of_IN proliferation_NN ,_, as_RB well_RB as_IN expression/repression_NN of_IN differentiation-associated_JJ genes_NNS ._.
Long_JJ term_NN culture_NN of_IN TPA-differentiated_`` U-937_JJ cells_NNS in_IN the_DT absence_NN of_IN phorbol_NN ester_NN for_IN 32-36_CD days_NNS resulted_VBD in_IN a_DT process_NN of_IN retrodifferentiation_NN ._.
The_DT retrodifferentiated_JJ cells_NNS detached_VBN from_IN the_DT substrate_`` and_CC reinitiated_`` proliferation_NN ._.
Other_JJ cellular_JJ parameters_NNS ,_, such_JJ as_IN glycosidase_`` activities_NNS ,_, cytokine_-RRB- release_NN ,_, and_CC filament_`` expression_NN ,_, returned_VBN to_TO levels_NNS similar_JJ to_TO that_DT observed_VBN in_IN uninduced_JJ cells_NNS ._.
Treatment_NNP of_IN U-937_`` cells_NNS with_IN TPA_NNP resulted_VBD in_IN a_DT rapid_JJ translocation_NN of_IN protein_NN kinase_`` C_$ (_-LRB- PKC_NNP )_-RRB- from_IN the_DT cytosol_NN to_TO cell_NN membrane_NN fractions_NNS within_IN 2-8_CD min_NN ._.
Increased_VBN levels_NNS of_IN membrane-associated_# PKC_NNP activity_NN persisted_VBD until_IN 17-29_CD days_NNS ._.
However_RB ,_, longer_JJR periods_NNS of_IN incubation_NN were_VBD associated_VBN with_IN a_DT return_NN to_TO the_DT distribution_NN of_IN PKC_NNP in_IN control_NN cells_NNS ._.
Activation_NN of_IN PKC_NNP has_VBZ been_VBN implicated_VBN in_IN the_DT regulation_NN of_IN certain_JJ immediate_JJ early_JJ response_NN genes_NNS ,_, and_CC in_IN the_DT present_JJ studies_NNS ,_, TPA_NNP rapidly_RB induced_VBD c-fos_NNS and_CC c-jun_JJ gene_NN expression_NN ._.
Levels_NNS of_IN c-fos_`` and_CC c-jun_`` transcripts_NNS remained_VBD elevated_JJ during_IN periods_NNS of_IN PKC_NNP activation_NN and_CC also_RB returned_VBD to_TO levels_NNS observed_VBN in_IN control_NN cells_NNS by_IN 30-36_CD days_NNS ,_, when_WRB the_DT cells_NNS entered_VBD retrodifferentiation_NN ._.
Staurosporine_NNP ,_, a_DT nonspecific_JJ inhibitor_NN of_IN PKC_NNP ,_, partially_RB blocked_VBD TPA-induced_NNP adherence_NN and_CC growth_NN inhibition_NN and_CC concomitantly_RB prevented_VBD TPA-induced_NNP c-fos_`` and_CC c-jun_`` gene_NN expression_NN ._.
(_-LRB- ABSTRACT_`` TRUNCATED_JJ AT_`` 250_CD WORDS_NNS )_-RRB-
The_DT promoter_NN of_IN the_DT CD19_`` gene_NN is_VBZ a_DT target_NN for_IN the_DT B-cell-specific_NNP transcription_NN factor_NN BSAP_NNP ._.
The_DT CD19_NNP protein_NN is_VBZ expressed_VBN on_IN the_DT surface_NN of_IN all_DT B-lymphoid_JJ cells_NNS with_IN the_DT exception_NN of_IN terminally_RB differentiated_VBN plasma_NN cells_NNS and_CC has_VBZ been_VBN implicated_VBN as_IN a_DT signal-transducing_NN receptor_NN in_IN the_DT control_NN of_IN proliferation_NN and_CC differentiation_NN ._.
Here_RB we_PRP demonstrate_VBP complete_JJ correlation_NN between_IN the_DT expression_NN pattern_NN of_IN the_DT CD19_NNP gene_NN and_CC the_DT B-cell-specific_JJ transcription_NN factor_NN BSAP_`` in_IN a_DT large_JJ panel_NN of_IN B-lymphoid_JJ cell_NN lines_NNS ._.
The_DT human_JJ CD19_NN gene_NN has_VBZ been_VBN cloned_VBN ,_, and_CC several_JJ BSAP-binding_`` sites_NNS have_VBP been_VBN mapped_VBN by_IN in_IN vitro_`` protein-DNA_`` binding_JJ studies_NNS ._.
In_IN particular_JJ ,_, a_DT high-affinity_`` BSAP-binding_NNP site_NN instead_RB of_IN a_DT TATA_NNP sequence_NN is_VBZ located_VBN in_IN the_DT -30_`` promoter_NN region_NN upstream_RB of_IN a_DT cluster_NN of_IN heterogeneous_JJ transcription_NN start_VB sites_NNS ._.
Moreover_RB ,_, this_DT site_NN is_VBZ occupied_VBN by_IN BSAP_NNP in_IN vivo_`` in_IN a_DT CD19-expressing_JJ B-cell_NNP line_NN but_CC not_RB in_IN plasma_NN or_CC HeLa_NNP cells_NNS ._.
This_DT high-affinity_`` site_NN has_VBZ been_VBN conserved_VBN in_IN the_DT promoters_NNS of_IN both_DT human_JJ and_CC mouse_NN CD19_# genes_NNS and_CC was_VBD furthermore_RB shown_VBN to_TO confer_VB B-cell_NNP specificity_NN to_TO a_DT beta-globin_`` reporter_NN gene_NN in_IN transient_JJ transfection_NN experiments_NNS ._.
In_IN addition_NN ,_, BSAP_NNP was_VBD found_VBN to_TO be_VB the_DT only_JJ abundant_JJ DNA-binding_`` activity_NN of_IN B-cell_`` nuclear_JJ extracts_NNS that_WDT interacts_VBZ with_IN the_DT CD19_NN promoter_NN ._.
Together_RB ,_, this_DT evidence_NN strongly_RB implicates_VBZ BSAP_# in_IN the_DT regulation_NN of_IN the_DT CD19_`` gene_NN ._.
Reduced_VBN susceptibility_NN to_TO HIV-1_-RRB- infection_NN of_IN ethyl-methanesulfonate-treated_# CEM_NNP subclones_NNS correlates_VBZ with_IN a_DT blockade_NN in_IN their_PRP$ protein_NN kinase_`` C_$ signaling_VBG pathway_NN ._.
We_PRP have_VBP described_VBN the_DT isolation_NN of_IN chemically_RB induced_`` CEM_`` subclones_NNS that_WDT express_VBP CD4_`` receptors_NNS and_CC bind_NN soluble_`` gp120_NN ,_, yet_RB show_VBP a_DT markedly_RB reduced_VBN susceptibility_NN to_TO infection_NN with_IN HIV-1_NN ._.
Two_CD subclones_NNS were_VBD found_VBN to_TO have_VB an_DT abnormal_JJ response_NN to_TO the_DT protein_NN kinase_`` C_$ (_-LRB- PKC_NNP )_-RRB- activator_# PMA_NNP ._.
PMA_-LRB- treatment_NN induced_VBN CD3_`` and_CC CD25_`` (_-LRB- IL-2R_NN )_-RRB- receptors_`` on_IN the_DT parental_JJ line_NN and_CC on_IN other_JJ ethyl-methanesulfonate-derived_`` subclones_NNS ,_, but_CC not_RB on_IN these_DT two_CD mutants_NNS ._.
Direct_JJ assays_`` of_IN PKC_NNP activity_NN were_VBD conducted_VBN ._.
Total_JJ cellular_JJ PKC_`` enzymatic_JJ activity_NN was_VBD found_VBN to_TO be_VB normal_JJ in_IN these_DT subclones_NNS ._.
PMA-induced_JJ CD4_NN down-modulation_NN occurred_VBD normally_RB ._.
In_IN addition_NN ,_, activation_NN of_IN c-raf_`` kinase_`` was_VBD normal_JJ ._.
Since_IN HIV-1_`` long_JJ terminal_NN repeat_NN contains_VBZ two_CD functional_JJ nuclear_JJ factor_NN kB_NNP (_-LRB- NF-kB_NNP )_-RRB- regulatory_JJ elements_NNS ,_, we_PRP studied_VBD the_DT ability_NN of_IN PMA_NNP to_TO induce_VB NF-kB_NNP binding_`` activity_NN by_IN different_JJ assays_NNS ._.
Chloramphenicol_-LRB- acetyl_NN transferase_`` (_-LRB- CAT_NN )_-RRB- assays_VBZ using_VBG the_DT HIV-1_-RRB- (_-LRB- -139_`` )_-RRB- long_JJ terminal_NN repeat-CAT_NN construct_VB showed_VBN no_DT PMA_`` induction_NN of_IN CAT_JJ activity_NN in_IN these_DT subclones_NNS (_-LRB- unlike_IN the_DT parental_JJ line_NN and_CC other_JJ subclones_NNS )_-RRB- ._.
Okadaic_JJ acid_NN ,_, an_DT inhibitor_`` of_IN phosphatases_NNS 1_CD and_CC 2A_-RRB- ,_, did_VBD not_RB overcome_VB the_DT defect_`` in_IN these_DT subclones_NNS ._.
Gel_NNP retardation_`` assays_`` ,_, using_VBG a_DT 32P-probe_`` containing_VBG the_DT HIV-1_`` NF-kB_NNP probe_NN and_CC nuclear_JJ extracts_NNS from_IN PMA-treated_JJ cells_NNS ,_, showed_VBD significantly_RB reduced_VBN induction_NN of_IN nuclear_JJ NF-kB_NNP binding_`` proteins_NNS in_IN these_DT two_CD subclones_NNS compared_VBN with_IN wild_JJ type_NN CEM_NNP and_CC a_DT control_NN subclone_`` ._.
Deoxycholate_JJ treatment_NN of_IN cytoplasmic_JJ extracts_NNS from_IN these_DT subclones_NNS released_VBD much_RB reduced_VBN NF-kB_NNP binding_JJ proteins_NNS from_IN their_PRP$ cytoplasmic_JJ pools_NNS ._.
Thus_RB ,_, reduced_VBD levels_NNS of_IN PKC-induced_`` nuclear_JJ NF-kB_`` activity_NN in_IN two_CD T_JJ cell_NN subclones_NNS did_VBD not_RB affect_VB their_PRP$ normal_JJ cell_NN growth_NN ,_, but_CC correlated_`` with_IN a_DT pronounced_VBN reduction_NN in_IN their_PRP$ susceptibility_NN to_TO HIV-1_-RRB- infection_NN ._.
Eicosanoids_NNS in_IN breast_NN cancer_NN patients_NNS before_RB and_CC after_IN mastectomy_`` ._.
In_IN 19_CD patients_NNS with_IN a_DT malignant_JJ breast_NN tumor_NN ,_, tumor_NN tissue_NN and_CC blood_NN were_VBD taken_VBN to_TO determine_VB the_DT eicosanoid_`` profile_NN and_CC platelet_NN aggregation_NN ._.
Values_NNS were_VBD compared_VBN with_IN those_DT of_IN patients_NNS with_IN benign_JJ tumors_NNS (_-LRB- n_NN =_SYM 4_CD )_-RRB- ,_, or_CC undergoing_VBG a_DT mammary_JJ reduction_NN (_-LRB- n_RB =_SYM 7_CD )_-RRB- ._.
Postoperatively_RB ,_, blood_NN was_VBD taken_VBN as_RB well_RB in_IN order_NN to_TO compare_VB pre-_JJ and_CC postoperative_JJ values_NNS ._.
Eicosanoids_NNS were_VBD measured_VBN in_IN peripheral_JJ blood_NN monocytes_NNS and_CC mammary_JJ tissue_NN by_IN means_NNS of_IN HPLC_NNP ;_: furthermore_`` ,_, TXA2_CD ,_, 6-keto-PGF1_CD alpha_NN ,_, and_CC PGE2_-RRB- were_VBD determined_VBN by_IN RIA_NNP ._.
Differences_NNS in_IN pre-_JJ and_CC postoperative_JJ values_NNS of_IN cancer_NN patients_NNS were_VBD seen_VBN in_IN plasma_NN RIA_NNP values_NNS :_: PGE2_`` and_CC 6-k-PGF1_`` alpha_NN were_VBD significantly_RB higher_JJR preoperatively_RB when_WRB compared_VBN with_IN postoperatively_RB ,_, however_RB ,_, such_JJ differences_NNS were_VBD seen_VBN in_IN the_DT control_NN groups_NNS as_RB well_RB ._.
Compared_VBN to_TO benign_JJ tumor_NN or_CC mammary_JJ reduction_NN test_NN material_NN the_DT eicosanoid_JJ profile_NN of_IN tissue_NN obtained_VBN from_IN malignant_JJ mammary_`` tumors_NNS showed_VBD important_JJ differences_NNS ._.
Except_IN for_IN PGF2_`` alpha_NN ,_, HHT_NNP and_CC 15-HETE_`` no_DT detectable_JJ quantities_NNS of_IN eicosanoids_NNS were_VBD found_VBN in_IN the_DT non-tumor_`` material_NN ,_, whereas_IN in_IN the_DT malignant_JJ tumor_NN material_NN substantial_JJ quantities_NNS of_IN a_DT number_NN of_IN eicosanoid_`` metabolites_NNS were_VBD present_JJ ._.
Statistically_RB significant_JJ correlations_NNS could_MD be_VB established_VBN between_IN patient/histopathology_NN data_NNS and_CC the_DT results_NNS of_IN the_DT platelet_NN aggregation_NN assays_`` ,_, e.g._FW between_IN menopausal_JJ status_NN and_CC ADP_NNP aggregation_NN ;_: oestrogen_NN receptor_NN (_-LRB- +/-_`` )_-RRB- and_CC collagen_`` and_CC arachidonic_`` acid_NN aggregation_NN ,_, inflammatory_JJ cell_NN infiltration_NN score_NN and_CC arachidonic_`` acid_NN aggregation_NN and_CC fibrosis_`` score_NN and_CC ADP_NNP aggregation_NN ._.
The_DT results_NNS show_VBP that_IN eicosanoid_JJ synthesis_NN in_IN material_NN from_IN mammary_JJ cancer_NN patients_NNS is_VBZ different_JJ from_IN that_DT in_IN benign_JJ mammary_JJ tissue_NN ._.
The_DT implications_NNS ,_, in_IN particular_JJ ,_, in_IN relation_NN to_TO future_JJ prognosis_NN of_IN the_DT patient_NN ,_, remain_VBP obscure_JJ ._.
c-myc_JJ mRNA_`` expression_NN in_IN minor_JJ salivary_JJ glands_NNS of_IN patients_NNS with_IN Sjogren_NNP 's_POS syndrome_NN ._.
c-myc_JJ protooncogene_NN is_VBZ implicated_VBN in_IN the_DT pathogenesis_NN of_IN B_NNP cell_NN lymphoid_# malignancies_NNS and_CC high_JJ levels_NNS of_IN c-myc_`` mRNA_`` expression_NN are_VBP observed_VBN in_IN activated_VBN blood_NN mononuclear_JJ cells_NNS ._.
Sjogren_NNP 's_POS syndrome_NN (_-LRB- SS_NNP )_-RRB- is_VBZ characterized_VBN by_IN lymphocytic_JJ infiltrates_NNS of_IN exocrine_`` glands_NNS ,_, remarkable_JJ B_NNP cell_NN hyperreactivity_NN and_CC a_DT strong_JJ predisposition_NN to_TO B_NNP cell_NN neoplasia_NN ._.
In_IN this_DT study_NN ,_, c-myc_JJ protooncogene_NN mRNA_`` expression_NN in_IN 29_CD labial_`` minor_JJ salivary_`` gland_`` biopsies_NNS from_IN patients_NNS with_IN primary_JJ SS_NNP and_CC 15_CD controls_NNS was_VBD examined_VBN using_VBG in_IN situ_`` hybridization_NN histochemistry_NN ._.
Two_CD 40mer_`` oligonucleotides_`` from_IN the_DT 1st_`` and_CC the_DT 2nd_`` exon_`` of_IN the_DT c-myc_JJ gene_NN ,_, labeled_VBN with_IN 35S_NNS ,_, were_VBD used_VBN as_IN probes_NNS ._.
To_TO detect_VB the_DT origin_NN of_IN the_DT cell_NN hybridized_`` with_IN a_DT c-myc_JJ probe_NN ,_, a_DT combined_VBN immunochemistry_NN in_IN situ_`` hybridization_NN histochemistry_NN technique_NN was_VBD used_VBN ._.
High_JJ c-myc_`` mRNA_`` expression_NN was_VBD detected_VBN on_IN acinar_`` epithelial_JJ cells_NNS ._.
c-myc_NN did_VBD not_RB correlate_`` with_IN c-fos_NNS and_CC c-jun_JJ protein_NN expression_NN ._.
Stronger_# c-myc_`` mRNA_`` expression_NN was_VBD detected_VBN in_IN labial_`` salivary_JJ glands_NNS of_IN patients_NNS with_IN longer_JJR disease_NN duration_NN (_-LRB- p_NN less_JJR than_IN or_CC equal_JJ to_TO 0.002_CD )_-RRB- and_CC more_RBR intense_JJ T_JJ lymphocyte_`` infiltrates_NNS (_-LRB- p_NN less_JJR than_IN 0.05_CD )_-RRB- although_IN these_DT patients_NNS revealed_VBD no_DT hypergammaglobulinemia_NN ._.
No_DT correlation_NN was_VBD observed_VBN between_IN c-myc_JJ mRNA_NNP and_CC B_NNP lymphocyte_`` monoclonicity_NN or_CC lymphoma_NN ._.
In_IN conclusion_NN ,_, strong_JJ c-myc_JJ mRNA_NNP expression_NN was_VBD observed_VBN on_IN epithelial_JJ cells_NNS of_IN labial_`` salivary_JJ glands_NNS from_IN patients_NNS with_IN primary_JJ SS_NNP ._.
Our_PRP$ findings_NNS may_MD indicate_VB the_DT presence_NN of_IN a_DT reactivated_-LRB- virus_NN hosted_`` in_IN these_DT cells_NNS ._.
Cytoplasmic_JJ domain_NN heterogeneity_NN and_CC functions_NNS of_IN IgG_NNP Fc_NNP receptors_`` in_IN B_NNP lymphocytes_NNS ._.
B_NNP lymphocytes_NNS and_CC macrophages_NNS express_VBP closely_RB related_VBN immunoglobulin_NN G_NNP (_-LRB- IgG_NNP )_-RRB- Fc_NNP receptors_NNS (_-LRB- Fc_NNP gamma_NN RII_NNP )_-RRB- that_IN differ_VBP only_RB in_IN the_DT structures_NNS of_IN their_PRP$ cytoplasmic_JJ domains_NNS ._.
Because_IN of_IN cell_NN type-specific_JJ alternative_NN messenger_NN RNA_`` splicing_NN ,_, B-cell_NNP Fc_NNP gamma_NN RII_NNP contains_VBZ an_DT insertion_NN of_IN 47_CD amino_JJ acids_NNS that_IN participates_NNS in_IN determining_VBG receptor_NN function_NN in_IN these_DT cells_NNS ._.
Transfection_NN of_IN an_DT Fc_NNP gamma_NN RII-negative_JJ B-cell_`` line_NN with_IN complementary_JJ DNA_NNP 's_POS encoding_VBG the_DT two_CD splice_NN products_NNS and_CC various_JJ receptor_NN mutants_NNS indicated_VBD that_IN the_DT insertion_NN was_VBD responsible_JJ for_IN preventing_VBG both_DT Fc_NNP gamma_`` RII-mediated_JJ endocytosis_NN and_CC Fc_NNP gamma_`` RII-mediated_JJ antigen_NN presentation_NN ._.
The_DT insertion_NN was_VBD not_RB required_VBN for_IN Fc_NNP gamma_NN RII_`` to_TO modulate_VB surface_NN immunoglobulin-triggered_JJ B-cell_NNP activation_NN ._.
Instead_RB ,_, regulation_NN of_IN activation_NN involved_VBN a_DT region_NN of_IN the_DT cytoplasmic_JJ domain_NN common_JJ to_TO both_DT the_DT lymphocyte_`` and_CC macrophage_NN receptor_NN isoforms_NNS ._.
In_IN contrast_NN ,_, the_DT insertion_NN did_VBD contribute_VB to_TO the_DT formation_NN of_IN caps_NNS in_IN response_NN to_TO receptor_NN cross-linking_`` ,_, consistent_JJ with_IN suggestions_NNS that_IN the_DT lymphocyte_'' but_CC not_RB macrophage_`` form_VB of_IN the_DT receptor_NN can_MD associate_VB with_IN the_DT detergent-insoluble_JJ cytoskeleton_NN ._.
Every_DT enhancer_NN works_VBZ with_IN every_DT promoter_NN for_IN all_PDT the_DT combinations_NNS tested_VBN :_: could_MD new_JJ regulatory_JJ pathways_`` evolve_NN by_IN enhancer_`` shuffling_VBG ?_.
The_DT promoters_NNS and_CC enhancers_`` of_IN cell_NN type-specific_JJ genes_NNS are_VBP often_RB conserved_`` in_IN evolution_NN ,_, and_CC hence_RB one_PRP might_MD expect_VB that_IN a_DT given_VBN enhancer_NN has_VBZ evolved_VBN to_TO work_VB best_JJS with_IN its_PRP$ own_JJ promoter_NN ._.
While_IN this_DT expectation_NN may_MD be_VB realized_VBN in_IN some_DT cases_NNS ,_, we_PRP have_VBP not_RB found_VBN evidence_NN for_IN it_PRP ._.
A_DT total_NN of_IN 27_CD combinations_NNS of_IN different_JJ promoters_NNS and_CC enhancers_NNS were_VBD tested_VBN by_IN transfection_NN into_IN cultured_JJ cells_NNS ._.
We_PRP found_VBD that_IN the_DT relative_JJ efficiency_NN of_IN the_DT enhancers_NNS is_VBZ approximately_RB the_DT same_JJ ,_, irrespective_'' of_IN the_DT type_NN of_IN promoter_NN used_VBN ,_, i.e._FW ,_, there_EX was_VBD no_DT strong_JJ preference_NN for_IN any_DT given_VBN enhancer/promoter_NN combination_NN ._.
Notably_RB ,_, we_PRP do_VBP not_RB see_VB particularly_RB strong_JJ transcription_NN when_WRB the_DT immunoglobulin_`` kappa_NN enhancer_NN (_-LRB- or_CC the_DT immunoglobulin_`` heavy_JJ chain_NN enhancer_NN )_-RRB- is_VBZ used_VBN to_TO activate_VB a_DT kappa_`` gene_NN promoter_NN ._.
We_PRP propose_VBP that_IN a_DT generally_RB permissive_JJ enhancer/promoter_NN interaction_NN is_VBZ of_IN evolutionary_JJ benefit_NN for_IN higher_JJR eukaryotes_NNS :_: by_IN enhancer_`` shuffling_VBG ,_, genes_NNS could_MD be_VB easily_RB brought_VBN under_IN a_DT new_JJ type_NN of_IN inducibility/cell_JJ type_NN specificity_NN ._.
Heterodimerization_NNP and_CC transcriptional_JJ activation_NN in_IN vitro_NN by_IN NF-kappa_NNP B_NNP proteins_VBZ ._.
The_DT NF-kappa_NNP B_NNP family_NN of_IN transcription_NN proteins_NNS represents_VBZ multiple_JJ DNA_NNP binding_NN ,_, rel_VB related_VBN polypeptides_NNS that_WDT contribute_VBP to_TO regulation_NN of_IN genes_NNS involved_VBN in_IN immune_JJ responsiveness_NN and_CC inflammation_NN ,_, as_RB well_RB as_IN activation_NN of_IN the_DT HIV_`` long_JJ terminal_NN repeat_NN ._.
In_IN this_DT study_NN multiple_JJ NF-kappa_NNP B_NNP related_VBD polypeptides_NNS ranging_VBG from_IN 85_CD to_TO 45_CD kDa_NN were_VBD examined_VBN for_IN their_PRP$ capacity_NN to_TO interact_`` with_IN the_DT PRDII_`` regulatory_JJ element_NN of_IN interferon_`` beta_NN and_CC were_VBD shown_VBN to_TO possess_VB distinct_JJ intrinsic_JJ DNA_NNP binding_WP$ affinities_NNS for_IN this_DT NF-kappa_NNP B_NNP site_NN and_CC form_NN multiple_JJ DNA_NNP binding_`` homo-_`` and_CC heterodimer_`` complexes_`` in_IN co-renaturation_NN experiments_NNS ._.
Furthermore_RB ,_, using_VBG DNA_NNP templates_NNS containing_VBG two_CD copies_NNS of_IN the_DT PRDII_NNP domain_NN linked_VBN to_TO the_DT rabbit_NN beta_NN globin_NN gene_NN ,_, the_DT purified_`` polypeptides_`` specifically_RB stimulated_VBN NF-kappa_NNP B_NNP dependent_JJ transcription_NN in_IN an_DT in_IN vitro_`` reconstitution_NN assay_NN as_IN heterodimers_NNS but_CC not_RB as_IN p50_`` homodimers_NNS ._.
These_DT experiments_NNS emphasize_VBP the_DT role_NN of_IN NF-kappa_NNP B_NNP dimerization_NN as_IN a_DT distinct_JJ level_NN of_IN transcriptional_JJ control_NN that_WDT may_MD permit_VB functional_JJ diversification_NN of_IN a_DT limited_JJ number_NN of_IN regulatory_JJ proteins_NNS ._.
Oct2_NN transactivation_NN from_IN a_DT remote_JJ enhancer_NN position_NN requires_VBZ a_DT B-cell-restricted_JJ activity_NN ._.
Previous_JJ cotransfection_NN experiments_NNS had_VBD demonstrated_VBN that_IN ectopic_JJ expression_NN of_IN the_DT lymphocyte-specific_JJ transcription_NN factor_NN Oct2_NNP could_MD efficiently_RB activate_VB a_DT promoter_NN containing_VBG an_DT octamer_NN motif_NN ._.
Oct2_NNP expression_NN was_VBD unable_JJ to_TO stimulate_VB a_DT multimerized_JJ octamer_NN enhancer_`` element_NN in_IN HeLa_NNP cells_NNS ,_, however_RB ._.
We_PRP have_VBP tested_VBN a_DT variety_NN of_IN Oct2_NNP isoforms_`` generated_VBN by_IN alternative_JJ splicing_NN for_IN the_DT capability_NN to_TO activate_VB an_DT octamer_NN enhancer_NN in_IN nonlymphoid_JJ cells_NNS and_CC a_DT B-cell_NNP line_NN ._.
Our_PRP$ analyses_`` show_NN that_IN several_JJ Oct2_`` isoforms_NNS can_MD stimulate_VB from_IN a_DT remote_JJ position_NN but_CC that_IN this_DT stimulation_NN is_VBZ restricted_VBN to_TO B_NNP cells_NNS ._.
This_DT result_NN indicates_VBZ the_DT involvement_NN of_IN either_CC a_DT B-cell-specific_JJ cofactor_NN or_CC a_DT specific_JJ modification_NN of_IN a_DT cofactor_`` or_CC the_DT Oct2_`` protein_NN in_IN Oct2-mediated_JJ enhancer_NN activation_NN ._.
Mutational_JJ analyses_NNS indicate_VBP that_IN the_DT carboxy-terminal_JJ domain_NN of_IN Oct2_NNP is_VBZ critical_JJ for_IN enhancer_NN activation_NN ._.
Moreover_RB ,_, this_DT domain_NN conferred_VBD enhancing_VBG activity_NN when_WRB fused_VBN to_TO the_DT Oct1_`` protein_NN ,_, which_WDT by_IN itself_PRP was_VBD unable_JJ to_TO stimulate_VB from_IN a_DT remote_JJ position_NN ._.
The_DT glutamine-rich_JJ activation_NN domain_NN present_NN in_IN the_DT amino-terminal_JJ portion_NN of_IN Oct2_`` and_CC the_DT POU_NNP domain_NN contribute_VBP only_RB marginally_RB to_TO the_DT transactivation_NN function_NN from_IN a_DT distal_JJ position_NN ._.
Induction_NN of_IN the_DT POU_`` domain_NN transcription_NN factor_NN Oct-2_`` during_IN T-cell_NNP activation_`` by_IN cognate_`` antigen_`` ._.
Oct-2_NN is_VBZ a_DT transcription_NN factor_NN that_WDT binds_VBZ specifically_RB to_TO octamer_# DNA_NNP motifs_`` in_IN the_DT promoters_NNS of_IN immunoglobulin_NN and_CC interleukin-2_JJ genes_NNS ._.
All_DT tumor_NN cell_NN lines_NNS from_IN the_DT B-cell_NNP lineage_NN and_CC a_DT few_JJ from_IN the_DT T-cell_NNP lineage_`` express_JJ Oct-2_NN ._.
To_TO address_VB the_DT role_NN of_IN Oct-2_'' in_IN the_DT T-cell_NNP lineage_NN ,_, we_PRP studied_VBD the_DT expression_NN of_IN Oct-2_NNP mRNA_NNP and_CC protein_NN in_IN nontransformed_JJ human_NN and_CC mouse_NN T_JJ cells_NNS ._.
Oct-2_NNP was_VBD found_VBN in_IN CD4+_`` and_CC CD8+_`` T_JJ cells_NNS prepared_JJ from_IN human_JJ peripheral_JJ blood_NN and_CC in_IN mouse_NN lymph_`` node_`` T_JJ cells_NNS ._.
In_IN a_DT T-cell_# clone_`` specific_JJ for_IN pigeon_NN cytochrome_`` c_NN in_IN the_DT context_NN of_IN I-Ek_NNP ,_, Oct-2_NNP was_VBD induced_VBN by_IN antigen_JJ stimulation_NN ,_, with_IN the_DT increase_NN in_IN Oct-2_NNP protein_NN seen_VBN first_JJ at_IN 3_CD h_NN after_IN activation_NN and_CC continuing_VBG for_IN at_IN least_JJS 24_CD h_NN ._.
Oct-2_-LRB- mRNA_`` induction_NN during_IN antigen-driven_JJ T-cell_JJ activation_NN was_VBD blocked_VBN by_IN cyclosporin_`` A_DT ,_, as_RB well_RB as_IN by_IN protein_NN synthesis_NN inhibitors_NNS ._.
These_DT results_NNS suggest_VBP that_IN Oct-2_NNP participates_`` in_IN transcriptional_JJ regulation_NN during_IN T-cell_NNP activation_NN ._. The_DT relatively_RB delayed_VBN kinetics_NNS of_IN Oct-2_`` induction_NN suggests_VBZ that_IN Oct-2_-RRB- mediates_VBZ the_DT changes_NNS in_IN gene_NN expression_NN which_WDT occur_VBP many_JJ hours_NNS or_CC days_NNS following_VBG antigen_JJ stimulation_NN of_IN T_JJ lymphocytes_NNS ._.
(_-LRB- Changes_`` in_IN plasma_NN interleukin-1_NN and_CC their_PRP$ possible_JJ relationship_NN with_IN the_DT changes_NNS in_IN glucocorticoid_NN receptor_NN in_IN aged_JJ long-distance_JJ runner_NN )_-RRB-
For_IN the_DT study_NN of_IN the_DT changes_NNS in_IN plasma_NN interleukin-1_CD (_-LRB- IL-1_NN )_-RRB- and_CC their_PRP$ possible_JJ relationship_NN with_IN the_DT changes_NNS in_IN glucocorticoid_NN receptor_NN (_-LRB- GR_NNP )_-RRB- ,_, plasma_NN IL-1_NNP and_CC GR_NNP in_IN peripheral_JJ blood_NN leukocytes_`` in_IN aged_JJ long-distance_NN runner_NN were_VBD measured_VBN simultaneously_RB ._.
The_DT activity_NN of_IN IL-1_NNP was_VBD expressed_VBN as_IN its_PRP$ ability_NN to_TO stimulate_VB 3H-TdR_JJ incorporation_NN in_IN the_DT thymocytes_NNS of_IN C57_CD mice_NNS ._.
GR_NNP was_VBD determined_VBN by_IN whole_JJ cell_NN assay_NN with_IN 3H-Dex_NNP ._.
The_DT results_NNS showed_VBD that_IN the_DT activity_NN of_IN plasma_NN IL-1_NN in_IN aged_JJ long-distance_NN runner_NN was_VBD 209_CD %_NN ,_, 223_CD %_NN and_CC 145_CD %_NN of_IN the_DT control_NN at_IN 14.7-18.7_CD ,_, 3.8-7.0_CD and_CC 1.5-2.6_CD KD_NNP fractions_NNS ._.
The_DT GR_NNP in_IN peripheral_JJ blood_NN leukocytes_`` in_IN aged_JJ runner_NN was_VBD 65_CD %_NN of_IN the_DT control_NN ._.
Possible_JJ relationship_NN between_IN the_DT changes_NNS in_IN IL-1_NNP and_CC GR_NNP in_IN aged_VBN long-distance_NN runner_NN and_CC its_PRP$ physiological_JJ significance_NN are_VBP discussed_VBN ._.
Transcription_-LRB- factor_NN AP-2_JJ activates_`` gene_NN expression_NN of_IN HTLV-I_NNP ._.
The_DT HTLV-I_NNP LTR_NNP contains_VBZ three_CD conserved_`` regulatory_JJ elements_NNS known_VBN as_IN 21_CD base_NN pair_NN repeats_NNS which_WDT are_VBP required_VBN for_IN stimulation_NN of_IN gene_NN expression_NN by_IN the_DT transactivator_`` protein_NN tax_NN ._.
Mutagenesis_NN indicates_VBZ that_IN the_DT 21_CD bp_`` repeats_NNS can_MD be_VB subdivided_VBN into_IN three_CD motifs_NNS ,_, A_DT ,_, B_NNP and_CC C_NNP ,_, each_DT of_IN which_WDT influences_VBZ the_DT level_NN of_IN tax_NN activation_NN ._.
The_DT A_DT site_NN in_IN the_DT 21_CD bp_`` repeat_NN has_VBZ strong_JJ homology_NN with_IN previously_RB described_VBN binding_`` sites_NNS for_IN the_DT transcription_`` factor_NN AP-2_NN ._.
We_PRP demonstrated_VBD that_IN AP-2_NNP mRNA_NNP was_VBD present_JJ in_IN T-lymphocytes_NNS and_CC that_IN cellular_JJ factors_NNS from_IN both_DT non-transformed_JJ and_CC transformed_VBN T-lymphocytes_NNS specifically_RB bound_VBN to_TO the_DT consensus_NN motif_`` for_IN AP-2_NN in_IN each_DT 21_CD bp_`` ._.
To_TO determine_VB the_DT role_NN of_IN AP-2_'' in_IN the_DT regulation_NN of_IN the_DT HTLV-I_NNP LTR_NNP gene_NN expression_NN ,_, we_PRP used_VBD an_DT AP-2_`` cDNA_NN in_IN DNA_NNP binding_`` and_CC transient_JJ expression_NN assays_`` ._.
Gel_NNP retardation_`` and_CC methylation_NN interference_NN studies_NNS revealed_VBD that_IN bacterially_RB produced_VBN AP-2_JJ bound_VBN specifically_RB and_CC with_IN high_JJ affinity_NN to_TO all_DT three_CD 21_CD bp_`` repeats_NNS ,_, and_CC that_IN it_PRP required_VBD the_DT core_NN sequence_NN AGGC_NNP for_IN specific_JJ binding_`` ._.
Binding_# of_IN AP-2_NNP prevented_VBD the_DT subsequent_JJ binding_NN of_IN members_NNS of_IN the_DT CREB/ATF_`` family_NN to_TO an_DT adjacent_JJ regulatory_JJ motif_NN in_IN the_DT 21_CD bp_`` repeat_NN ._.
Transfection_NN of_IN an_DT AP-2_JJ expression_NN construct_VB into_IN T-lymphocytes_NNP activated_VBD gene_NN expression_NN from_IN the_DT HTLV-I_NNP LTR_NNP ._.
At_IN least_JJS two_CD 21_CD bp_`` repeats_NNS were_VBD required_VBN for_IN high_JJ levels_NNS of_IN AP-2_NN activation_NN and_CC mutagenesis_NN of_IN the_DT AP-2_JJ consensus_NN binding_`` sequences_`` in_IN the_DT 21_CD bp_`` repeats_`` eliminate_VB this_DT activation_NN ._.
(_-LRB- ABSTRACT_`` TRUNCATED_JJ AT_`` 250_CD WORDS_NNS )_-RRB-
Cell_-LRB- cycle-dependent_JJ initiation_NN and_CC lineage-dependent_JJ abrogation_NN of_IN GATA-1_`` expression_NN in_IN pure_JJ differentiating_`` hematopoietic_JJ progenitors_NNS ._.
The_DT programmed_`` activation/repression_NN of_IN transcription_NN factors_NNS in_IN early_JJ hematopoietic_JJ differentiation_NN has_VBZ not_RB yet_RB been_VBN explored_VBN ._.
The_DT DNA-binding_JJ protein_NN GATA-1_NNP is_VBZ required_VBN for_IN normal_JJ erythroid_`` development_NN and_CC regulates_`` erythroid-expressed_JJ genes_NNS in_IN maturing_VBG erythroblasts_NNS ._.
We_PRP analyzed_VBD GATA-1_`` expression_NN in_IN early_JJ human_JJ adult_NN hematopoiesis_NN by_IN using_VBG an_DT in_IN vitro_`` system_NN in_IN which_WDT "_`` pure_JJ "_'' early_JJ hematopoietic_JJ progenitors_NNS are_VBP induced_VBN to_TO gradual_JJ and_CC synchronized_`` differentiation_`` selectively_RB along_IN the_DT erythroid_`` or_CC granulocyte-macrophage_NN pathway_NN by_IN differential_JJ treatment_NN with_IN hematopoietic_JJ growth_NN factors_NNS ._.
The_DT GATA-1_NNP gene_NN ,_, though_IN virtually_RB silent_JJ in_IN quiescent_JJ progenitors_NNS ,_, is_VBZ activated_VBN after_IN entrance_NN into_IN the_DT cell_NN cycle_NN upon_IN stimulation_NN with_IN hematopoietic_JJ growth_NN factors_NNS ._.
Subsequently_RB ,_, increasing_VBG expression_NN along_IN the_DT erythroid_`` pathway_NN contrasts_VBZ with_IN an_DT abrupt_JJ downregulation_NN in_IN the_DT granulocyte-macrophage_NN lineage_NN ._.
These_DT results_NNS suggest_VBP a_DT microenvironment-directed_JJ ,_, two-step_JJ model_NN for_IN GATA-1_`` expression_NN in_IN differentiating_VBG hematopoietic_JJ progenitors_NNS that_WDT involves_VBZ (_-LRB- i_FW )_-RRB- cycle-dependent_JJ initiation_NN and_CC (_-LRB- ii_`` )_-RRB- lineage-dependent_JJ maintenance_NN or_CC suppression_NN ._.
Hypothetically_RB ,_, on/off_IN switches_NNS of_IN lineage-restricted_JJ transactivators_NNS may_MD underlie_`` the_DT binary_JJ fate_NN decisions_NNS of_IN hematopoietic_JJ progenitors_NNS ._.
(_-LRB- Age-related_`` changes_NNS in_IN glucocorticoid_JJ and_CC mineralocorticoid_JJ receptors_NNS in_IN lymphocytes_NNS of_IN healthy_JJ persons_NNS and_CC patients_NNS with_IN hypertension_NN )_-RRB-
It_PRP has_VBZ been_VBN found_VBN that_IN the_DT number_NN of_IN glucocorticoid_JJ receptors_NNS in_IN lymphocytes_NNS of_IN the_DT peripheral_JJ blood_NN of_IN healthy_JJ elderly_JJ subjects_NNS increases_VBZ ,_, while_IN the_DT number_NN of_IN mineralocorticoid_JJ receptors_NNS decreases_NNS ._.
The_DT mechanisms_NNS of_IN hormone-receptor_NN interactions_NNS in_IN hypertension_NN are_VBP activated_VBN :_: the_DT number_NN of_IN glucocorticoid_JJ and_CC mineralocorticoid_JJ binding_`` sites_NNS grows_VBZ in_IN hypertensive_JJ patients_NNS ._.
Still_RB a_DT more_RBR essential_JJ rise_NN in_IN the_DT number_NN of_IN receptors_NNS is_VBZ observed_VBN in_IN mid-age_`` hypertensive_JJ patients_NNS than_IN in_IN elderly_JJ ones_NNS ._.
In_IN vivo_`` footprint_NN analysis_NN of_IN the_DT HLA-DRA_`` gene_NN promoter_NN :_: cell-specific_JJ interaction_NN at_IN the_DT octamer_NN site_NN and_CC up-regulation_NN of_IN X_NNP box_NN binding_`` by_IN interferon_# gamma_NN ._.
Analysis_NN of_IN the_DT major_JJ histocompatibility_NN complex_JJ class_NN II_NNP gene_NN promoter_NN DRA_NNP has_VBZ previously_RB identified_VBN at_IN least_JJS five_CD cis-acting_JJ regions_NNS required_VBN for_IN maximal_JJ expression_NN ._.
We_PRP have_VBP examined_VBN the_DT DRA_`` promoter_NN for_IN protein-DNA_`` interactions_NNS in_IN the_DT intact_JJ cell_NN ,_, which_WDT may_MD mediate_VB transcriptional_JJ activation_NN ._.
Using_VBG in_IN vivo_`` genomic_JJ footprinting_NN we_PRP identified_VBD interactions_NNS in_IN B-cell_`` lines_NNS at_IN the_DT octamer_NN site_NN and_CC the_DT Y_NNP ,_, X1_NNP ,_, and_CC X2_NNP boxes_NNS ._.
Class_NN II_NNP antigen_`` expressing_VBG T-cell_JJ lines_NNS maintained_VBN contacts_NNS identical_JJ to_TO B-cell_`` lines_NNS ,_, while_IN class_NN II-negative_JJ T-cell_`` lines_NNS exhibited_VBD no_DT interactions_NNS ._.
In_IN lymphoid_JJ cell_NN lines_NNS ,_, the_DT octamer_NN site_NN is_VBZ occupied_VBN and_CC required_VBN for_IN maximal_JJ expression_NN ._.
This_DT is_VBZ most_RBS likely_JJ due_JJ to_TO the_DT presence_NN of_IN the_DT lymphoid-specific_JJ OTF-2_`` factor_NN ._.
In_IN contrast_NN ,_, the_DT class_NN II-positive_JJ nonlymphoid_JJ glioblastoma_NN cell_NN line_NN does_VBZ not_RB exhibit_VB interactions_NNS at_IN the_DT octamer_`` site_NN despite_IN the_DT presence_NN of_IN the_DT ubiquitous_JJ OTF-1_NNP factor_NN and_CC an_DT open_JJ binding_NN site_NN ._.
Thus_RB ,_, the_DT DRA_NNP promoter_NN discriminates_`` against_IN OTF-1_NNP activation_`` at_IN the_DT level_NN of_IN DNA_NNP binding_`` in_IN the_DT glioblastoma_NN line_NN ._.
Interferon_NNP gamma_`` induces_`` class_NN II_NNP expression_NN in_IN this_DT glioblastoma_`` cell_NN line_NN and_CC ,_, in_IN parallel_RB ,_, up-regulates_# X1_`` and_CC X2_`` box_NN protein-DNA_NN interactions_NNS ,_, while_IN all_DT other_JJ interactions_NNS remain_VBP unchanged_JJ ._.
These_DT results_NNS suggest_VBP that_IN interferon_`` gamma_NNS functions_NNS on_IN a_DT poised_VBN promoter_NN by_IN altering_`` weak_JJ ,_, nonproductive_JJ interactions_NNS at_IN the_DT X_NNP boxes_NNS to_TO strong_JJ interactions_NNS ._.
These_DT findings_NNS provide_VBP direct_JJ in_IN vivo_JJ evidence_NN to_TO strongly_RB suggest_VB that_IN the_DT modulation_NN of_IN X1_NNP and_CC X2_NNP interactions_NNS is_VBZ an_DT important_JJ constituent_NN of_IN the_DT interferon_`` gamma_NN induction_NN pathway_NN ._.
Simple_NN derivation_NN of_IN TFIID-dependent_NNP RNA_NNP polymerase_WP$ II_NNP transcription_NN systems_NNS from_IN Schizosaccharomyces_`` pombe_`` and_CC other_JJ organisms_NNS ,_, and_CC factors_NNS required_VBN for_IN transcriptional_JJ activation_NN ._.
Resolution_NN of_IN whole_JJ cell_NN extract_VB through_IN two_CD chromatographic_JJ steps_NNS yields_VBZ a_DT single_JJ protein_NN fraction_NN requiring_VBG only_RB the_DT addition_NN of_IN TFIID_NN for_IN the_DT initiation_NN of_IN transcription_NN at_IN RNA_NNP polymerase_# II_NNP promoters_NNS ._.
This_DT approach_NN allows_VBZ the_DT convenient_JJ generation_NN of_IN RNA_NNP polymerase_WP$ II_NNP transcription_NN systems_NNS from_IN Saccharomyces_`` cerevisiae_NNS ,_, human_JJ lymphocytes_NNS ,_, and_CC Schizosaccharomyces_`` pombe_`` ._.
TFIIDs_NNS from_IN all_DT three_CD organisms_NNS are_VBP interchangeable_JJ among_IN all_DT three_CD systems_NNS ._.
The_DT S._NNP cerevisiae_NNS and_CC Sch._NNP pombe_`` systems_NNS support_VBP effects_NNS of_IN acidic_`` activator_`` proteins_NNS ,_, provided_VBD a_DT further_JJ protein_NN fraction_NN from_IN S._NNP cerevisiae_`` is_VBZ supplied_VBN ._.
This_DT further_JJ fraction_NN is_VBZ distinct_JJ from_IN the_DT mediator_NN of_IN transcriptional_JJ activation_NN described_VBD previously_RB and_CC represents_VBZ a_DT second_JJ component_NN in_IN addition_NN to_TO general_JJ initiation_NN factors_NNS that_WDT may_MD facilitate_VB a_DT response_NN to_TO acidic_`` activators_NNS ._.
NF-kappa_NNP B-dependent_NNP induction_`` of_IN the_DT NF-kappa_NNP B_NNP p50_`` subunit_`` gene_NN promoter_NN underlies_`` self-perpetuation_NN of_IN human_JJ immunodeficiency_NN virus_NN transcription_NN in_IN monocytic_JJ cells_NNS ._.
The_DT molecular_JJ mechanisms_NNS underlying_VBG the_DT sustained_VBN nuclear_JJ translocation_NN of_IN NF-kappa_NNP B_NNP observed_VBD in_IN U937_CD monocytic_JJ cells_NNS chronically_RB infected_VBD with_IN human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV_NNP )_-RRB- were_VBD studied_VBN ._.
The_DT activity_NN of_IN the_DT promoter_NN regulating_VBG the_DT synthesis_NN of_IN the_DT p105_`` precursor_NN of_IN the_DT NF-kappa_NNP B_NNP p50_`` subunit_NN was_VBD enhanced_VBN in_IN these_DT cells_NNS ._.
Deletions_NNS in_IN this_DT promoter_NN indicated_VBD that_IN this_DT upregulation_NN was_VBD mediated_`` through_IN the_DT NF-kappa_NNP B-_-RRB- but_CC not_RB the_DT AP-1-binding_JJ motif_NN ,_, by_IN bona_-RRB- fide_`` p50/p65_CD heterodimers_NNS ._.
Analysis_NN of_IN cytosolic_JJ extracts_NNS indicated_VBD that_IN NF-kappa_NNP B_NNP levels_NNS were_VBD increased_VBN in_IN HIV-infected_JJ cells_NNS ._.
In_IN contrast_NN to_TO the_DT transient_JJ NF-kappa_NNP B_NNP activation_NN induced_`` by_IN phorbol_NN ester_NN ,_, the_DT permanent_JJ NF-kappa_NNP B_NNP translocation_NN induced_`` by_IN HIV_NNP infection_NN was_VBD not_RB dependent_JJ on_IN PKC_NNP isoenzymes_`` alpha_NN and_CC beta_NN as_IN shown_VBN by_IN the_DT use_NN of_IN a_DT specific_JJ inhibitor_`` (_-LRB- GF_NNP 109203X_NNP )_-RRB- ._.
These_DT observations_NNS indicate_VBP that_IN during_IN chronic_NN HIV_`` infection_NN of_IN U937_CD cells_NNS ,_, continuous_JJ NF-kappa_NNP B_NNP (_-LRB- p50/p65_NN )_-RRB- translocation_NN results_NNS in_IN p105_CD promoter_NN upregulation_`` with_IN subsequent_JJ cytosolic_NN NF-kappa_NNP B_NNP accumulation_NN ,_, ready_JJ for_IN further_JJ translocation_NN ._.
This_DT HIV-mediated_JJ mechanism_NN results_NNS in_IN a_DT self-perpetuating_JJ loop_NN of_IN NF-kappa_NNP B_NNP production_NN ._.
The_DT development_NN of_IN functionally_RB responsive_JJ T_JJ cells_NNS ._.
The_DT work_NN reviewed_VBN in_IN this_DT article_NN separates_`` T_JJ cell_NN development_NN into_IN four_CD phases_NNS ._.
First_RB is_VBZ an_DT expansion_NN phase_NN prior_RB to_TO TCR_NNP rearrangement_NN ,_, which_WDT appears_VBZ to_TO be_VB correlated_VBN with_IN programming_NN of_IN at_IN least_JJS some_DT response_NN genes_NNS for_IN inducibility_NN ._.
This_DT phase_NN can_MD occur_VB to_TO some_DT extent_NN outside_IN of_IN the_DT thymus_NN ._.
However_RB ,_, the_DT profound_JJ T_JJ cell_NN deficit_NN of_IN nude_JJ mice_NNS indicates_VBZ that_IN the_DT thymus_NN is_VBZ by_IN far_RB the_DT most_RBS potent_JJ site_NN for_IN inducing_VBG the_DT expansion_NN per_IN se_`` ,_, even_RB if_IN other_JJ sites_NNS can_MD induce_VB some_DT response_NN acquisition_NN ._.
Second_JJ is_VBZ a_DT controlled_JJ phase_NN of_IN TCR_NNP gene_NN rearrangement_NN ._.
The_DT details_NNS of_IN the_DT regulatory_JJ mechanism_NN that_WDT selects_VBZ particular_JJ loci_`` for_IN rearrangement_NN are_VBP still_RB not_RB known_VBN ._.
It_PRP seems_VBZ that_IN the_DT rearrangement_NN of_IN the_DT TCR_NNP gamma_NN loci_`` in_IN the_DT gamma_`` delta_JJ lineage_NN may_MD not_RB always_RB take_VB place_NN at_IN a_DT developmental_JJ stage_NN strictly_RB equivalent_JJ to_TO the_DT rearrangement_NN of_IN TCR_NNP beta_NN in_IN the_DT alpha_`` beta_JJ lineage_NN ,_, and_CC it_PRP is_VBZ not_RB clear_JJ just_RB how_WRB early_JJ the_DT two_CD lineages_NNS diverge_VBP ._.
In_IN the_DT TCR_NNP alpha_`` beta_JJ lineage_NN ,_, however_RB ,_, the_DT final_JJ gene_NN rearrangement_`` events_NNS are_VBP accompanied_VBN by_IN rapid_JJ proliferation_NN and_CC an_DT interruption_NN in_IN cellular_JJ response_NN gene_NN inducibility_NN ._.
The_DT loss_NN of_IN conventional_JJ responsiveness_NN is_VBZ probably_RB caused_VBN by_IN alterations_NNS at_IN the_DT level_NN of_IN signaling_VBG ,_, and_CC may_MD be_VB a_DT manifestation_NN of_IN the_DT physiological_JJ state_NN that_WDT is_VBZ a_DT precondition_NN for_IN selection_NN ._.
Third_LS is_VBZ the_DT complex_JJ process_NN of_IN selection_NN ._.
Whereas_IN peripheral_`` T_JJ cells_NNS can_MD undergo_VB forms_NNS of_IN positive_JJ selection_NN (_-LRB- by_IN antigen-driven_JJ clonal_JJ expansion_NN )_-RRB- and_CC negative_JJ selection_NN (_-LRB- by_IN abortive_JJ stimulation_NN leading_VBG to_TO anergy_`` or_CC death_NN )_-RRB- ,_, neither_CC is_VBZ exactly_RB the_DT same_JJ phenomenon_NN that_WDT occurs_VBZ in_IN the_DT thymic_JJ cortex_NN ._.
Negative_JJ selection_NN in_IN the_DT cortex_NN appears_VBZ to_TO be_VB a_DT suicidal_JJ inversion_NN of_IN antigen_# responsiveness_NN :_: instead_RB of_IN turning_VBG on_RP IL-2_`` expression_NN ,_, the_DT activated_`` cell_NN destroys_VBZ its_PRP$ own_JJ chromatin_NN ._.
The_DT genes_NNS that_WDT need_VBP to_TO be_VB induced_VBN for_IN this_DT response_NN are_VBP not_RB yet_RB identified_VBN ,_, but_CC it_PRP is_VBZ unquestionably_RB a_DT form_NN of_IN activation_NN ._.
It_PRP is_VBZ interesting_JJ that_IN in_IN humans_NNS and_CC rats_NNS ,_, cortical_JJ thymocytes_NNS undergoing_VBG negative_JJ selection_NN can_MD still_RB induce_VB IL-2R_JJ alpha_NN expression_NN and_CC even_RB be_VB rescued_VBN in_IN vitro_NN ,_, if_IN exogenous_JJ IL-2_NN is_VBZ provided_VBN ._.
Perhaps_RB murine_`` thymocytes_NNS are_VBP denied_VBN this_DT form_NN of_IN rescue_NN because_IN they_PRP shut_VBD off_RP IL-2R_JJ beta_JJ chain_NN expression_NN at_IN an_DT earlier_JJR stage_NN or_CC because_IN they_PRP may_MD be_VB uncommonly_JJ Bcl-2_`` deficient_JJ (_-LRB- cf._`` Sentman_NNP et_NNP al._`` ,_, 1991_CD ;_: Strasser_NNP et_NNP al._`` ,_, 1991_CD )_-RRB- ._.
Even_RB so_RB ,_, medullary_'' thymocytes_`` remain_VB at_IN least_JJS partially_RB susceptible_JJ to_TO negative_JJ selection_NN even_RB as_IN they_PRP continue_VBP to_TO mature_VB ._.
SRC-related_JJ proto-oncogenes_NNS and_CC transcription_NN factors_NNS in_IN primary_JJ human_JJ T_JJ cells_NNS :_: modulation_NN by_IN cyclosporin_`` A_DT and_CC FK506_NNP ._.
Activation_NN of_IN T_JJ lymphocytes_NNS induces_`` transcription_NN of_IN genes_NNS encoding_`` for_IN lymphokines_NNS ._.
Interleukin-2_# (_-LRB- IL-2_NN )_-RRB- gene_NN expression_NN is_VBZ controlled_VBN transcriptionally_RB by_IN the_DT cooperative_JJ activity_NN of_IN specific_JJ trans-activating_JJ factors_NNS that_WDT bind_VBP to_TO the_DT IL-2_`` enhancer_NN ._.
Cyclosporin_# A_DT (_-LRB- CsA_NN )_-RRB- and_CC FK506_NNP inhibit_VBP the_DT production_NN of_IN IL-2_`` in_IN T_JJ lymphocytes_NNS at_IN the_DT level_NN of_IN gene_NN transcription_NN ._.
A_DT member_NN of_IN the_DT src_`` gene_NN family_NN ,_, the_DT lymphocyte-specific_JJ protein_NN tyrosine_NN kinase_`` ,_, p56lck_NN ,_, has_VBZ been_VBN implicated_VBN in_IN IL-2_JJ production_NN ._.
CsA_NNP was_VBD found_VBN not_RB to_TO inhibit_VB lck_`` gene_NN expression_NN ,_, nor_CC the_DT activity_NN of_IN the_DT lck_`` gene_NN product_NN ._.
However_RB ,_, CsA_NNP and_CC FK506_NNP inhibit_VB the_DT appearance_NN of_IN DNA_NNP binding_`` activity_NN of_IN factors_NNS that_WDT bind_VBP to_TO the_DT NF-AT_`` and_CC AP-1_`` sites_NNS in_IN the_DT IL-2_NN enhancer_NN ._.
Since_IN the_DT induction_NN of_IN NF-AT_`` and_CC AP-1_`` is_VBZ induced_VBN by_IN the_DT same_JJ stimuli_NNS that_IN stimulate_VB IL-2_JJ production_NN ,_, these_DT results_NNS indicate_VBP that_IN the_DT immunosuppressant_JJ action_NN of_IN CsA_NNP and_CC FK506_NNP is_VBZ exerted_VBN at_IN the_DT level_NN of_IN these_DT trans-activating_JJ factors_NNS ._.
TAR-independent_JJ transactivation_NN by_IN Tat_NNP in_IN cells_NNS derived_VBN from_IN the_DT CNS_NNS :_: a_DT novel_NN mechanism_NN of_IN HIV-1_`` gene_NN regulation_NN ._.
The_DT Tat_NNP protein_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_-LRB- HIV-1_NNP )_-RRB- is_VBZ essential_JJ for_IN productive_JJ infection_NN and_CC is_VBZ a_DT potential_JJ target_NN for_IN antiviral_JJ therapy_NN ._.
Tat_NNP ,_, a_DT potent_JJ activator_NN of_IN HIV-1_`` gene_NN expression_NN ,_, serves_VBZ to_TO greatly_RB increase_VB the_DT rate_NN of_IN transcription_NN directed_VBN by_IN the_DT viral_`` promoter_NN ._.
This_DT induction_NN ,_, which_WDT seems_VBZ to_TO be_VB an_DT important_JJ component_NN in_IN the_DT progression_NN of_IN acquired_VBN immune_JJ deficiency_NN syndrome_NN (_-LRB- AIDS_NNP )_-RRB- ,_, may_MD be_VB due_JJ to_TO increased_VBN transcriptional_JJ initiation_NN ,_, increased_VBD transcriptional_JJ elongation_NN ,_, or_CC a_DT combination_NN of_IN these_DT processes_NNS ._.
Much_JJ attention_NN has_VBZ been_VBN focused_VBN on_IN the_DT interaction_NN of_IN Tat_NNP with_IN a_DT specific_JJ RNA_NNP target_NN termed_VBD TAR_`` (_-LRB- transactivation_NN responsive_JJ )_-RRB- which_WDT is_VBZ present_JJ in_IN the_DT leader_NN sequence_NN of_IN all_DT HIV-1_NNP mRNAs_NNP ._.
This_DT interaction_NN is_VBZ believed_VBN to_TO be_VB an_DT important_JJ component_NN of_IN the_DT mechanism_NN of_IN transactivation_NN ._.
In_IN this_DT report_NN we_PRP demonstrate_VBP that_IN in_IN certain_JJ CNS-derived_JJ cells_NNS Tat_# is_VBZ capable_JJ of_IN activating_VBG HIV-1_`` through_IN a_DT TAR-independent_JJ pathway_NN ._.
A_DT Tat-responsive_JJ element_NN is_VBZ found_VBN upstream_RB within_IN the_DT viral_`` promoter_NN that_IN in_IN glial-derived_JJ cell_NN lines_NNS allows_VBZ transactivation_NN in_IN the_DT absence_NN of_IN TAR_NN ._.
Deletion_NN mapping_NN and_CC hybrid_NN promoter_NN constructs_NNS demonstrate_VBP that_IN the_DT newly_RB identified_VBN Tat-responsive_JJ element_NN corresponds_VBZ to_TO a_DT sequence_NN within_IN the_DT viral_`` long_JJ terminal_NN repeat_NN (_-LRB- LTR_NNP )_-RRB- previously_RB identified_VBN as_IN the_DT HIV-1_`` enhancer_NN ,_, or_CC NF-kappa_NNP B_NNP domain_NN ._.
DNA_NNP band-shift_JJ analysis_NN reveals_VBZ NF-kappa_NNP B_NNP binding_`` activity_NN in_IN glial_JJ cells_NNS that_WDT differs_VBZ from_IN that_IN present_JJ in_IN T_`` lymphoid_JJ cells_NNS ._.
Further_RB ,_, we_PRP observe_VBP that_IN TAR-deleted_JJ mutants_NNS of_IN HIV-1_NNP demonstrate_VBP normal_JJ late_JJ gene_NN expression_NN in_IN glial_JJ cells_NNS as_IN evidenced_VBN by_IN syncytia_NN formation_NN and_CC production_NN of_IN viral_JJ p24_NN antigen_NN ._.
(_-LRB- ABSTRACT_`` TRUNCATED_JJ AT_`` 250_CD WORDS_NNS )_-RRB-
Bcl-2_NN :_: a_DT repressor_NN of_IN lymphocyte_# death_NN ._.
The_DT genes_NNS and_CC mechanisms_NNS that_IN control_NN programmed_`` cell_NN death_NN are_VBP currently_RB the_DT subject_NN of_IN intense_JJ study_NN ._.
The_DT bcl-2_NN gene_NN ,_, a_DT repressor_NN of_IN lymphocyte_`` death_NN ,_, is_VBZ perhaps_RB the_DT best_JJS understood_VBN of_IN the_DT programmed_`` cell_NN death_NN associated_VBN genes_NNS ._.
Here_RB ,_, Stanley_NNP Korsmeyer_NNP provides_VBZ a_DT brief_JJ overview_NN of_IN bcl-2_NN ,_, concentrating_VBG on_IN its_PRP$ roles_NNS in_IN B-_-RRB- and_CC T-cell_JJ development_NN and_CC in_IN oncogenesis_NN ._.
Mitogen_NN stimulation_NN of_IN T-cells_`` increases_NNS c-Fos_# and_CC c-Jun_JJ protein_NN levels_NNS ,_, AP-1_NNP binding_`` and_CC AP-1_`` transcriptional_JJ activity_NN ._.
We_PRP have_VBP analysed_`` the_DT effect_NN of_IN mitogenic_JJ lectins_NNS on_IN c-Fos_NNS and_CC c-Jun_JJ protein_NN levels_NNS as_RB well_RB as_IN on_IN activator_NN protein-1_CD (_-LRB- AP-1_NNP )_-RRB- binding_`` and_CC enhancer_`` activity_NN in_IN Jurkat_NNP T-cells_NNP ._.
Both_DT c-Fos_-RRB- and_CC c-Jun_JJ protein_NN levels_NNS were_VBD increased_VBN after_IN Con_NNP A_DT and_CC PHA_NNP stimulation_NN ._.
Since_IN T-cell_NNP stimulation_NN increases_VBZ both_DT intracellular_JJ Ca2+_NNP and_CC cAMP_NNP levels_NNS and_CC activates_NNS protein_NN kinase_`` C_$ (_-LRB- PKC_NNP )_-RRB- ,_, the_DT possible_JJ involvement_NN of_IN these_DT intracellular_JJ messengers_NNS in_IN c-Fos_`` and_CC c-Jun_`` induction_NN was_VBD tested_VBN ._.
PMA_NNP ,_, which_WDT directly_RB activates_VBZ PKC_NNP ,_, mimicked_VBD the_DT effect_NN of_IN the_DT lectins_NNS on_IN c-Fos_`` and_CC c-Jun_`` ,_, but_CC elevation_NN of_IN either_DT intracellular_JJ Ca2+_NN or_CC cAMP_NN levels_NNS had_VBD little_RB or_CC no_DT effect_NN ._.
The_DT mitogen-induced_JJ increase_NN of_IN c-Fos_`` and_CC c-Jun_`` immunoreactivity_NN was_VBD inhibited_VBN by_IN H-7_`` ,_, a_DT kinase_`` inhibitor_`` with_IN relatively_RB high_JJ specificity_NN for_IN PKC_NNP ,_, and_CC less_RBR efficiently_RB by_IN H-8_`` ,_, a_DT structurally_RB related_VBN kinase_`` inhibitor_NN less_RBR active_JJ on_IN PKC_NNP ,_, but_CC more_RBR active_JJ on_IN cyclic_`` nucleotide-dependent_JJ kinases_NNS ._.
Con_# A_DT stimulation_NN was_VBD found_VBN to_TO increase_VB both_DT binding_`` of_IN AP-1_`` to_TO the_DT AP-1_`` consensus_NN sequence_NN ,_, TRE_NN ,_, and_CC AP-1_NNP enhancer_`` activity_NN ,_, in_IN Jurkat_NNP cells_NNS ._.
PMA_NNP was_VBD also_RB found_VBN to_TO increase_VB the_DT AP-1_`` enhancer_NN activity_NN ,_, whereas_IN elevation_NN of_IN Ca2+_NNP or_CC cAMP_NNP had_VBD only_RB minor_JJ effects_NNS ._.
We_PRP conclude_VBP that_IN stimulation_NN with_IN mitogenic_JJ lectins_NNS is_VBZ sufficient_JJ to_TO increase_VB both_DT c-Fos_`` and_CC c-Jun_`` protein_NN levels_NNS ,_, AP-1_NNP binding_`` and_CC AP-1_`` enhancer_`` activity_NN in_IN Jurkat_NNP cells_NNS and_CC that_IN they_PRP act_VBP via_IN mechanisms_NNS that_WDT could_MD involve_VB the_DT activation_NN of_IN PKC_NNP ._.
Functional_JJ interaction_NN between_IN the_DT two_CD zinc_`` finger_NN domains_`` of_IN the_DT v-erb_`` A_DT oncoprotein_NN ._.
The_DT v-erb_`` A_DT oncogene_NN of_IN avian_JJ erythroblastosis_NN virus_NN is_VBZ a_DT mutated_`` and_CC virally_RB transduced_VBN copy_NN of_IN a_DT host_NN cell_NN gene_NN encoding_VBG a_DT thyroid_`` hormone_NN receptor_NN ._.
The_DT protein_NN expressed_VBN by_IN the_DT v-erb_`` A_DT oncogene_`` binds_NNS to_TO DNA_NNP and_CC acts_VBZ as_IN a_DT dominant_JJ negative_JJ inhibitor_NN of_IN both_DT the_DT thyroid_`` hormone_NN receptor_NN and_CC the_DT closely_RB related_JJ retinoic_JJ acid_NN receptor_NN ._.
The_DT v-erb_`` A_DT protein_NN has_VBZ sustained_VBN two_CD amino_`` acid_NN alterations_NNS within_IN its_PRP$ DNA-binding_JJ domain_NN relative_JJ to_TO that_DT of_IN c-erb_`` A_DT ,_, one_CD of_IN which_WDT ,_, at_IN serine_NN 61_CD ,_, is_VBZ known_VBN to_TO be_VB important_JJ for_IN v-erb_`` A_DT function_NN in_IN the_DT neoplastic_JJ cell_NN ._.
We_PRP report_VBP here_RB that_IN the_DT second_JJ alteration_NN ,_, at_IN threonine_CD 78_CD ,_, also_RB plays_VBZ an_DT important_JJ ,_, although_IN more_RBR indirect_JJ ,_, role_NN :_: alteration_`` of_IN the_DT sequence_NN at_IN threonine_CD 78_CD such_JJ that_IN it_PRP resembles_VBZ that_IN of_IN c-erb_`` A_DT can_MD act_VB as_IN an_DT intragenic_JJ suppressor_NN and_CC can_MD partially_RB restore_VB function_NN to_TO a_DT v-erb_`` A_DT protein_NN rendered_VBN defective_JJ due_JJ to_TO a_DT mutation_`` at_IN position_NN 61_CD ._.
Threonine_CD 78_CD lies_NNS within_IN the_DT D-box_`` of_IN the_DT v-erb_`` A_DT protein_NN ,_, a_DT region_NN thought_VBD to_TO mediate_VB receptor-receptor_NN dimerizations_NNS ,_, and_CC is_VBZ not_RB in_IN physical_JJ proximity_NN to_TO the_DT serine_`` at_IN position_NN 61_CD ._.
It_PRP therefore_RB appears_VBZ that_IN an_DT indirect_JJ interaction_NN occurs_VBZ between_IN these_DT two_CD sites_NNS and_CC that_IN this_DT interaction_NN is_VBZ crucial_JJ for_IN v-erb_JJ A_DT function_NN ._.
Pax-5_# encodes_VBZ the_DT transcription_NN factor_NN BSAP_NNP and_CC is_VBZ expressed_VBN in_IN B_NNP lymphocytes_NNS ,_, the_DT developing_VBG CNS_NNS ,_, and_CC adult_JJ testis_NN ._.
BSAP_NNP has_VBZ been_VBN identified_VBN previously_RB as_IN a_DT transcription_NN factor_NN that_WDT is_VBZ expressed_VBN at_IN early_RB ,_, but_CC not_RB late_JJ ,_, stages_NNS of_IN B-cell_NNP differentiation_NN ._.
Biochemical_JJ purification_NN and_CC cDNA_`` cloning_NN has_VBZ now_RB revealed_VBN that_IN BSAP_NNP belongs_VBZ to_TO the_DT family_NN of_IN paired_`` domain_NN proteins_NNS ._.
BSAP_NNP is_VBZ encoded_VBN by_IN the_DT Pax-5_`` gene_NN and_CC has_VBZ been_VBN highly_RB conserved_`` between_IN human_NN and_CC mouse_NN ._.
An_DT intact_JJ paired_`` domain_NN was_VBD shown_VBN to_TO be_VB both_DT necessary_JJ and_CC sufficient_JJ for_IN DNA_NNP binding_-RRB- of_IN BSAP_NNP ._.
Binding_VBG studies_NNS with_IN several_JJ BSAP_NNP recognition_NN sequences_`` demonstrated_VBD that_IN the_DT sequence_NN specificity_NN of_IN BSAP_NNP differs_`` from_IN that_IN of_IN the_DT distantly_RB related_VBN paired_`` domain_NN protein_NN Pax-1_NN ._.
During_IN embryogenesis_NN ,_, the_DT BSAP_NNP gene_NN is_VBZ transiently_RB expressed_VBN in_IN the_DT mesencephalon_`` and_CC spinal_JJ cord_NN with_IN a_DT spatial_JJ and_CC temporal_JJ expression_NN pattern_NN that_WDT is_VBZ distinct_JJ from_IN that_IN of_IN other_JJ Pax_`` genes_NNS in_IN the_DT developing_JJ central_JJ nervous_JJ system_NN (_-LRB- CNS_-RRB- )_-RRB- ._.
Later_RB ,_, the_DT expression_NN of_IN the_DT BSAP_NNP gene_NN shifts_VBZ to_TO the_DT fetal_`` liver_NN where_WRB it_PRP correlates_VBZ with_IN the_DT onset_NN of_IN B_NNP lymphopoiesis_NN ._.
BSAP_-LRB- expression_NN persists_NNS in_IN B_NNP lymphocytes_`` and_CC is_VBZ also_RB seen_VBN in_IN the_DT testis_NN of_IN the_DT adult_NN mouse_NN ._.
All_DT of_IN this_DT evidence_NN indicates_VBZ that_IN the_DT transcription_NN factor_NN BSAP_NNP may_MD not_RB only_RB play_VB an_DT important_JJ role_NN in_IN B-cell_NNP differentiation_NN but_CC also_RB in_IN neural_JJ development_NN and_CC spermatogenesis_NN ._.
Okadaic_JJ acid_NN is_VBZ a_DT potent_JJ inducer_NN of_IN AP-1_NNP ,_, NF-kappa_NNP B_NNP ,_, and_CC tumor_NN necrosis_NN factor-alpha_NN in_IN human_JJ B_NNP lymphocytes_`` ._.
Treatment_NNP of_IN human_JJ B_NNP lymphocytes_`` with_IN an_DT optimal_JJ concentration_NN of_IN okadaic_JJ acid_NN ,_, an_DT inhibitor_`` of_IN phosphatases_NNS 1_CD and_CC 2A_NNP ,_, resulted_VBD in_IN the_DT induction_NN of_IN the_DT transcription_NN factor_NN ,_, AP-1_NNP and_CC a_DT marked_JJ increase_NN in_IN NF-kappa_NNP B_NNP levels_NNS ._.
In_IN contrast_NN ,_, no_DT effect_NN on_IN the_DT levels_NNS of_IN the_DT octamer_`` binding_`` proteins_NNS ,_, Oct-1_-RRB- or_CC Oct-2_-RRB- ,_, were_VBD found_VBN ._.
Since_IN both_DT AP-1_NNP and_CC NF-kappa_NNP B_NNP have_VBP been_VBN reported_VBN to_TO be_VB important_JJ in_IN the_DT induction_NN of_IN the_DT tumor_NN necrosis_NN factor-alpha_`` (_-LRB- TNF-alpha_NNP )_-RRB- gene_NN we_PRP examined_VBD the_DT effects_NNS of_IN okadaic_JJ acid_NN on_IN TNF-alpha_NNP mRNA_NNP levels_NNS ._.
Treatment_NNP with_IN okadaic_JJ acid_NN resulted_VBD in_IN a_DT striking_JJ increase_NN in_IN TNF-alpha_NNP mRNA_NNP transcripts_`` within_IN 1_CD h_NN of_IN stimulation_NN and_CC large_JJ amounts_NNS of_IN TNF-alpha_NNP were_VBD released_VBN into_IN the_DT culture_NN media_NNS ._.
Although_IN okadaic_JJ acid_NN provides_VBZ a_DT potent_JJ inductive_JJ signal_NN for_IN AP-1_NNP and_CC NF-kappa_NNP B_NNP it_PRP did_VBD not_RB induce_VB either_DT B_NNP cell_NN proliferation_NN or_CC immunoglobulin_NN secretion_NN ._.
A_DT novel_JJ Ets-related_NNP transcription_`` factor_NN ,_, Elf-1_NNP ,_, binds_'' to_TO human_JJ immunodeficiency_NN virus_NN type_NN 2_CD regulatory_JJ elements_NNS that_WDT are_VBP required_VBN for_IN inducible_JJ trans_`` activation_NN in_IN T_JJ cells_NNS ._.
Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_-LRB- HIV-1_NN )_-RRB- and_CC HIV-2_`` are_VBP structurally_RB related_VBN retroviruses_NNS which_WDT both_DT cause_VB AIDS_NNP in_IN humans_NNS ._.
Although_IN both_DT viruses_NNS establish_VBP latency_NN in_IN quiescent_JJ human-peripheral-blood_`` T_JJ cells_NNS ,_, the_DT asymptomatic_JJ phase_NN of_IN HIV-2_JJ infection_NN may_MD be_VB more_JJR prolonged_VBN than_IN that_IN of_IN HIV-1_NNP ._.
The_DT latent_JJ phases_NNS of_IN both_DT HIV-1_NNP and_CC HIV-2_`` infection_NN have_VBP been_VBN shown_VBN to_TO be_VB disrupted_VBN by_IN T-cell_NNP activation_NN ,_, a_DT process_NN that_WDT requires_VBZ host_NN cell_NN transcription_NN factors_NNS ._.
In_IN the_DT case_NN of_IN HIV-1_`` ,_, the_DT transcription_NN factor_NN NF-kappa_NNP B_NNP is_VBZ sufficient_JJ for_IN inducible_`` transcriptional_JJ activation_NN ._.
In_IN contrast_NN ,_, factors_NNS in_IN addition_NN to_TO NF-kappa_NNP B_NNP are_VBP required_VBN to_TO activate_VB HIV-2_`` transcription_NN in_IN infected_JJ T_JJ cells_NNS ._.
In_IN this_DT report_NN ,_, we_PRP demonstrate_VBP that_IN a_DT novel_JJ Ets-related_NNP transcription_`` factor_NN ,_, Elf-1_NNP ,_, binds_VBZ specifically_RB to_TO two_CD purine-rich_JJ motifs_NNS in_IN the_DT HIV-2_`` enhancer_NN ._.
Mutagenesis_WP$ experiments_NNS demonstrated_VBD that_IN these_DT Elf-1_NNP binding_# sites_NNS are_VBP required_VBN for_IN induction_NN of_IN HIV-2_`` transcription_NN following_VBG T-cell-receptor-mediated_`` T-cell_JJ activation_NN ._.
Moreover_RB ,_, Elf-1_'' is_VBZ the_DT only_JJ factor_NN present_NN in_IN activated_`` T-cell_JJ nuclear_JJ extracts_NNS that_WDT binds_VBZ to_TO these_DT sites_NNS in_IN electrophoretic_`` mobility_JJ shift_NN assays_NNS ._.
Thus_RB ,_, Elf-1_'' is_VBZ a_DT novel_JJ transcription_NN factor_NN that_WDT appears_VBZ to_TO be_VB required_VBN for_IN the_DT T-cell-receptor-mediated_`` trans_`` activation_NN of_IN HIV-2_JJ gene_NN expression_NN ._.
These_DT results_NNS may_MD explain_VB differences_NNS in_IN the_DT clinical_JJ spectra_NN of_IN diseases_NNS caused_VBN by_IN HIV-1_NNP and_CC HIV-2_`` and_CC may_MD also_RB have_VB implications_NNS for_IN the_DT design_NN of_IN therapeutic_JJ approaches_NNS to_TO HIV-2_CD infection_NN ._.
Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD Nef_NNP protein_NN inhibits_`` NF-kappa_-RRB- B_NNP induction_NN in_IN human_JJ T_JJ cells_NNS ._.
Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_-LRB- HIV-1_NNP )_-RRB- can_MD establish_VB a_DT persistent_JJ and_CC latent_JJ infection_NN in_IN CD4+_`` T_JJ lymphocytes_NNS (_-LRB- W.C.Greene_NNP ,_, N.Engl.J._NNP Med.324_NNP :_: 308-317_CD ,_, 1991_CD ;_: S.M.Schnittman_NNP ,_, M.C.Psallidopoulos_NNP ,_, H.C._NNP Lane_NNP ,_, L.Thompson_NNP ,_, M.Baseler_NNP ,_, F.Massari_NNP ,_, C.H.Fox_NNP ,_, N.P.Salzman_NNP ,_, and_CC A.S.Fauci_NNP ,_, Science_NNP 245_CD :_: 305-308_CD ,_, 1989_CD )_-RRB- ._.
Production_NN of_IN HIV-1_NNP from_IN latently_RB infected_JJ cells_NNS requires_VBZ host_NN cell_NN activation_NN by_IN T-cell_NNP mitogens_`` (_-LRB- T.Folks_NNS ,_, D.M.Powell_NNP ,_, M.M.Lightfoote_NNP ,_, S.Benn_NNP ,_, M.A._NNP Martin_NNP ,_, and_CC A.S.Fauci_NNP ,_, Science_NNP 231_CD :_: 600-602_CD ,_, 1986_CD ;_: D.Zagury_`` ,_, J._NNP Bernard_NNP ,_, R.Leonard_NNP ,_, R.Cheynier_NNP ,_, M.Feldman_NNP ,_, P.S.Sarin_NNP ,_, and_CC R.C._NNP Gallo_NNP ,_, Science_NNP 231_CD :_: 850-853_CD ,_, 1986_CD )_-RRB- ._.
This_DT activation_NN is_VBZ mediated_VBN by_IN the_DT host_NN transcription_NN factor_NN NF-kappa_NNP B_NNP (_-LRB- G.Nabel_NNP and_CC D.Baltimore_NNP ,_, Nature_NNP (_-LRB- London_NNP )_-RRB- 326_CD :_: 711-717_CD ,_, 1987_CD )_-RRB- ._.
We_PRP report_VBP here_RB that_IN the_DT HIV-1-encoded_JJ Nef_NNP protein_NN inhibits_VBZ the_DT induction_NN of_IN NF-kappa_NNP B_NNP DNA-binding_`` activity_NN by_IN T-cell_JJ mitogens_NNS ._.
However_RB ,_, Nef_'' does_VBZ not_RB affect_VB the_DT DNA-binding_`` activity_NN of_IN other_JJ transcription_NN factors_NNS implicated_VBN in_IN HIV-1_`` regulation_NN ,_, including_VBG SP-1_NNP ,_, USF_NNP ,_, URS_'' ,_, and_CC NF-AT_RB ._.
Additionally_RB ,_, Nef_'' inhibits_VBZ the_DT induction_NN of_IN HIV-1-_`` and_CC interleukin_`` 2-directed_JJ gene_NN expression_NN ,_, and_CC the_DT effect_NN on_IN HIV-1_NNP transcription_NN depends_VBZ on_IN an_DT intact_JJ NF-kappa_NNP B-binding_NNP site_NN ._.
These_DT results_NNS indicate_VBP that_IN defective_JJ recruitment_NN of_IN NF-kappa_NNP B_NNP may_MD underlie_VB Nef_NNP 's_POS negative_JJ transcriptional_JJ effects_NNS on_IN the_DT HIV-1_NNP and_CC interleukin_`` 2_CD promoters_NNS ._.
Further_JJ evidence_NN suggests_VBZ that_IN Nef_`` inhibits_NNS NF-kappa_WP$ B_NNP induction_NN by_IN interfering_VBG with_IN a_DT signal_NN derived_VBN from_IN the_DT T-cell_`` receptor_NN complex_NN ._.
(_-LRB- Effect_NN of_IN antihypertensive_JJ therapy_NN with_IN captopril_NN on_IN gluco-_NN and_CC mineralocorticoid_JJ receptors_NNS of_IN peripheral_JJ blood_NN lymphocytes_NNS in_IN hypertensive_JJ patients_NNS of_IN various_JJ age_NN )_-RRB-
Binding_# of_IN 3H-dexamethasone_NNP and_CC 3H-aldosterone_NNP by_IN peripheral_`` lymphocyte_`` receptors_NNS was_VBD investigated_VBN in_IN healthy_JJ persons_NNS and_CC hypertensive_JJ patients_NNS before_IN and_CC after_IN 2-week_JJ captopril_NN treatment_NN ._.
The_DT number_NN of_IN glucocorticoid_JJ and_CC mineralocorticoid_JJ binding_`` sites_NNS was_VBD increased_VBN in_IN hypertensives_`` vs_`` normotensives_NNS ._.
The_DT treatment_NN with_IN the_DT ACE_NNP inhibitor_`` captopril_NN led_VBD to_TO activation_`` of_IN hormone-receptor_NN interactions_NNS ._.
There_EX was_VBD a_DT more_RBR marked_JJ rise_NN of_IN the_DT number_NN of_IN receptors_NNS in_IN middle-aged_JJ (_-LRB- 44-55_`` years_NNS )_-RRB- hypertensives_VBZ vs_`` elderly_JJ (_-LRB- 61-80_JJ years_NNS )_-RRB- subjects_VBZ after_IN captopril_NN treatment_NN ._.
Leukotriene_NNP B4_NNP transcriptionally_RB activates_VBZ interleukin-6_JJ expression_NN involving_VBG NK-chi_NNP B_NNP and_CC NF-IL6_NNP ._.
Leukotriene_NNP B4_NNP (_-LRB- LTB4_NNP )_-RRB- is_VBZ a_DT notable_JJ participant_NN in_IN inflammation_NN and_CC chemotaxis_`` ._.
It_PRP is_VBZ ,_, however_RB ,_, still_RB unclear_JJ whether_IN LTB4_-RRB- acts_VBZ in_IN this_DT regard_NN directly_RB or_CC indirectly_RB by_IN stimulating_VBG the_DT release_NN of_IN chemotactic_`` and_CC inflammatory_JJ cytokines_NNS ._.
Here_RB we_PRP report_VBP that_IN LTB4_NNP induces_VBZ synthesis_NN of_IN interleukin_# (_-LRB- IL_NNP )_-RRB- -6_NN by_IN human_JJ blood_NN monocytes_`` through_IN transcriptional_JJ activation_NN of_IN the_DT IL-6_`` gene_NN ._.
We_PRP furthermore_`` demonstrate_VBP that_IN this_DT process_NN involves_VBZ activation_NN of_IN the_DT transcription_NN factor_NN NF-chi_NNP B_NNP and_CC ,_, to_TO a_DT lesser_JJR extent_NN ,_, of_IN NF-IL6_NNP ,_, while_IN the_DT activity_NN of_IN the_DT transcription_NN factor_NN AP-1_`` ,_, shown_VBN to_TO otherwise_RB confer_`` IL-6_`` inducibility_NN ,_, appeared_VBD to_TO be_VB unaffected_JJ by_IN LTB4_NNP ._.
Involvement_NN of_IN NF-chi_NNP B_NNP and_CC NF-IL6_NNP in_IN induction_NN of_IN IL-6_`` transcription_NN by_IN monocytes_NNS was_VBD demonstrated_VBN using_VBG deleted_VBN forms_NNS of_IN the_DT IL-6_NN promoter_NN ._.
Activation_NN of_IN the_DT IL-6_`` promoter_NN by_IN LTB4_NNP was_VBD not_RB only_RB associated_VBN with_IN accumulation_NN of_IN the_DT respective_JJ transcripts_NNS but_CC resulted_VBD in_IN synthesis_NN of_IN functional_JJ IL-6_-RRB- protein_NN as_RB well_RB ._.
In_IN addition_NN ,_, LTB4_NNP mediated_VBD transactivation_NN of_IN a_DT heterologous_`` promoter_NN construct_VB containing_VBG the_DT NF-chi_NNP B_NNP or_CC the_DT NF-IL6_`` enhancer_NN ,_, but_CC not_RB the_DT AP-1_NNP enhancer_NN ._.
The_DT signaling_VBG events_NNS mediating_VBG this_DT effect_NN appeared_VBD to_TO involve_VB the_DT release_NN of_IN H2O2_NNP ,_, since_IN LTB4_NNP failed_VBD to_TO induce_VB NF-chi_NNP B_NNP or_CC NF-IL6_NNP in_IN the_DT presence_NN of_IN the_DT scavenger_NN of_IN H2O2_NNP ,_, N-acetyl-L-cysteine_NNP ._.
Estrogen_-LRB- binding_`` sites_NNS in_IN peripheral_JJ blood_NN monocytes_NNS and_CC effects_NNS of_IN danazol_NN on_IN their_PRP$ sites_NNS in_IN vitro_NN ._.
1_LS ._. This_DT study_NN was_VBD designed_VBN to_TO investigate_VB the_DT presence_NN of_IN estrogen_NN type_NN I_PRP (_-LRB- high_JJ affinity_NN ,_, low_JJ capacity_NN )_-RRB- and_CC type_NN II_NNP (_-LRB- low_JJ affinity_NN ,_, high_JJ capacity_NN )_-RRB- binding_VBG sites_NNS in_IN human_JJ peripheral_JJ blood_NN monocytes_NNS and_CC the_DT effects_NNS of_IN danazol_`` on_IN these_DT sites_NNS ._.
2_LS ._. These_DT two_CD types_NNS of_IN estrogen_NN binding_# sites_NNS existed_VBD in_IN human_JJ peripheral_JJ blood_NN monocytes_NNS ._.
3_LS ._. Danazol_`` bound_VBN to_TO these_DT sites_NNS in_IN high_JJ concentration_NN (_-LRB- 10(-6)_JJ M_NNP ,_, clinical_JJ serum_NN concentration_NN during_IN danazol_JJ therapy_NN )_-RRB- and_CC decreased_VBD the_DT number_NN of_IN both_DT sites_NNS ._.
4_LS ._. It_PRP is_VBZ suggested_VBN that_IN danazol_# has_VBZ an_DT anti-estrogenic_JJ action_NN to_TO the_DT monocytes_`` through_IN the_DT competition_NN and_CC suppression_NN of_IN estrogen_`` binding_`` sites_NNS as_RB seen_VBN in_IN the_DT estrogen_NN target_NN organ_NN ._.
(_-LRB- Mechanism_NN of_IN action_NN of_IN steroid_`` hormones_NNS ._. I_PRP ._. Estrogens_'' )_-RRB-
The_DT steroid_NN hormone_NN are_VBP very_RB versatile_`` molecules_NNS :_: although_IN they_PRP are_VBP related_VBN among_IN them_PRP by_IN their_PRP$ chemical_NN structure_NN ,_, they_PRP have_VBP very_RB diverse_JJ functions_NNS and_CC including_VBG antagonic_NN ._.
Their_PRP$ action_NN mechanism_NN is_VBZ not_RB completely_RB cleared_VBN ._.
The_DT estrogens_`` participate_VB in_IN the_DT regulation_NN of_IN practically_RB all_PDT the_DT reproductive_JJ and_CC sexual_JJ events_NNS of_IN the_DT female_NN ,_, although_IN the_DT intracellular_JJ actions_NNS by_IN which_WDT they_PRP take_VBP place_NN are_VBP not_RB well_RB known_VBN and_CC the_DT proposed_VBN models_NNS do_VBP not_RB adequately_RB satisfy_VB the_DT questions_NNS ._.
Currently_RB it_PRP is_VBZ accepted_VBN the_DT existence_NN of_IN a_DT cytoplasmic_JJ and/or_CC nuclear_JJ receptor_NN ,_, without_IN explaining_VBG satisfactorily_RB how_WRB the_DT hormones_NNS come_VBP to_TO the_DT nucleus_`` ._.
The_DT endocrine_`` events_NNS that_WDT are_VBP rapidly_RB expressed_VBN (_-LRB- seconds_NNS )_-RRB- are_VBP due_JJ to_TO a_DT possible_JJ interaction_NN with_IN cellular_JJ membrane_NN ._.
The_DT purpose_NN of_IN this_DT review_NN is_VBZ to_TO analyze_VB and_CC concilliate_VB the_DT reported_VBN data_NNS on_IN the_DT mechanism_NN of_IN action_NN of_IN estrogens_NNS ._.
Stable_JJ expression_NN of_IN transdominant_JJ Rev_NNP protein_NN in_IN human_JJ T_`` cells_NNS inhibits_NNS human_JJ immunodeficiency_NN virus_NN replication_NN ._.
The_DT human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV_NNP )_-RRB- Rev_NNP protein_NN is_VBZ essential_JJ for_IN viral_JJ structural_JJ protein_NN expression_NN (_-LRB- Gag_NNP ,_, Pol_NNP ,_, and_CC Env_NNP )_-RRB- and_CC ,_, hence_RB ,_, for_IN viral_JJ replication_NN ._.
In_IN transient_JJ transfection_NN assays_`` ,_, mutant_JJ forms_NNS of_IN Rev_NNP have_VBP been_VBN identified_VBN that_IN inhibit_VBP wild-type_JJ Rev_NNP activity_NN and_CC therefore_RB suppress_`` viral_JJ replication_NN ._.
To_TO determine_VB whether_IN such_JJ transdominant_JJ Rev_NNP proteins_NNS could_MD provide_VB long-term_JJ protection_NN against_IN HIV_NNP infection_NN without_IN affecting_VBG T_JJ cell_NN function_NN ,_, T_'' leukemia_`` cell_NN lines_NNS were_VBD stably_RB transduced_VBN with_IN a_DT retroviral_NN vector_NN encoding_VBG a_DT transdominant_JJ mutant_`` of_IN the_DT Rev_NNP protein_NN ,_, M10_NNP ._.
While_IN all_PDT the_DT M10-expressing_JJ cell_NN lines_NNS remained_VBD infectable_JJ by_IN HIV-1_# ,_, these_DT same_JJ cells_NNS failed_VBD to_TO support_VB a_DT productive_JJ replication_`` cycle_NN when_WRB infected_VBN with_IN a_DT cloned_`` isolate_`` of_IN HIV-1_NN ._.
In_IN addition_NN ,_, two_CD out_IN of_IN three_CD M10-expressing_`` CEM_`` clones_NNS were_VBD also_RB resistant_`` to_TO highly_RB productive_JJ infection_NN by_IN a_DT heterogeneous_JJ HIV-1_NNP pool_NN ._.
Expression_NN of_IN M10_NNP did_VBD not_RB affect_VB induction_NN of_IN HIV_NNP transcription_`` mediated_`` by_IN the_DT kappa_`` B_NNP regulatory_JJ element_NN or_CC Tat_NNP ._.
Importantly_RB ,_, constitutive_JJ expression_NN of_IN Rev_NNP M10_NNP did_VBD not_RB alter_VB the_DT secretion_NN of_IN interleukin_NN 2_CD in_IN response_NN to_TO mitogen_NN stimulation_NN of_IN EL-4_-RRB- and_CC Jurkat_NNP cells_NNS ._.
The_DT inhibition_NN of_IN HIV_`` infection_NN in_IN cells_NNS stably_RB expressing_VBG a_DT transdominant_JJ Rev_NNP protein_NN ,_, in_IN the_DT absence_NN of_IN any_DT deleterious_JJ effect_NN on_IN T_JJ cell_NN function_NN ,_, suggests_VBZ that_IN such_PDT a_DT strategy_NN could_MD provide_VB a_DT therapeutic_JJ effect_NN in_IN the_DT T_JJ lymphocytes_NNS of_IN acquired_VBN immunodeficiency_NN syndrome_NN patients_NNS ._.
Glucocorticoid_JJ receptor_NN in_IN patients_NNS with_IN lupus_`` nephritis_NN :_: relationship_NN between_IN receptor_NN levels_NNS in_IN mononuclear_`` leukocytes_NNS and_CC effect_NN of_IN glucocorticoid_JJ therapy_NN ._.
We_PRP investigated_VBD the_DT clinical_JJ significance_NN of_IN glucocorticoid_JJ receptor_NN determination_NN in_IN 20_CD patients_NNS with_IN systemic_JJ lupus_NN erythematosus_`` (_-LRB- SLE_NNP )_-RRB- who_WP afterwards_RB developed_VBD nephrotic_JJ syndrome_NN ._.
Glucocorticoid_JJ receptor_NN concentrations_NNS in_IN mononuclear_JJ leukocytes_NNS (_-LRB- MNL_NNP )_-RRB- in_IN these_DT patients_NNS were_VBD comparable_JJ with_IN those_DT in_IN both_DT other_JJ patients_NNS with_IN SLE_NNP and_CC healthy_JJ persons_NNS ._.
Improvement_NN in_IN urinary_JJ protein_NN excretion_NN and_CC in_IN disease_NN activity_NN ,_, which_WDT was_VBD scored_VBN according_VBG to_TO the_DT SLE_NNP Disease_NNP Activity_NNP Index_NNP system_NN of_IN the_DT University_NNP of_IN Toronto_NNP ,_, closely_RB related_VBN to_TO the_DT glucocorticoid_NN receptor_NN concentrations_NNS in_IN MNL_NNP isolated_VBD from_IN the_DT corresponding_JJ patients_NNS ._.
In_IN summary_NN ,_, glucocorticoid_JJ receptor_NN determination_NN in_IN patients_NNS with_IN lupus_`` nephritis_NN may_MD be_VB a_DT predictive_JJ clue_NN for_IN assessing_VBG responsiveness_NN to_TO glucocorticoid_JJ therapy_NN ._.
Selection_NN of_IN optimal_JJ kappa_NN B/Rel_NNP DNA-binding_NNP motifs_`` :_: interaction_NN of_IN both_DT subunits_NNS of_IN NF-kappa_NNP B_NNP with_IN DNA_NNP is_VBZ required_VBN for_IN transcriptional_JJ activation_NN ._.
Analysis_NN of_IN the_DT p50_NN and_CC p65_NN subunits_NNS of_IN the_DT NF-kappa_NNP B_NNP transcription_`` factor_NN complex_NN has_VBZ revealed_VBN that_IN both_DT proteins_NNS can_MD interact_`` with_IN related_JJ DNA_NNP sequences_`` through_IN either_DT homo-_`` or_CC heterodimer_`` formation_NN ._.
In_IN addition_NN ,_, the_DT product_NN of_IN the_DT proto-oncogene_NN c-rel_`` can_MD bind_NN to_TO similar_JJ DNA_NNP motifs_`` by_IN itself_PRP or_CC as_IN a_DT heterodimer_NN with_IN p50_CD or_CC p65_CD ._.
However_RB ,_, these_DT studies_NNS have_VBP used_VBN a_DT limited_JJ number_NN of_IN known_VBN kappa_NN B_NNP DNA_NNP motifs_`` ,_, and_CC the_DT question_NN of_IN the_DT optimal_JJ DNA_NNP sequences_NNS preferred_VBN by_IN each_DT homodimer_NN has_VBZ not_RB been_VBN addressed_VBN ._.
Using_VBG purified_JJ recombinant_`` p50_CD ,_, p65_CD ,_, and_CC c-Rel_NNP proteins_VBZ ,_, optimal_JJ DNA-binding_`` motifs_NNS were_VBD selected_VBN from_IN a_DT pool_NN of_IN random_JJ oligonucleotides_NNS ._.
Alignment_NN of_IN the_DT selected_VBN sequences_NNS allowed_VBD us_PRP to_TO predict_VB a_DT consensus_NN sequence_NN for_IN binding_'' of_IN the_DT individual_JJ homodimeric_JJ Rel-related_JJ proteins_NNS ,_, and_CC DNA-protein_NNP binding_JJ analysis_NN of_IN the_DT selected_VBN DNA_NNP sequences_NNS revealed_VBD sequence_NN specificity_NN of_IN the_DT proteins_NNS ._.
Contrary_JJ to_TO previous_JJ assumptions_NNS ,_, we_PRP observed_VBD that_IN p65_CD homodimers_NNS can_MD interact_VB with_IN a_DT subset_`` of_IN DNA_NNP sequences_`` not_RB recognized_VBN by_IN p50_CD homodimers_NNS ._.
Differential_JJ binding_`` affinities_NNS were_VBD also_RB obtained_VBN with_IN p50-_JJ and_CC c-Rel-selected_JJ sequences_NNS ._.
Using_VBG either_CC a_DT p50-_NN or_CC p65-selected_JJ kappa_NN B_NNP motif_NN ,_, which_WDT displayed_VBD differential_JJ binding_NN with_IN respect_NN to_TO the_DT other_JJ protein_NN ,_, little_JJ to_TO no_DT binding_NN was_VBD observed_VBN with_IN the_DT heterodimeric_JJ NF-kappa_NNP B_NNP complex_NN ._.
Similarly_RB ,_, in_IN transfection_NN experiments_NNS in_IN which_WDT the_DT selective_JJ kappa_NN B_NNP binding_`` sites_NNS were_VBD used_VBN to_TO drive_VB the_DT expression_NN of_IN a_DT chloramphenicol_NN acetyltransferase_`` reporter_NN construct_VB ,_, the_DT p65-_JJ and_CC p50-selected_JJ motifs_NNS were_VBD activated_`` only_RB in_IN the_DT presence_NN of_IN p65_CD and_CC p50/65_CD (_-LRB- a_DT chimeric_JJ protein_NN with_IN the_DT p50_CD DNA_NNP binding_`` domain_NN and_CC p65_`` activation_NN domain_NN )_-RRB- expression_NN vectors_NNS ,_, respectively_RB ,_, and_CC neither_DT demonstrated_VBD a_DT significant_JJ response_NN to_TO stimuli_`` that_DT induce_VB NF-kappa_NNP B_NNP activity_NN ._.
These_DT findings_NNS demonstrate_VBP that_IN interaction_NN of_IN both_DT subunits_NNS of_IN the_DT heterodimeric_JJ NF-kappa_NNP B_NNP complex_JJ with_IN DNA_NNP is_VBZ required_VBN for_IN DNA_NNP binding_`` and_CC transcriptional_JJ activation_NN and_CC suggest_VB that_IN transcriptional_JJ activation_NN mediated_VBN by_IN the_DT individual_JJ rel-related_JJ proteins_NNS will_MD differ_VB dramatically_RB ,_, depending_VBG on_IN the_DT specific_JJ kappa_`` B_NNP motifs_`` present_RB ._.
Characterization_NN of_IN a_DT new_JJ tissue-specific_JJ transcription_NN factor_NN binding_VBG to_TO the_DT simian_`` virus_NN 40_CD enhancer_NN TC-II_`` (_-LRB- NF-kappa_NNP B_NNP )_-RRB- element_NN ._.
We_PRP have_VBP biochemically_RB and_CC functionally_RB characterized_VBD a_DT new_JJ transcription_NN factor_NN ,_, NP-TCII_NNP ,_, which_WDT is_VBZ present_JJ in_IN nuclei_`` from_IN unstimulated_JJ T_CD and_CC B_NNP lymphocytes_NNS but_CC is_VBZ not_RB found_VBN in_IN nonhematopoietic_JJ cells_NNS ._.
This_DT factor_NN has_VBZ a_DT DNA-binding_`` specificity_NN similar_JJ to_TO that_IN of_IN NF-kappa_NNP B_NNP but_CC is_VBZ unrelated_JJ to_TO this_DT or_CC other_JJ Rel_`` proteins_NNS by_IN functional_JJ and_CC biochemical_JJ criteria_NNS ._.
It_PRP can_MD also_RB be_VB distinguished_VBN from_IN other_JJ previously_RB described_VBN lymphocyte-specific_JJ DNA-binding_`` proteins_NNS ._.
The_DT candidate_NN oncoprotein_NN Bcl-3_NN is_VBZ an_DT antagonist_NN of_IN p50/NF-kappa_NN B-mediated_# inhibition_NN ._.
The_DT candidate_NN oncogene_`` bcl-3_NN was_VBD discovered_VBN as_IN a_DT translocation_NN into_IN the_DT immunoglobulin_`` alpha-locus_NN in_IN some_DT cases_NNS of_IN B-cell_NNP chronic_JJ lymphocytic_`` leukaemias_NNS ._.
The_DT protein_NN Bcl-3_`` contains_VBZ seven_CD so-called_JJ ankyrin_`` repeats_NNS ._.
Similar_JJ repeat_NN motifs_NNS are_VBP found_VBN in_IN a_DT number_NN of_IN diverse_JJ regulatory_JJ proteins_NNS but_CC the_DT motifs_`` of_IN Bcl-3_NN are_VBP most_RBS closely_RB related_VBN to_TO those_DT found_VBN in_IN I_PRP kappa_`` B_NNP proteins_VBZ in_IN which_WDT the_DT ankyrin_`` repeat_NN domain_NN is_VBZ thought_VBN to_TO be_VB directly_RB involved_VBN in_IN inhibition_NN of_IN NF-kappa_NNP B_NNP activity_NN ._.
No_DT biological_JJ function_NN has_VBZ yet_RB been_VBN described_VBN for_IN Bcl-3_NN ,_, but_CC it_PRP was_VBD noted_VBN recently_RB that_IN Bcl-3_JJ interferes_NNS with_IN DNA-binding_-RRB- of_IN the_DT p50_`` subunit_NN of_IN NF-kappa_NNP B_NNP in_IN vitro_NN ._.
Here_RB we_PRP demonstrate_VBP that_IN Bcl-3_NNP can_MD aid_VB kappa_`` B_NNP site-dependent_`` transcription_NN in_IN vivo_`` by_IN counteracting_VBG the_DT inhibitory_JJ effects_NNS of_IN p50/NF-kappa_NN B_NNP homodimers_NNS ._.
Bcl-3_NN may_MD therefore_RB aid_VB activation_NN of_IN select_JJ NF-kappa_NNP B-regulated_NNP genes_NNS ,_, including_VBG those_DT of_IN the_DT human_JJ immunodeficiency_NN virus_NN ._.
A_DT microtitre_JJ assay_NN system_NN for_IN glucocorticoid_JJ receptors_NNS :_: decreased_VBN receptor_NN concentration_NN in_IN myocardial_JJ infarction_NN ._.
A_DT major_JJ difficulty_NN in_IN determination_NN of_IN glucocorticoid_JJ receptor_NN sites_NNS is_VBZ the_DT very_RB complicated_JJ assay_NN procedure_NN ._.
Therefore_RB ,_, we_PRP describe_VBP a_DT microtitre_`` assay_NN system_NN for_IN glucocorticoid_JJ receptors_NNS which_WDT is_VBZ a_DT whole-cell_JJ competitive_JJ binding_`` radioassay_NN using_VBG (3H)-dexamethasone_-LRB- as_IN radioligand_NN ._.
This_DT modification_NN of_IN a_DT previously_RB described_VBN protocol_NN simplifies_NNS and_CC reduces_VBZ laboratory_NN work_NN and_CC allows_VBZ assay_NN reproducibility_NN to_TO be_VB controlled_VBN more_JJR reliably_RB ._.
Thus_RB enabled_VBN to_TO perform_VB the_DT test_NN on_IN multiple_JJ blood_NN samples_NNS in_IN parallel_RB ,_, we_PRP investigated_VBD cardiac_JJ infarction_NN patients_NNS over_IN a_DT 12-day_JJ period_NN to_TO test_NN if_IN glucocorticoid_NN receptor_NN binding_NN is_VBZ altered_VBN in_IN this_DT '_'' stressful_`` '_'' disease_NN ._.
On_IN the_DT first_JJ day_NN of_IN the_DT disease_NN ,_, glucocorticoid_NN receptor_NN capacity_NN was_VBD significantly_RB decreased_VBN without_IN alteration_NN of_IN the_DT receptor-ligand_`` affinity_NN ,_, whereas_IN on_IN days_NNS 4_CD and_CC 12_CD the_DT number_NN of_IN receptor_NN sites_NNS was_VBD normal_JJ again_RB ._.
This_DT result_NN fits_VBZ well_RB into_IN the_DT general_JJ observation_NN of_IN stress-induced_JJ down-regulation_NN of_IN immune_JJ responses_NNS ._.
Regulation_NN of_IN c-jun_JJ expression_NN during_IN induction_NN of_IN monocytic_JJ differentiation_NN by_IN okadaic_JJ acid_NN ._.
The_DT present_JJ work_NN has_VBZ examined_VBN the_DT effects_NNS of_IN okadaic_JJ acid_NN ,_, an_DT inhibitor_NN of_IN type_NN 1_CD and_CC 2A_`` protein_NN phosphatases_NNS ,_, on_IN the_DT regulation_NN of_IN c-jun_JJ expression_NN during_IN monocytic_JJ differentiation_NN of_IN U-937_CD leukemia_NN cells_NNS ._.
The_DT results_NNS demonstrate_VBP that_IN okadaic_JJ acid_NN treatment_NN is_VBZ associated_VBN with_IN induction_NN of_IN a_DT differentiated_`` monocyte_`` phenotype_`` characterized_VBN by_IN :_: (_-LRB- a_DT )_-RRB- growth_NN arrest_NN ;_: (_-LRB- b_NN )_-RRB- increases_VBZ in_IN Mac-1_NNP cell_NN surface_NN antigen_JJ expression_NN ;_: (_-LRB- c_NN )_-RRB- down-regulation_NN of_IN c-myc_`` transcripts_NNS ;_: and_CC (_-LRB- d_NN )_-RRB- induction_NN of_IN tumor_NN necrosis_`` factor_NN gene_NN expression_NN ._.
This_DT induction_NN of_IN monocytic_JJ differentiation_NN was_VBD associated_VBN with_IN transient_NN increases_NNS in_IN c-jun_`` mRNA_`` levels_NNS ,_, which_WDT were_VBD maximal_`` at_IN 6_CD h_NN ._.
Similar_JJ effects_NNS were_VBD obtained_VBN for_IN the_DT c-fos_`` gene_NN ._.
Run-on_JJ analysis_NN demonstrated_VBN detectable_JJ levels_NNS of_IN c-jun_JJ transcription_NN in_IN U-937_CD cells_NNS and_CC that_IN this_DT rate_NN is_VBZ increased_VBN approximately_RB 40-fold_`` following_VBG okadaic_JJ acid_JJ exposure_NN ._.
c-jun_JJ mRNA_`` levels_NNS were_VBD superinduced_VBN in_IN cells_NNS treated_VBN with_IN both_DT okadaic_JJ acid_NN and_CC cycloheximide_NN ,_, whereas_IN inhibition_NN of_IN protein_NN synthesis_NN had_VBD little_RB ,_, if_IN any_DT ,_, effect_NN on_IN okadaic_JJ acid-induced_`` c-jun_JJ transcription_NN ._.
The_DT half-life_NN of_IN c-jun_`` mRNA_NNP was_VBD similar_JJ (_-LRB- 45-50_JJ min_NN )_-RRB- in_IN both_DT untreated_JJ and_CC okadaic_JJ acid-induced_`` cells_NNS ._.
In_IN contrast_NN ,_, treatment_NN with_IN both_DT okadaic_JJ acid_NN and_CC cycloheximide_NN was_VBD associated_VBN with_IN stabilization_`` (_-LRB- t_NN 1/2_CD =_SYM 90_CD min_NN )_-RRB- of_IN c-jun_`` transcripts_NNS ._.
Taken_VBN together_RB ,_, these_DT findings_NNS indicate_VBP that_IN the_DT induction_NN of_IN c-jun_JJ transcription_NN by_IN okadaic_JJ acid_NN is_VBZ controlled_VBN primarily_RB by_IN a_DT transcriptional_JJ mechanism_NN ._.
Since_IN previous_JJ studies_NNS have_VBP demonstrated_VBN that_IN the_DT c-jun_JJ gene_NN is_VBZ autoinduced_VBN by_IN Jun/AP-1_`` ,_, we_PRP also_RB studied_VBD transcription_NN of_IN c-jun_`` promoter_NN (_-LRB- positions_NNS -132/+170_`` )_-RRB- -reporter_JJ gene_NN constructs_`` with_IN and_CC without_IN a_DT mutated_`` AP-1_`` element_NN ._.
(_-LRB- ABSTRACT_`` TRUNCATED_JJ AT_`` 250_CD WORDS_NNS )_-RRB-
Activation_NN of_IN NF-kappa_NNP B_NNP by_IN interleukin_VBG 2_CD in_IN human_JJ blood_NN monocytes_NNS ._.
We_PRP report_VBP here_RB that_IN interleukin_NN 2_CD (_-LRB- IL-2_NN )_-RRB- acts_VBZ on_IN human_JJ blood_NN monocytes_`` by_IN enhancing_VBG binding_JJ activity_NN of_IN the_DT transcription_NN factor_NN NF-kappa_NNP B_NNP to_TO its_PRP$ consensus_NN sequence_NN in_IN the_DT 5'_JJ regulatory_JJ enhancer_`` region_NN of_IN the_DT IL-2_`` receptor_NN alpha_NN chain_NN (_-LRB- p55_CD )_-RRB- ._.
Similarly_RB ,_, IL-2_-LRB- activates_NNS NF-kappa_# B_NNP in_IN the_DT human_JJ monocytic_JJ cell_NN line_NN U_NNP 937_CD ,_, but_CC not_RB in_IN resting_VBG human_JJ T-cells_NNS ._.
This_DT effect_NN is_VBZ detectable_JJ within_IN 15_CD min_NN and_CC peaks_NNS 1_CD h_NN after_IN exposure_NN to_TO IL-2_`` ._.
Enhanced_NNP NF-kappa_NNP B_NNP binding_`` activity_NN is_VBZ followed_VBN by_IN functional_JJ activation_NN in_IN that_DT inducibility_NN of_IN the_DT IL-2_`` receptor_NN alpha_NN chain_NN is_VBZ mediated_VBN by_IN enhanced_JJ NF-kappa_NNP B_NNP binding_`` and_CC that_IN a_DT heterologous_`` promoter_NN containing_VBG the_DT NF-kappa_NNP B_NNP consensus_NN sequence_NN (_-LRB- -291_CD to_TO -245_CD )_-RRB- of_IN the_DT IL-2_`` receptor_NN alpha_NN chain_NN gene_NN is_VBZ activated_VBN ._.
In_IN addition_NN ,_, IL-2_'' is_VBZ capable_JJ of_IN increasing_VBG transcript_JJ levels_NNS of_IN the_DT p50_`` gene_NN coding_NN for_IN the_DT p50_`` subunit_NN of_IN the_DT NF-kappa_NNP B_NNP transcription_`` factor_NN ,_, whereas_IN mRNA_`` levels_NNS of_IN the_DT p65_NN NF-kappa_NNP B_NNP gene_NN remained_VBD unchanged_JJ ._.
Single_JJ point_NN estimation_NN of_IN glucocorticoid_JJ receptors_NNS in_IN lymphocytes_NNS of_IN normal_JJ subjects_NNS and_CC of_IN children_NNS under_IN long_JJ term_NN glucocorticoid_JJ treatment_NN ._.
A_DT single_JJ point_NN assay_NN of_IN glucocorticoid_JJ receptors_NNS (_-LRB- GR_NNP )_-RRB- in_IN human_JJ lymphocytes_NNS based_VBN on_IN the_DT measurement_NN of_IN specific_JJ dexamethasone_`` binding_`` has_VBZ been_VBN developed_VBN and_CC compared_VBN with_IN a_DT common_JJ multi-point_JJ Scatchard_NNP analysis_NN ._.
The_DT assay_NN conditions_NNS -_: concentration_NN of_IN the_DT ligand_NN 20_CD nmol/l_NN ,_, incubation_'' time_NN 2_CD h_NN and_CC the_DT cell_NN count_NN 2-6_`` mil._`` cells/tube_NN in_IN the_DT assay_NN volume_NN 0.25_CD ml_NN were_VBD found_VBN to_TO be_VB optimal_`` ._.
An_DT attempt_NN was_VBD also_RB undertaken_VBN to_TO use_VB a_DT cell_NN harvester_NN for_IN the_DT separation_NN of_IN cells_NNS from_IN unbound_JJ ligand_NN ._.
Though_RB specifically_RB bound_JJ dexamethasone_NN measured_VBN by_IN whole-cell_JJ assay_NN and_CC that_IN using_VBG cell_NN harvester_NN correlated_`` well_RB ,_, almost_RB by_IN one_CD order_NN lower_JJR values_NNS obtained_VBN with_IN the_DT latter_JJ method_NN render_`` it_PRP non-applicable_JJ for_IN receptor_NN quantitation_NN ._.
The_DT results_NNS from_IN 9_CD healthy_JJ volunteers_NNS (_-LRB- average_NN GR_NNP concentration_NN 7131_CD +/-_JJ 1256_CD sites/cell_NN )_-RRB- correlated_VBN excellently_RB with_IN those_DT obtained_VBN by_IN the_DT Scatchard_NNP analysis_NN ._.
The_DT single_JJ point_NN assay_NN has_VBZ been_VBN also_RB applied_VBN for_IN determination_NN of_IN GH_NNP in_IN 10_CD children_NNS treated_VBN with_IN large_JJ doses_NNS of_IN prednisone_NN ._.
The_DT average_JJ values_NNS from_IN healthy_JJ volunteers_NNS did_VBD not_RB differ_VB significantly_RB from_IN those_DT found_VBN in_IN these_DT children_NNS ,_, though_RB much_RB broader_JJR range_NN was_VBD found_VBN in_IN patients_NNS ._.
A_DT novel_NN B_NNP cell-derived_VBD coactivator_`` potentiates_`` the_DT activation_NN of_IN immunoglobulin_`` promoters_NNS by_IN octamer-binding_JJ transcription_NN factors_NNS ._.
A_DT novel_NN B_NNP cell-restricted_`` activity_NN ,_, required_VBN for_IN high_JJ levels_NNS of_IN octamer/Oct-dependent_JJ transcription_NN from_IN an_DT immunoglobulin_`` heavy_JJ chain_NN (_-LRB- IgH_NNP )_-RRB- promoter_NN ,_, was_VBD detected_VBN in_IN an_DT in_IN vitro_NN system_NN consisting_VBG of_IN HeLa_NNP cell-derived_JJ extracts_`` complemented_`` with_IN fractionated_`` B_NNP cell_NN nuclear_JJ proteins_NNS ._.
The_DT factor_NN responsible_JJ for_IN this_DT activity_NN was_VBD designated_VBN Oct_NNP coactivator_`` from_IN B_NNP cells_NNS (_-LRB- OCA-B_NNP )_-RRB- ._.
OCA-B_# stimulates_VBZ the_DT transcription_NN from_IN an_DT IgH_`` promoter_NN in_IN conjunction_NN with_IN either_DT Oct-1_NNP or_CC Oct-2_`` but_CC shows_VBZ no_DT significant_JJ effect_NN on_IN the_DT octamer/Oct-dependent_JJ transcription_NN of_IN the_DT ubiquitously_RB expressed_VBN histone_NN H2B_NN promoter_NN and_CC the_DT transcription_NN of_IN USF-_NNP and_CC Sp1-regulated_JJ promoters_NNS ._.
Taken_VBN together_RB ,_, our_PRP$ results_NNS suggest_VB that_IN OCA-B_NNP is_VBZ a_DT tissue-_NN ,_, promoter-_# ,_, and_CC factor-specific_JJ coactivator_NN and_CC that_DT OCA-B_NNP may_MD be_VB a_DT major_JJ determinant_NN for_IN B_NNP cell-specific_JJ activation_NN of_IN immunoglobulin_JJ promoters_NNS ._.
In_IN light_NN of_IN the_DT evidence_NN showing_VBG physical_JJ and_CC functional_JJ interactions_NNS between_IN Oct_NNP factors_NNS and_CC OCA-B_# ,_, we_PRP propose_VBP a_DT mechanism_NN of_IN action_NN for_IN OCA-B_NNP and_CC discuss_VB the_DT implications_NNS of_IN OCA-B_NNP for_IN the_DT transcriptional_JJ regulation_NN of_IN other_JJ tissue-specific_JJ promoters_NNS ._.
The_DT regulation_NN of_IN the_DT human_JJ tumor_NN necrosis_`` factor_NN alpha_NN promoter_NN region_NN in_IN macrophage_NN ,_, T_JJ cell_NN ,_, and_CC B_NNP cell_NN lines_NNS ._.
The_DT 1311-base_JJ pair_NN human_JJ tumor_NN necrosis_NN factor_NN (_-LRB- TNF_NNP )_-RRB- alpha_`` promoter_NN region_NN was_VBD fused_VBN to_TO the_DT luciferase_`` (_-LRB- Luc_NNP )_-RRB- reporter_NN gene_NN and_CC studied_VBN in_IN a_DT transient_JJ transfection_NN system_NN in_IN three_CD TNF_`` producing_VBG cell_NN lines_NNS ,_, the_DT U937_CD macrophage_`` cell_NN line_NN ,_, the_DT MLA_NNP 144_CD T_JJ cell_NN line_NN ,_, and_CC the_DT 729-6_`` B_NNP cell_NN line_NN ._.
This_DT full_JJ length_NN promoter_NN construct_VB can_MD be_VB induced_VBN by_IN phorbol_`` 13-myristate_JJ acetate_NN (_-LRB- PMA_NNP )_-RRB- in_IN each_DT of_IN these_DT cell_NN types_NNS ._.
Analysis_NN of_IN a_DT series_NN of_IN 5'-truncations_NNS showed_VBD several_JJ peaks_NNS of_IN basal_# and_CC PMA_NNP induced_VBD activity_NN suggesting_VBG the_DT presence_NN of_IN several_JJ positive_JJ and_CC negative_JJ regulatory_JJ elements_NNS ._.
A_DT PMA_`` responsive_JJ element_NN was_VBD localized_VBN to_TO a_DT region_NN between_IN -95_CD and_CC -36_CD bp_`` relative_JJ to_TO the_DT transcription_NN start_VBP site_NN ._.
Within_IN this_DT region_NN ,_, single_JJ AP-2-_-RRB- and_CC AP-1-like_JJ consensus_NN sequences_NNS were_VBD noted_VBN ._.
These_DT AP-2_NNP and_CC AP-1_NNP sites_NNS were_VBD each_DT modified_VBN with_IN a_DT double_JJ point_NN mutation_NN ._.
A_DT modest_JJ (_-LRB- 20-50_`` %_NN )_-RRB- reduction_NN in_IN TNF_`` promoter_NN activity_NN was_VBD observed_VBN with_IN the_DT AP-2_`` site_NN mutation_NN ._.
However_RB ,_, mutation_NN of_IN the_DT AP-1_NNP site_NN markedly_RB diminished_VBD both_CC the_DT basal_`` and_CC PMA-activated_`` promoter_NN activity_NN ._.
Also_RB co-transfections_NNS of_IN the_DT wild-type_JJ promoter_NN construct_VB with_IN an_DT AP-1/c-jun_JJ expression_NN vector_NN resulted_VBD in_IN augmented_JJ basal_`` and_CC PMA-induced_`` promoter_NN activity_NN ._.
Redox_NN status_NN of_IN cells_NNS influences_VBZ constitutive_`` or_CC induced_`` NF-kappa_-RRB- B_NNP translocation_NN and_CC HIV_`` long_JJ terminal_NN repeat_NN activity_NN in_IN human_JJ T_# and_CC monocytic_JJ cell_NN lines_NNS ._.
We_PRP have_VBP tested_VBN the_DT hypothesis_NN that_IN cellular_JJ activation_`` events_NNS occurring_VBG in_IN T_JJ lymphocytes_NNS and_CC monocytes_NNS and_CC mediated_`` through_IN translocation_NN of_IN the_DT transcription_NN factor_NN NF-kappa_NNP B_NNP are_VBP dependent_JJ upon_IN the_DT constitutive_JJ redox_NN status_NN of_IN these_DT cells_NNS ._.
We_PRP used_VBD phenolic_`` ,_, lipid-soluble_'' ,_, chain-breaking_NN antioxidants_NNS (_-LRB- butylated_`` hydroxyanisole_JJ (_-LRB- BHA_`` )_-RRB- ,_, nordihydroquairetic_JJ acid_NN ,_, or_CC alpha-tocopherol_`` (_-LRB- vitamin_NN E_NNP )_-RRB- to_TO show_VB that_DT peroxyl_`` radical_JJ scavenging_NN in_IN unstimulated_`` and_CC PMA-_`` or_CC TNF-stimulated_JJ cells_NNS blocks_NNS the_DT functions_NNS depending_VBG on_IN NF-kappa_NNP B_NNP activation_NN ._.
BHA_NNP was_VBD found_VBN to_TO suppress_VB not_RB only_RB PMA-_`` or_CC TNF-induced_# ,_, but_CC also_RB constitutive_`` ,_, HIV-enhancer_NNP activity_NN concomitant_`` to_TO an_DT inhibition_NN of_IN NF-kappa_NNP B_NNP binding_`` activity_NN in_IN both_DT lymphoblastoid_JJ T_`` (_-LRB- J.Jhan_NNP )_-RRB- and_CC monocytic_JJ (_-LRB- U937_NN )_-RRB- cell_NN lines_NNS ._.
This_DT was_VBD also_RB true_JJ for_IN KBF_# (_-LRB- p50_NN homodimer_NN )_-RRB- binding_`` activity_NN in_IN U937_CD cells_NNS ._.
Secretion_NN of_IN TNF_'' ,_, the_DT product_NN of_IN another_DT NF-kappa_NNP B-dependent_NNP gene_NN ,_, was_VBD abolished_VBN by_IN BHA_NNP in_IN PMA-stimulated_NNP U937_CD cells_NNS ._.
The_DT anti-oxidative_JJ effect_NN of_IN BHA_NNP was_VBD accompanied_VBN by_IN an_DT increase_NN in_IN thiol_NN ,_, but_CC not_RB glutathione_`` ,_, content_NN in_IN stimulated_VBN and_CC unstimulated_`` T_JJ cell_NN ,_, whereas_IN TNF_NNP stimulation_NN itself_PRP barely_RB modified_VBN the_DT cellular_JJ thiol_NN level_NN ._.
Oxidative_JJ stress_NN obtained_VBN by_IN the_DT addition_NN of_IN H2O2_NN to_TO the_DT culture_NN medium_NN of_IN J.Jhan_NNP or_CC U937_CD cells_NNS could_MD not_RB by_IN itself_PRP induce_VB NF-kappa_NNP B_NNP activation_NN ._.
These_DT observations_NNS suggest_VBP that_IN TNF_NNP and_CC PMA_NNP do_VBP not_RB lead_VB to_TO NF-kappa_NNP B_NNP activation_`` through_IN induction_NN of_IN changes_NNS in_IN the_DT cell_NN redox_NN status_NN ._.
Rather_RB ,_, TNF_NNP and_CC PMA_NNP can_MD exert_VB their_PRP$ effect_NN only_RB if_IN cells_NNS are_VBP in_IN an_DT appropriate_JJ redox_NN status_NN ,_, because_IN prior_JJ modification_NN toward_IN reduction_NN with_IN BHA_NNP treatment_NN prevents_VBZ this_DT activation_NN ._.
It_PRP appears_VBZ that_IN a_DT basal_`` redox_NN equilibrium_NN tending_`` toward_IN oxidation_NN is_VBZ a_DT prerequisite_`` for_IN full_JJ activation_NN of_IN transduction_NN pathways_NNS regulating_VBG the_DT activity_NN of_IN NF-kappa_NNP B-dependent_NNP genes_NNS ._.
Expression_NN of_IN c-fos_NNS ,_, c-jun_# and_CC jun_`` B_NNP in_IN peripheral_`` blood_NN lymphocytes_`` from_IN young_JJ and_CC elderly_JJ adults_NNS ._.
The_DT expression_NN of_IN c-fos_NNS ,_, c-jun_# and_CC jun_`` B_NNP proto-oncogenes_`` was_VBD studied_VBN in_IN phytohemagglutinin_`` (_-LRB- PHA_NNP )_-RRB- activated_VBD peripheral_JJ blood_NN lymphocytes_NNS (_-LRB- PBL_NNP )_-RRB- from_IN young_JJ and_CC aged_JJ humans_NNS ._.
Specific_NNP mRNAs_`` for_IN c-fos_NNS and_CC c-jun_`` were_VBD detectable_`` within_IN 30_CD min_NN after_IN cell_NN activation_NN and_CC reached_VBD maximal_JJ levels_NNS within_IN 2_CD h_NN ._.
Both_DT c-fos_NNS and_CC jun_`` B_NNP mRNAs_NNP decreased_VBD to_TO pre-activation_# levels_NNS within_IN 6_CD h_NN ,_, while_IN c-jun_`` mRNA_`` remained_VBD elevated_JJ ._.
In_IN PHA-activated_NNP PBL_NNP ,_, no_DT age-related_`` differences_NNS were_VBD observed_VBN in_IN c-fos_`` or_CC jun_`` B_NNP mRNA_NNP expression_NN ._.
However_RB ,_, c-jun_JJ mRNA_`` levels_NNS decreased_VBD significantly_RB (_-LRB- 1.73_CD +/-_`` 0.08_CD vs._CC 1.16_CD +/-_`` 0.09_CD arbitrary_JJ units_NNS ,_, P_NNP &lt[[SEMICOLON]]_NNP 0.01_CD ,_, young_JJ vs._FW old_JJ )_-RRB- in_IN PBL_NNP from_IN elderly_JJ individuals_NNS activated_`` with_IN PHA_NNP ._.
Because_IN previous_JJ work_NN has_VBZ demonstrated_VBN that_IN T_JJ cells_NNS from_IN elderly_JJ individuals_NNS may_MD display_VB normal_JJ proliferative_`` responses_NNS when_WRB activated_VBN via_IN the_DT anti-CD2_JJ pathway_NN ,_, c-jun_# and_CC jun_`` B_NNP mRNA_NNP expression_NN was_VBD also_RB studied_VBN in_IN anti-CD2-activated_JJ purified_`` T_JJ cells_NNS ._.
No_DT age-related_JJ differences_NNS were_VBD found_VBN in_IN the_DT expression_NN of_IN either_DT of_IN these_DT two_CD proto-oncogenes_NNS by_IN anti-CD2_JJ activated_`` T_JJ cells_NNS ._.
These_DT results_NNS suggest_VBP that_IN the_DT decreased_VBN IL-2_NN production_NN and_CC proliferative_JJ response_NN displayed_VBN by_IN PHA-activated_# PBL_`` from_IN elderly_JJ adults_NNS may_MD be_VB related_VBN to_TO age-related_JJ changes_NNS in_IN c-jun_`` mRNA_`` expression_NN and_CC in_IN the_DT ratio_NN of_IN c-fos_NNS to_TO c-jun_`` mRNA_`` ._.
Characterization_NN of_IN a_DT novel_JJ T_NNP lymphocyte_`` protein_NN which_WDT binds_VBZ to_TO a_DT site_NN related_VBN to_TO steroid/thyroid_JJ hormone_NN receptor_NN response_NN elements_NNS in_IN the_DT negative_JJ regulatory_JJ sequence_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN long_JJ terminal_JJ repeat_NN ._.
We_PRP have_VBP previously_RB identified_VBN a_DT T_JJ lymphocyte_`` protein_NN which_WDT binds_VBZ to_TO a_DT site_NN within_IN the_DT LTR_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_-LRB- HIV-1_NN )_-RRB- and_CC exerts_VBZ an_DT inhibitory_JJ effect_NN on_IN virus_NN gene_NN expression_NN ._.
The_DT palindromic_JJ site_NN (_-LRB- site_NN B_NNP )_-RRB- recognized_VBN by_IN this_DT protein_NN is_VBZ related_VBN to_TO the_DT palindromic_JJ binding_`` sites_NNS of_IN members_NNS of_IN the_DT steroid/thyroid_`` hormone_NN receptor_NN family_NN ._.
Here_RB we_PRP characterize_VBP the_DT T_JJ cell_NN protein_NN binding_# to_TO this_DT site_NN as_IN a_DT 100_CD kD_NNP protein_NN which_WDT is_VBZ most_RBS abundant_JJ in_IN T_JJ cells_NNS and_CC which_WDT binds_VBZ to_TO site_NN B_NNP as_IN a_DT 200_CD kD_NN complex_JJ ._.
This_DT protein_NN is_VBZ distinct_JJ from_IN other_JJ members_NNS of_IN the_DT steroid/thyroid_`` hormone_NN receptor_NN family_NN including_VBG the_DT COUP_`` protein_NN which_WDT has_VBZ a_DT closely_RB related_VBN DNA_NNP binding_JJ specificity_NN ._.
A_DT mechanism_NN for_IN the_DT antiinflammatory_JJ effects_NNS of_IN corticosteroids_`` :_: the_DT glucocorticoid_NN receptor_NN regulates_VBZ leukocyte_`` adhesion_NN to_TO endothelial_JJ cells_NNS and_CC expression_NN of_IN endothelial-leukocyte_JJ adhesion_NN molecule_`` 1_CD and_CC intercellular_JJ adhesion_NN molecule_`` 1_CD ._.
Corticosteroids_NNS are_VBP the_DT preeminent_`` antiinflammatory_JJ agents_NNS although_IN the_DT molecular_JJ mechanisms_NNS that_WDT impart_VBP their_PRP$ efficacy_NN have_VB not_RB been_VBN defined_VBN ._.
The_DT endothelium_NN plays_VBZ a_DT critical_JJ role_NN in_IN inflammation_NN by_IN directing_VBG circulating_VBG leukocytes_NNS into_IN extravascular_JJ tissues_NNS by_IN expressing_VBG adhesive_JJ molecules_NNS for_IN leukocytes_NNS (_-LRB- e.g._FW ,_, endothelial-leukocyte_JJ adhesion_NN molecule_NN 1_CD (_-LRB- ELAM-1_NN )_-RRB- and_CC intercellular_JJ adhesion_NN molecule_NN 1_CD (_-LRB- ICAM-1_NN )_-RRB- ._.
We_PRP therefore_RB determined_VBD whether_IN corticosteroids_`` suppress_`` inflammation_NN by_IN inhibiting_VBG endothelial_JJ expression_NN of_IN adhesion_NN molecules_`` for_IN neutrophils_NNS (_-LRB- polymorphonuclear_`` leukocytes_NNS )_-RRB- ._.
Preincubation_NN of_IN endothelial_JJ cells_NNS with_IN endotoxin_`` (_-LRB- lipopolysaccharide_NN (_-LRB- LPS_NNP )_-RRB- ,_, 1_CD microgram/ml_NN )_-RRB- led_VBN to_TO a_DT 4-fold_JJ increase_NN in_IN subsequent_JJ adherence_NN of_IN polymorphonuclear_`` leukocytes_NNS (_-LRB- P_NNP <_`` 0.0001_CD ,_, n_RB =_SYM 10_CD )_-RRB- to_TO endothelial_`` cells_NNS ,_, an_DT increase_NN that_WDT was_VBD markedly_RB attenuated_VBN when_WRB endothelial_JJ cells_NNS were_VBD treated_VBN with_IN dexamethasone_`` (_-LRB- IC50_`` <_NN 1_CD nM_NNP ,_, P_NNP <_`` 0.0001_CD ,_, n_RB =_SYM 6_CD or_CC 7_CD )_-RRB- during_IN preincubation_NN with_IN LPS_NNS ._.
Moreover_RB ,_, the_DT steroid_`` receptor_NN agonist_JJ cortisol_NN (_-LRB- 10_CD microM_`` )_-RRB- ,_, but_CC not_RB its_PRP$ inactive_JJ metabolite_NN tetrahydrocortisol_NN (_-LRB- 10_CD microM_`` )_-RRB- ,_, diminished_VBD LPS-induced_`` endothelial_JJ cell_NN adhesiveness_NN ._.
Further_JJ evidence_NN that_IN the_DT action_NN of_IN dexamethasone_NN was_VBD mediated_VBN through_IN ligation_NN of_IN corticosteroid_`` receptors_NNS (_-LRB- human_JJ glucocorticoid_NN receptors_NNS (_-LRB- hGRs_NN )_-RRB- )_-RRB- was_VBD provided_VBN by_IN experiments_NNS utilizing_VBG the_DT steroid_JJ antagonist_NN RU-486_NNP ._.
RU-486_NNP (_-LRB- 10_CD microM_`` )_-RRB- ,_, which_WDT prevents_VBZ translocation_NN of_IN ligated_`` hGR_NN to_TO the_DT nucleus_`` by_IN inhibiting_VBG dissociation_NN of_IN hGR_NN from_IN heat_NN shock_NN protein_NN 90_CD ,_, completely_RB aborted_JJ the_DT effect_NN of_IN dexamethasone_`` on_IN adhesiveness_NN of_IN endothelial_JJ cells_NNS (_-LRB- P_NNP <_`` 0.0005_CD ,_, n_RB =_SYM 3_CD )_-RRB- ._.
Treatment_NNP of_IN endothelial_JJ cells_NNS with_IN LPS_NNS (_-LRB- 1_CD microgram/ml_`` )_-RRB- stimulated_VBD transcription_NN of_IN ELAM-1_NN ,_, as_IN shown_VBN by_IN Northern_JJ blot_NN analysis_NN ,_, and_CC expression_NN of_IN membrane-associated_`` ELAM-1_NNP and_CC ICAM-1_NNP ,_, as_IN shown_VBN by_IN quantitative_JJ immunofluorescence_`` (_-LRB- both_DT P_NNP <_`` 0.001_CD ,_, n_RB =_SYM 9_CD )_-RRB- ._.
Dexamethasone_NNP markedly_RB inhibited_VBD LPS-stimulated_JJ accumulation_NN of_IN mRNA_NNP for_IN ELAM-1_NNP and_CC expression_NN of_IN ELAM-1_NNP and_CC ICAM-1_NNP (_-LRB- IC50_NNP <_`` 10_CD nM_`` ,_, both_DT P_NNP <_`` 0.001_CD ,_, n_RB =_SYM 4-9_JJ )_-RRB- ;_: inhibition_`` of_IN expression_NN by_IN dexamethasone_NN was_VBD reversed_VBN by_IN RU-486_NNP (_-LRB- both_DT P_NNP <_`` 0.005_CD ,_, n_RB =_SYM 4-6_`` )_-RRB- ._.
As_IN in_IN the_DT adhesion_NN studies_NNS ,_, cortisol_'' but_CC not_RB tetrahydrocortisol_`` inhibited_JJ expression_NN of_IN ELAM-1_NNP and_CC ICAM-1_`` (_-LRB- both_DT P_NNP <_`` 0.005_CD ,_, n_RB =_SYM 3_CD or_CC 4_CD )_-RRB- ._.
In_IN contrast_NN ,_, sodium_NN salicylate_`` (_-LRB- 1_CD mM_`` )_-RRB- inhibited_`` neither_DT adhesion_NN nor_CC expression_NN of_IN these_DT adhesion_NN molecules_NNS ._.
These_DT studies_NNS suggest_VBP that_IN antagonism_NN by_IN dexamethasone_NN of_IN endotoxin-induced_JJ inflammation_NN is_VBZ a_DT specific_JJ instance_NN of_IN the_DT general_JJ biological_JJ principle_NN that_IN the_DT glucocorticoid_NN receptor_NN is_VBZ a_DT hormone-dependent_JJ regulator_NN of_IN transcription_NN ._.
Membrane_# receptors_NNS for_IN aldosterone_NN :_: a_DT novel_NN pathway_NN for_IN mineralocorticoid_JJ action_NN ._.
Rapid_NNP nongenomic_JJ in_IN vitro_JJ effects_NNS of_IN aldosterone_NN on_IN intracellular_JJ electrolytes_NNS ,_, cell_NN volume_NN ,_, and_CC Na(+)-H+_NNP antiport_`` have_VBP been_VBN found_VBN in_IN human_JJ mononuclear_`` leukocytes_NNS (_-LRB- HML_NNP )_-RRB- ._.
Binding_# of_IN 125I-labeled_JJ aldosterone_NN to_TO plasma_NN membranes_NNS of_IN HML_`` shares_NNS important_JJ features_NNS with_IN these_DT functional_JJ data_NNS ._.
This_DT includes_VBZ a_DT very_RB low_JJ apparent_JJ dissociation_NN constant_JJ (_-LRB- Kd_# )_-RRB- of_IN 0.1_CD nM_`` for_IN both_DT aldosterone_`` and_CC the_DT effect_NN on_IN the_DT Na(+)-H(+)-antiport_NNP ,_, a_DT high_JJ turnover_NN rate_NN ,_, and_CC the_DT almost_RB exclusive_JJ binding_`` selectivity_NN for_IN aldosterone_NN ._.
Dexamethasone_NN ,_, RU_NNP 26988_CD ,_, corticosterone_'' ,_, ouabain_NN ,_, amiloride_'' ,_, and_CC 18-hydroxyprogesterone_JJ were_VBD inactive_JJ as_IN ligands_NNS ._.
Deoxycorticosterone_WP$ acetate_NN had_VBD an_DT intermediate_JJ activity_NN with_IN an_DT apparent_JJ Kd_NN of_IN 100_CD nM_NNP ._.
These_DT findings_NNS are_VBP the_DT first_JJ to_TO demonstrate_VB membrane_`` binding_NN of_IN aldosterone_`` being_VBG compatible_JJ with_IN major_JJ aspects_NNS of_IN its_PRP$ nongenomic_JJ effects_NNS ._.
Reticuloendotheliosis_-LRB- virus_NN long_JJ terminal_JJ repeat_NN elements_NNS are_VBP efficient_JJ promoters_NNS in_IN cells_NNS of_IN various_JJ species_NNS and_CC tissue_NN origin_NN ,_, including_VBG human_JJ lymphoid_`` cells_NNS ._.
Promiscuous_JJ transcriptional_JJ activity_NN of_IN the_DT reticuloendotheliosis_NN virus_NN (_-LRB- REV_NNP )_-RRB- long_JJ terminal_NN repeat_NN (_-LRB- LTR_NNP )_-RRB- was_VBD detected_VBN in_IN transient_JJ expression_NN assays_`` using_VBG LTR-chloramphenicol_NNP acetyltransferase-encoding_# gene_NN chimeras_NNS ,_, and_CC cells_NNS of_IN diverse_JJ species_NNS and_CC tissue_NN type_NN ;_: levels_NNS of_IN expression_NN from_IN two_CD different_JJ REV_`` LTRs_NNP correlate_`` with_IN reports_NNS of_IN pathogenicity_NN of_IN the_DT respective_JJ viruses_NNS in_IN vivo_`` ._.
REVs_NNS do_VBP not_RB encode_VB a_DT transactivator_NN targeted_VBN to_TO the_DT viral_`` LTR_`` ,_, and_CC cells_NNS infected_JJ with_IN Marek_NNP 's_POS disease_NN virus_NN ,_, a_DT herpesvirus_NN with_IN an_DT overlapping_`` host_NN range_NN ,_, do_VBP not_RB express_VB factors_NNS that_WDT preferentially_RB enhance_VB expression_NN from_IN REV_NNP or_CC avian_JJ sarcoma/leukemia_NN virus_NN LTRs_`` ._.
REV_NNP LTRs_NNP work_NN efficiently_RB in_IN human_JJ lymphoid_`` cells_NNS ,_, and_CC are_VBP viable_JJ alternatives_NNS to_TO promoters_NNS commonly_RB used_VBN for_IN expression_NN of_IN cloned_JJ genes_NNS ._.
They_PRP may_MD also_RB prove_VB useful_JJ in_IN the_DT identification_NN of_IN new_JJ ,_, ubiquitous_JJ cellular_JJ transcription_NN factors_NNS ._.
Natural_JJ variants_NNS of_IN the_DT HIV-1_`` long_JJ terminal_NN repeat_NN :_: analysis_NN of_IN promoters_NNS with_IN duplicated_`` DNA_NNP regulatory_JJ motifs_NNS ._.
Sequence_NN variation_NN in_IN the_DT long_JJ terminal_NN repeat_NN (_-LRB- LTR_NNP )_-RRB- region_NN of_IN HIV-1_NNP was_VBD analyzed_VBN in_IN viral_JJ isolates_NNS of_IN 17_CD infected_JJ individuals_NNS ._.
Two_CD classes_NNS of_IN LTR_NNP size_NN variants_NNS were_VBD found_VBN ._.
One_CD HIV-1_`` variant_NN was_VBD detected_VBN containing_VBG an_DT additional_JJ binding_`` site_NN for_IN the_DT transcription_`` factor_NN Sp1_NN ._.
Another_DT LTR_`` size_NN variation_NN was_VBD observed_VBN in_IN four_CD patients_NNS in_IN a_DT region_NN just_RB upstream_RB of_IN the_DT NF-kappa_NNP B_NNP enhancer_NN ._.
This_DT variation_NN was_VBD the_DT result_NN of_IN a_DT duplication_NN of_IN a_DT short_JJ DNA_NNP sequence_NN (_-LRB- CTG-motif_NNP )_-RRB- ._.
Cell_-LRB- culture_NN experiments_NNS demonstrated_VBD that_IN the_DT natural_JJ variant_NN with_IN four_CD Sp1_`` sites_NNS had_VBD a_DT slightly_RB higher_JJR promoter_NN activity_NN and_CC viral_JJ replication_NN rate_NN than_IN the_DT isogenic_JJ control_NN LTR_`` with_IN three_CD Sp1_CD sites_NNS ._.
No_DT positive_JJ effect_NN of_IN the_DT duplicated_`` CTG-motif_NNP could_MD be_VB detected_VBN ._.
In_IN order_NN to_TO measure_VB small_JJ differences_NNS in_IN virus_NN production_NN more_RBR accurately_RB ,_, equal_JJ amounts_NNS of_IN a_DT size_NN variant_`` and_CC the_DT wild-type_JJ plasmid_NN were_VBD cotransfected_`` into_IN T-cells_NNS ._.
The_DT virus_NN with_IN four_CD Sp1_`` sites_NNS did_VBD outgrow_VB the_DT three_CD Sp1_`` virus_NN in_IN 35_CD days_NNS of_IN culture_NN and_CC CTG-monomer_`` virus_NN outcompeted_VBD the_DT CTG-dimer_`` virus_NN in_IN 42_CD days_NNS ._.
Based_VBN on_IN these_DT results_NNS we_PRP estimate_VBP a_DT 5-10_JJ %_NN difference_NN in_IN virus_NN production_NN of_IN the_DT LTR_NNP variants_`` when_WRB compared_VBN to_TO that_IN of_IN wild-type_JJ ._.
SCL_NNP and_CC related_VBN hemopoietic_JJ helix-loop-helix_NN transcription_NN factors_NNS ._.
The_DT helix-loop-helix_`` (_-LRB- HLH_NNP )_-RRB- proteins_NNS are_VBP a_DT family_NN of_IN transcription_NN factors_NNS that_WDT include_VBP proteins_NNS critical_JJ to_TO differentiation_`` and_CC development_NN in_IN species_NNS ranging_VBG from_IN plants_NNS to_TO mammals_NNS ._.
Five_CD members_NNS of_IN this_DT family_NN (_-LRB- MYC_NNP ,_, SCL_NNP ,_, TAL-2_NN ,_, LYL-1_NNP and_CC E2A_NNP )_-RRB- are_VBP implicated_VBN in_IN oncogenic_JJ events_NNS in_IN human_JJ lymphoid_`` tumors_NNS because_IN of_IN their_PRP$ consistent_JJ involvement_NN in_IN chromosomal_`` translocations_NNS ._.
Although_IN activated_# in_IN T_JJ cell_NN leukemias_`` ,_, expression_NN of_IN SCL_NNP and_CC LYL-1_NNP is_VBZ low_JJ or_CC undetectable_JJ in_IN normal_JJ T_JJ cell_NN populations_NNS ._.
SCL_NNP is_VBZ expressed_VBN in_IN erythroid_NN ,_, megakaryocyte_NN and_CC mast_NN cell_NN populations_NNS (_-LRB- the_DT same_JJ cell_NN lineages_NNS as_IN GATA-1_NNP ,_, a_DT zinc-finger_`` transcription_NN factor_NN )_-RRB- ._.
In_IN addition_NN ,_, both_DT SCL_NNP and_CC GATA-1_NNP undergo_VBP coordinate_VB modulation_NN during_IN chemically_RB induced_`` erythroid_`` differentiation_NN of_IN mouse_NN erythroleukemia_NN cells_NNS and_CC are_VBP down-modulated_`` during_IN myeloid_JJ differentiation_NN of_IN human_JJ K562_NN cells_NNS ,_, thus_RB implying_VBG a_DT role_NN for_IN SCL_NNP in_IN erythroid_`` differentiation_`` events_NNS ._.
However_RB ,_, in_IN contrast_NN to_TO GATA-1_NNP ,_, SCL_NNP is_VBZ expressed_VBN in_IN the_DT developing_VBG brain_NN ._.
Studies_NNS of_IN the_DT function_NN of_IN SCL_NNP suggest_VBP it_PRP is_VBZ also_RB important_JJ in_IN proliferation_NN and_CC self-renewal_JJ events_NNS in_IN erythroid_JJ cells_NNS ._.
Transcription_NN of_IN the_DT hypersensitive_JJ site_NN HS2_CD enhancer_NN in_IN erythroid_JJ cells_NNS ._.
In_IN the_DT human_JJ genome_NN ,_, the_DT erythroid-specific_JJ hypersensitive_JJ site_NN HS2_`` enhancer_`` regulates_VBZ the_DT transcription_NN of_IN the_DT downstream_`` beta-like_JJ globin_NN genes_NNS 10-50_CD kilobases_NNS away_RB ._.
The_DT mechanism_NN of_IN HS2_NNP enhancer_`` function_NN is_VBZ not_RB known_VBN ._.
The_DT present_JJ study_NN employs_VBZ RNA_NNP protection_NN assays_VBZ to_TO analyze_VB the_DT transcriptional_JJ status_NN of_IN the_DT HS2_`` enhancer_NN in_IN transfected_`` recombinant_JJ chloramphenicol_NN acetyltransferase_`` (_-LRB- CAT_NN )_-RRB- plasmids_NNS ._.
In_IN erythroid_`` K562_`` cells_NNS in_IN which_WDT the_DT HS2_CD enhancer_NN is_VBZ active_JJ ,_, the_DT HS2_NNP sequence_NN directs_VBZ the_DT synthesis_NN of_IN long_JJ enhancer_`` transcripts_NNS that_WDT are_VBP initiated_VBN apparently_RB from_IN within_IN the_DT enhancer_NN and_CC elongated_`` through_IN the_DT intervening_VBG DNA_NNP into_IN the_DT cis-linked_`` CAT_JJ gene_NN ._.
In_IN nonerythroid_`` HL-60_JJ cells_NNS in_IN which_WDT the_DT HS2_NNP enhancer_NN is_VBZ inactive_JJ ,_, long_JJ enhancer_NN transcripts_NNS are_VBP not_RB detectable_JJ ._.
Splitting_VBG the_DT HS2_`` enhancer_NN between_IN two_CD tandem_`` Ap1_`` sites_NNS abolishes_VBZ the_DT synthesis_NN of_IN a_DT group_NN of_IN long_JJ enhancer_`` transcripts_NNS and_CC results_NNS in_IN loss_NN of_IN enhancer_NN function_NN and_CC transcriptional_JJ silencing_`` of_IN the_DT cis-linked_JJ CAT_JJ gene_NN ._.
In_IN directing_VBG the_DT synthesis_NN of_IN RNA_NNP through_IN the_DT intervening_VBG DNA_NNP and_CC the_DT gene_NN by_IN a_DT tracking_NN and_CC transcription_NN mechanism_NN ,_, the_DT HS2_`` enhancer_NN may_MD (_-LRB- i_NN )_-RRB- open_VBP up_RP the_DT chromatin_NN structure_NN of_IN a_DT gene_NN domain_NN and_CC (_-LRB- ii_NNS )_-RRB- deliver_VBP enhancer_`` binding_`` proteins_NNS to_TO the_DT promoter_NN sequence_NN where_WRB they_PRP may_MD stimulate_VB the_DT transcription_NN of_IN the_DT gene_NN at_IN
Phorbol_NN ester_NN reduces_VBZ constitutive_JJ nuclear_JJ NF_NNP kappa_NN B_NNP and_CC inhibits_`` HIV-1_JJ production_NN in_IN mature_JJ human_JJ monocytic_JJ cells_NNS ._.
NF_NNP kappa_`` B_NNP is_VBZ a_DT potent_JJ mediator_NN of_IN specific_JJ gene_NN expression_NN in_IN human_JJ monocytes_NNS and_CC has_VBZ been_VBN shown_VBN to_TO play_VB a_DT role_NN in_IN transcription_NN of_IN the_DT HIV-1_`` genome_`` in_IN promonocytic_JJ leukemias_NNS ._.
There_EX is_VBZ little_JJ information_NN available_JJ on_IN the_DT response_NN of_IN NF_NNP kappa_`` B_NNP to_TO cytokines_NNS in_IN normal_JJ human_JJ monocytes_NNS ._.
We_PRP have_VBP used_VBN a_DT 32P-labeled_JJ oligonucleotide_`` derived_VBD from_IN human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV-1_`` )_-RRB- long_JJ terminal_NN repeat_NN ,_, which_WDT contains_VBZ a_DT tandem_`` repeat_NN of_IN the_DT NF_NNP kappa_NN B_NNP binding_`` sequence_NN ,_, as_IN a_DT probe_NN in_IN a_DT gel_`` retardation_NN assay_NN to_TO study_VB this_DT transcription_NN factor_NN ._.
Using_VBG this_DT assay_NN ,_, we_PRP have_VBP detected_VBN NF_NNP kappa_NN B_NNP in_IN extracts_`` of_IN nuclei_`` from_IN normal_JJ human_JJ monocytes_NNS ._.
Treatment_NNP of_IN normal_JJ monocytes_NNS with_IN 12-0-tetradecanoyl_JJ phorbol-13-acetate_`` (_-LRB- TPA_NNP )_-RRB- for_IN 4-24_JJ h_NN caused_VBD the_DT complete_JJ disappearance_NN of_IN NF_NNP kappa_`` B_NNP from_IN nuclear_JJ extracts_NNS of_IN monocytes_NNS ._.
A_DT similar_JJ result_NN was_VBD obtained_VBN with_IN the_DT mature_JJ monocytic_JJ leukemia_NN cell_NN line_NN THP-1_NN ._.
The_DT constitutive_JJ transcription_NN factor_NN SP1_`` was_VBD unaffected_JJ by_IN addition_NN of_IN TPA_NNP ._.
The_DT disappearance_NN of_IN NF_NNP kappa_NN B_NNP from_IN the_DT nucleus_NN was_VBD concentration_NN dependent_JJ between_IN 10_CD and_CC 50_CD ng/ml_`` of_IN phorbol_NN ester_NN ._.
In_IN THP-1_JJ cells_NNS ,_, TPA_NNP also_RB induced_VBD a_DT new_JJ ,_, faster-migrating_JJ NF_NNP kappa_NN B_NNP species_NN not_RB induced_`` in_IN monocytes_NNS ._.
Protein_NNP kinase_`` C_$ inhibitor_`` staurosporine_JJ ,_, but_CC not_RB cyclic_JJ nucleotide-dependent_JJ protein_NN kinase_`` inhibitor_`` HA-1004_-RRB- ,_, also_RB dramatically_RB reduced_VBN constitutive_JJ levels_NNS of_IN nuclear_JJ NF_NNP kappa_NN B_NNP ._.
Finally_RB ,_, TPA_NNP addition_NN to_TO monocytes_NNS infected_VBN with_IN HIV-1_`` inhibited_JJ HIV-1_NN replication_NN ,_, as_IN determined_VBN by_IN reverse_JJ transcriptase_`` assays_NNS ,_, in_IN a_DT concentration-dependent_JJ manner_NN ._.
These_DT results_NNS are_VBP in_IN striking_JJ contrast_NN to_TO the_DT increase_NN in_IN nuclear_JJ NF_NNP kappa_NN B_NNP and_CC HIV-1_NNP replication_`` induced_`` by_IN phorbol_NN esters_NNS in_IN promonocytic_JJ leukemia_`` cells_NNS U937_CD and_CC HL-60_CD ,_, and_CC emphasize_VB the_DT importance_NN of_IN studying_VBG cytokine_JJ regulation_NN of_IN HIV-1_NNP in_IN normal_JJ monocytes_NNS ._.
Ablation_NN of_IN transplanted_VBN HTLV-I_NNP Tax-transformed_# tumors_NNS in_IN mice_NNS by_IN antisense_JJ inhibition_NN of_IN NF-kappa_NNP B_NNP (_-LRB- published_VBN erratum_NN appears_VBZ in_IN Science_NNP 1993_CD Mar_NNP 12_CD ;_: 259_CD (_-LRB- 5101_CD )_-RRB- :_: 1523_CD )_-RRB-
Mice_NNP transgenic_`` for_IN the_DT human_JJ T_`` cell_NN leukemia_NN virus_NN (_-LRB- HTLV-I_NNP )_-RRB- Tax_NNP gene_NN develop_VB fibroblastic_JJ tumors_NNS that_IN express_JJ NF-kappa_NNP B-inducible_`` early_JJ genes_NNS ._.
In_IN vitro_`` inhibition_NN of_IN NF-kappa_NNP B_NNP expression_NN by_IN antisense_`` oligodeoxynucleotides_NNS (_-LRB- ODNs_NNP )_-RRB- inhibited_`` growth_NN of_IN these_DT culture-adapted_JJ Tax-transformed_`` fibroblasts_NNS as_RB well_RB as_IN an_DT HTLV-I-transformed_JJ human_JJ lymphocyte_NN line_NN ._.
In_IN contrast_NN ,_, antisense_JJ inhibition_NN of_IN Tax_NNP itself_PRP had_VBD no_DT apparent_JJ effect_NN on_IN cell_NN growth_NN ._.
Mice_-LRB- treated_VBN with_IN antisense_NN to_TO NF-kappa_NNP B_NNP ODNs_NNP showed_VBD rapid_JJ regression_NN of_IN transplanted_`` fibrosarcomas_NNS ._.
This_DT suggests_VBZ that_IN NF-kappa_NNP B_NNP expression_NN may_MD be_VB necessary_JJ for_IN the_DT maintenance_NN of_IN the_DT malignant_JJ phenotype_`` and_CC provides_VBZ a_DT therapeutic_JJ approach_NN for_IN HTLV-I-associated_JJ disease_NN ._.
Inhibition_NN of_IN anti-CD3_JJ monoclonal_JJ antibody-induced_JJ T-cell_`` proliferation_NN by_IN dexamethasone_NN ,_, isoproterenol_'' ,_, or_CC prostaglandin_`` E2_NN either_CC alone_RB or_CC in_IN combination_NN ._.
1_LS ._. The_DT purpose_NN of_IN these_DT studies_NNS was_VBD to_TO investigate_VB the_DT modulation_NN of_IN the_DT proliferation_NN of_IN human_JJ T_JJ cells_NNS obtained_VBN from_IN peripheral_JJ blood_NN by_IN dexamethasone_`` (_-LRB- DEX_NNP )_-RRB- ,_, isoproterenol_FW (_-LRB- ISO_NN )_-RRB- ,_, and_CC prostaglandin_`` E2_`` (_-LRB- PGE2_NN )_-RRB- ._.
The_DT former_JJ two_CD substances_NNS interact_`` with_IN T_JJ cells_NNS via_IN the_DT glucocorticoid_`` and_CC beta-adrenergic_JJ receptors_NNS respectively_RB ._.
When_WRB occupied_VBN by_IN their_PRP$ natural_JJ ligands_NNS ,_, glucocorticosteroids_NNS and_CC catecholamines_NNS ,_, these_DT receptors_NNS have_VBP a_DT role_NN in_IN modulating_VBG T-cell_JJ function_NN during_IN stress_NN ._.
During_IN the_DT inflammatory_JJ response_NN increased_VBD levels_NNS of_IN PGE2_NNP bind_NN to_TO their_PRP$ receptors_NNS on_IN T_JJ cells_NNS and_CC thus_RB alter_VB responsiveness_NN ._.
Proliferation_NN of_IN T_JJ cells_NNS was_VBD induced_VBN by_IN immobilized_`` anti-CD3_JJ monoclonal_JJ antibody_NN (_-LRB- mAb_NNP )_-RRB- in_IN the_DT presence_NN or_CC absence_NN of_IN an_DT additional_JJ costimulatory_JJ signal_NN delivered_VBN by_IN anti-CD28_-RRB- mAb_NNP ._.
2_LS ._. Various_`` physiologic_`` concentrations_NNS of_IN DEX_NNP ,_, ISO_'' ,_, or_CC PGE2_CD were_VBD added_VBN at_IN the_DT time_NN of_IN initiation_NN of_IN the_DT cultures_NNS and_CC subsequent_JJ proliferation_NN of_IN the_DT unstimulated_`` T_JJ cells_NNS was_VBD determined_VBN ._.
The_DT results_NNS demonstrate_VBP that_IN physiologic_`` concentrations_NNS of_IN all_DT three_CD of_IN these_DT agents_NNS inhibit_VBP the_DT anti-CD3_`` mAb-induced_JJ proliferation_NN of_IN T_JJ cells_NNS ._.
3_LS ._. Although_IN DEX_NNP and_CC PGE2_NNP were_VBD equipotent_`` in_IN suppressing_VBG T-cell_`` proliferation_NN ,_, ISO_NNP was_VBD much_RB less_RBR effective_JJ ._.
4_LS ._. Because_IN concomitant_JJ elevations_NNS in_IN the_DT peripheral_JJ levels_NNS of_IN these_DT substances_NNS may_MD occur_VB ,_, experiments_NNS were_VBD performed_VBN to_TO determine_VB the_DT T-cell_JJ inhibitory_JJ effects_NNS of_IN DEX_NNP together_RB with_IN either_DT PGE2_NNP or_CC ISO_NNP ._.
Synergistic_JJ suppression_NN of_IN T-cell_NNP proliferation_NN was_VBD observed_VBN when_WRB various_JJ concentrations_NNS of_IN DEX_NNP and_CC PGE2_NNP ,_, but_CC not_RB DEX_NNP and_CC ISO_NNP ,_, were_VBD added_VBN to_TO cultures_NNS ._.
This_DT synergistic_JJ suppression_NN could_MD not_RB be_VB explained_VBN by_IN an_DT increase_NN in_IN cAMP_`` accumulation_NN in_IN T_JJ cells_NNS stimulated_VBN with_IN DEX_NNP and_CC PGE2_NNP ._.
5_CD ._. Finally_RB ,_, the_DT addition_NN of_IN anti-CD28_JJ mAb_NN to_TO anti-CD3_JJ mAb-stimulated_`` T_JJ cells_NNS overcame_VBD much_RB of_IN the_DT suppression_NN of_IN proliferation_NN induced_VBN by_IN PGE2_NNP or_CC ISO_`` but_CC less_RBR so_RB than_IN that_IN induced_VBN by_IN DEX_NNP ._.
Targeted_VBN degradation_NN of_IN c-Fos_# ,_, but_CC not_RB v-Fos_NNP ,_, by_IN a_DT phosphorylation-dependent_JJ signal_NN on_IN c-Jun_NN ._.
The_DT proto-oncogene_JJ products_NNS c-Fos_`` and_CC c-Jun_# heterodimerize_`` through_IN their_PRP$ leucine_NN zippers_NNS to_TO form_VB the_DT AP-1_NNP transcription_NN factor_NN ._.
The_DT transcriptional_JJ activity_NN of_IN the_DT heterodimer_NN is_VBZ regulated_VBN by_IN signal-dependent_JJ phosphorylation_NN and_CC dephosphorylation_NN events_NNS ._.
The_DT stability_NN of_IN c-Fos_-RRB- was_VBD found_VBN to_TO also_RB be_VB controlled_VBN by_IN intracellular_JJ signal_NN transduction_NN ._.
In_IN transient_JJ expression_NN and_CC in_IN vitro_`` degradation_`` experiments_NNS ,_, the_DT stability_NN of_IN c-Fos_-RRB- was_VBD decreased_VBN when_WRB the_DT protein_NN was_VBD dimerized_`` with_IN phosphorylated_JJ c-Jun_NN ._.
c-Jun_JJ protein_NN isolated_VBN from_IN phorbol_`` ester-induced_`` cells_NNS did_VBD not_RB target_NN c-Fos_`` for_IN degradation_NN ,_, which_WDT suggests_VBZ that_DT c-Fos_# is_VBZ transiently_RB stabilized_VBN after_IN stimulation_NN of_IN cell_NN growth_NN ._.
v-Fos_JJ protein_NN ,_, the_DT retroviral_JJ counterpart_NN of_IN c-Fos_`` ,_, was_VBD not_RB susceptible_JJ to_TO degradation_`` targeted_VBN by_IN c-Jun_`` ._.
Mutations_-LRB- in_IN the_DT Pit-1_`` gene_NN in_IN children_NNS with_IN combined_JJ pituitary_JJ hormone_NN deficiency_NN ._.
Pit-1_NN is_VBZ a_DT pituitary-specific_JJ transcription_NN factor_NN that_WDT binds_VBZ to_TO and_CC transactivates_VBZ promoters_NNS of_IN growth_NN hormone_NN and_CC prolactin_NN genes_NNS ._.
In_IN three_CD unrelated_JJ Japanese_JJ children_NNS with_IN combined_JJ pituitary_JJ hormone_NN deficiency_NN ,_, we_PRP identified_VBD three_CD point_NN mutations_NNS in_IN the_DT Pit-1_`` gene_NN ,_, Pro24Leu_NNP ,_, Arg143Gln_NNP ,_, and_CC Arg271Trp_NNP ,_, located_VBN on_IN the_DT major_JJ transactivation_NN region_NN ,_, POU-specific_NNP domain_NN ,_, and_CC POU-homeodomain_NNP ,_, respectively_RB ._.
Calcitriol_NN :_: a_DT hematolymphopoietrope_NN ?_. (_-LRB- editorial_NN )_-RRB-
A_DT MEDLINE_`` search_NN of_IN the_DT English-language_JJ literature_NN was_VBD conducted_VBN using_VBG the_DT indexing_NN terms_NNS '_POS immunology_NN ,_, calcitriol_NN and_CC vitamin_NN D_NNP '_'' to_TO identify_VB studies_NNS indicating_VBG a_DT role_NN for_IN calcitriol_NN as_IN a_DT primary_JJ immunomodulator_NN ._.
Sixty-six_CD papers_NNS published_VBN between_IN January_NNP 1956_CD and_CC June_NNP 1991_CD were_VBD identified_VBN ._.
Forty-five_-RRB- of_IN these_DT reports_NNS are_VBP cited_VBN in_IN this_DT review_NN ._.
The_DT data_NNS strongly_RB suggest_VB an_DT endocrine_NN ,_, autocrine_'' and/or_CC paracrine_JJ role_NN for_IN calcitriol_NN in_IN immune_JJ regulation_NN ._.
No_DT unifying_JJ hypothesis_NN has_VBZ yet_RB emerged_VBN explaining_VBG this_DT collection_NN of_IN data_NNS ._.
This_DT paper_NN provides_VBZ a_DT brief_JJ review_NN of_IN immune_JJ properties_NNS currently_RB attributed_VBN to_TO calcitriol_`` ._.
Activation_NN of_IN protein_NN kinase_`` C_$ and_CC elevation_`` of_IN cAMP_NNP interact_`` synergistically_RB to_TO raise_VB c-Fos_# and_CC AP-1_`` activity_NN in_IN Jurkat_NNP cells_NNS ._.
We_PRP have_VBP earlier_RB found_VBN that_IN in_IN Jurkat_`` cells_NNS activation_NN of_IN protein_NN kinase_`` C_$ (_-LRB- PKC_NNP )_-RRB- enhances_VBZ the_DT cyclic_JJ adenosine_NN monophosphate_`` (_-LRB- cAMP_NN )_-RRB- accumulation_NN induced_`` by_IN adenosine_NN receptor_NN stimulation_NN or_CC activation_NN of_IN Gs_`` ._.
Here_RB we_PRP have_VBP therefore_RB examined_VBN the_DT effect_NN of_IN the_DT phorbol_'' ester_NN PMA_`` (_-LRB- phorbol_NN 12-myristate_JJ 13-acetate_`` )_-RRB- which_WDT stimulates_VBZ PKC_NNP and_CC a_DT combination_NN of_IN the_DT adenosine_NN receptor_NN agonist_JJ NECA_`` (_-LRB- 5'-(N-ethyl)-carboxamido_JJ adenosine_NN )_-RRB- and_CC forskolin_`` to_TO raise_VB cAMP_NNP ,_, on_IN the_DT levels_NNS of_IN c-Fos_`` and_CC Jun_`` and_CC on_IN the_DT binding_`` and_CC transcriptional_JJ activity_NN of_IN the_DT transcription_NN factor_NN ,_, activator_NN protein-1_NN (_-LRB- AP-1_NNP )_-RRB- ._.
PMA_NN treatment_NN caused_VBN a_DT concentration-_JJ and_CC time-dependent_JJ increase_NN in_IN both_DT c-Fos_# and_CC Jun_NNP immunoreactivity_`` in_IN contrast_NN to_TO cAMP_NNP elevation_NN that_WDT had_VBD only_RB a_DT slight_JJ effect_NN ._.
Both_DT PMA_NNP and_CC the_DT combination_NN of_IN NECA_NNP and_CC forskolin_`` acted_VBN together_RB either_DT to_TO increase_VB (_-LRB- c-Fos_# )_-RRB- or_CC decrease_VB (_-LRB- Jun_NNP )_-RRB- protein_NN levels_NNS as_RB well_RB as_IN increasing_VBG AP-1_`` binding_NN ,_, as_IN judged_VBN by_IN gel-shift_JJ assay_NN ,_, and_CC AP-1_NNP transcriptional_JJ activity_NN ._.
Furthermore_RB there_EX was_VBD a_DT clear-cut_JJ synergy_NN between_IN the_DT PKC_NNP stimulator_`` and_CC the_DT cAMP_# elevating_VBG agents_NNS ._.
The_DT results_NNS demonstrate_VBP that_IN the_DT simultaneous_JJ activation_NN of_IN PKC_NNP and_CC elevation_`` of_IN cAMP_NN leads_VBZ to_TO an_DT enhanced_JJ AP-1_`` transcriptional_JJ activity_NN in_IN a_DT T-leukemia_JJ cell_NN line_NN ,_, suggesting_VBG that_IN the_DT previously_RB observed_VBN interaction_NN between_IN the_DT parallel_JJ signal_NN transduction_`` pathways_`` may_MD have_VB functional_JJ consequences_NNS at_IN the_DT level_NN of_IN gene_NN transcription_NN ._.
The_DT use_NN of_IN interferon-gamma-treated_JJ U937_CD cells_NNS in_IN chemiluminescence_NN assays_`` to_TO detect_VB red_JJ cell_NN ,_, platelet_NN and_CC granulocyte_NN antibodies_NNS of_IN potential_JJ clinical_JJ significance_NN ._.
The_DT chemiluminescent_`` (_-LRB- CL_NN )_-RRB- response_NN of_IN interferon-gamma-treated_JJ U937_CD (_-LRB- IFN-U937_-RRB- )_-RRB- cells_NNS to_TO sensitized_`` target_VB cells_NNS has_VBZ been_VBN used_VBN to_TO detect_VB red_JJ cell_NN ,_, platelet_NN and_CC granulocyte_NN antibodies_NNS ._.
A_DT clone_NN of_IN U937_CD cells_NNS was_VBD selected_VBN which_WDT expressed_VBD Fc_NNP receptor_NN I_PRP (_-LRB- Fc_NNP gamma_`` RI_NNP )_-RRB- and_CC which_WDT ,_, after_IN incubation_NN with_IN IFN-gamma_NNP for_IN 72_CD h_NN ,_, was_VBD capable_JJ of_IN generating_VBG high_JJ levels_NNS of_IN lucigenin-enhanced_JJ CL_NN ._.
The_DT CL_NN responses_NNS of_IN IFN-U937_CD cells_NNS and_CC peripheral_JJ blood_NN human_JJ monocytes_NNS to_TO sensitized_`` red_JJ cells_NNS ,_, platelets_NNS or_CC granulocytes_NNS were_VBD then_RB compared_VBN ._.
Assays_# using_VBG monocytes_NNS or_CC IFN-U937_JJ cells_NNS were_VBD of_IN comparable_JJ sensitivity_NN for_IN detection_NN of_IN antibodies_NNS against_IN all_DT three_CD types_NNS of_IN target_NN cell_NN ._.
In_IN addition_NN ,_, the_DT use_NN of_IN IFN-U937_JJ cells_NNS reduced_VBN interassay_NN variation_NN and_CC simplified_JJ assay_NN performance_NN ._.
The_DT potential_JJ clinical_JJ usefulness_NN of_IN these_DT CL_NN assays_`` was_VBD suggested_VBN by_IN the_DT ability_NN of_IN both_DT monocytes_NNS and_CC IFN-U937_JJ cells_NNS to_TO respond_VB to_TO red_JJ cells_NNS ,_, platelets_NNS or_CC granulocytes_NNS sensitized_`` with_IN sera_NN from_IN pregnant_JJ women_NNS whose_WP$ babies_NNS had_VBD either_DT haemolytic_JJ disease_NN of_IN the_DT newborn_JJ (_-LRB- HDN_NN )_-RRB- ,_, alloimmune_'' thrombocytopenia_NN or_CC alloimmune_`` neutropenia_`` respectively_RB ._.
In_IN addition_NN ,_, monocytes_NNS and_CC IFN-U937_JJ cells_NNS both_DT responded_VBD to_TO red_JJ cells_NNS sensitized_`` with_IN antibodies_NNS against_IN a_DT variety_NN of_IN specificities_NNS of_IN assumed_VBN (_-LRB- although_IN not_RB documented_VBN )_-RRB- clinical_JJ significance_NN for_IN blood_NN transfusion_NN recipients_NNS ._.
In_IN contrast_NN ,_, monocytes_NNS and_CC IFN-U937_JJ cells_NNS responded_VBD only_RB weakly_RB to_TO red_JJ cells_NNS sensitized_VBN with_IN either_DT anti-D_`` in_IN sera_NN from_IN mothers_NNS of_IN babies_NNS unaffected_JJ by_IN HDN_NNP ,_, or_CC with_IN antisera_`` containing_VBG high_JJ titre_`` antibodies_NNS with_IN specificities_NNS not_RB normally_RB associated_VBN with_IN significantly_RB reduced_VBN red_JJ cell_NN survival_NN ._.
Photoaffinity_NN labeling_NN of_IN plasma_NN membrane_NN receptors_`` for_IN aldosterone_NN from_IN human_JJ mononuclear_`` leukocytes_NNS ._.
Non-genomic_JJ effects_NNS of_IN aldosterone_NN on_IN the_DT sodium-proton-antiport_`` have_VBP been_VBN shown_VBN in_IN human_JJ mononuclear_`` leukocytes_NNS which_WDT could_MD be_VB related_VBN to_TO a_DT new_JJ aldosterone_`` membrane_NN receptor_NN ._.
In_IN the_DT present_JJ paper_NN plasma_NN membranes_NNS from_IN human_JJ mononuclear_`` leukocytes_NNS were_VBD covalently_RB photolabeled_VBN with_IN a_DT (125I)-aldosterone_JJ derivative_NN ._.
Sodium_NNP dodecyl_`` sulfate-polyacrylamide_`` gel_`` electrophoresis_NN showed_VBD significant_JJ aldosterone_NN binding_NN at_IN a_DT molecular_JJ weight_NN of_IN approximately_RB 50000_CD Dalton_NNP which_WDT was_VBD absent_JJ with_IN 1_CD microM_`` cold_JJ aldosterone_NN ,_, but_CC not_RB cortisol_`` in_IN the_DT binding_JJ media_NNS ._.
The_DT presence_NN of_IN the_DT sulfhydryl_`` agent_NN dithiothreitol_NN did_VBD not_RB affect_VB results_NNS suggesting_VBG the_DT absence_NN of_IN disulfide_`` bridges_NNS in_IN the_DT steroid_`` binding_JJ domain_NN of_IN the_DT receptor_NN ._.
These_DT data_NNS are_VBP the_DT first_JJ to_TO define_VB the_DT molecular_JJ weight_NN of_IN the_DT membrane_NN receptor_NN for_IN aldosterone_NN ._.
Alpha-lipoic_JJ acid_NN is_VBZ a_DT potent_JJ inhibitor_NN of_IN NF-kappa_NNP B_NNP activation_NN in_IN human_JJ T_JJ cells_NNS ._.
Acquired_-LRB- immunodeficiency_NN syndrome_NN (_-LRB- AIDS_NNP )_-RRB- results_VBZ from_IN infection_NN with_IN a_DT human_JJ immunodeficiency_NN virus_NN (_-LRB- HIV_NNP )_-RRB- ._.
The_DT long_JJ terminal_NN repeat_NN (_-LRB- LTR_NNP )_-RRB- region_NN of_IN HIV_NNP proviral_-RRB- DNA_NNP contains_VBZ binding_# sites_NNS for_IN nuclear_JJ factor_NN kappa_NN B_NNP (_-LRB- NF-kappa_NNP B_NNP )_-RRB- ,_, and_CC this_DT transcriptional_JJ activator_NN appears_VBZ to_TO regulate_VB HIV_NNP activation_NN ._.
Recent_JJ findings_NNS suggest_VBP an_DT involvement_NN of_IN reactive_JJ oxygen_NN species_NNS (_-LRB- ROS_NNP )_-RRB- in_IN signal_NN transduction_NN pathways_NNS leading_VBG to_TO NF-kappa_NNP B_NNP activation_NN ._.
The_DT present_JJ study_NN was_VBD based_VBN on_IN reports_NNS that_IN antioxidants_NNS which_WDT eliminate_VBP ROS_NNS should_MD block_VB the_DT activation_NN of_IN NF-kappa_NNP B_NNP and_CC subsequently_RB HIV_NNP transcription_NN ,_, and_CC thus_RB antioxidants_NNS can_MD be_VB used_VBN as_IN therapeutic_JJ agents_NNS for_IN AIDS_NNP ._.
Incubation_NN of_IN Jurkat_`` T_JJ cells_NNS (_-LRB- 1_CD x_`` 10(6)_JJ cells/ml_NN )_-RRB- with_IN a_DT natural_JJ thiol_`` antioxidant_JJ ,_, alpha-lipoic_JJ acid_NN ,_, prior_RB to_TO the_DT stimulation_NN of_IN cells_NNS was_VBD found_VBN to_TO inhibit_VB NF-kappa_NNP B_NNP activation_NN induced_`` by_IN tumor_NN necrosis_NN factor-alpha_NN (_-LRB- 25_CD ng/ml_`` )_-RRB- or_CC by_IN phorbol_`` 12-myristate_JJ 13-acetate_`` (_-LRB- 50_CD ng/ml_`` )_-RRB- ._.
The_DT inhibitory_JJ action_NN of_IN alpha-lipoic_JJ acid_NN was_VBD found_VBN to_TO be_VB very_RB potent_JJ as_IN only_JJ 4_CD mM_NN was_VBD needed_VBN for_IN a_DT complete_JJ inhibition_NN ,_, whereas_IN 20_CD mM_NN was_VBD required_VBN for_IN N-acetylcysteine_NNP ._.
These_DT results_NNS indicate_VBP that_IN alpha-lipoic_JJ acid_NN may_MD be_VB effective_JJ in_IN AIDS_NNP therapeutics_`` ._.
Activation_NN of_IN lymphokine_`` genes_NNS in_IN T_JJ cells_NNS :_: role_NN of_IN cis-acting_VBG DNA_NNP elements_NNS that_WDT respond_VBP to_TO T_VB cell_NN activation_NN signals_NNS ._.
Activation_NN of_IN T_JJ cells_NNS is_VBZ initiated_VBN by_IN the_DT recognition_NN of_IN antigen_NN on_IN antigen_# presenting_VBG cells_NNS to_TO exert_VB the_DT effector_NN functions_NNS in_IN immune_JJ and_CC inflammatory_JJ responses_NNS ._.
Two_CD types_NNS of_IN helper_`` T_JJ cell_NN (_-LRB- Th_# )_-RRB- clones_NNS (_-LRB- Th1_CD and_CC Th2_CD )_-RRB- are_VBP defined_VBN on_IN the_DT basis_NN of_IN different_JJ patterns_NNS of_IN cytokine_`` (_-LRB- lymphokine_NN )_-RRB- secretion_NN ._.
They_PRP determine_VBP the_DT outcome_NN of_IN an_DT antigenic_JJ response_NN toward_IN humoral_JJ or_CC cell-mediated_JJ immunity_NN ._.
Although_IN lymphokine_`` genes_NNS are_VBP coordinately_RB regulated_VBN upon_IN antigen_JJ stimulation_NN ,_, they_PRP are_VBP regulated_VBN by_IN the_DT mechanisms_NNS common_JJ to_TO all_DT as_RB well_RB as_IN those_DT which_WDT are_VBP unique_JJ to_TO each_DT gene_NN ._.
For_IN most_JJS lymphokine_`` genes_NNS ,_, a_DT combination_NN of_IN phorbol_NN esters_NNS (_-LRB- phorbol_NN 12-myristate_JJ 13_CD acetate_NN ,_, PMA_NNP )_-RRB- and_CC calcium_NN ionophores_NNS (_-LRB- A23187_CD )_-RRB- is_VBZ required_VBN for_IN their_PRP$ maximal_JJ induction_NN ._.
Yet_RB phorbol_JJ ester_`` alone_RB or_CC calcium_`` ionophore_RB alone_JJ produce_VBP several_JJ lymphokines_NNS ._.
The_DT production_NN of_IN the_DT granulocyte-macrophage_JJ colony_NN stimulating_JJ factor_NN (_-LRB- GM-CSF_NNP )_-RRB- is_VBZ completely_RB dependent_JJ on_IN the_DT two_CD signals_NNS ._.
We_PRP have_VBP previously_RB found_VBN a_DT cis-acting_JJ region_NN spanning_VBG the_DT GM-CSF_`` promoter_NN region_NN (_-LRB- positions_NNS -95_CD to_TO +27_CD )_-RRB- that_IN confers_VBZ inducibility_NN to_TO reporter_NN genes_NNS in_IN transient_JJ transfection_NN assays_NNS ._.
Further_JJ analysis_NN identified_VBN three_CD elements_NNS required_VBN for_IN efficient_JJ induction_NN ,_, referred_VBD to_TO as_IN GM2_NNP ,_, GC-box_NNP and_CC conserved_`` lymphokine_`` element_NN (_-LRB- CLE0_NN )_-RRB- ._.
GM2_NNP defines_VBZ a_DT binding_`` site_NN for_IN protein_NN (_-LRB- s_VBZ )_-RRB- whose_WP$ binding_NN is_VBZ inducible_JJ by_IN PMA_NNP ._.
One_CD protein_NN ,_, NF-GM2_-RRB- is_VBZ similar_JJ to_TO the_DT transcription_NN factor_NN NF-kB_NNP ._.
GC-box_NN is_VBZ a_DT binding_`` site_NN for_IN constitutively_RB bound_VBN proteins_NNS ._.
CLEO_NN defines_VBZ a_DT binding_`` site_NN for_IN protein_NN (_-LRB- s_VBZ )_-RRB- whose_WP$ optimum_JJ binding_NN is_VBZ stimulated_VBN by_IN PMA_NNP and_CC A23187_CD ._.
Viral_JJ trans-activators_NNS such_JJ as_IN Tax_NNP (_-LRB- human_JJ T_`` cell_NN leukemia_NN virus-1_NN ,_, HTLV-1_NNP )_-RRB- and_CC E2_`` (_-LRB- bovine_`` papilloma_NN virus_NN ,_, BPV_NNP )_-RRB- proteins_NNS are_VBP other_JJ agents_NNS which_WDT activate_VBP lymphokine_`` gene_NN expression_NN by_IN bypassing_VBG T_JJ cell_NN receptor_NN (_-LRB- TCR_NNP )_-RRB- mediated_VBD signaling_VBG ._.
The_DT trans-activation_NN domain_NN of_IN E2_NNP and_CC Tax_NNP is_VBZ interchangeable_JJ although_IN they_PRP have_VBP no_DT obvious_JJ sequence_NN homology_NN between_IN them_PRP ._.
The_DT viral_JJ trans-activators_NNS appear_VBP to_TO target_VB specific_JJ DNA_NNP binding_JJ protein_NN such_JJ as_IN NF-kB_NNP and_CC Sp1_NNP to_TO cis-acting_`` DNA_NNP site_NN and_CC promote_VB lymphokine_JJ gene_NN expression_NN without_IN TCR-mediated_JJ stimulation_NN ._.
I_PRP kappa_`` B/MAD-3_`` masks_NNS the_DT nuclear_JJ localization_NN signal_NN of_IN NF-kappa_NNP B_NNP p65_NN and_CC requires_VBZ the_DT transactivation_NN domain_NN to_TO inhibit_VB NF-kappa_NNP B_NNP p65_NN DNA_NNP binding_`` ._.
The_DT active_JJ nuclear_JJ form_NN of_IN the_DT NF-kappa_NNP B_NNP transcription_`` factor_NN complex_NN is_VBZ composed_VBN of_IN two_CD DNA_NNP binding_# subunits_NNS ,_, NF-kappa_NNP B_NNP p65_NN and_CC NF-kappa_NNP B_NNP p50_NN ,_, both_DT of_IN which_WDT share_NN extensive_JJ N-terminal_JJ sequence_NN homology_NN with_IN the_DT v-rel_`` oncogene_JJ product_NN ._.
The_DT NF-kappa_NNP B_NNP p65_`` subunit_NN provides_VBZ the_DT transactivation_NN activity_NN in_IN this_DT complex_JJ and_CC serves_VBZ as_IN an_DT intracellular_`` receptor_NN for_IN a_DT cytoplasmic_JJ inhibitor_NN of_IN NF-kappa_NNP B_NNP ,_, termed_VBD I_PRP kappa_`` B_NNP ._.
In_IN contrast_NN ,_, NF-kappa_NNP B_NNP p50_NN alone_RB fails_VBZ to_TO stimulate_VB kappa_`` B-directed_-LRB- transcription_NN ,_, and_CC based_VBN on_IN prior_RB in_IN vitro_NN studies_NNS ,_, is_VBZ not_RB directly_RB regulated_VBN by_IN I_PRP kappa_`` B_NNP ._.
To_TO investigate_VB the_DT molecular_JJ basis_NN for_IN the_DT critical_JJ regulatory_JJ interaction_NN between_IN NF-kappa_NNP B_NNP and_CC I_PRP kappa_`` B/MAD-3_NNP ,_, a_DT series_NN of_IN human_JJ NF-kappa_NNP B_NNP p65_NN mutants_NNS was_VBD identified_VBN that_IN functionally_RB segregated_VBN DNA_NNP binding_`` ,_, I_PRP kappa_`` B-mediated_`` inhibition_NN ,_, and_CC I_PRP kappa_`` B-induced_`` nuclear_JJ exclusion_NN of_IN this_DT transcription_NN factor_NN ._.
Results_NNS from_IN in_IN vivo_# expression_NN studies_NNS performed_VBN with_IN these_DT NF-kappa_NNP B_NNP p65_NN mutants_NNS revealed_VBD the_DT following_VBG :_: 1_CD )_-RRB- I_PRP kappa_`` B/MAD-3_`` completely_RB inhibits_VBZ NF-kappa_NNP B_NNP p65-dependent_JJ transcriptional_JJ activation_NN mediated_`` through_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD kappa_NN B_NNP enhancer_`` in_IN human_JJ T_`` lymphocytes_NNS ,_, 2_CD )_-RRB- the_DT binding_`` of_IN I_PRP kappa_`` B/MAD-3_-LRB- to_TO NF-kappa_NNP B_NNP p65_NN is_VBZ sufficient_JJ to_TO retarget_VB NF-kappa_NNP B_NNP p65_`` from_IN the_DT nucleus_`` to_TO the_DT cytoplasm_NN ,_, 3_CD )_-RRB- selective_JJ deletion_NN of_IN the_DT functional_JJ nuclear_JJ localization_NN signal_NN present_RB in_IN the_DT Rel_NNP homology_NN domain_NN of_IN NF-kappa_NNP B_NNP p65_NN disrupts_VBZ its_PRP$ ability_NN to_TO engage_VB I_PRP kappa_`` B/MAD-3_`` ,_, and_CC 4_CD )_-RRB- the_DT unique_JJ C-terminus_NN of_IN NF-kappa_NNP B_NNP p65_`` attenuates_VBZ its_PRP$ own_JJ nuclear_JJ localization_NN and_CC contains_VBZ sequences_NNS that_WDT are_VBP required_VBN for_IN I_PRP kappa_`` B-mediated_JJ inhibition_NN of_IN NF-kappa_NNP B_NNP p65_NN DNA_NNP binding_`` activity_NN ._.
Together_RB ,_, these_DT findings_NNS suggest_VBP that_IN the_DT nuclear_JJ localization_NN signal_NN and_CC transactivation_NN domain_NN of_IN NF-kappa_NNP B_NNP p65_`` constitute_VB a_DT bipartite_JJ system_NN that_WDT is_VBZ critically_RB involved_VBN in_IN the_DT inhibitory_JJ function_NN of_IN I_PRP kappa_`` B/MAD-3_-RRB- ._.
Unexpectedly_RB ,_, our_PRP$ in_IN vivo_`` studies_NNS also_RB demonstrate_VBP that_IN I_PRP kappa_`` B/MAD-3_`` binds_NNS directly_RB to_TO NF-kappa_NNP B_NNP p50_NN ._.
This_DT interaction_NN is_VBZ functional_JJ as_IN it_PRP leads_VBZ to_TO retargeting_`` of_IN NF-kappa_NNP B_NNP p50_`` from_IN the_DT nucleus_`` to_TO the_DT cytoplasm_NN ._.
However_RB ,_, no_DT loss_NN of_IN DNA_NNP binding_`` activity_NN is_VBZ observed_VBN ,_, presumably_RB reflecting_VBG the_DT unique_JJ C-terminal_JJ domain_NN that_WDT is_VBZ distinct_JJ from_IN that_IN present_JJ in_IN NF-kappa_NNP B_NNP p65_NN ._.
Surrogate_VB thyroglobulin_NN receptors_NNS and_CC T_JJ cell_NN proliferation_NN in_IN Hashimoto_NNP 's_POS thyroiditis_NN ._.
Immunoglobulin_NNP molecules_`` on_IN the_DT surface_NN of_IN a_DT B_NNP lymphocyte_`` are_VBP the_DT endogenous_JJ "_`` receptors_NNS "_'' to_TO which_WDT specific_JJ antigens_`` bind_NN ._.
Studies_NNS in_IN mice_NNS have_VBP shown_VBN that_IN a_DT monoclonal_JJ antibody_NN ,_, conjugated_'' with_IN palmitate_NN to_TO provide_VB a_DT lipid_`` tail_NN ,_, can_MD be_VB inserted_VBN into_IN the_DT cell_NN membrane_NN to_TO provide_VB a_DT "_`` surrogate_`` "_'' antigen_NN receptor_NN ._.
We_PRP have_VBP investigated_VBN whether_IN a_DT palmitate_NN conjugate_NN of_IN a_DT human_JJ monoclonal_`` antibody_NN specific_NN for_IN thyroglobulin_`` (_-LRB- TG_NNP )_-RRB- could_MD function_VB as_IN a_DT surrogate_JJ TG_NNP receptor_NN on_IN blood_NN mononuclear_JJ cells_NNS separated_VBN into_IN fractions_NNS enriched_`` for_IN T_JJ cells_NNS or_CC depleted_`` of_IN T_JJ cells_NNS (_-LRB- non-T_JJ cells_NNS )_-RRB- ._.
Using_VBG flow_NN cytometry_NN ,_, we_PRP detected_VBD surrogate_JJ TG_NNP receptors_`` on_IN non-T_JJ (_-LRB- but_CC not_RB on_IN T_JJ )_-RRB- cells_NNS from_IN 11_CD of_IN 11_CD individuals_NNS studied_VBD (_-LRB- 5_CD Hashimoto_NNP patients_NNS and_CC 6_CD control_NN donors_NNS )_-RRB- ._.
In_IN contrast_NN ,_, endogenous_JJ TG_`` receptors_NNS could_MD only_RB be_VB detected_VBN on_IN non-T_JJ cells_NNS from_IN 1_CD of_IN 3_CD Hashimoto_NNP patients_NNS and_CC from_IN 0_CD of_IN 4_CD control_NN donors_NNS ._.
Because_IN of_IN the_DT efficient_JJ binding_NN of_IN TG_NNP by_IN surrogate_JJ receptors_NNS on_IN non-T_JJ cells_NNS ,_, we_PRP assessed_VBD the_DT ability_NN of_IN such_JJ cells_NNS to_TO present_VB TG_NNP to_TO T_VB cells_NNS ._.
Proliferation_NN in_IN response_NN to_TO TG_NNP was_VBD observed_VBN in_IN T_JJ cells_NNS from_IN only_RB 1_CD of_IN 5_CD Hashimoto_NNP patients_NNS ._.
This_DT low_JJ frequency_NN of_IN response_NN was_VBD no_RB different_JJ from_IN that_DT previously_RB detected_VBN using_VBG cultures_NNS of_IN T_JJ cells_NNS and_CC autologous_`` dendritic_JJ cells_NNS ._.
Therefore_RB ,_, the_DT successful_JJ generation_NN of_IN surrogate_JJ receptors_NNS on_IN non-T_JJ cells_NNS is_VBZ not_RB associated_VBN with_IN more_RBR efficient_JJ TG_NNP presentation_NN of_IN T_JJ cells_NNS ._.
Furthermore_RB ,_, the_DT significance_NN of_IN the_DT present_JJ study_NN is_VBZ that_IN the_DT T_JJ cells_NNS ,_, not_RB the_DT antigen-presenting_JJ cells_NNS ,_, are_VBP likely_JJ to_TO be_VB the_DT limiting_VBG element_NN in_IN the_DT T_JJ cell_NN proliferative_JJ response_NN to_TO TG_NNP and_CC other_JJ thyroid_`` autoantigens_NNS ._.
Aldosterone-specific_JJ membrane_`` receptors_NNS and_CC rapid_JJ non-genomic_JJ actions_NNS of_IN mineralocorticoids_NNS ._.
Functional_JJ studies_NNS in_IN extrarenal_JJ ,_, non-epithelial_JJ cells_NNS such_JJ as_IN smooth_JJ muscle_NN cells_NNS and_CC more_RBR recently_RB circulating_VBG human_JJ lymphocytes_NNS have_VBP provided_VBN increasing_VBG evidence_NN that_IN aldosterone_'' produces_VBZ not_RB only_RB classical_JJ genomic_`` effects_NNS ,_, but_CC also_RB rapid_JJ ,_, non-genomic_JJ effects_NNS on_IN transmembrane_`` electrolyte_JJ movements_NNS ._.
These_DT involve_VBP activation_NN of_IN the_DT sodium/proton_`` exchanger_NN of_IN the_DT cell_NN membrane_NN at_IN very_RB low_JJ ,_, physiological_JJ concentrations_NNS of_IN aldosterone_NN with_IN an_DT acute_JJ onset_NN within_IN 1-2_CD min_NN ._.
A_DT second_JJ messenger_NN cascade_NN involved_VBN is_VBZ the_DT inositol_`` 1,4,5-trisphosphate/calcium_JJ pathway_NN which_WDT responds_VBZ over_IN the_DT same_JJ rapid_JJ time_NN course_NN ._.
Such_JJ changes_NNS clearly_RB can_MD not_RB be_VB explained_VBN by_IN genomic_JJ mechanisms_NNS ,_, which_WDT are_VBP responsible_JJ for_IN later_RB effects_NNS than_IN the_DT membrane_NN related_VBN rapid_JJ responses_NNS ._.
The_DT mechanisms_NNS underlying_VBG these_DT rapid_JJ effects_NNS of_IN aldosterone_NN on_IN electrolytes_NNS have_VBP been_VBN extensively_RB studied_VBN in_IN human_JJ lymphocytes_NNS ,_, which_WDT thus_RB may_MD represent_VB valuable_JJ tools_NNS in_IN the_DT delineation_NN of_IN the_DT receptor-effector_`` mechanisms_NNS involved_VBN ._.
The_DT unique_JJ characteristics_NNS of_IN this_DT new_JJ pathway_NN for_IN steroid_JJ action_NN include_VBP its_PRP$ rapid_JJ time_NN course_NN ,_, 10,000-fold_JJ selectivity_NN for_IN aldosterone_NN over_IN cortisol_`` and_CC the_DT ineffectiveness_NN of_IN spironolactones_NNS ,_, classical_JJ mineralocorticoid_`` antagonists_NNS ,_, as_IN antagonists_NNS of_IN the_DT response_NN ._.
Cellular_NNP immune_JJ and_CC cytokine_JJ pathways_NNS resulting_VBG in_IN tissue_NN factor_NN expression_NN and_CC relevance_NN to_TO septic_JJ shock_NN ._.
Cells_# of_IN monocyte_`` lineage_`` serve_VB as_IN effector_NN cells_NNS in_IN the_DT cellular_JJ immune_JJ response_NN ._.
In_IN addition_NN ,_, they_PRP respond_VBP to_TO LPS_`` and_CC cytokines_`` with_IN activation_NN and_CC expression_NN of_IN inflammatory_`` effector_`` gene_NN products_NNS similar_JJ to_TO those_DT elicited_VBN by_IN the_DT antigen_`` driven_JJ response_NN ._.
The_DT response_NN to_TO antigen_`` proceeds_NNS at_IN the_DT T_JJ helper_`` cell_NN level_NN through_IN two_CD independent_JJ forms_NNS of_IN cellular_JJ collaboration_NN ,_, contact_NN and_CC lymphokine_NN ._.
We_PRP review_VBP the_DT control_NN of_IN expression_NN of_IN the_DT Tissue_NNP Factor_NNP (_-LRB- TF_NNP )_-RRB- gene_NN and_CC the_DT function_NN of_IN the_DT TF_NNP protein_NN ._.
The_DT enhanced_JJ initiation_NN of_IN transcription_NN of_IN the_DT TF_NNP gene_NN appears_VBZ to_TO require_VB engagement_NN of_IN a_DT 56_CD bp_NN LPS_NNP Response_NNP Element_NNP ,_, an_DT enhancer_NN that_WDT is_VBZ engaged_VBN by_IN both_DT AP-1_`` type_NN heterodimeric_JJ complexes_NNS as_RB well_RB as_IN NF_NNP kappa_`` B_NNP like_IN heterodimeric_JJ complexes_NNS ._.
Dissociation_NN of_IN NF_NNP kappa_NN B_NNP from_IN Ig_NNP kappa_`` B_NN by_IN cytokine_`` and_CC LPS_`` stimulation_NN ,_, and_CC possibly_RB activated_VBD T_JJ cells_NNS ,_, may_MD represent_VB a_DT common_JJ pathway_NN to_TO induction_`` of_IN the_DT TF_NNP and_CC other_JJ inflammatory_JJ genes_NNS ._.
Enhancement_NN of_IN expression_NN of_IN TF_NNP is_VBZ observed_VBN upon_IN adhesion_NN of_IN Mo_NNP to_TO endothelial_`` cells_NNS and_CC extracellular_JJ matrix_`` proteins_NNS ,_, as_RB well_RB as_IN upon_IN engagement_NN of_IN leukocyte_`` integrins_NNS ._.
The_DT biological_JJ effects_NNS that_WDT follow_VBP from_IN expression_NN of_IN TF_NNP by_IN vascular_JJ cells_NNS have_VBP been_VBN resolved_VBN by_IN analysis_NN of_IN function_NN aided_VBN by_IN the_DT use_NN of_IN recombinant_NN full_JJ length_NN TF_NNP and_CC truncated_`` surface_NN domain_NN of_IN TF_NNP ._.
The_DT rules_NNS of_IN assembly_NN of_IN the_DT cognate_`` ligands_`` of_IN TF_NNP ,_, namely_RB the_DT zymogen_NN plasma_NN factors_NNS VII_# and_CC the_DT serine_NN protease_NN factor_NN VIIa_NNP ,_, with_IN the_DT soluble_JJ surface_NN domain_NN of_IN TF_`` in_IN free_JJ solution_NN ,_, in_IN the_DT presence_NN of_IN phospholipid_JJ surfaces_NNS and_CC cell_NN surface_NN and_CC of_IN the_DT anchored_VBN TF_NNP molecule_`` have_VBP been_VBN described_VBN ._.
It_PRP is_VBZ evident_JJ that_IN assembly_NN of_IN the_DT surface_NN domain_NN of_IN TF_NNP with_IN VIIa_NNP to_TO form_VB the_DT binary_JJ TF.VIIa_NNP complex_JJ induces_VBZ a_DT significant_JJ increase_NN in_IN the_DT Kcat_`` of_IN the_DT catalytic_JJ domain_NN of_IN VIIa_NNP for_IN small_JJ peptidyl_`` substrates_NNS and_CC more_JJR profoundly_RB for_IN protein_NN substrate_NN ._.
This_DT provides_VBZ substantial_JJ evidence_NN for_IN an_DT allosteric_JJ effect_NN on_IN the_DT catalytic_JJ cleft_NN of_IN VIIa_NNP that_WDT is_VBZ imparted_VBN by_IN binding_VBG to_TO TF_NNP ,_, its_PRP$ cognate_`` catalytic_JJ cofactor_NN ._.
It_PRP is_VBZ also_RB evident_JJ that_IN the_DT TF.VIIa_NNP complex_NN is_VBZ proteolytically_RB active_JJ and_CC can_MD activate_VB the_DT zymogen_`` plasma_NN factor_NN X_NNP to_TO the_DT serine_NN protease_NN Xa_NNP in_IN free_JJ solution_NN ,_, inferring_'' that_WDT extended_VBD substrate_JJ recognition_NN by_IN induced_`` structural_JJ loci_`` of_IN the_DT TF.VIIa_NNP complex_NN are_VBP created_VBN from_IN either_RB or_CC both_DT proteins_VBZ to_TO constitute_VB a_DT new_JJ recognition_NN structure_NN ._.
It_PRP is_VBZ also_RB evident_JJ that_IN association_NN of_IN X_NNP with_IN charged_VBN phospholipid_`` surfaces_NNS enhances_VBZ the_DT proteolytic_JJ activation_NN of_IN this_DT zymogen_NN by_IN increasing_VBG recognition_NN and_CC susceptibility_NN of_IN the_DT sessile_NN peptide_`` bond_NN deduced_VBN from_IN the_DT markedly_`` decreased_VBD Km_NNP and_CC increased_VBD Kcat_NNP ._.
